

# MGMT Gene Silencing and Benefit from Temozolomide

New England Journal of Medicine

352, 997-1003

DOI: [10.1056/nejmoa043331](https://doi.org/10.1056/nejmoa043331)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiforme. , 0, , 37-52.		1
2	Chemisorption Theory. Progress in Surface and Membrane Science, 1975, 9, 71-161.	0.9	46
3	Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. International Journal of Oncology, 1992, 33, 469.	1.4	10
4	Clinical application of the blink reflex with stimulation of the mental nerve in lesions of the inferior alveolar nerve. Neurology, 1994, 44, 2356-2356.	1.5	28
5	Radiotherapy plus adjuvant temozolomide for the treatment of glioblastoma—a paradigm shift. Nature Clinical Practice Oncology, 2005, 2, 334-335.	4.3	5
6	Chemotherapy in Brain Metastases. Neurosurgery, 2005, 57, S4-S4-S4-65.	0.6	36
7	Treatment of astrocytomas. Current Opinion in Neurology, 2005, 18, 632-638.	1.8	23
8	An update on oligodendroglial neoplasms. Current Opinion in Neurology, 2005, 18, 639-644.	1.8	10
9	10 Questions About Temozolomide and the Treatment of Brain Tumors. Neurologist, 2005, 11, 362-365.	0.4	5
10	New Approaches to Drug Development in Pediatric Oncology. Cancer Journal (Sudbury, Mass ), 2005, 11, 324-330.	1.0	18
11	Cellular Response to DNA Damage. Annals of the New York Academy of Sciences, 2005, 1066, 243-258.	1.8	31
13	Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurology, The, 2005, 4, 413-422.	4.9	66
14	Low-grade gliomas: an update on pathology and therapy. Lancet Neurology, The, 2005, 4, 760-770.	4.9	113
15	Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer, 2005, 104, 1478-1486.	2.0	76
16	Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer, 2005, 104, 1693-1699.	2.0	47
19	Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme. Current Neurology and Neuroscience Reports, 2005, 5, 167-168.	2.0	1
20	Optimal role of temozolomide in the treatment of malignant gliomas. Current Neurology and Neuroscience Reports, 2005, 5, 198-206.	2.0	168
21	Neuro-Oncology in a Nutshell. Journal of Neuro-Oncology, 2005, 72, 93-93.	1.4	0

#	ARTICLE	IF	CITATIONS
22	Chemotherapy for Brain Tumors – A New Beginning. <i>New England Journal of Medicine</i> , 2005, 352, 1036-1038.	13.9	86
23	Drug Insight: temozolomide as a treatment for malignant glioma – impact of a recent trial. <i>Nature Clinical Practice Neurology</i> , 2005, 1, 88-95.	2.7	50
24	Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2005, 23, 7178-7187.	0.8	220
25	The molecular epidemiology of gliomas in adults. <i>Neurosurgical Focus</i> , 2005, 19, 1-11.	1.0	61
26	Avoiding glucocorticoid administration in a neurooncological case. <i>Cancer Biology and Therapy</i> , 2005, 4, 1186-1189.	1.5	9
27	Temozolomide: a milestone in the pharmacotherapy of brain tumors. <i>Future Oncology</i> , 2005, 1, 747-754.	1.1	38
28	Treatment of Brain Tumors. <i>New England Journal of Medicine</i> , 2005, 352, 2350-2353.	13.9	11
29	Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16759-16764.	3.3	270
30	Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 25-32.	1.4	8
31	Chemotherapy for malignant glioma. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 41-49.	1.4	9
33	Role of O6-Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 1247-1255.	1.3	10
34	Health-related quality of life and symptom research in glioblastoma multiforme patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 763-774.	0.7	14
35	Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma. <i>Clinical Cancer Research</i> , 2005, 11, 7861-7865.	3.2	61
37	Teratogens as Anticancer Drugs. <i>Cell Cycle</i> , 2005, 4, 1518-1521.	1.3	90
38	The Role of Radio- and Chemotherapy in Glioblastoma. <i>Oncology Research and Treatment</i> , 2005, 28, 315-317.	0.8	77
39	Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 683-690.	1.4	5
40	Patients with High-Grade Gliomas Harboring Deletions of Chromosomes 9p and 10q Benefit from Temozolomide Treatment. <i>Neoplasia</i> , 2005, 7, 883-893.	2.3	55
41	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 987-996.	13.9	17,395

#	ARTICLE	IF	CITATIONS
42	Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O6-methylguanine-DNA methyltransferase in patients with glioblastoma. <i>Medical Hypotheses</i> , 2005, 65, 819-820.	0.8	0
43	Insoluble fibrin may reduce turbulence and bind blood components into clots. <i>Medical Hypotheses</i> , 2005, 65, 820-821.	0.8	9
44	Adding temozolomide to radiotherapy prolongs survival in people with glioblastoma. <i>Cancer Treatment Reviews</i> , 2005, 31, 577-581.	3.4	1
46	Epigenetics of cervical cancer. An overview and therapeutic perspectives. <i>Molecular Cancer</i> , 2005, 4, 38.	7.9	183
47	Epigenetic silencing of the MGMT gene in cancer. <i>Biochemistry and Cell Biology</i> , 2005, 83, 429-437.	0.9	78
48	Radiosensitizers in Brain Cancer. <i>American Journal of Cancer</i> , 2006, 5, 363-370.	0.4	1
49	New and Emerging Radiosensitizers and Radioprotectors. <i>Cancer Investigation</i> , 2006, 24, 444-456.	0.6	41
50	Precision and Performance Characteristics of Bisulfite Conversion and Real-Time PCR (MethyLight) for Quantitative DNA Methylation Analysis. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 209-217.	1.2	361
51	DNA repair gene inactivation in non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1728-1729.	0.6	1
52	Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1593-1607.	1.1	32
53	Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 2715-2722.	0.8	690
54	Chemotherapy in the treatment of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 755-767.	1.1	19
55	Genomic Profiling Identifies Discrete Deletions Associated with Translocations in Glioblastoma Multiforme. <i>Cell Cycle</i> , 2006, 5, 783-791.	1.3	61
56	Glioblastoma multiforme: advances in postsurgical management. <i>Community Oncology</i> , 2006, 3, 678-683.	0.2	4
57	Inroads in managing malignant gliomas renew hope. <i>Community Oncology</i> , 2006, 3, 684.	0.2	0
59	Current Role of Radiation Therapy in the Management of Malignant Brain Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 431-453.	0.9	7
60	Recent Advances in the Treatment of Malignant Astrocytoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1253-1265.	0.8	285
61	A Changing Paradigm of Glioma Biology. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 1171-1191.	0.9	2

#	ARTICLE	IF	CITATIONS
62	Genetic and Epigenetic Biomarkers in Cancer. <i>Molecular Diagnosis and Therapy</i> , 2006, 10, 1-15.	1.6	34
63	Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. <i>Journal of Clinical Oncology</i> , 2006, 24, 4412-4417.	0.8	152
64	Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. <i>Current Opinion in Pharmacology</i> , 2006, 6, 355-363.	1.7	86
65	Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. <i>Cancer Treatment Reviews</i> , 2006, 32, 261-276.	3.4	84
66	Recent developments in the use of chemotherapy in brain tumours. <i>European Journal of Cancer</i> , 2006, 42, 582-588.	1.3	108
67	Quantitation of chromosome 1p and 19q deletions in glial tumours by interphase FISH on formalin-fixed paraffin-embedded tissue. <i>Journal of Clinical Neuroscience</i> , 2006, 13, 96-101.	0.8	13
68	Emerging cancer therapeutic opportunities target DNA-repair systems. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 338-344.	4.0	117
69	Chemotherapy of High-Grade Astrocytomas. , 2006, , 347-363.		1
70	Epigenetic alterations in human brain tumors in a Brazilian population. <i>Genetics and Molecular Biology</i> , 2006, 29, 413-422.	0.6	2
71	Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas. <i>Oncology Reports</i> , 2006, 16, 127.	1.2	8
72	Glioma and Other Neuroepithelial Neoplasms. , 2006, , 674-694.		0
73	Molecular and cellular approaches to patient management in oncology. <i>Personalized Medicine</i> , 2006, 3, 299-310.	0.8	0
74	Current Status of Clinical Trials for Glioblastoma. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 265-281.	0.4	20
75	Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 43-51.	0.4	19
76	The Role of Chemotherapy in the Treatment of Malignant Astrocytomas. <i>Canadian Journal of Neurological Sciences</i> , 2006, 33, 127-140.	0.3	14
77	Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Glioblastoma Multiforme. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2006, 1, 37-52.	0.0	2
78	Glioma Therapy in Adults. <i>Neurologist</i> , 2006, 12, 279-292.	0.4	121
79	Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. <i>Anti-Cancer Drugs</i> , 2006, 17, 969-975.	0.7	16

#	ARTICLE	IF	CITATIONS
80	New approaches to primary brain tumor treatment. <i>Anti-Cancer Drugs</i> , 2006, 17, 1003-1016.	0.7	45
81	Molecular changes in brain tumors: prognostic and therapeutic impact. <i>Current Opinion in Oncology</i> , 2006, 18, 623-630.	1.1	12
82	New Treatments for Malignant Gliomas: Careful Evaluation and Cautious Optimism Required. <i>Annals of Internal Medicine</i> , 2006, 144, 371.	2.0	18
83	A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. <i>Oncology Reports</i> , 2006, 16, 1117.	1.2	21
84	VARIANT OF THE CHEK2GENE AS A PROGNOSTIC MARKER IN GLIOBLASTOMA MULTIFORME. <i>Neurosurgery</i> , 2006, 59, 1078-1085.	0.6	19
85	O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. <i>Journal of Neurochemistry</i> , 2006, 96, 766-776.	2.1	290
86	Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 27-34.	1.1	4
87	Target for cancer therapy: proliferating cells or stem cells. <i>Leukemia</i> , 2006, 20, 385-391.	3.3	172
88	Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 99-111.	2.0	32
89	Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 181-193.	2.0	97
90	[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: Clinical outcomes and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 886-891.	0.4	55
91	Chemotherapy Resistance. , 2006, , 89-104.		1
92	Temozolomide after Radiotherapy for Newly Diagnosed High-grade Glioma and Unfavorable Low-grade Glioma in Children. <i>Journal of Neuro-Oncology</i> , 2006, 76, 313-319.	1.4	76
93	Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. <i>Journal of Neuro-Oncology</i> , 2006, 77, 219-220.	1.4	3
94	Asterosaponin 1, a cytostatic compound from the starfish <i>Culcita novaeguineae</i> , functions by inducing apoptosis in human glioblastoma U87MG cells. <i>Journal of Neuro-Oncology</i> , 2006, 79, 235-241.	1.4	31
95	Complications of a temozolomide overdose: a case report. <i>Journal of Neuro-Oncology</i> , 2006, 80, 57-61.	1.4	11
96	Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2006, 80, 215-217.	1.4	2
100	Temozolomide for recurrent or progressive high-grade malignant glioma: Results of an Austrian multicenter observational study. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 230-238.	1.0	6

#	ARTICLE	IF	CITATIONS
101	Malignant glioma: Neuropathology and Neurobiology. Wiener Medizinische Wochenschrift, 2006, 156, 332-337.	0.5	46
102	Chemotherapy for malignant gliomas. Wiener Medizinische Wochenschrift, 2006, 156, 346-350.	0.5	6
103	Clinical aspects of molecular biology for the diagnosis and treatment of esophageal cancer. Esophagus, 2006, 3, 91-94.	1.0	0
104	Role of temozolomide in pediatric brain tumors. Child's Nervous System, 2006, 22, 652-661.	0.6	35
105	A phase II trial of O 6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemotherapy and Pharmacology, 2006, 58, 634-639.	1.1	35
106	Chemotherapeutic options for primary brain tumors. Current Treatment Options in Oncology, 2006, 7, 467-478.	1.3	15
107	Predictive and prognostic markers in human glioblastomas. Current Treatment Options in Oncology, 2006, 7, 490-504.	1.3	30
108	Recent advances in the treatment of oligodendrogliomas. Current Neurology and Neuroscience Reports, 2006, 6, 212-217.	2.0	2
109	Advances in the treatment of primary brain tumors: Dawn of a new era?. Current Oncology Reports, 2006, 8, 45-49.	1.8	8
110	The evolution of chemoradiation for glioblastoma: A modern success story. Current Oncology Reports, 2006, 8, 50-53.	1.8	6
111	Correlative studies in neuro-oncology trials: Should they influence treatment?. Current Oncology Reports, 2006, 8, 54-57.	1.8	5
112	Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genetics and Cytogenetics, 2006, 166, 46-55.	1.0	22
113	Neuro-oncology: setting new standards of management. Lancet Neurology, The, 2006, 5, 8-9.	4.9	1
114	Novel Radiation-Enhancing Agents in Malignant Gliomas. Seminars in Radiation Oncology, 2006, 16, 29-37.	1.0	23
115	Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma. Pathology International, 2006, 56, 510-515.	0.6	21
116	Targeting the p53 tumor suppressor gene function in glioblastomas using small chemical molecules. Drug Development Research, 2006, 67, 790-800.	1.4	1
117	Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas. Cancer, 2006, 106, 1358-1363.	2.0	200
118	Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors. Cancer, 2006, 107, 162-170.	2.0	57

#	ARTICLE	IF	CITATIONS
119	Reclassification of oligoastrocytomas by loss of heterozygosity studies. <i>International Journal of Cancer</i> , 2006, 119, 84-90.	2.3	51
120	MGMT methylation: A marker of response to temozolomide in low-grade gliomas. <i>Annals of Neurology</i> , 2006, 60, 740-743.	2.8	196
121	Molecular markers of gliomas: a clinical approach. <i>Neurological Research</i> , 2006, 28, 538-541.	0.6	10
122	Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P. <i>Clinical Cancer Research</i> , 2006, 12, 3843-3850.	3.2	135
123	Using molecular information to guide brain tumor therapy. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 232-233.	2.7	16
124	Glioblastoma—more questions than answers?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 60-61.	4.3	2
125	Treatment options for glioblastoma. <i>Neurosurgical Focus</i> , 2006, 20, E19.	1.0	37
126	Management of malignant glioma: steady progress with multimodal approaches. <i>Neurosurgical Focus</i> , 2006, 20, E3.	1.0	65
127	Brain tumors: molecular biology and targeted therapies. <i>Annals of Oncology</i> , 2006, 17, x191-x197.	0.6	23
128	Treatment of Glioblastoma Multiforme. <i>Archives of Neurology</i> , 2006, 63, 337.	4.9	44
129	Early Genetic Changes Involved in Low-Grade Astrocytic Tumor Development. <i>Current Molecular Medicine</i> , 2006, 6, 645-650.	0.6	19
130	Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 2563-2569.	0.8	447
131	Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2006, 24, 190-205.	0.8	108
132	Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 4746-4753.	0.8	171
133	Autophagy, the Trojan horse to combat glioblastomas. <i>Neurosurgical Focus</i> , 2006, 20, E7.	1.0	107
134	Genome-wide Hypomethylation in Human Glioblastomas Associated with Specific Copy Number Alteration, Methylenetetrahydrofolate Reductase Allele Status, and Increased Proliferation. <i>Cancer Research</i> , 2006, 66, 8469-8476.	0.4	203
135	Past, Present, and Future Strategies in the Treatment of High-Grade Glioma in Children. <i>Cancer Investigation</i> , 2006, 24, 77-81.	0.6	34
136	Epigenomic Profiling Reveals Novel and Frequent Targets of Aberrant DNA Methylation-Mediated Silencing in Malignant Glioma. <i>Cancer Research</i> , 2006, 66, 7490-7501.	0.4	153



#	ARTICLE	IF	CITATIONS
137	O6-Methylguanine-DNA Methyltransferase Expression Strongly Correlates With Outcome in Childhood Malignant Gliomas: Results From the CCG-945 Cohort. <i>Journal of Clinical Oncology</i> , 2006, 24, 3431-3437.	0.8	167
138	Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma. <i>Oncologist</i> , 2006, 11, 165-180.	1.9	357
139	Molecular Genetics of Brain Tumors—An Overview. , 2006, , 115-122.		1
140	Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 749-765.	0.9	4
141	Phase II Study of Temozolomide in Relapsed or Refractory High-Risk Neuroblastoma: A Joint Soci�t� Fran�aise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group—New Agents Group Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 5259-5264.	0.8	58
142	Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma. <i>Cancer Research</i> , 2006, 66, 6665-6674.	0.4	135
143	Diagnosis and Treatment of Recurrent High-Grade Astrocytoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1273-1280.	0.8	164
144	Adjuvant treatment of high grade gliomas. <i>Annals of Oncology</i> , 2006, 17, x186-x190.	0.6	11
145	Molecular Biology of Human Gliomas. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 185-194.	0.8	27
146	Molecular Diagnostics as a Tool to Personalize Treatment in Adult Glioma Patients. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 215-229.	0.8	19
147	A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy. <i>Cancer Research</i> , 2006, 66, 3987-3991.	0.4	383
148	YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas. <i>Clinical Cancer Research</i> , 2006, 12, 5698-5704.	3.2	168
149	Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2531-2539.	1.9	82
150	Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response. <i>Journal of Clinical Oncology</i> , 2006, 24, 1246-1252.	0.8	65
151	New treatment strategies for malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1087-1104.	1.1	117
152	Targeted Modulation of MGMT: Clinical Implications: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 328-331.	3.2	221
153	Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2182-2192.	1.9	51
154	Temozolomide: a milestone in neuro-oncology and beyond?. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1187-1204.	1.1	76

#	ARTICLE	IF	CITATIONS
155	Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). <i>British Journal of Cancer</i> , 2006, 95, 1155-1160.	2.9	221
156	Tumor Necrosis Factor- $\alpha$ -Induced Protein 3 As a Putative Regulator of Nuclear Factor- $\kappa$ B-Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 274-287.	0.8	127
157	Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms. <i>Clinical Cancer Research</i> , 2006, 12, 4738-4746.	3.2	195
158	Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide. <i>Journal of Clinical Oncology</i> , 2007, 25, 1470-1475.	0.8	187
159	Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 897-906.	0.6	56
160	Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2007, 25, 4722-4729.	0.8	1,285
161	Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1583-1593.	3.0	339
162	Glioblastoma multiforme: evidence-based approach to therapy. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, S23-S27.	1.1	33
163	Glioma. , 2007, , 433-444.		5
164	Methylguanine Methyltransferase Testing in Glioblastoma: When and How?. <i>Journal of Clinical Oncology</i> , 2007, 25, 1459-1460.	0.8	51
165	Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation. <i>Journal of Biological Chemistry</i> , 2007, 282, 21206-21212.	1.6	199
166	Identification of Differentially Regulated Splice Variants and Novel Exons in Glial Brain Tumors Using Exon Expression Arrays. <i>Cancer Research</i> , 2007, 67, 5635-5642.	0.4	81
167	O6-Methylguanine-DNA Methyltransferase Regulation by p53 in Astrocytic Cells. <i>Cancer Research</i> , 2007, 67, 580-584.	0.4	72
168	Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. <i>British Journal of Cancer</i> , 2007, 96, 960-969.	2.9	32
169	Long-term survival with glioblastoma multiforme. <i>Brain</i> , 2007, 130, 2596-2606.	3.7	748
170	Management of glioblastoma. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3133-3146.	0.9	40
171	S-Alkylthiolation of O6-methylguanine-DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 349-361.	1.5	14
172	Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 6252-6256.	3.2	50

#	ARTICLE	IF	CITATIONS
173	Use of Molecular Biomarkers for Predicting the Response to Radiotherapy With or Without Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4075-4083.	0.8	61
174	DNA Methylation Damage: Formation, Repair and Biological Consequences. , 2007, , 99-121.		5
175	Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis. <i>Clinical Cancer Research</i> , 2007, 13, 7341-7356.	3.2	68
176	Breast cancer prognostication and prediction in the postgenomic era. <i>Annals of Oncology</i> , 2007, 18, 1293-1306.	0.6	55
177	Methylated-CpG island recovery assay-assisted microarrays for cancer diagnosis. <i>Expert Opinion on Medical Diagnostics</i> , 2007, 1, 99-108.	1.6	0
178	Aiding and ABTâ€™ing treatment for glioblastoma. <i>Cancer Biology and Therapy</i> , 2007, 6, 802-804.	1.5	1
179	Cancer stem cell and cancer stemloids: From biology to therapy. <i>Cancer Biology and Therapy</i> , 2007, 6, 1684-1690.	1.5	97
180	New developments in the treatment of malignant gliomas. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1313-1326.	1.4	18
181	Epigenetic Aberrations in Malignant Gliomas: An Open Door Leading to Better Understanding and Treatment. <i>Epigenetics</i> , 2007, 2, 147-150.	1.3	26
182	Expression of O6-methylguanineâ€™deoxyribose nucleic acid methyltransferase and temozolomide response in a patient with a malignant spinal cord astrocytoma. <i>Journal of Neurosurgery: Spine</i> , 2007, 6, 447-450.	0.9	8
183	Brain Tumors: Current Issues in Diagnosis and Management. <i>Seminars in Neurology</i> , 2007, 27, 312-324.	0.5	10
185	Pediatric CNS tumors: current treatment and future directions. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1029-1042.	1.4	22
186	Realizing the Promise of Pharmacogenomics: Opportunities and Challenges. <i>Biotechnology Law Report</i> , 2007, 26, 261-291.	0.1	5
187	Phase I Trial of Single-Dose Temozolomide and Continuous Administration of <i>O</i></i>6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report. <i>Clinical Cancer Research</i> , 2007, 13, 6712-6718.	3.2	62
189	Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir. <i>Cancer Research</i> , 2007, 67, 4467-4473.	0.4	118
190	Phase I Trial of Polifeprosan 20 With Carmustine Implant Plus Continuous Infusion of Intravenous O6-Benzylguanine in Adults With Recurrent Malignant Glioma: New Approaches to Brain Tumor Therapy CNS Consortium Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 399-404.	0.8	78
191	The 1p-Encoded Protein Stathmin and Resistance of Malignant Gliomas to Nitrosoureas. <i>Journal of the National Cancer Institute</i> , 2007, 99, 639-652.	3.0	49
192	Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 2986-2991.	3.2	438

#	ARTICLE	IF	CITATIONS
193	Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival. <i>Clinical Cancer Research</i> , 2007, 13, 2606-2613.	3.2	144
194	Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007, 18, ii69-ii70.	0.6	15
195	Genome-wide epigenome interactions in cancer. <i>Human Molecular Genetics</i> , 2007, 16, R96-R105.	1.4	60
196	A novel application of melting curves: utility of peak area calculation for relative methylation quantification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 867-73.	1.4	7
197	Differential Sensitivity of Malignant Glioma Cells to Methylating and Chloroethylating Anticancer Drugs: p53 Determines the Switch by Regulating <i>xpc, ddb2</i> , and DNA Double-Strand Breaks. <i>Cancer Research</i> , 2007, 67, 11886-11895.	0.4	96
198	Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas. <i>Clinical Cancer Research</i> , 2007, 13, 1429-1437.	3.2	38
199	Novel Mechanism whereby Nuclear Factor $\kappa$ B Mediates DNA Damage Repair through Regulation of <i>O6-Methylguanine-DNA-Methyltransferase</i> . <i>Cancer Research</i> , 2007, 67, 8952-8959.	0.4	123
200	Outcome in adult low-grade glioma. <i>Neurology</i> , 2007, 69, 1366-1373.	1.5	120
201	Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2540-2545.	0.8	95
202	DNA repair after irradiation in glioma cells and normal human astrocytes. <i>Neuro-Oncology</i> , 2007, 9, 404-411.	0.6	49
203	Adenovirus-Based Strategies Overcome Temozolomide Resistance by Silencing the O6-Methylguanine-DNA Methyltransferase Promoter. <i>Cancer Research</i> , 2007, 67, 11499-11504.	0.4	130
204	Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2046-2053.	3.2	163
205	Mechanisms of Disease: genetic predictors of response to treatment in brain tumors. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 362-374.	4.3	36
206	Efficacy of Temozolomide Is Correlated With 1p Loss and Methylation of the Deoxyribonucleic Acid Repair Gene MGMT in Malignant Gliomas. <i>Neurologia Medico-Chirurgica</i> , 2007, 47, 341-350.	1.0	24
207	Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. <i>Journal of Applied Clinical Medical Physics</i> , 2007, 8, 47-60.	0.8	82
209	Incorporating molecular tools into clinical trials and treatment for gliomas?. <i>Current Opinion in Neurology</i> , 2007, 20, 708-711.	1.8	9
210	Editorial: what is new in the treatment of gliomas?. <i>Current Opinion in Neurology</i> , 2007, 20, 704-707.	1.8	11
211	New chemotherapy options for the treatment of malignant gliomas. <i>Anti-Cancer Drugs</i> , 2007, 18, 621-632.	0.7	16

#	ARTICLE	IF	CITATIONS
212	Function and Malfunction of Hematopoietic Stem Cells in Primary Bone Marrow Failure Syndromes. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 39-52.	0.6	37
213	Molecular targeted therapies and chemotherapy in malignant gliomas. <i>Current Opinion in Oncology</i> , 2007, 19, 598-605.	1.1	46
214	New molecular targets in malignant gliomas. <i>Current Opinion in Neurology</i> , 2007, 20, 712-718.	1.8	32
215	Molecular genetic markers as predictors of response to chemotherapy in gliomas. <i>Current Opinion in Oncology</i> , 2007, 19, 606-611.	1.1	56
216	High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 65-82.	0.6	22
217	Molecular Genetic Analysis of p53 Intratumoral Heterogeneity in Human Astrocytic Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 944-954.	0.9	26
218	Predictive and Prognostic Markers in Neuro-Oncology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 1074-1081.	0.9	42
219	Coincidence vs Cause: Cure in Three Glioblastoma Patients Treated with Brachytherapy. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, 339-342.	0.3	11
220	Adjuvant Chemotherapy for Adults with Malignant Glioma: A Systematic Review. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, 402-410.	0.3	24
221	Efficient DNA extraction from 25-year-old paraffin-embedded tissues: study of 365 samples. <i>Pathology</i> , 2007, 39, 345-348.	0.3	68
222	Insulin-like growth factor type I biology and targeting in malignant gliomas. <i>Neuroscience</i> , 2007, 145, 795-811.	1.1	100
223	Targeting DNA repair as a promising approach in cancer therapy. <i>European Journal of Cancer</i> , 2007, 43, 1791-1801.	1.3	89
224	Potential biochemical therapy of glioma cancer. <i>Biochemical and Biophysical Research Communications</i> , 2007, 362, 225-229.	1.0	29
225	Signaling adaptor protein Crk is indispensable for malignant feature of glioblastoma cell line KMG4. <i>Biochemical and Biophysical Research Communications</i> , 2007, 362, 976-981.	1.0	38
226	Diagnosis and pathogenesis of gliomas. <i>Current Diagnostic Pathology</i> , 2007, 13, 180-192.	0.4	12
229	The Unfolded Protein Response Regulator GRP78/BiP as a Novel Target for Increasing Chemosensitivity in Malignant Gliomas. <i>Cancer Research</i> , 2007, 67, 9809-9816.	0.4	392
230	Genetic Pathways to Primary and Secondary Glioblastoma. <i>American Journal of Pathology</i> , 2007, 170, 1445-1453.	1.9	1,250
231	Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas. <i>Oncologist</i> , 2007, 12, 1395-1403.	1.9	232

#	ARTICLE	IF	CITATIONS
232	Staging of cancer. European Journal of Cancer, Supplement, 2007, 5, 7-14.	2.2	1
233	Análisis de la presencia de mutaciones por pérdida de heterocigocidad de 1p/19q en tumores cerebrales de estirpe glial. Neurocirugía, 2007, 18, 285-293.	0.2	3
235	The therapeutic potential of O <sup>6</sup> -alkylguanine DNA alkyltransferase inhibitors. Expert Opinion on Investigational Drugs, 2007, 16, 1573-1584.	1.9	36
237	Central Nervous System Tumors. Mayo Clinic Proceedings, 2007, 82, 1271-1286.	1.4	255
238	Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. British Journal of Neurosurgery, 2007, 21, 583-587.	0.4	30
239	Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail. Expert Review of Anticancer Therapy, 2007, 7, 663-674.	1.1	23
240	The economics of temozolomide in brain cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 1923-1929.	0.9	4
241	Cancer Pharmacogenomics. Molecular Diagnosis and Therapy, 2007, 11, 361-380.	1.6	25
242	Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment. Clinical Cancer Research, 2007, 13, 2038-2045.	3.2	384
243	Adjuvant therapy in glioblastomas: false steps and real advances. Expert Review of Anticancer Therapy, 2007, 7, 607-608.	1.1	1
244	Temozolomide and Radiation in Low-Grade and Anaplastic Gliomas: Temoradiation. Cancer Investigation, 2007, 25, 776-784.	0.6	18
245	Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis. Journal of Molecular Diagnostics, 2007, 9, 368-381.	1.2	194
246	Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. Journal of Clinical Oncology, 2007, 25, 4127-4136.	0.8	474
247	Diagnosis and Treatment of High-Grade Astrocytoma. Neurologic Clinics, 2007, 25, 1111-1139.	0.8	86
248	Novel Therapies for Malignant Gliomas. Neurologic Clinics, 2007, 25, 1141-1171.	0.8	17
249	Anaplastic Oligodendroglioma and Oligoastrocytoma. Neurologic Clinics, 2007, 25, 1089-1109.	0.8	50
250	Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Research, 2007, 35, e41-e41.	6.5	460
251	Management of Patients with Low-Grade Gliomas. Neurologic Clinics, 2007, 25, 1073-1088.	0.8	16

#	ARTICLE	IF	CITATIONS
252	Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 89.	0.8	10
253	Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. <i>Journal of Neurosurgery</i> , 2007, 107, 610-616.	0.9	74
254	Proteomic analysis of gliomas. <i>British Journal of Neurosurgery</i> , 2007, 21, 576-582.	0.4	26
255	Advanced MRI in the management of adult gliomas. <i>British Journal of Neurosurgery</i> , 2007, 21, 550-561.	0.4	71
256	MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?. <i>Disease Markers</i> , 2007, 23, 97-104.	0.6	51
257	TUMORS OF THE BRAIN. , 2007, , 1324-1339.		0
258	Synergistic antiglioma activity of radiotherapy and enzastaurin. <i>Annals of Neurology</i> , 2007, 61, 153-161.	2.8	72
259	Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. <i>International Journal of Cancer</i> , 2007, 121, 2458-2464.	2.3	140
260	Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors. <i>Cancer</i> , 2007, 110, 1542-1550.	2.0	185
261	Predicting Outcome of Patients with High-grade Gliomas After Radiotherapy using Quantitative Analysis of T1-weighted Magnetic Resonance Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1476-1483.	0.4	7
262	Differential Radiosensitizing Potential of Temozolomide in MGMT Promoter Methylated Glioblastoma Multiforme Cell Lines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1246-1253.	0.4	59
263	From expert opinion to evidence-based: changes in the gold standard of primary brain tumour diagnosis. <i>Journal of Pathology</i> , 2007, 213, 1-3.	2.1	7
264	MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. <i>Pediatric Blood and Cancer</i> , 2007, 48, 403-407.	0.8	176
265	Temozolomide in pediatric low-grade glioma. <i>Pediatric Blood and Cancer</i> , 2007, 49, 808-811.	0.8	51
266	Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. <i>Oncogene</i> , 2007, 26, 186-197.	2.6	440
267	Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. <i>Oncogene</i> , 2007, 26, 583-593.	2.6	119
268	Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. <i>Oncogene</i> , 2007, 26, 5010-5016.	2.6	43
269	Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. <i>Oncogene</i> , 2007, 26, 6229-6237.	2.6	68

#	ARTICLE	IF	CITATIONS
270	Cancer epigenomics: DNA methylomes and histone-modification maps. <i>Nature Reviews Genetics</i> , 2007, 8, 286-298.	7.7	1,916
271	A phase II study of temozolomide therapy for poor-risk patients aged $\geq 60$ years with acute myeloid leukemia: low levels of MGMT predict for response. <i>Leukemia</i> , 2007, 21, 821-824.	3.3	19
272	The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. <i>British Journal of Cancer</i> , 2007, 97, 302-307.	2.9	94
273	A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. <i>Laboratory Investigation</i> , 2007, 87, 392-397.	1.7	65
274	MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. <i>Laboratory Investigation</i> , 2007, 87, 1055-1065.	1.7	161
275	Targeting brain-tumor stem cells. <i>Nature Biotechnology</i> , 2007, 25, 193-194.	9.4	70
276	Aberrant Hypermethylation of p14ARF and O6-methylguanine-DNA Methyltransferase Genes in Astrocytoma Progression. <i>Brain Pathology</i> , 2007, 17, 5-10.	2.1	55
277	RESEARCH ARTICLE: An Orthotopic Skull Base Model of Malignant Meningioma. <i>Brain Pathology</i> , 2008, 18, 172-179.	2.1	33
278	Why we will need to learn new skills to control cancer. <i>Internal Medicine Journal</i> , 2007, 37, 201-204.	0.5	2
279	Human primary brain tumor cell growth inhibition in serum-free medium optimized for neuron survival. <i>Brain Research</i> , 2007, 1157, 156-166.	1.1	10
280	Tracking Normalization of Brain Tumor Vasculature by Magnetic Imaging and Proangiogenic Biomarkers. <i>Cancer Cell</i> , 2007, 11, 6-8.	7.7	37
281	MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. <i>DNA Repair</i> , 2007, 6, 1079-1099.	1.3	549
282	DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. <i>DNA Repair</i> , 2007, 6, 1100-1115.	1.3	154
283	Malignant astrocytic glioma: genetics, biology, and paths to treatment. <i>Genes and Development</i> , 2007, 21, 2683-2710.	2.7	1,952
284	Designing clinical trials for brain tumors: The next generation. <i>Current Oncology Reports</i> , 2007, 9, 49-54.	1.8	4
285	Therapeutic advances for glioblastoma multiforme: Current status and future prospects. <i>Current Oncology Reports</i> , 2007, 9, 66-70.	1.8	49
286	Impact of molecular profiling on clinical trial design for glioblastoma. <i>Current Oncology Reports</i> , 2007, 9, 71-79.	1.8	9
287	Postoperative Radiotherapy of Glioblastoma Multiforme. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 695-702.	1.0	31



#	ARTICLE	IF	CITATIONS
288	The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. <i>Journal of Molecular Medicine</i> , 2007, 85, 497-509.	1.7	74
290	A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007, 81, 271-277.	1.4	61
291	Prognostic factors for anaplastic astrocytomas. <i>Journal of Neuro-Oncology</i> , 2007, 81, 295-303.	1.4	33
292	Local recurrence and distant metastasis of supratentorial primitive neuro-ectodermal tumor in an adult patient successfully treated with intensive induction chemotherapy and maintenance temozolomide. <i>Journal of Neuro-Oncology</i> , 2007, 82, 113-116.	1.4	13
293	Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007, 82, 133-139.	1.4	56
294	A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2007, 82, 207-209.	1.4	37
295	Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. <i>Journal of Neuro-Oncology</i> , 2007, 82, 281-288.	1.4	79
296	Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007, 83, 91-93.	1.4	93
297	Frequent but borderline methylation of p16 INK4a and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. <i>Journal of Neuro-Oncology</i> , 2007, 83, 17-29.	1.4	28
298	MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. <i>Journal of Neuro-Oncology</i> , 2007, 83, 173-179.	1.4	87
299	Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. <i>Journal of Neuro-Oncology</i> , 2007, 84, 179-183.	1.4	11
300	Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data. <i>Journal of Neuro-Oncology</i> , 2007, 84, 201-211.	1.4	11
301	Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. <i>Journal of Neuro-Oncology</i> , 2007, 84, 119-129.	1.4	19
302	Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. <i>Journal of Neuro-Oncology</i> , 2007, 85, 207-211.	1.4	126
303	Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2007, 85, 281-287.	1.4	71
304	Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. <i>Pituitary</i> , 2007, 10, 81-86.	1.6	73
306	Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. <i>Acta Neurochirurgica</i> , 2007, 149, 245-253.	0.9	109
307	Prognostic and Predictive Markers in Glioma and Other Neuroepithelial Tumors. <i>Current Problems in Cancer</i> , 2008, 32, 97-123.	1.0	16

#	ARTICLE	IF	CITATIONS
308	Brain Tumor Stem Cells. <i>Current Problems in Cancer</i> , 2008, 32, 124-142.	1.0	22
309	Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2008, 87, 71-78.	1.4	86
310	The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2008, 88, 43-50.	1.4	28
311	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. <i>Journal of Neuro-Oncology</i> , 2008, 88, 97-103.	1.4	195
312	Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. <i>Journal of Neuro-Oncology</i> , 2008, 88, 105-113.	1.4	42
313	Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status. <i>Journal of Neuro-Oncology</i> , 2008, 88, 185-188.	1.4	10
314	Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2008, 89, 97-103.	1.4	128
315	Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2008, 89, 339-357.	1.4	20
316	Diagnosis of malignant glioma: role of neuropathology. <i>Journal of Neuro-Oncology</i> , 2008, 89, 287-311.	1.4	88
317	FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report. <i>Journal of Neuro-Oncology</i> , 2008, 90, 47-51.	1.4	12
318	Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2008, 90, 293-299.	1.4	21
319	Methylation-specific multiplex ligation-dependent probe amplification in meningiomas. <i>Journal of Neuro-Oncology</i> , 2008, 90, 267-273.	1.4	9
320	An overview of cancer multidrug resistance: a still unsolved problem. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 3145-3167.	2.4	375
321	A combination of IFN- $\gamma$ 2 and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 653-659.	1.1	60
326	Molekular definierte Chemotherapien und zielgerichtete Therapien bei malignen Gliomen. <i>Onkopipeline</i> , 2008, 1, 11-16.	0.0	0
327	Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas. <i>Current Treatment Options in Oncology</i> , 2008, 9, 23-31.	1.3	48
328	Glioblastoma multiforme. <i>Current Treatment Options in Neurology</i> , 2008, 10, 285-294.	0.7	7
329	Adult high-grade malignant gliomas. <i>Oncology Reviews</i> , 2008, 2, 195-198.	0.8	0

#	ARTICLE	IF	CITATIONS
330	Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. <i>Acta Neuropathologica</i> , 2008, 115, 249-259.	3.9	68
331	Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. <i>BMC Medical Genomics</i> , 2008, 1, 52.	0.7	181
332	Discovery of DNA methylation markers in cervical cancer using relaxation ranking. <i>BMC Medical Genomics</i> , 2008, 1, 57.	0.7	32
333	External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma. <i>Cancer</i> , 2008, 113, 559-565.	2.0	4
334	Temozolomide for recurrent low-grade spinal cord gliomas in adults. <i>Cancer</i> , 2008, 113, 1019-1024.	2.0	62
335	Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium. <i>Cancer</i> , 2008, 113, 1953-1968.	2.0	716
336	Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule. <i>Cancer</i> , 2008, 113, 2152-2157.	2.0	115
337	Chemotherapy for glioblastoma. <i>Cancer</i> , 2008, 113, 2617-2622.	2.0	6
338	MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. <i>International Journal of Cancer</i> , 2008, 122, 1391-1399.	2.3	96
339	Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. <i>International Journal of Cancer</i> , 2008, 122, 2429-2436.	2.3	62
340	Enhanced expression of NADPH oxidase Nox4 in human gliomas and its roles in cell proliferation and survival. <i>International Journal of Cancer</i> , 2008, 123, 787-792.	2.3	85
341	Infrequent promoter methylation of the <i>MGMT</i> gene in liver metastases from uveal melanoma. <i>International Journal of Cancer</i> , 2008, 123, 1215-1218.	2.3	20
342	Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. <i>International Journal of Cancer</i> , 2008, 123, 2955-2960.	2.3	74
343	Glioblastoma in the elderly: An age-old problem. <i>Annals of Neurology</i> , 2008, 64, 597-599.	2.8	11
344	Glioblastoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 139-152.	2.0	156
345	DNA Methylation: Its Role in Cancer Development and Therapy. <i>Current Problems in Cancer</i> , 2008, 32, 187-235.	1.0	62
346	A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis. <i>Analytical Biochemistry</i> , 2008, 377, 62-71.	1.1	57
347	Development of an O6-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O6-benzylguanine to the protein. <i>Analytical Biochemistry</i> , 2008, 383, 44-51.	1.1	35

#	ARTICLE	IF	CITATIONS
348	Defining the Standard of Care for High-grade Glioma – a NICE Deal for Patients. <i>Clinical Oncology</i> , 2008, 20, 97-98.	0.6	2
349	Association of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation with p53 Mutation Occurrence in Non-Small Cell Lung Cancer with Different Histology, Gender, and Smoking Status. <i>Annals of Surgical Oncology</i> , 2008, 15, 3272-3277.	0.7	55
350	Epigenetics and dermatological disease. <i>Pharmacogenomics</i> , 2008, 9, 1835-1850.	0.6	52
351	Heterogeneity of Human Glioblastoma: Glutathione-S-Transferase and Methylguanine-Methyltransferase. <i>Cancer Investigation</i> , 2008, 26, 597-609.	0.6	32
352	Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. <i>Clinical Cancer Research</i> , 2008, 14, 2900-2908.	3.2	319
353	Comprehensive genomic characterization defines human glioblastoma genes and core pathways. <i>Nature</i> , 2008, 455, 1061-1068.	13.7	6,879
354	Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. <i>British Journal of Cancer</i> , 2008, 98, 1830-1838.	2.9	30
355	Survival from brain tumours in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2008, 99, S102-S103.	2.9	3
356	Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?. <i>British Journal of Cancer</i> , 2008, 99, 1153-1160.	2.9	61
357	The Evolution of Our Understanding on Glioma. <i>Brain Pathology</i> , 2008, 18, 455-463.	2.1	23
358	Anti-O6-Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*. <i>Brain Pathology</i> , 2008, 18, 520-532.	2.1	189
359	Radiation-induced glioblastoma in a medulloblastoma patient: A case report with molecular features. <i>Neuropathology</i> , 2008, 28, 633-639.	0.7	20
360	Alterations in S-adenosylhomocysteine metabolism decrease O6-methylguanine DNA methyltransferase gene expression without affecting promoter methylation. <i>Biochemical Pharmacology</i> , 2008, 75, 2100-2111.	2.0	11
361	Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma. <i>Brain Research</i> , 2008, 1188, 173-181.	1.1	21
362	Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis. <i>Brain Research</i> , 2008, 1239, 216-225.	1.1	18
363	Methylation status of MGMT gene promoter in meningiomas. <i>Cancer Genetics and Cytogenetics</i> , 2008, 187, 25-27.	1.0	29
364	Ethical and Legal Issues in Nutritional Genomics. <i>Journal of the American Dietetic Association</i> , 2008, 108, 36-40.	1.3	17
365	The genetics of clinical outcome in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 183-199.	1.1	49

#	ARTICLE	IF	CITATIONS
366	A Personalized Approach to Cancer Treatment: How Biomarkers Can Help. <i>Clinical Chemistry</i> , 2008, 54, 1770-1779.	1.5	136
367	Biomarkers of Clinical Responsiveness in Brain Tumor Patients. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 199-208.	1.6	11
368	Resistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response. <i>Pharmacology</i> , 2008, 81, 275-300.	0.9	150
369	Structure-Based Discovery of Novel Non-nucleosidic DNA Alkyltransferase Inhibitors: Virtual Screening and in Vitro and in Vivo Activities. <i>Journal of Chemical Information and Modeling</i> , 2008, 48, 844-854.	2.5	31
370	Malignant Gliomas in Adults. <i>New England Journal of Medicine</i> , 2008, 359, 492-507.	13.9	3,647
371	Radiotherapy and temozolomide in glioblastoma: Predictive factors of response to the treatment. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 136-137.	2.2	0
372	Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 86.	3.5	89
373	Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model. <i>Neoplasia</i> , 2008, 10, 1383-1392.	2.3	110
375	Chemotherapy for Malignant Brain Tumors of Childhood. <i>Journal of Child Neurology</i> , 2008, 23, 1149-1159.	0.7	85
376	Hypericin uptake: A prognostic marker for survival in high-grade glioma. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 778-783.	0.8	12
377	Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 1-8.	0.8	21
379	Recent advances in the treatment of central nervous system tumors. <i>Update on Cancer Therapeutics</i> , 2008, 3, 49-79.	0.9	2
380	Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor Regression. <i>Clinical Cancer Research</i> , 2008, 14, 7717-7725.	3.2	113
384	Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 373, 539-544.	1.0	41
385	DNA repair deficiency as a therapeutic target in cancer. <i>Current Opinion in Genetics and Development</i> , 2008, 18, 80-86.	1.5	167
386	DNA repair and cancer stem-like cells â€œ Potential partners in glioma drug resistance?. <i>Cancer Treatment Reviews</i> , 2008, 34, 558-567.	3.4	125
387	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. <i>Lancet Oncology, The</i> , 2008, 9, 29-38.	5.1	487
388	The potential role and application of PARP inhibitors in cancer treatment. <i>British Medical Bulletin</i> , 2008, 89, 23-40.	2.7	88

#	ARTICLE	IF	CITATIONS
389	Epigenetics in Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 1148-1159.	13.9	3,251
390	Nomograms as clinicobiological predictors of survival in glioblastoma. <i>Lancet Oncology</i> , The, 2008, 9, 5-6.	5.1	8
391	Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. <i>Lancet Oncology</i> , The, 2008, 9, 453-461.	5.1	990
392	How not to treat cancer. <i>Lancet Oncology</i> , The, 2008, 9, 504-505.	5.1	3
393	Psychosocial and supportive-care needs in high-grade glioma. <i>Lancet Oncology</i> , The, 2008, 9, 884-891.	5.1	156
395	“MGMT for pt mgmt” Is Methylguanine-DNA Methyltransferase Testing Ready for Patient Management?. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 308-310.	1.2	9
397	Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 343-359.	1.1	54
398	Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 332-337.	1.2	168
401	A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma. <i>Cancer Investigation</i> , 2008, 26, 269-277.	0.6	39
402	Adjuvant temozolomide: how long and how much?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 663-665.	1.1	2
403	Mechanisms of Disease: temozolomide and glioblastoma—look to the future. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 476-486.	4.3	132
404	Brain tumor stem cells: will understanding a new paradigm lead to improved therapies?. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 511-514.	1.4	0
405	Computational epigenetics. <i>Bioinformatics</i> , 2008, 24, 1-10.	1.8	180
406	Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years?. <i>British Journal of Neurosurgery</i> , 2008, 22, 339-349.	0.4	40
407	The role of temozolomide in newly-diagnosed glioblastoma multiforme. <i>British Journal of Neurosurgery</i> , 2008, 22, 456-456.	0.4	0
408	Correlation of O <sup>6</sup> -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. <i>Journal of Clinical Oncology</i> , 2008, 26, 4189-4199.	0.8	725
409	<i>In vitro</i> and <i>In vivo</i> Radiosensitization Induced by the DNA Methylating Agent Temozolomide. <i>Clinical Cancer Research</i> , 2008, 14, 931-938.	3.2	104
410	Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177. <i>Journal of Clinical Oncology</i> , 2008, 26, 5603-5609.	0.8	255

#	ARTICLE	IF	CITATIONS
411	Temozolomide-Mediated Radiosensitization of Human Glioma Cells in a Zebrafish Embryonic System. <i>Cancer Research</i> , 2008, 68, 3396-3404.	0.4	75
412	Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma. <i>Neuro-Oncology</i> , 2008, 10, 330-340.	0.6	41
413	Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2299-2304.	0.8	66
414	Non-Hodgkin's Lymphoma in Patients With Glioma Treated With Temozolomide. <i>Journal of Clinical Oncology</i> , 2008, 26, 4518-4519.	0.8	29
415	Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme. <i>Clinical Cancer Research</i> , 2008, 14, 8205-8212.	3.2	327
416	Genomic predictors of interindividual differences in response to DNA damaging agents. <i>Genes and Development</i> , 2008, 22, 2621-2626.	2.7	59
417	Identifying candidate genes involved in brain tumor formation. <i>Upsala Journal of Medical Sciences</i> , 2008, 113, 1-38.	0.4	15
418	Epigenetic changes in gliomas. <i>Cancer Biology and Therapy</i> , 2008, 7, 1326-1334.	1.5	29
419	Management of Malignant Glioma &ndash; Quo Vadis?. <i>Onkologie</i> , 2008, 31, 300-302.	1.1	6
420	Concurrent Chemoradiotherapy for Malignant Glioma: Dead End or Highway?. <i>Onkologie</i> , 2008, 31, 430-431.	1.1	0
421	Association between response to primary treatments and MGMT status in glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1781-1786.	1.1	7
422	Translational research in glioblastoma multiforme: molecular criteria for patient selection. <i>Future Oncology</i> , 2008, 4, 219-228.	1.1	16
423	Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii83-ii85.	0.6	17
424	Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. <i>Future Oncology</i> , 2008, 4, 525-534.	1.1	27
425	Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 3387-3394.	0.8	264
426	Pseudoprogression in Glioblastoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4359-4359.	0.8	48
427	Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. <i>Neuro-Oncology</i> , 2008, 10, 98-103.	0.6	109
428	Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. <i>Annals of Oncology</i> , 2008, 19, vii209-vii216.	0.6	31

#	ARTICLE	IF	CITATIONS
429	FDG-PET imaging for the evaluation of anti-glioma agents in a rat model. <i>Neuro-Oncology</i> , 2008, 10, 292-299.	0.6	20
430	Significance of Epidermal Growth Factor Receptor in the Radiation Resistance of Glioblastoma Tumors. , 2008, , .		0
431	The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) influences overall survival of patients with glioblastoma multiforme. <i>Neuro-Oncology</i> , 2008, 10, 548-552.	0.6	16
432	Engineering of clinical glioma treatment: Prediction of pro-invasive molecular events in treated gliomas. <i>Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine</i> , 2008, 222, 1149-1160.	1.0	2
433	Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. <i>Neurology</i> , 2008, 70, 590-595.	1.5	44
435	Aberrant Promoter Methylation of Multiple Genes during Pathogenesis of Bladder Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2786-2794.	1.1	72
436	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. <i>Clinical Cancer Research</i> , 2008, 14, 7068-7073.	3.2	166
437	Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. <i>Neuro-Oncology</i> , 2008, 10, 300-308.	0.6	88
438	Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas. <i>Neurology</i> , 2008, 71, 365-373.	1.5	24
439	Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan. <i>Journal of Clinical Oncology</i> , 2008, 26, 271-278.	0.8	259
440	Molecular Predictors in Glioblastoma. <i>Archives of Neurology</i> , 2008, 65, 877-83.	4.9	62
441	Nitrosoureas Inhibit the Stathmin-Mediated Migration and Invasion of Malignant Glioma Cells. <i>Cancer Research</i> , 2008, 68, 5267-5272.	0.4	34
442	Clinical Experience with $^{211}\text{At}$ -Emitting $^{211}\text{At}$ : Treatment of Recurrent Brain Tumor Patients with $^{211}\text{At}$ -Labeled Chimeric Antitnascin Monoclonal Antibody 81C6. <i>Journal of Nuclear Medicine</i> , 2008, 49, 30-38.	2.8	345
443	DNA Repair Enzyme Expression and Differential Response to Temozolomide in a Patient With Both Glioblastoma and Metastatic Pancreatic Neuroendocrine Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 4843-4844.	0.8	5
444	A novel tool to analyze MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> , 2008, 10, 1019-1024.	0.6	74
445	From Bench to Bedside: A Case of Rapid Reversal of Bortezomib-Induced Neuropathic Pain by the TRPM8 Activator, Menthol. <i>Journal of Clinical Oncology</i> , 2008, 26, 4519-4520.	0.8	48
446	Is it Appropriate to Redefine the Indication for Stereotactic Brain Biopsy in the MRI Era? Correlation with Final Histological Diagnosis in Supratentorial Gliomas. <i>Minimally Invasive Neurosurgery</i> , 2008, 51, 109-113.	0.9	10
448	Epigenetic markers in human gliomas: prospects for therapeutic intervention. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1475-1496.	1.4	5



#	ARTICLE	IF	CITATIONS
449	Applications of emerging molecular technologies in glioblastoma multiforme. Expert Review of Neurotherapeutics, 2008, 8, 1497-1506.	1.4	22
450	Procarbazine â€“ A Traditional Drug in the Treatment of Malignant Gliomas. Current Medicinal Chemistry, 2008, 15, 1376-1387.	1.2	12
451	The Epigenetics of Cancer in Children. Klinische Padiatrie, 2008, 220, 333-341.	0.2	17
452	Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. Future Oncology, 2008, 4, 689-704.	1.1	13
453	Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma. Cancer Research, 2008, 68, 5706-5715.	0.4	269
454	Cilengitide: an integrin-targeting arginineâ€“glycineâ€“aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opinion on Investigational Drugs, 2008, 17, 1225-1235.	1.9	174
455	Anaplastic astrocytomas: biology and treatment. Expert Review of Neurotherapeutics, 2008, 8, 575-586.	1.4	8
456	Stem Cellâ€“Related â€œSelf-Renewalâ€“Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma. Journal of Clinical Oncology, 2008, 26, 3015-3024.	0.8	631
457	Emerging drugs for malignant glioma. Expert Opinion on Emerging Drugs, 2008, 13, 81-94.	1.0	15
459	Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction. Oncology Reports, 2008, , .	1.2	5
460	Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Molecular Medicine Reports, 2008, 1, 863-7.	1.1	18
461	MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma. Applied Immunohistochemistry and Molecular Morphology, 2008, 16, 59-65.	0.6	105
462	Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1-15.	0.9	84
463	The 2007 WHO classification of tumors of the central nervous system â€“ what has changed?. Current Opinion in Neurology, 2008, 21, 720-727.	1.8	112
464	The Biology of Brain Tumors. Neuroradiology Journal, 2008, 21, 7-9.	0.6	0
465	Introduction: immunity, diagnosis, vector, and beneficial uses of neurotropic viruses. , 2008, , 263-264.		0
466	Viral oncolysis of glioblastoma. , 2008, , 407-423.		0
467	Editorial review: Targets for glioma treatment: from bench to bedside. Current Opinion in Oncology, 2008, 20, 650-651.	1.1	8

#	ARTICLE	IF	CITATIONS
468	Ependymomas of the adult: molecular biology and treatment. <i>Current Opinion in Neurology</i> , 2008, 21, 754-761.	1.8	75
469	Congenital Brain Tumors. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 326-331.	0.3	24
470	Careful Exclusion of Non-neoplastic Brain Components is Required for an Appropriate Evaluation of O6-methylguanine-DNA Methyltransferase Status in Glioma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1220-1227.	2.1	56
472	GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME. <i>Neurosurgery</i> , 2008, 62, 753-766.	0.6	1,107
473	Gliomas With 1p/19q Codeletion:a.k.a. Oligodendroglioma. <i>Cancer Journal (Sudbury, Mass )</i> , 2008, 14, 352-357.	1.0	81
475	Galectins in Malignant Gliomas: Expression, Functions, and Possible Therapeutic Options. , 0, , 223-234.		1
476	Ischemic Colitis, An Unusual Complication of Colonoscopy. <i>Southern Medical Journal</i> , 2008, 101, 972-973.	0.3	2
477	The Nose Knows Cancer Recurrence. <i>Southern Medical Journal</i> , 2008, 101, 970.	0.3	0
478	Overlooked Aspartame-Induced Hypertension. <i>Southern Medical Journal</i> , 2008, 101, 969.	0.3	2
479	Serious Cardioembolic Stroke Resulting from an Overlooked Left Ventricular Noncompaction. <i>Southern Medical Journal</i> , 2008, 101, 969-970.	0.3	8
481	2 Pathology and Molecular Classification. , 2008, , .		0
482	17 Systemic Chemotherapy. , 2008, , .		0
483	Temozolomide: from cytotoxic to molecularly-targeted agent. , 2008, , 157-XI.		4
484	Current available therapies and future directions in the treatment of malignant gliomas. <i>Biologics: Targets and Therapy</i> , 0, , 15.	3.0	3
485	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastomaâ€”A Critical Review. <i>Clinical Medicine Oncology</i> , 2008, 2, CMO.S390.	0.2	54
486	Cancer Genomics. , 2008, , 267-282.		0
487	Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma. <i>Sarcoma</i> , 2008, 2008, 1-7.	0.7	17
490	Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. <i>Cancer Management and Research</i> , 0, Volume 1, 137-150.	0.9	8

#	ARTICLE	IF	CITATIONS
491	Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. <i>Core Evidence</i> , 2009, 4, 93.	4.7	25
492	Molecular Pathology: <i>Neuropathology</i> . , 2009, , 551-587.		0
494	Outcome of Newly Diagnosed Glioblastoma Patients Treated by Radiotherapy plus Concomitant and Adjuvant Temozolomide: A Long-Term Analysis. <i>Tumori</i> , 2009, 95, 191-197.	0.6	51
497	Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry. <i>Drug Design, Development and Therapy</i> , 2009, 2, 289.	2.0	20
498	Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug Development. <i>PLoS ONE</i> , 2009, 4, e5209.	1.1	102
499	Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia. <i>PLoS ONE</i> , 2009, 4, e5947.	1.1	95
500	In silico enhanced restriction enzyme based methylation analysis of the human glioblastoma genome using Agilent 244K CpG Island microarrays. <i>Frontiers in Neuroscience</i> , 2009, 3, 57.	1.4	2
501	Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. <i>Hormones</i> , 2009, 8, 303-306.	0.9	24
503	Epigenetic biomarker development. <i>Epigenomics</i> , 2009, 1, 99-110.	1.0	112
504	Oligodendrogliomas: Molecular Biology and Treatment. <i>Oncologist</i> , 2009, 14, 155-163.	1.9	68
505	<i>MSH6</i> Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance. <i>Clinical Cancer Research</i> , 2009, 15, 4622-4629.	3.2	344
506	The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. <i>Neuro-Oncology</i> , 2009, 11, 22-32.	0.6	12
507	Advances in the genetics of glioblastoma: are we reaching critical mass?. <i>Nature Reviews Neurology</i> , 2009, 5, 419-426.	4.9	105
508	Potential Therapeutic Effect of Glycogen Synthase Kinase 3 $\beta$ Inhibition against Human Glioblastoma. <i>Clinical Cancer Research</i> , 2009, 15, 887-897.	3.2	108
509	Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 579-584.	0.8	354
510	Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database. <i>Journal of Clinical Oncology</i> , 2009, 27, 733-739.	0.8	107
511	A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. <i>British Journal of Cancer</i> , 2009, 100, 1245-1249.	2.9	23
512	Nimotuzumab in pediatric glioma. <i>Future Oncology</i> , 2009, 5, 1349-1361.	1.1	25

#	ARTICLE	IF	CITATIONS
513	Motexafin gadolinium: a novel radiosensitizer for brain tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2171-2180.	0.9	15
514	Folate Supplementation Limits the Aggressiveness of Glioma via the Remethylation of DNA Repeats Element and Genes Governing Apoptosis and Proliferation. <i>Clinical Cancer Research</i> , 2009, 15, 3519-3529.	3.2	62
515	Experience with irinotecan for the treatment of malignant glioma. <i>Neuro-Oncology</i> , 2009, 11, 80-91.	0.6	144
516	Anaplastic Glioma: How to Prognosticate Outcome and Choose a Treatment Strategy. <i>Journal of Clinical Oncology</i> , 2009, 27, 5861-5862.	0.8	48
517	Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. <i>Neuro-Oncology</i> , 2009, 11, 468-476.	0.6	87
518	Associations between Polymorphisms in DNA Repair Genes and Glioblastoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1118-1126.	1.1	81
519	6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 338-345.	3.2	358
520	MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951. <i>Journal of Clinical Oncology</i> , 2009, 27, 5881-5886.	0.8	232
521	Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study. <i>Neuroepidemiology</i> , 2009, 32, 21-29.	1.1	87
522	Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2009, 15, 6683-6693.	3.2	180
523	Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent 6-methylguanine-DNA methyltransferase. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3276-3284.	1.9	49
524	Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression. <i>Oncology Reports</i> , 2009, 22, 199-204.	1.2	41
525	Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults. <i>Clinical Cancer Research</i> , 2009, 15, 330-337.	3.2	147
526	Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity. <i>Clinical Cancer Research</i> , 2009, 15, 4401-4414.	3.2	95
527	Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2243-2254.	1.9	103
528	Head's Up on the Treatment of Malignant Glioma Patients. <i>Oncology Nursing Forum</i> , 2009, 36, E232-E240.	0.5	10
529	Phase II Trial of Temozolomide Plus O <sup>6</sup> -Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1262-1267.	0.8	280
530	Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4155-4161.	0.8	149

#	ARTICLE	IF	CITATIONS
531	Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. <i>Neuro-Oncology</i> , 2009, 11, 109-121.	0.6	111
532	Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2009, 11, 842-852.	0.6	110
533	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. <i>Neuro-Oncology</i> , 2009, 11, 737-746.	0.6	71
534	The Impact of the DNA-Repair Gene <i>MGMT</i> in Malignant Gliomas. <i>Neuroepidemiology</i> , 2009, 32, 30-31.	1.1	0
535	Elderly Patients with Glioblastoma Multiforme – An Underestimated Subpopulation?. <i>Neuroepidemiology</i> , 2009, 33, 23-24.	1.1	5
536	Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. <i>Oncology Reports</i> , 2009, 22, 773-9.	1.2	13
537	The prognostic role of Beclin 1 protein expression in high-grade gliomas. <i>Autophagy</i> , 2009, 5, 930-936.	4.3	134
538	Cell Cycle Effects and Increased Adduct Formation by Temozolomide Enhance the Effect of Cytotoxic and Targeted Agents in Lung Cancer Cell Lines. <i>Journal of Chemotherapy</i> , 2009, 21, 338-346.	0.7	10
539	Changing the clinical picture of challenging tumors: tales becoming reality?. <i>Future Oncology</i> , 2009, 5, 785-802.	1.1	1
540	Epigenetics of neurological cancers. <i>Future Oncology</i> , 2009, 5, 1615-1629.	1.1	20
541	The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1087-1098.	1.4	79
542	Current concepts and newer developments in the treatment of malignant gliomas. <i>Indian Journal of Cancer</i> , 2009, 46, 88.	0.2	14
543	Evidence-based adjuvant therapy for gliomas: Current concepts and newer developments. <i>Indian Journal of Cancer</i> , 2009, 46, 96.	0.2	12
544	Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. <i>Annals of Oncology</i> , 2009, 20, 182-187.	0.6	60
545	A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. <i>Annals of Oncology</i> , 2009, 20, 175-181.	0.6	116
546	High Specificity of Quantitative Methylation-Specific PCR Analysis for <i>MGMT</i> Promoter Hypermethylation Detection in Gliomas. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-8.	3.0	23
547	Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM. <i>Molecular Therapy</i> , 2009, 17, 199-207.	3.7	346
548	Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression. <i>Clinical Cancer Research</i> , 2009, 15, 6113-6127.	3.2	68

#	ARTICLE	IF	CITATIONS
549	Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. <i>Neuro-Oncology</i> , 2009, 11, 747-756.	0.6	79
550	Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. <i>Neuro-Oncology</i> , 2009, 11, 803-818.	0.6	43
551	Current concepts in the pathology and genetics of gliomas. <i>Indian Journal of Cancer</i> , 2009, 46, 108.	0.2	11
552	<i>MGMT</i> METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neurology</i> , 2009, 73, 1509-1510.	1.5	99
553	Dnmt3/transcription factor interactions as crucial players in targeted DNA methylation. <i>Epigenetics</i> , 2009, 4, 487-499.	1.3	184
554	Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model. <i>Clinical Cancer Research</i> , 2009, 15, 1989-1997.	3.2	36
555	Treatment of Nelson's syndrome with temozolomide. <i>European Journal of Endocrinology</i> , 2009, 160, 115-119.	1.9	70
556	Molecular Neuropathology of Gliomas. <i>International Journal of Molecular Sciences</i> , 2009, 10, 184-212.	1.8	42
557	Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. <i>Neuro-Oncology</i> , 2009, 11, 281-291.	0.6	289
558	Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. <i>Neuro-Oncology</i> , 2009, 11, 348-356.	0.6	147
559	DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy. <i>Molecular Cancer Research</i> , 2009, 7, 989-999.	1.5	176
560	Epigenetic Deregulation of DNA Repair and Its Potential for Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 5026-5031.	3.2	54
561	Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3861-3867.	0.8	159
562	New (alternative) temozolomide regimens for the treatment of glioma. <i>Neuro-Oncology</i> , 2009, 11, 69-79.	0.6	142
563	Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2009, 110, 583-588.	0.9	252
564	Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 407-414.	1.9	89
565	The DNA Damage Response: Implications on Cancer Formation and Treatment. , 2009, , .		6
566	Epigenetic mechanisms in glioblastoma multiforme. <i>Seminars in Cancer Biology</i> , 2009, 19, 188-197.	4.3	154

#	ARTICLE	IF	CITATIONS
567	Chemotherapy for Malignant Gliomas. <i>Seminars in Radiation Oncology</i> , 2009, 19, 150-154.	1.0	16
568	Molecular Advances of Brain Tumors in Radiation Oncology. <i>Seminars in Radiation Oncology</i> , 2009, 19, 171-178.	1.0	56
569	Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. <i>BMC Cancer</i> , 2009, 9, 101.	1.1	28
570	RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study. <i>BMC Cancer</i> , 2009, 9, 308.	1.1	83
571	Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults. <i>BMC Cancer</i> , 2009, 9, 372.	1.1	137
572	Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. <i>BMC Cancer</i> , 2009, 9, 444.	1.1	166
573	Absence of MGMT promoter methylation in endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 112, 224-228.	0.6	19
574	High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. <i>Cancer Genetics and Cytogenetics</i> , 2009, 188, 77-82.	1.0	28
575	Targeting the Molecular Defect in BRCA-Deficient Tumors for Cancer Therapy. <i>Cancer Cell</i> , 2009, 16, 89-90.	7.7	12
576	EGF receptor inhibitors in the treatment of glioblastoma multiform: Old clinical allies and newly emerging therapeutic concepts. <i>European Journal of Pharmacology</i> , 2009, 625, 23-30.	1.7	25
577	Epigenetics and cancer treatment. <i>European Journal of Pharmacology</i> , 2009, 625, 131-142.	1.7	189
578	Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. <i>Lancet Neurology</i> , The, 2009, 8, 1056-1072.	4.9	528
579	Molecularly targeted therapies for glioma. <i>Annals of Neurology</i> , 2009, 66, 717-729.	2.8	22
580	Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. <i>International Journal of Cancer</i> , 2009, 124, 2872-2879.	2.3	32
581	Elevated levels of MIC <sup>1</sup> /GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. <i>International Journal of Cancer</i> , 2009, 125, 2624-2630.	2.3	80
582	O <sup>6</sup> -methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas. <i>Cancer</i> , 2009, 115, 1070-1080.	2.0	48
583	Phase 1 trial of temozolomide plus irinotecan plus O <sup>6</sup> -benzylguanine in adults with recurrent malignant glioma. <i>Cancer</i> , 2009, 115, 2964-2970.	2.0	28
584	Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. <i>Cancer</i> , 2009, 115, 3501-3511.	2.0	123

#	ARTICLE	IF	CITATIONS
585	Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma. <i>Cancer</i> , 2009, 115, 3512-3518.	2.0	207
586	Prognostic impact of O <sup>6</sup> -methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation. <i>Cancer</i> , 2009, 115, 4783-4794.	2.0	83
587	Determination of DNA methylation by COBRA: A comparative study of CGE with LIF detection and conventional gel electrophoresis. <i>Electrophoresis</i> , 2009, 30, 3063-3070.	1.3	13
588	Genomic aberrations in 80 cases of primary glioblastoma multiforme: Pathogenetic heterogeneity and putative cytogenetic pathways. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 908-924.	1.5	38
589	Dendritic-cell- and peptide-based vaccination strategies for glioma. <i>Neurosurgical Review</i> , 2009, 32, 265-273.	1.2	38
590	Glioblastomes: aspects moléculaires et prise en charge actuelle. <i>Oncologie</i> , 2009, 11, 67-71.	0.2	1
591	Long-term survivors of glioblastoma: clinical features and molecular analysis. <i>Acta Neurochirurgica</i> , 2009, 151, 1349-1358.	0.9	72
592	High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. <i>Acta Neuropathologica</i> , 2009, 118, 745-754.	3.9	60
593	Rechallenge with temozolomide in patients with recurrent gliomas. <i>Journal of Neurology</i> , 2009, 256, 734-741.	1.8	92
594	Molecular Epigenetics and Genetics in Neuro-Oncology. <i>Neurotherapeutics</i> , 2009, 6, 436-446.	2.1	52
595	Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O <sup>6</sup> -Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 212-219.	0.4	77
596	Cytotoxic Effects of Temozolomide and Radiation are Additive- and Schedule-Dependent. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1511-1519.	0.4	57
597	Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2009, 91, 95-100.	1.4	90
598	Aberrant MGMT (O <sup>6</sup> -methylguanine-DNA methyltransferase) promoter methylation in choroid plexus tumors. <i>Journal of Neuro-Oncology</i> , 2009, 91, 151-155.	1.4	17
599	Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2009, 91, 199-206.	1.4	114
600	Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. <i>Journal of Neuro-Oncology</i> , 2009, 92, 23-31.	1.4	80
601	Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma—analysis of O <sup>6</sup> -methylguanine-DNA methyltransferase status. <i>Journal of Neuro-Oncology</i> , 2009, 92, 227-232.	1.4	18
602	Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study. <i>Journal of Neuro-Oncology</i> , 2009, 93, 253-260.	1.4	13



#	ARTICLE	IF	CITATIONS
603	Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2009, 94, 57-62.	1.4	25
604	Cerebral glioblastoma with oligodendroglial component: analysis of 36 cases. <i>Journal of Neuro-Oncology</i> , 2009, 94, 129-134.	1.4	45
605	The evolution and application of techniques in molecular biology to human brain tumors: a 25-year perspective. <i>Journal of Neuro-Oncology</i> , 2009, 92, 261-273.	1.4	7
606	Management of newly diagnosed glioblastoma: guidelines development, value and application. <i>Journal of Neuro-Oncology</i> , 2009, 93, 1-23.	1.4	42
607	Glioma-associated endothelial cells are chemoresistant to temozolomide. <i>Journal of Neuro-Oncology</i> , 2009, 95, 13-22.	1.4	44
608	Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. <i>Journal of Neuro-Oncology</i> , 2009, 95, 151-163.	1.4	41
609	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. <i>Journal of Neuro-Oncology</i> , 2009, 95, 393-400.	1.4	53
610	The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. <i>Journal of Neuro-Oncology</i> , 2009, 95, 401-411.	1.4	157
611	Glioblastoma multiforme. <i>Current Treatment Options in Neurology</i> , 2009, 11, 297-305.	0.7	3
612	Aberrantly methylated MGMT, hMLH1 and hMSH2 in tumor and serum DNA of gliomas patients. <i>Chinese Journal of Clinical Oncology</i> , 2009, 6, 42-46.	0.0	0
613	Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 241-246.	2.0	148
614	Molecular profiling in glioblastoma: Prelude to personalized treatment. <i>Current Oncology Reports</i> , 2009, 11, 53-61.	1.8	17
615	Molecular profiling of oligodendrogliomas: Impact on prognosis, treatment, and future directions. <i>Current Oncology Reports</i> , 2009, 11, 62-67.	1.8	9
618	Temozolomide "what regimen in what situation?". <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 8-9.	0.3	0
619	Brain cancer stem cells. <i>Journal of Molecular Medicine</i> , 2009, 87, 1087-1095.	1.7	58
620	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 769-75.	1.1	89
621	Temozolomide in malignant gliomas: current use and future targets. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 647-655.	1.1	160
622	Genomic instability and the selection of treatments for cancer. <i>Journal of Pathology</i> , 2010, 220, 281-289.	2.1	56

#	ARTICLE	IF	CITATIONS
623	Interferon-β, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma. <i>Pediatric Blood and Cancer</i> , 2009, 53, 37-41.	0.8	10
624	MGMT as a potential stratification marker in relapsed high-grade glioma of children: The HIT-GBM experience. <i>Pediatric Blood and Cancer</i> , 2010, 54, 228-237.	0.8	19
625	Stereotactic radiosurgery for glioblastoma: retrospective analysis. <i>Radiation Oncology</i> , 2009, 4, 11.	1.2	73
626	Correlation of chromosomes 1p and 19q status and expressions of O <sup>6</sup> -methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study. <i>Neuropathology and Applied Neurobiology</i> , 2009, 35, 367-379.	1.8	21
627	Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. <i>Neuropathology and Applied Neurobiology</i> , 2009, 35, 380-393.	1.8	38
628	Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. <i>Cancer Science</i> , 2009, 100, 165-172.	1.7	26
629	Genetic alterations and signaling pathways in the evolution of gliomas. <i>Cancer Science</i> , 2009, 100, 2235-2241.	1.7	374
630	Low O <sup>6</sup> -methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. <i>Clinical Endocrinology</i> , 2009, 71, 226-233.	1.2	125
631	New advances that enable identification of glioblastoma recurrence. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 648-657.	12.5	134
632	DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis. <i>Oncogene</i> , 2009, 28, 2667-2677.	2.6	45
633	The context and potential of epigenetics in oncology. <i>British Journal of Cancer</i> , 2009, 100, 571-577.	2.9	98
634	Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. <i>British Journal of Cancer</i> , 2009, 100, 758-763.	2.9	144
635	Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. <i>British Journal of Cancer</i> , 2009, 101, 124-131.	2.9	281
636	Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. <i>Neuropathology</i> , 2009, 29, 443-449.	0.7	37
637	<i>RASSF1A</i> , <i>BLU</i> , <i>NORE1A</i> , <i>PTEN</i> and <i>MGMT</i> Expression and Promoter Methylation in Gliomas and Glioma Cell Lines and Evidence of Deregulated Expression of <i>de novo</i> DNMTs. <i>Brain Pathology</i> , 2009, 19, 279-292.	2.1	47
638	Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments. <i>Brain Pathology</i> , 2009, 19, 674-693.	2.1	2,884
639	Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics. <i>Brain Pathology</i> , 2009, 19, 661-671.	2.1	69
640	Accelerated Hypofractionated Intensity-Modulated Radiotherapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma Multiforme: A Safety and Efficacy Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 473-478.	0.4	67

#	ARTICLE	IF	CITATIONS
641	Operative Techniques for Gliomas and the Value of Extent of Resection. <i>Neurotherapeutics</i> , 2009, 6, 478-486.	2.1	155
642	Concomitant (without Adjuvant) Temozolomide and Radiation to Treat Glioblastoma: a Retrospective Study. <i>Clinical Oncology</i> , 2009, 21, 19-22.	0.6	12
643	Combined Radio- and Chemotherapy of Brain Tumours in Adult Patients. <i>Clinical Oncology</i> , 2009, 21, 515-524.	0.6	30
644	Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 199-210.	2.0	25
645	Preoperative Intensity-Modulated Radiotherapy Combined with Temozolomide for Locally Advanced Soft-Tissue Sarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 810-816.	0.4	16
646	Twenty-Year Survival in Glioblastoma: A Case Report and Molecular Profile. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1162-1165.	0.4	21
647	High-quality genomic DNA extraction from formalin-fixed and paraffin-embedded samples deparaffinized using mineral oil. <i>Analytical Biochemistry</i> , 2009, 395, 265-267.	1.1	109
648	Adenoviral virotherapy for malignant brain tumors. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 737-747.	1.4	29
649	Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide. <i>Cancer Biology and Therapy</i> , 2009, 8, 452-457.	1.5	25
650	Molecular Pathology of Oligodendroglial Tumors. <i>Recent Results in Cancer Research</i> , 2009, 171, 25-49.	1.8	16
651	CpG Methylation Analysisâ€”Current Status of Clinical Assays and Potential Applications in Molecular Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 266-278.	1.2	46
652	Pharmaceutical Perspectives of Cancer Therapeutics. , 2009, , .		15
653	Targeting DNA repair pathways: A novel approach to reduce cancer therapeutic resistance. <i>Cancer Treatment Reviews</i> , 2009, 35, 590-596.	3.4	51
654	MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. <i>European Journal of Cancer</i> , 2009, 45, 146-153.	1.3	51
655	Adjuvant 5-FU based chemotherapy for colon cancer: Match or miss the mismatch?. <i>European Journal of Cancer</i> , 2009, 45, 316-317.	1.3	2
656	Methylated genes as new cancer biomarkers. <i>European Journal of Cancer</i> , 2009, 45, 335-346.	1.3	92
657	Silencing of MGMT expression by promoter hypermethylation in the metaplasiaâ€”dysplasiaâ€”carcinoma sequence of Barrettâ€™s esophagus. <i>Cancer Letters</i> , 2009, 275, 117-126.	3.2	40
658	Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastomas: Single-center experience. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 679-682.	0.6	38

#	ARTICLE	IF	CITATIONS
659	The neurosurgical role of epigenome. <i>World Neurosurgery</i> , 2009, 71, 159-160.	1.3	1
660	Lâ€™hyperméthylation des gènes suppresseurs de tumeur comme marqueur en cancérologie. <i>Immuno-Analyse Et Biologie Spécialisée</i> , 2009, 24, 9-15.	0.0	0
661	Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations. <i>Human Pathology</i> , 2009, 40, 934-941.	1.1	23
662	Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 502-510.	3.2	89
663	DNA methylation changes in prostate cancer: current developments and future clinical implementation. <i>Expert Review of Molecular Diagnostics</i> , 2009, 9, 243-257.	1.5	61
664	PCR-Based Methods for Detecting Single-Locus DNA Methylation Biomarkers in Cancer Diagnostics, Prognostics, and Response to Treatment. <i>Clinical Chemistry</i> , 2009, 55, 1471-1483.	1.5	189
665	Methylation-Specific PCR. <i>Methods in Molecular Biology</i> , 2009, 507, 305-323.	0.4	45
666	Diffusion Imaging for Therapy Response Assessment of Brain Tumor. <i>Neuroimaging Clinics of North America</i> , 2009, 19, 559-571.	0.5	44
667	Gene Regulation by Methylation. <i>Recent Results in Cancer Research</i> , 2009, 171, 217-239.	1.8	23
668	Temozolomide and cisplatin in relapsed/refractory acute leukemia. <i>Journal of Hematology and Oncology</i> , 2009, 2, 21.	6.9	19
669	Glioblastoma multiforme: a review of where we have been and where we are going. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1061-1083.	1.9	432
670	Nested PCR. , 2008, , 2043-2043.		0
671	Pediatric Gliomas. <i>Recent Results in Cancer Research</i> , 2009, 171, 67-81.	1.8	35
672	Gliomas. <i>Recent Results in Cancer Research</i> , 2009, , .	1.8	15
673	NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. <i>Journal of Clinical Oncology</i> , 2009, 27, 5874-5880.	0.8	743
674	Pediatric High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas. <i>Journal of Child Neurology</i> , 2009, 24, 1409-1417.	0.7	84
675	MethMarker: user-friendly design and optimization of gene-specific DNA methylation assays. <i>Genome Biology</i> , 2009, 10, R105.	13.9	25
676	Gliomatosis cerebri type II: two case reports. <i>Journal of Medical Case Reports</i> , 2009, 3, .	0.4	6

#	ARTICLE	IF	CITATIONS
677	Textbook of Personalized Medicine. , 2009, , .		74
678	Low-grade oligodendroglioma: current treatments and future hopes. Expert Review of Anticancer Therapy, 2009, 9, 1651-1661.	1.1	9
679	Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv126-iv128.	0.6	103
680	The safety of temozolomide in the treatment of malignancies. Expert Opinion on Drug Safety, 2009, 8, 493-499.	1.0	64
681	Association BetweenMGMTPromoter Hypermethylation and p53 Mutation in Glioblastoma. Cancer Investigation, 2009, 27, 825-829.	0.6	29
682	Insights into pharmacotherapy of malignant glioma in adults. Expert Opinion on Pharmacotherapy, 2009, 10, 2279-2290.	0.9	7
683	Targeted Therapies for Malignant Glioma. BioDrugs, 2009, 23, 25-35.	2.2	45
684	Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Review of Neurotherapeutics, 2009, 9, 1815-1836.	1.4	39
685	Sagopilone crosses the bloodâ€“brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro-Oncology, 2009, 11, 158-166.	0.6	68
686	MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. Journal of Clinical Pathology, 2009, 62, 715-723.	1.0	18
687	Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. British Journal of Neurosurgery, 2009, 23, 351-363.	0.4	48
688	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, The, 2009, 10, 459-466.	5.1	6,451
689	A silver lining on the horizon for glioblastoma. Lancet Oncology, The, 2009, 10, 434-435.	5.1	20
690	Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide. Journal of Clinical Oncology, 2009, 27, 1257-1261.	0.8	128
691	Emerging Subspecialties in Neurology: Neuro-oncology. Neurology, 2009, 72, e51-3.	1.5	3
692	Targeted Therapies for Malignant Brain Tumors. , 2009, , 475-519.		0
694	Therapeutic Advances in Malignant Glioma: Current Status and Future Prospects. Neuroimaging Clinics of North America, 2009, 19, 647-656.	0.5	25
695	The History and Future of Chemotherapy for Melanoma. Hematology/Oncology Clinics of North America, 2009, 23, 583-597.	0.9	66

#	ARTICLE	IF	CITATIONS
696	Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network. <i>Journal of Clinical Oncology</i> , 2009, 27, 5743-5750.	0.8	534
697	Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications. <i>Clinical Cancer Research</i> , 2009, 15, 3927-3937.	3.2	225
698	Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With <i>MGMT</i> Promoter Methylation Status. <i>Journal of Clinical Oncology</i> , 2009, 27, 1275-1279.	0.8	311
699	Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. <i>Anti-Cancer Drugs</i> , 2009, 20, 659-667.	0.7	6
700	Diagnostic and prognostic markers in gliomas. <i>Current Opinion in Oncology</i> , 2009, 21, 537-542.	1.1	40
701	Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 760-769.	0.7	7
702	Immunohistochemistry in the Diagnosis of Intracranial Neoplasms. <i>Contemporary Neurosurgery</i> , 2009, 31, 1-4.	0.2	0
703	Combining drugs and radiotherapy: from the bench to the bedside. <i>Current Opinion in Neurology</i> , 2009, 22, 625-632.	1.8	19
704	Classification and management of anaplastic gliomas. <i>Current Opinion in Neurology</i> , 2009, 22, 650-656.	1.8	11
705	Neurophysiological Mapping of Functional Systems With an Emphasis on Language Localization During Glioma Resection. <i>Neurosurgery Quarterly</i> , 2009, 19, 255-263.	0.1	0
706	Treatment of recurrent high-grade gliomas. <i>Current Opinion in Neurology</i> , 2009, 22, 657-664.	1.8	30
707	THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND MGMT PROTEIN IN GLIOBLASTOMAS. <i>Neurosurgery</i> , 2009, 65, 866-875.	0.6	115
708	Treatment of glioblastoma in older patients. <i>Aging Health</i> , 2009, 5, 113-125.	0.3	0
709	Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. <i>Current Opinion in Neurology</i> , 2009, 22, 619-624.	1.8	8
711	Glioblastoma Multiforme Associated With Klinefelter Syndrome -Case Report-. <i>Neurologia Medico-Chirurgica</i> , 2009, 49, 532-535.	1.0	0
712	p15 promoter methylation - A novel prognostic marker in glioblastoma patients. <i>International Journal of Oncology</i> , 2009, 34, 1743-8.	1.4	23
713	Effect of IFN- $\beta$ on human glioma cell lines with temozolomide resistance. <i>International Journal of Oncology</i> , 2009, 35, 139-48.	1.4	42
714	Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM. <i>Canadian Journal of Neurological Sciences</i> , 2009, 36, 617-622.	0.3	62

#	ARTICLE	IF	CITATIONS
715	Recurrent PNET with MGMT Methylation Responds to Temozolomide. Canadian Journal of Neurological Sciences, 2009, 36, 654-657.	0.3	5
716	The 10q25.3-26.1 G protein-coupled receptor gene GPR26 is epigenetically silenced in human gliomas. International Journal of Oncology, 2009, 35, 1123-31.	1.4	10
717	Epigenetic Modulation in Hematologic Malignancies: Challenges and Progress. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, S-1-S-12.	2.3	8
718	Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety. Current Gene Therapy, 2009, 9, 409-421.	0.9	48
719	Glioblastomas With Giant Cell and Sarcomatous Features in Patients With Turcot Syndrome Type 1. Neurosurgery, 2010, 67, 811-817.	0.6	22
720	Anti-Convulsants and Gene Expression in Malignant Gliomas. Neurosurgery, 2010, 67, N24-N26.	0.6	2
721	Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. Personalized Medicine, 2010, 7, 121-124.	0.8	2
722	Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival. Journal of Neuropathology and Experimental Neurology, 2010, 69, 729-736.	0.9	76
725	Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 753-768.	0.9	539
726	Long-Term Survival of a Patient with Glioblastoma. Canadian Journal of Neurological Sciences, 2010, 37, 289-292.	0.3	4
727	Clinical Significance of Molecular Biomarkers in Glioblastoma. Canadian Journal of Neurological Sciences, 2010, 37, 625-630.	0.3	42
728	Glioma Diagnosis: Immunohistochemistry and Beyond. Advances in Anatomic Pathology, 2010, 17, 187-201.	2.4	54
729	Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. Anti-Cancer Drugs, 2010, 21, 963-967.	0.7	18
730	O 6-Methylguanine DNA Methyltransferase Gene Promoter Methylation Status in Gliomas and Its Correlation With Other Molecular Alterations: First Indian Report With Review of Challenges for Use in Customized Treatment. Neurosurgery, 2010, 67, 1681-1691.	0.6	40
731	Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007. Neurosurgery, 2010, 67, 446-458.	0.6	73
732	Brain Metastasis of Undifferentiated Sarcoma and Response to Temozolomide Treatment -Case Report-. Neurologia Medico-Chirurgica, 2010, 50, 689-693.	1.0	10
734	Higher pAkt Expression Predicts a Significant Worse Prognosis in Glioblastomas. Journal of Radiation Research, 2010, 51, 343-348.	0.8	53
736	Short-term Radiotherapy followed by Adjuvant Chemotherapy in Poor-Prognosis Patients with Glioblastoma. Tumori, 2010, 96, 60-64.	0.6	24

#	ARTICLE	IF	CITATIONS
737	Demethylating Agents in the Treatment of Cancer. <i>Pharmaceuticals</i> , 2010, 3, 2022-2044.	1.7	50
738	Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas. <i>Child's Nervous System</i> , 2010, 26, 1051-1056.	0.6	30
739	DNA methylation: a form of epigenetic control of gene expression. <i>The Obstetrician and Gynaecologist</i> , 2010, 12, 37-42.	0.2	117
740	Malignant Gliomas: New Translational Therapies. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 655-666.	1.9	17
741	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. <i>Nature Reviews Neurology</i> , 2010, 6, 39-51.	4.9	644
742	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 391-397.	1.1	27
744	Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 3663-3681.	2.4	124
745	Aplastic Anemia as a Cause of Death in a Patient with Glioblastoma Multiforme Treated with Temozolomide. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 452-457.	1.0	21
748	Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 670-676.	0.4	50
749	A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. <i>Journal of Theoretical Biology</i> , 2010, 262, 553-565.	0.8	56
750	Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features. <i>Child's Nervous System</i> , 2010, 26, 137-143.	0.6	8
751	MGMT gene promoter methylation in pediatric glioblastomas. <i>Child's Nervous System</i> , 2010, 26, 1613-1618.	0.6	38
752	Molecular diagnostics of gliomas: state of the art. <i>Acta Neuropathologica</i> , 2010, 120, 567-584.	3.9	243
753	Molecular diagnostics of gliomas: the clinical perspective. <i>Acta Neuropathologica</i> , 2010, 120, 585-592.	3.9	127
754	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. <i>Acta Neuropathologica</i> , 2010, 120, 707-718.	3.9	719
755	Association of the GNB3 825T-allele with better survival in patients with glioblastoma multiforme. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1423-1429.	1.2	9
756	O 6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. <i>International Journal of Clinical Oncology</i> , 2010, 15, 352-358.	1.0	60
758	Conventional radiotherapy followed by IMRT as a boost in combination with chemotherapy treatment for high-grade gliomas: prognostic factors and outcomes. <i>Chinese-German Journal of Clinical Oncology</i> , 2010, 9, 337-343.	0.1	0



#	ARTICLE	IF	CITATIONS
759	Analysis of MGMT promoter methylation status on intraoperative fresh tissue section from frameless neuronavigation needle biopsy: a preliminary study of ten patients. <i>Acta Neurochirurgica</i> , 2010, 152, 1189-1196.	0.9	11
760	Molecular genetics, imaging and treatment of oligodendroglial tumours. <i>Acta Neurochirurgica</i> , 2010, 152, 1815-1825.	0.9	8
761	The role of temozolomide in neuro-oncology. <i>Memo - Magazine of European Medical Oncology</i> , 2010, 3, 15-17.	0.3	0
762	Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting. <i>Protein and Cell</i> , 2010, 1, 638-655.	4.8	204
763	MGMT promoter methylation in malignant gliomas. <i>Targeted Oncology</i> , 2010, 5, 161-165.	1.7	66
764	Targeting integrins in malignant glioma. <i>Targeted Oncology</i> , 2010, 5, 175-181.	1.7	83
765	Molecular markers in gliomas: impact for the clinician. <i>Targeted Oncology</i> , 2010, 5, 201-210.	1.7	21
766	Newly Diagnosed High-Grade Gliomas. <i>Current Treatment Options in Neurology</i> , 2010, 12, 309-320.	0.7	5
767	MGMT Immunoexpression in Silent Subtype 3 Pituitary Adenomas: Possible Therapeutic Implications. <i>Endocrine Pathology</i> , 2010, 21, 161-165.	5.2	18
768	Low Immunohistochemical Expression of MGMT in ACTH Secreting Pituitary Tumors of Patients with Nelson Syndrome. <i>Endocrine Pathology</i> , 2010, 21, 227-229.	5.2	18
769	The Role of Temozolomide in Elderly Patients with Glioblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 155-157.	2.0	0
770	Personalized Treatment—The Promise of Molecular Genetics Diagnostics. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, S2-S5.	0.9	1
771	Potential adenovirus-mediated gene therapy of glioma cancer. <i>Biotechnology Letters</i> , 2010, 32, 11-18.	1.1	14
772	Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. <i>Journal of Neuro-Oncology</i> , 2010, 97, 311-322.	1.4	169
773	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. <i>Journal of Neuro-Oncology</i> , 2010, 97, 389-392.	1.4	72
774	Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. <i>Journal of Neuro-Oncology</i> , 2010, 98, 1-7.	1.4	46
775	Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. <i>Journal of Neuro-Oncology</i> , 2010, 96, 321-329.	1.4	51
776	Extended-schedule dose-dense temozolomide in refractory gliomas. <i>Journal of Neuro-Oncology</i> , 2010, 96, 417-422.	1.4	50

#	ARTICLE	IF	CITATIONS
777	Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGAâ€‘substance Pâ€‘ results from a phase I study. <i>Journal of Neuro-Oncology</i> , 2010, 100, 129-136.	1.4	52
778	Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. <i>Journal of Neuro-Oncology</i> , 2010, 100, 209-215.	1.4	17
779	Radiation-induced cerebellar high-grade glioma accompanied by meningioma and cavernoma 29Â‘years after the treatment of medulloblastoma: a case report. <i>Journal of Neuro-Oncology</i> , 2010, 100, 299-303.	1.4	18
780	Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010, 100, 311-319.	1.4	4
781	Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. <i>Journal of Neuro-Oncology</i> , 2010, 100, 177-186.	1.4	48
782	Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 100, 407-415.	1.4	54
783	MGMT immunoeexpression in aggressive pituitary adenoma and carcinoma. <i>Pituitary</i> , 2010, 13, 367-379.	1.6	51
784	Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. <i>Lancet Neurology</i> , The, 2010, 9, 717-726.	4.9	251
785	The DNA methylome of glioblastoma multiforme. <i>Neurobiology of Disease</i> , 2010, 39, 40-46.	2.1	50
786	Experimental approaches for the treatment of malignant gliomas. , 2010, 128, 1-36.		72
787	Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 166-193.	157.7	1,182
788	Cancer Epigenetics. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 376-392.	157.7	399
789	BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. <i>BMC Cancer</i> , 2010, 10, 30.	1.1	77
790	Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. <i>BMC Cancer</i> , 2010, 10, 48.	1.1	33
791	Potential therapeutic implications of cancer stem cells in glioblastoma. <i>Biochemical Pharmacology</i> , 2010, 80, 654-665.	2.0	179
792	Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. <i>Cancer Cell</i> , 2010, 17, 98-110.	7.7	6,138
793	Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. <i>Cancer Cell</i> , 2010, 17, 510-522.	7.7	2,078
794	Intensive chemotherapy improves survival in pediatric highâ€‘grade glioma after gross total resection: results of the HITâ€‘GBMâ€‘ protocol. <i>Cancer</i> , 2010, 116, 705-712.	2.0	116

#	ARTICLE	IF	CITATIONS
795	Dose-dense temozolomide regimens. <i>Cancer</i> , 2010, 116, 2868-2877.	2.0	89
796	Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. <i>International Journal of Cancer</i> , 2010, 126, 2584-2593.	2.3	114
797	MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. <i>International Journal of Cancer</i> , 2010, 127, 2106-2118.	2.3	97
798	Combined use of neuroradiology and <sup>1</sup> H-MR spectroscopy may provide an intervention limiting diagnosis of glioblastoma multiforme. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 32, 1038-1044.	1.9	18
799	Simultaneous Integrated Boost Intensity-Modulated Radiotherapy in Patients With High-Grade Gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 390-397.	0.4	54
800	Irradiation of Pediatric High-Grade Spinal Cord Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1451-1456.	0.4	29
801	Intratumoral Hypoxic Gradient Drives Stem Cells Distribution and MGMT Expression in Glioblastoma. <i>Stem Cells</i> , 2010, 28, 851-862.	1.4	262
802	Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the children's oncology group. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1066-1071.	0.8	24
803	Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 159-167.	1.0	171
804	Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. <i>Apmis</i> , 2010, 118, 585-594.	0.9	36
805	Epigenetic aberrations and therapeutic implications in gliomas. <i>Cancer Science</i> , 2010, 101, 1331-1336.	1.7	25
806	O <sup>6</sup> -methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 356-358.	1.8	14
807	Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. <i>British Journal of Cancer</i> , 2010, 103, 29-35.	2.9	89
808	Effect of alternative temozolomide schedules on glioblastoma O <sup>6</sup> -methylguanine-DNA methyltransferase activity and survival. <i>British Journal of Cancer</i> , 2010, 103, 498-504.	2.9	15
809	MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. <i>British Journal of Cancer</i> , 2010, 103, 820-826.	2.9	45
810	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. <i>British Journal of Cancer</i> , 2010, 103, 1588-1596.	2.9	58
811	Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O <sup>6</sup> -methylguanine-DNA methyltransferaseP140K. <i>Gene Therapy</i> , 2010, 17, 389-399.	2.3	45
812	Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. <i>Heredity</i> , 2010, 105, 152-160.	1.2	25

#	ARTICLE	IF	CITATIONS
813	Personalized medicine in oncology: the future is now. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 363-366.	21.5	265
814	Glioma Pathophysiology: Insights Emerging from Proteomics. <i>Brain Pathology</i> , 2010, 20, 691-703.	2.1	60
815	Fixation of Brain Tumor Biopsy Specimens with RCL2 Results in Well-Preserved Histomorphology, Immunohistochemistry and Nucleic Acids. <i>Brain Pathology</i> , 2010, 20, 1010-1020.	2.1	22
816	Role of bevacizumab therapy in the management of glioblastoma. <i>Cancer Management and Research</i> , 2010, , 97.	0.9	11
817	DNA Damage Induced by Alkylating Agents and Repair Pathways. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-7.	0.8	205
818	Gliomas in Adults. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2010, 107, 799-807; quiz 808.	0.6	63
819	Mesenchymal Migration as a Therapeutic Target in Glioblastoma. <i>Journal of Oncology</i> , 2010, 2010, 1-17.	0.6	70
820	Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model. <i>International Journal of Oncology</i> , 2010, 37, 879-90.	1.4	4
821	Treatment of Glioblastoma in Elderly Patients: An Overview of Current Treatments and Future Perspective. <i>Tumori</i> , 2010, 96, 650-658.	0.6	8
822	Human Flt3L Generates Dendritic Cells from Canine Peripheral Blood Precursors: Implications for a Dog Glioma Clinical Trial. <i>PLoS ONE</i> , 2010, 5, e11074.	1.1	30
823	Disruption of Dnmt1/PCNA/UHRF1 Interactions Promotes Tumorigenesis from Human and Mice Glial Cells. <i>PLoS ONE</i> , 2010, 5, e11333.	1.1	120
824	Development of a Novel Fluorescence Assay Based on the Use of the Thrombin-Binding Aptamer for the Detection of O6-Alkylguanine-DNA Alkyltransferase Activity. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-9.	0.8	20
825	Selection of chemotherapy for glioblastoma expressing O6-methylguanine-DNA methyltransferase. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 53-57.	0.8	4
826	Temozolomide in malignant glioma. <i>OncoTargets and Therapy</i> , 2010, 3, 139.	1.0	29
827	A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. <i>Neuro-Oncology</i> , 2010, 12, 500-7.	0.6	22
828	Epigenomics in cancer management. <i>Cancer Management and Research</i> , 0, , 255.	0.9	46
829	Pathology and Molecular Genetics of Common Brain Tumors. <i>Blue Books of Neurology</i> , 2010, 36, 1-36.	0.1	0
830	The future role of personalized medicine in the treatment of glioblastoma multiforme. <i>Pharmacogenomics and Personalized Medicine</i> , 2010, 3, 111.	0.4	17

#	ARTICLE	IF	CITATIONS
831	Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. <i>European Journal of Endocrinology</i> , 2010, 163, 843-851.	1.9	86
832	The implications of heterogeneous DNA methylation for the accurate quantification of methylation. <i>Epigenomics</i> , 2010, 2, 561-573.	1.0	126
833	Recent Advances in Therapy for Glioblastoma. <i>Archives of Neurology</i> , 2010, 67, 279-83.	4.9	234
834	Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study. <i>Neuro-Oncology</i> , 2010, 12, 608-613.	0.6	34
835	Cytostatic and cytotoxic drugs. <i>Side Effects of Drugs Annual</i> , 2010, , 827-842.	0.6	0
836	MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. <i>Neuro-Oncology</i> , 2010, 12, 822-833.	0.6	74
837	O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. <i>Neuro-Oncology</i> , 2010, 12, 28-36.	0.6	75
838	A multigene predictor of outcome in glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 49-57.	0.6	334
840	Tumor O <sup>6</sup> -methylguanine-DNA Methyltransferase Inactivation by Oral Lomeguatrib. <i>Clinical Cancer Research</i> , 2010, 16, 743-749.	3.2	36
841	Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide. <i>Oncologist</i> , 2010, 15, 765-771.	1.9	46
842	Global Histone Modification Patterns as Prognostic Markers to Classify Glioma Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2888-2896.	1.1	72
843	Therapy for Recurrent High-Grade Gliomas: Does Continuous Dose-Intense Temozolomide Have a Role?. <i>Journal of Clinical Oncology</i> , 2010, 28, 1977-1979.	0.8	11
844	Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma. <i>Radiology</i> , 2010, 256, 575-584.	3.6	167
845	Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2712-2718.	0.8	389
846	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2010, 28, e696-e697.	0.8	0
847	A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2010, 112, 997-1004.	0.9	125
848	Epigenetic Downregulation of Mitogen-Activated Protein Kinase Phosphatase MKP-2 Relieves Its Growth Suppressive Activity in Glioma Cells. <i>Cancer Research</i> , 2010, 70, 1689-1699.	0.4	66
849	O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. <i>Neuro-Oncology</i> , 2010, 12, 283-288.	0.6	110

#	ARTICLE	IF	CITATIONS
850	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4722-4729.	0.8	702
851	Temozolomide-Induced Myelodysplasia. <i>Advances in Hematology</i> , 2010, 2010, 1-5.	0.6	15
852	New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers. <i>Clinical Cancer Research</i> , 2010, 16, 4688-4694.	3.2	114
853	Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. <i>Neuro-Oncology</i> , 2010, 12, 243-256.	0.6	32
854	Oligodendroglioma cell lines containing t(1;19)(q10;p10). <i>Neuro-Oncology</i> , 2010, 12, 745-755.	0.6	77
855	Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. <i>Neuro-Oncology</i> , 2010, 12, 173-180.	0.6	142
856	Sensitivity to temozolomide in brain tumor initiating cells. <i>Neuro-Oncology</i> , 2010, 12, 756-760.	0.6	59
857	A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 1071-1077.	0.6	100
858	Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2051-2057.	0.8	324
859	Analysis of Self-Inactivating Lentiviral Vector Integration Sites and Flanking Gene Expression in Human Peripheral Blood Progenitor Cells After Alkylator Chemotherapy. <i>Human Gene Therapy</i> , 2010, 21, 943-956.	1.4	7
860	A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2010, 113, 192-198.	0.9	112
861	Update on molecular findings, management and outcome in low-grade gliomas. <i>Nature Reviews Neurology</i> , 2010, 6, 695-701.	4.9	128
862	Malignant Gliomas in Adults. <i>Blue Books of Neurology</i> , 2010, 36, 99-120.	0.1	6
863	Frequent MGMT (O6-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. <i>Radiology and Oncology</i> , 2010, 44, 113-20.	0.6	11
864	MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 116-121.	0.6	316
865	A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 1167-1172.	0.6	28
866	Temozolomide for Adult Brain Stem Glioblastoma: Case Report of a Long-Term Survivor. <i>International Journal of Neuroscience</i> , 2010, 120, 787-791.	0.8	10
867	The Novel Hsp90 Inhibitor NXD30001 Induces Tumor Regression in a Genetically Engineered Mouse Model of Glioblastoma Multiforme. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2618-2626.	1.9	35

#	ARTICLE	IF	CITATIONS
868	Epigenetic Biomarkers. <i>Current Topics in Microbiology and Immunology</i> , 2010, 355, 189-216.	0.7	16
869	Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. <i>Annals of Oncology</i> , 2010, 21, 1718-1722.	0.6	34
870	Perils of Evidence-Based Medicine. <i>Perspectives in Biology and Medicine</i> , 2010, 53, 106-120.	0.3	49
871	Reversing HOXA9 Oncogene Activation by PI3K Inhibition: Epigenetic Mechanism and Prognostic Significance in Human Glioblastoma. <i>Cancer Research</i> , 2010, 70, 453-462.	0.4	132
872	Nuclear factor IA is expressed in astrocytomas and is associated with improved survival. <i>Neuro-Oncology</i> , 2010, 12, 122-132.	0.6	36
873	Intraoperative stimulation techniques for functional pathway preservation and glioma resection. <i>Neurosurgical Focus</i> , 2010, 28, E1.	1.0	166
874	Pediatric CNS Tumors. <i>Pediatric Oncology</i> , 2010, , .	0.5	11
876	Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy. <i>Neurological Research</i> , 2010, 32, 690-694.	0.6	16
877	Topoisomerase I Inhibitors in the Treatment of Primary CNS Malignancies: An Update on Recent Trends. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 683-696.	0.9	14
878	Current Therapeutic Paradigms in Glioblastoma. <i>Reviews on Recent Clinical Trials</i> , 2010, 5, 14-27.	0.4	64
879	Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre study. <i>Oncology Reports</i> , 2010, 23, 1655-62.	1.2	55
880	Gene expression profiling predicts response to temozolomide in malignant gliomas. <i>International Journal of Oncology</i> , 2010, 36, 1367-77.	1.4	68
881	Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2010, 112, 50-56.	0.9	28
884	Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. <i>Journal of Neurosurgery</i> , 2010, 112, 33-42.	0.9	38
885	Diagnostic and prognostic molecular markers in common adult gliomas. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 637-649.	1.5	5
886	Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O <sup>6</sup> -Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E280-E290.	1.8	139
889	Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis. <i>Current Cancer Therapy Reviews</i> , 2010, 6, 13-18.	0.2	3
890	Chemoradiation for Glioblastoma. <i>Current Drug Therapy</i> , 2010, 5, 157-163.	0.2	0

#	ARTICLE	IF	CITATIONS
891	Long-term outcomes in children with glioblastoma. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 6, 145-149.	0.8	72
892	PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors. <i>Cancer Research</i> , 2010, 70, 5457-5464.	0.4	218
893	Extended O <sup>6</sup> -Methylguanine Methyltransferase Promoter Hypermethylation Following <i>n</i> -Butylideneephthalide Combined with 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) on Inhibition of Human Hepatocellular Carcinoma Cell Growth. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 1630-1638.	2.4	28
894	Management of Diffuse Low-Grade Cerebral Gliomas. <i>Neurologic Clinics</i> , 2010, 28, 1037-1059.	0.8	19
895	Transferrin Receptor 2 Is Frequently and Highly Expressed in Glioblastomas. <i>Translational Oncology</i> , 2010, 3, 123-134.	1.7	106
896	Glioblastoma therapy: going beyond Hercules Columns. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 507-514.	1.4	44
897	Epigenetic Alterations as Cancer Diagnostic, Prognostic, and Predictive Biomarkers. <i>Advances in Genetics</i> , 2010, 71, 125-176.	0.8	85
898	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. <i>Future Oncology</i> , 2010, 6, 1407-1414.	1.1	23
899	Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1537-1544.	1.4	155
900	Next Generation DNA Sequencing and the Future of Genomic Medicine. <i>Genes</i> , 2010, 1, 38-69.	1.0	60
901	Pathology and Classification of Tumors of the Nervous System. , 2010, , 3-75.		8
902	High-Grade Astrocytoma/Glioblastoma. , 2010, , 147-161.		1
904	Gli1 is a potential target for alleviating multidrug resistance of gliomas. <i>Journal of the Neurological Sciences</i> , 2010, 288, 156-166.	0.3	67
905	The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma. <i>Journal of the Neurological Sciences</i> , 2010, 294, 112-118.	0.3	19
906	O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. <i>Lung Cancer</i> , 2010, 68, 484-490.	0.9	29
907	Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational Applications. <i>Oncology</i> , 2010, 78, 103-114.	0.9	93
908	ROS accumulation and IGF-1R inhibition contribute to fenofibrate/PPAR $\alpha$ -mediated inhibition of Glioma cell motility in vitro. <i>Molecular Cancer</i> , 2010, 9, 159.	7.9	81
909	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. <i>Molecular Cancer</i> , 2010, 9, 234.	7.9	37



#	ARTICLE	IF	CITATIONS
910	FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors. <i>Molecular Cancer</i> , 2010, 9, 270.	7.9	22
911	High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study. <i>Journal of Translational Medicine</i> , 2010, 8, 115.	1.8	31
912	Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. <i>Nutrition and Metabolism</i> , 2010, 7, 33.	1.3	209
914	Molecular Tools: Biology, Prognosis, and Therapeutic Triage. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 273-282.	0.5	7
915	Intensity modulated radiation therapy versus three dimensional conformal radiation therapy for treatment of high grade glioma: A radiobiological modeling study. <i>Journal of X-Ray Science and Technology</i> , 2010, 18, 393-402.	0.7	4
916	High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v190-v193.	0.6	262
917	The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. <i>Neurological Research</i> , 2010, 32, 816-820.	0.6	39
918	Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4592-4599.	1.8	202
919	Direct DNA Methylation Profiling Using Methyl Binding Domain Proteins. <i>Analytical Chemistry</i> , 2010, 82, 5012-5019.	3.2	58
920	The Role of the Epigenome in Human Cancers. , 2010, , 471-486.		0
925	Virotherapy against malignant glioma stem cells. <i>Cancer Letters</i> , 2010, 289, 1-10.	3.2	35
926	miR-195, miR-455-3p and miR-10a are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. <i>Cancer Letters</i> , 2010, 296, 241-248.	3.2	215
927	Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. <i>European Journal of Cancer</i> , 2010, 46, 9-20.	1.3	108
928	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. <i>European Journal of Cancer</i> , 2010, 46, 2166-2177.	1.3	71
929	MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. <i>European Journal of Cancer</i> , 2010, 46, 2127-2133.	1.3	26
930	Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 76, 371-375.	2.0	15
931	An epigenetic mechanism for capecitabine resistance in mesothelioma. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1465-1470.	1.0	35
932	Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. <i>Neuro-Oncology</i> , 2010, 12, 540-548.	0.6	61

#	ARTICLE	IF	CITATIONS
933	Role of Aberrant Cell Cycle in the Growth and Pathogenesis of Glioblastoma. , 2010, , 131-151.		0
934	Metabolomic Patterns in Glioblastoma and Changes during Radiotherapy: A Clinical Microdialysis Study. Journal of Proteome Research, 2010, 9, 2909-2919.	1.8	89
935	The Pathobiology of Glioma Tumors. Annual Review of Pathology: Mechanisms of Disease, 2010, 5, 33-50.	9.6	197
936	An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. NeuroImage, 2010, 49, 1398-1405.	2.1	193
937	MGMT-Independent Temozolomide Resistance in Pediatric Glioblastoma Cells Associated with a PI3-Kinase-Mediated HOX/Stem Cell Gene Signature. Cancer Research, 2010, 70, 9243-9252.	0.4	152
938	Hypoxia Increases the Expression of Stem-Cell Markers and Promotes Clonogenicity in Glioblastoma Neurospheres. American Journal of Pathology, 2010, 177, 1491-1502.	1.9	306
940	Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells. Journal of Biomedical Research, 2010, 24, 424-435.	0.7	20
942	Chemotherapy for Glioblastoma: Past, Present, and Future. , 2010, , 203-216.		2
943	Molecularly Targeted Therapies for Astrocytomas. , 2010, , 231-265.		1
944	An Omics Perspective on Cancer Research. , 2010, , .		20
946	Immunohistology of the Nervous System. , 2010, , 820-889.		8
947	Astrocytic and Oligodendroglial Tumors. , 2010, , 63-102.		4
948	Genomic Evaluation of Brain Tumors and Gliomas. , 2010, , 522-531.		0
949	Three-dimensional Nuclear Telomere Architecture Is Associated with Differential Time to Progression and Overall Survival in Glioblastoma Patients. Neoplasia, 2010, 12, 183-191.	2.3	46
951	Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report. Journal of Medical Case Reports, 2010, 4, 274.	0.4	16
952	Translational Medicine: Application of Omics for Drug Target Discovery and Validation. , 2010, , 235-247.		4
953	Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. British Journal of Radiology, 2010, 83, 596-603.	1.0	39
954	NF- $\kappa$ B and STAT3 signaling in glioma: targets for future therapies. Expert Review of Neurotherapeutics, 2010, 10, 575-586.	1.4	118

#	ARTICLE	IF	CITATIONS
955	Neuro-oncology, a decade of temozolomide and beyond. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1675-1677.	1.1	19
956	The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. <i>British Journal of Neurosurgery</i> , 2011, 25, 459-469.	0.4	35
957	Knockdown of the Potential Cancer Stem-Like Cell Marker Rex-1 Improves Chemotherapeutic Effects in Gliomas. <i>Human Gene Therapy</i> , 2011, 22, 1551-1562.	1.4	10
958	Towards personalized therapy for patients with glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1935-1944.	1.1	16
959	Epigenetic-based companion diagnostics. <i>Personalized Medicine</i> , 2011, 8, 623-631.	0.8	1
960	Biology, genetics and imaging of glial cell tumours. <i>British Journal of Radiology</i> , 2011, 84, S90-S106.	1.0	59
961	Diagnostic Molecular Pathology in Practice. , 2011, , .		2
962	Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. <i>Neurology</i> , 2011, 76, 1918-1924.	1.5	167
963	Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 441-446.	0.9	45
964	Multiple craniotomies in the management of multifocal and multicentric glioblastoma. <i>Journal of Neurosurgery</i> , 2011, 114, 576-584.	0.9	77
966	Trimodal Glioblastoma Treatment Consisting of Concurrent Radiotherapy, Temozolomide, and the Novel TGF- $\beta$ 2 Receptor I Kinase Inhibitor LY2109761. <i>Neoplasia</i> , 2011, 13, 537-IN14.	2.3	82
967	An extent of resection threshold for newly diagnosed glioblastomas. <i>Journal of Neurosurgery</i> , 2011, 115, 3-8.	0.9	1,323
968	Evolving strategies: future treatment of glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 519-532.	1.4	17
969	Childhood brain tumors: epidemiology, current management and future directions. <i>Nature Reviews Neurology</i> , 2011, 7, 495-506.	4.9	110
970	Editorial: Extent of resection. <i>Journal of Neurosurgery</i> , 2011, 115, 1-2.	0.9	24
971	NCI 60 Cell Line Screen. , 2011, , 2468-2468.		0
972	Cancer epigenetics: linking basic biology to clinical medicine. <i>Cell Research</i> , 2011, 21, 502-517.	5.7	260
973	Genome-Wide Epigenetic Modifications in Cancer. , 2011, 67, 25-49.		43

#	ARTICLE	IF	CITATIONS
974	Molecular Classification of Gliomas. , 2011, , 9-19.		0
977	Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP. Lung Cancer, 2011, 71, 130-136.	0.9	35
978	Newcastle Disease Virus. , 2011, , 2513-2513.		0
979	Convection-enhanced delivery of <sup>131</sup> I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opinion on Biological Therapy, 2011, 11, 799-806.	1.4	20
980	NUPR1. , 2011, , 2587-2587.		0
981	Cilengitide: an RGD pentapeptide $\alpha$ -DGEKQ and $\alpha$ -DGEKQ integrin inhibitor in development for glioblastoma and other malignancies. Future Oncology, 2011, 7, 339-354.	1.1	98
982	Epigenetics and Disease. , 2011, , .		5
983	Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited. Neoplasia, 2011, 13, 1113-IN6.	2.3	115
984	Principles of Anticancer Drug Development. , 2011, , .		0
985	Tumors of the Central Nervous System, Volume 2. , 2011, , .		3
988	Nested PCR. , 2011, , 2478-2478.		0
989	Investigational Therapies for Brain Metastases. Neurosurgery Clinics of North America, 2011, 22, 87-96.	0.8	4
990	Use of molecular markers for predicting therapy response in cancer patients. Cancer Treatment Reviews, 2011, 37, 151-159.	3.4	94
991	Malignant Gliomas: Diagnosis and Treatment. Disease-a-Month, 2011, 57, 558-569.	0.4	38
992	FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genetics, 2011, 204, 577-588.	0.2	50
994	Treatment of high-grade glioma in children and adolescents. Neuro-Oncology, 2011, 13, 1049-1058.	0.6	127
995	Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. Medical Hypotheses, 2011, 76, 410-413.	0.8	15
996	A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. Journal of Clinical Neuroscience, 2011, 18, 66-70.	0.8	59

#	ARTICLE	IF	CITATIONS
997	The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20yearsâ€™ experience at a single centre. Journal of Clinical Neuroscience, 2011, 18, 329-333.	0.8	62
998	A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan. Journal of Clinical Neuroscience, 2011, 18, 784-788.	0.8	6
999	Role of the GNAS1 T393C polymorphism in patients with glioblastoma multiforme. Journal of Clinical Neuroscience, 2011, 18, 1495-1499.	0.8	5
1000	Abnormal nitrosothiol metabolism in hepatocellular carcinoma. Journal of Hepatology, 2011, 54, 579-580.	1.8	2
1001	The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes and Development, 2011, 25, 2594-2609.	2.7	326
1002	Quality and Reliability of Large-Eddy Simulations II. ERCOFTAC Series, 2011, , .	0.1	10
1003	Nerve Growth Factor. , 2011, , 2477-2478.		0
1004	Treatment of recurrent high-grade gliomas. Community Oncology, 2011, 8, 171-177.	0.2	0
1005	Nuclear Remodeling as a Mechanism for Genomic Instability in Cancer. Advances in Cancer Research, 2011, 112, 77-126.	1.9	22
1006	Biomarkers of Glioma. , 0, , .		3
1007	DNA Repair, Cancer and Cancer Therapy - The Current State of Art. , 2011, , .		2
1008	Molecular Hallmarks of Gliomas. , 0, , .		5
1009	The Role of Isocitrate Dehydrogenase Mutations in Glioma Brain Tumors. , 0, , .		2
1010	Evolvement of Molecular Biomarkers in Targeted Therapy of Malignant Gliomas. , 2011, , .		1
1011	DNA Damage Protection and Induction of Repair by Dietary Phytochemicals and Cancer Prevention: What Do We Know?. , 0, , .		4
1012	Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy. Hormones, 2011, 10, 162-167.	0.9	45
1013	Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease. , 0, , 313-324.		0
1014	Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells. Experimental and Therapeutic Medicine, 2011, 2, 343-348.	0.8	4

#	ARTICLE	IF	CITATIONS
1015	Treatment results, including clinical prognostic factors and MGMT gene promoter methylation, in patients with glioblastoma multiforme in Warmia and Mazury Oncology Centre. <i>Wspolczesna Onkologia</i> , 2011, 4, 198-202.	0.7	2
1016	Gene Therapy of Glioblastoma: Anti " Gene Anti IGF-I Strategy. , 2011, , .		0
1017	Molecular Pathways of Glioblastoma and Glioblastoma Stem Cells. , 0, , .		0
1018	Novel Therapeutic Venues for Glioblastoma: Novel Rising Preclinical Treatment Opportunities. , 0, , .		0
1019	MicroRNA in Human Gliomas. , 2011, , .		0
1020	Glioma Stem Cells. , 2011, , .		0
1021	Brain Tumors and the Lynch Syndrome. , 2011, , .		1
1022	Portrait of Transcriptional Expression Profiles Displayed by Different Glioblastoma Cell Lines. , 0, , .		2
1023	Anti-Angiogenic Therapy for Malignant Glioma: Insights and Future Directions. , 2011, , .		1
1024	Genetics and Biology of Glioblastoma Multiforme. , 2011, , .		2
1025	Metabolism and Brain Cancer. <i>Clinics</i> , 2011, 66, 33-43.	0.6	96
1026	DNA Damage, Repair and Misrepair in Cancer and in Cancer Therapy. , 0, , .		1
1028	Glioblastoma Multiforme: Enhancing Survival and Quality of Life. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, 291-297.	0.3	29
1029	Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma. <i>Yonsei Medical Journal</i> , 2011, 52, 1031.	0.9	6
1030	Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme. <i>Current Oncology</i> , 2011, 18, 126-136.	0.9	87
1031	Combined Modality Approaches in the Management of Adult Glioblastoma. <i>Frontiers in Oncology</i> , 2011, 1, 36.	1.3	8
1032	Personalized medicine in oncology: vision or realistic concept?. <i>Wspolczesna Onkologia</i> , 2011, 1, 1-6.	0.7	1
1033	The Pivotal Roles of GSK3 <sup>β</sup> in Glioma Biology. , 0, , .		9

#	ARTICLE	IF	CITATIONS
1034	Overview and recent advances in neuropathology. Part 1: Central nervous system tumours. <i>Pathology</i> , 2011, 43, 88-92.	0.3	14
1035	Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM. <i>PLoS ONE</i> , 2011, 6, e16146.	1.1	89
1036	The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma. <i>PLoS ONE</i> , 2011, 6, e23332.	1.1	95
1037	Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme. <i>PLoS ONE</i> , 2011, 6, e25451.	1.1	239
1038	Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs. <i>PLoS ONE</i> , 2011, 6, e27183.	1.1	79
1039	Immunohistochemical Assessment of MGMT Expression and p53 Mutation in Glioblastoma Multiforme. <i>Tumori</i> , 2011, 97, 104-108.	0.6	10
1041	Multigene Sets for Clinical Application in Glioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 449-457.	2.3	6
1042	Glioma Stem Cell Maintenance: The Role of the Microenvironment. <i>Current Pharmaceutical Design</i> , 2011, 17, 2386-2401.	0.9	76
1043	Epidermal Growth Factor Receptor Vaccination for Glioblastoma Multiforme. <i>Neurosurgery</i> , 2011, 68, N20-N21.	0.6	3
1044	Predicting the First Site of Relapse for Cancerous Tumors Using Protein Expression Profiles. <i>Neurosurgery</i> , 2011, 69, N10-N12.	0.6	0
1045	A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report. <i>Neurosurgery</i> , 2011, 68, E1761-E1767.	0.6	69
1046	Postoperative Infection May Influence Survival in Patients With Glioblastoma: Simply a Myth?. <i>Neurosurgery</i> , 2011, 69, 864-869.	0.6	45
1047	Alteration in NFKBIA and EGFR in Glioblastoma Multiforme. <i>Neurosurgery</i> , 2011, 68, N14-N15.	0.6	3
1048	Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens. <i>Melanoma Research</i> , 2011, 21, 206-216.	0.6	9
1049	Stressed to Death: Targeting Endoplasmic Reticulum Stress Response Induced Apoptosis in Gliomas. <i>Current Pharmaceutical Design</i> , 2011, 17, 284-292.	0.9	60
1050	Effect of temozolomide on the U-118 glioma cell line. <i>Oncology Letters</i> , 2011, 2, 1165-1170.	0.8	49
1051	Grading of Gliomas: The Road From Eminence to Evidence. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 101-109.	0.9	51
1052	Antisense Strategies in Therapy of Gliomas. <i>Current Signal Transduction Therapy</i> , 2011, 6, 411-423.	0.3	2

#	ARTICLE	IF	CITATIONS
1053	New Perspectives in Glioma Immunotherapy. <i>Current Pharmaceutical Design</i> , 2011, 17, 2439-2467.	0.9	23
1054	Advances in Translational Research in Neuro-oncology. <i>Archives of Neurology</i> , 2011, 68, 303-8.	4.9	4
1055	Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. <i>Oncology Reports</i> , 2012, 27, 854-60.	1.2	69
1056	Novel clinical trials in neuro-oncology. <i>Clinical Investigation</i> , 2011, 1, 781-794.	0.0	1
1057	Inhibition of Sonic Hedgehog and Notch Pathways Enhances Sensitivity of CD133+ Glioma Stem Cells to Temozolomide Therapy. <i>Molecular Medicine</i> , 2011, 17, 103-112.	1.9	167
1058	IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. <i>Oncology Reports</i> , 2011, 26, 1479-85.	1.2	28
1059	Central Nervous System Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 352-400.	2.3	99
1060	Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. <i>Clinics</i> , 2011, 66, 1747-1755.	0.6	84
1061	Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. <i>Oncology Reports</i> , 2011, 26, 1305-13.	1.2	34
1062	IN1 immunohistochemical expression in glioblastoma: correlation with MGMT gene promoter methylation status and patient survival. <i>Pathology</i> , 2011, 43, 17-23.	0.3	9
1063	NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-1-S-32.	2.3	227
1064	Consensus Document on European Brain Research. <i>European Journal of Neuroscience</i> , 2011, 33, 768-818.	1.2	29
1065	Inactivation of O <sup>6</sup> -methylguanine-DNA methyltransferase by promoter hypermethylation: Association of epithelial ovarian carcinogenesis in specific histological types. <i>Journal of Obstetrics and Gynaecology Research</i> , 2011, 37, 851-860.	0.6	11
1066	MiR-195, miR-196b, miR-181c, miR-21 expression levels and O <sup>6</sup> -methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. <i>Cancer Science</i> , 2011, 102, 2186-2190.	1.7	145
1067	Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1133-1148.	1.7	139
1068	A UK-wide survey of follow-up practices for patients with high-grade glioma treated with radical intent. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 1-6.	0.9	11
1069	The methylation hypothesis: Do epigenetic chromatin modifications play a role in epileptogenesis?. <i>Epilepsia</i> , 2011, 52, 15-19.	2.6	93
1070	Cancer epigenetics reaches mainstream oncology. <i>Nature Medicine</i> , 2011, 17, 330-339.	15.2	1,102



#	ARTICLE	IF	CITATIONS
1071	DNA polymerases and cancer. <i>Nature Reviews Cancer</i> , 2011, 11, 96-110.	12.8	480
1072	A decade of exploring the cancer epigenome – biological and translational implications. <i>Nature Reviews Cancer</i> , 2011, 11, 726-734.	12.8	2,425
1073	The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. <i>Brain Pathology</i> , 2011, 21, 74-87.	2.1	150
1074	The Use of Global Profiling in Biomarker Development for Gliomas. <i>Brain Pathology</i> , 2011, 21, 88-95.	2.1	19
1075	Glioblastoma, Cancer Stem Cells and Hypoxia. <i>Brain Pathology</i> , 2011, 21, 119-129.	2.1	98
1076	Unraveling the Glioma Epigenome – From Molecular Mechanisms to Novel Biomarkers and Therapeutic Targets. <i>Brain Pathology</i> , 2011, 21, 619-632.	2.1	38
1077	Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2735-2744.	1.6	73
1078	Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy. <i>Seminars in Oncology</i> , 2011, 38, 236-242.	0.8	28
1079	Molecular Heterogeneity in Glioblastoma: Therapeutic Opportunities and Challenges. <i>Seminars in Oncology</i> , 2011, 38, 243-253.	0.8	69
1080	Understanding Glioblastoma Tumor Biology: The Potential to Improve Current Diagnosis and Treatments. <i>Seminars in Oncology</i> , 2011, 38, S2-S10.	0.8	102
1081	The Impact of Recent Data on the Optimization of Standards of Care in Newly Diagnosed Glioblastoma. <i>Seminars in Oncology</i> , 2011, 38, S11-S20.	0.8	16
1082	Recurrent Glioblastoma: A Fresh Look at Current Therapies and Emerging Novel Approaches. <i>Seminars in Oncology</i> , 2011, 38, S21-S33.	0.8	45
1083	Avastin in the Treatment for Radiation Necrosis: Exciting Results from a Recent Randomized Trial. <i>World Neurosurgery</i> , 2011, 75, 4-5.	0.7	8
1084	Stereotactic Radiosurgery for Recurrent High Grade Gliomas. <i>World Neurosurgery</i> , 2011, 76, 61-62.	0.7	8
1085	Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy. <i>Drug Discovery Today</i> , 2011, 16, 1044-1051.	3.2	41
1086	Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential. <i>Applied Radiation and Isotopes</i> , 2011, 69, 1737-1740.	0.7	49
1087	An overview of epigenetics and chemoprevention. <i>FEBS Letters</i> , 2011, 585, 2129-2136.	1.3	47
1088	Translational application of epigenetic alterations: Ovarian cancer as a model. <i>FEBS Letters</i> , 2011, 585, 2112-2120.	1.3	27

#	ARTICLE	IF	CITATIONS
1089	O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1816, 179-190.	3.3	142
1090	Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. <i>Neuro-Oncology</i> , 2011, 13, 1331-1338.	0.6	73
1091	Recent advancements in multimodality treatment of gliomas. <i>Future Oncology</i> , 2011, 7, 1169-1183.	1.1	52
1092	The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. <i>Nature Reviews Neuroscience</i> , 2011, 12, 495-508.	4.9	256
1093	Predictive and prognostic factors for gliomas. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 781-789.	1.1	54
1094	Glioblastoma: Temozolomide-Based Chemotherapy. , 2011, , 243-248.		0
1095	Molecular Pathogenesis. , 2011, , 27-44.		2
1096	Impact of <i>EGFR</i> Genetic Variants on Glioma Risk and Patient Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2610-2617.	1.1	37
1097	Molecular Subtypes of Gliomas. , 2011, , 25-29.		0
1098	O6-methylguanine DNA methyltransferase gene promoter methylation status in glioblastoma and its correlation with other prognostic markers. <i>Molecular and Cellular Toxicology</i> , 2011, 7, 425-430.	0.8	1
1099	An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 971-983.	1.1	31
1100	Supratentorial Glioblastoma Multiforme: The Role of Surgical Resection Versus Biopsy Among Older Patients. <i>Annals of Surgical Oncology</i> , 2011, 18, 239-245.	0.7	134
1101	Identification and Validation of DNA Methylation Markers to Predict Lymph Node Metastasis of Esophageal Squamous Cell Carcinomas. <i>Annals of Surgical Oncology</i> , 2011, 18, 1185-1194.	0.7	22
1102	Butylidenephthalide Suppresses Human Telomerase Reverse Transcriptase (TERT) in Human Glioblastomas. <i>Annals of Surgical Oncology</i> , 2011, 18, 3514-3527.	0.7	25
1103	Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 2937-2945.	0.7	54
1104	DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target. <i>Clinical Cancer Research</i> , 2011, 17, 6973-6984.	3.2	97
1105	Association of secondhand smoke exposures with DNA methylation in bladder carcinomas. <i>Cancer Causes and Control</i> , 2011, 22, 1205-1213.	0.8	38
1106	The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 397-408.	2.7	95

#	ARTICLE	IF	CITATIONS
1107	MGMT immunoexpression in adamantinomatous craniopharyngiomas. <i>Pituitary</i> , 2011, 14, 323-327.	1.6	7
1108	O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. <i>Journal of Neuro-Oncology</i> , 2011, 101, 477-486.	1.4	35
1109	MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. <i>Journal of Neuro-Oncology</i> , 2011, 101, 405-417.	1.4	25
1110	Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 1-7.	1.4	85
1111	Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. <i>Journal of Neuro-Oncology</i> , 2011, 102, 157-162.	1.4	48
1112	Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2011, 102, 255-260.	1.4	47
1113	Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. <i>Journal of Neuro-Oncology</i> , 2011, 102, 311-316.	1.4	95
1114	A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 102, 417-424.	1.4	60
1115	High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D Pilot study. <i>Journal of Neuro-Oncology</i> , 2011, 102, 433-442.	1.4	43
1116	Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. <i>Journal of Neuro-Oncology</i> , 2011, 103, 43-58.	1.4	119
1117	Expression of O6-methylguanine-DNA methyltransferase in childhood medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 103, 59-69.	1.4	12
1118	Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas. <i>Journal of Neuro-Oncology</i> , 2011, 103, 207-219.	1.4	15
1119	Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 103, 343-351.	1.4	21
1120	Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. <i>Journal of Neuro-Oncology</i> , 2011, 103, 361-370.	1.4	71
1121	Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2011, 103, 585-593.	1.4	27
1122	PI3Kinase signaling in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 103, 417-427.	1.4	66
1123	Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 104, 261-269.	1.4	54
1124	Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults. <i>Journal of Neuro-Oncology</i> , 2011, 104, 293-303.	1.4	18

#	ARTICLE	IF	CITATIONS
1125	Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. <i>Journal of Neuro-Oncology</i> , 2011, 104, 339-349.	1.4	45
1126	A multicenter phase I trial of combination therapy with interferon- $\beta$ and temozolomide for high-grade gliomas (INTEGRA study): the final report. <i>Journal of Neuro-Oncology</i> , 2011, 104, 573-577.	1.4	37
1127	MGMT promoter methylation and immunoeexpression in aggressive pituitary adenomas and carcinomas. <i>Journal of Neuro-Oncology</i> , 2011, 104, 647-657.	1.4	54
1128	The natural history of extracranial metastasis from glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2011, 105, 261-273.	1.4	168
1129	Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2011, 105, 325-335.	1.4	70
1130	Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life. <i>Journal of Neuro-Oncology</i> , 2011, 105, 337-344.	1.4	45
1131	Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 397-400.	1.4	20
1132	The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: a clinicopathologic and immunohistochemical study of 12 cases at a single institution. <i>Journal of Neuro-Oncology</i> , 2011, 105, 563-572.	1.4	7
1133	Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 105, 607-612.	1.4	26
1134	Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme " Results from a pilot study. <i>Wiener Klinische Wochenschrift</i> , 2011, 123, 199-203.	1.0	29
1135	Prospective comparison of the prognostic utility of the Mini Mental State Examination and the Montreal Cognitive Assessment in patients with brain metastases. <i>Supportive Care in Cancer</i> , 2011, 19, 1849-1855.	1.0	49
1136	MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. <i>Child's Nervous System</i> , 2011, 27, 1877-1883.	0.6	28
1137	Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. <i>Acta Neuropathologica</i> , 2011, 122, 495-510.	3.9	125
1138	Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue. <i>Brain Tumor Pathology</i> , 2011, 28, 25-31.	1.1	21
1139	O6-Methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma. <i>Brain Tumor Pathology</i> , 2011, 28, 127-135.	1.1	29
1140	MGMT promoter methylation and temozolomide response in choroid plexus carcinoma. <i>Brain Tumor Pathology</i> , 2011, 28, 259-263.	1.1	13
1141	New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. <i>Brain Tumor Pathology</i> , 2011, 28, 203-208.	1.1	7
1142	Rechallenge with temozolomide in recurrent glioma. <i>Neurological Sciences</i> , 2011, 32, 247-249.	0.9	5

#	ARTICLE	IF	CITATIONS
1143	Neuropathological diagnosis of brain tumours. <i>Neurological Sciences</i> , 2011, 32, 209-211.	0.9	18
1146	Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 548-554.	1.0	18
1147	MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. <i>Journal of Molecular Medicine</i> , 2011, 89, 1037-1050.	1.7	75
1148	Epilepsy in the cancer patient. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 489-501.	1.1	50
1149	Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 69-79.	1.7	158
1150	Primary Brain Tumors in the Elderly Population. <i>Current Treatment Options in Neurology</i> , 2011, 13, 427-435.	0.7	8
1151	High-Grade Gliomas. <i>Current Treatment Options in Neurology</i> , 2011, 13, 386-399.	0.7	26
1152	Cancer Stem Cells: The Final Frontier for Glioma Virotherapy. <i>Stem Cell Reviews and Reports</i> , 2011, 7, 119-129.	5.6	38
1153	BTECH: A Platform to Integrate Genomic, Transcriptomic and Epigenomic Alterations in Brain Tumors. <i>Neuroinformatics</i> , 2011, 9, 59-67.	1.5	5
1154	Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients. <i>Clinical and Translational Oncology</i> , 2011, 13, 677-685.	1.2	34
1155	Expression and distribution characteristics of human ortholog of mammalian enabled (hMena) in glioma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2011, 23, 312-316.	0.7	4
1156	Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment. <i>Current Oncology Reports</i> , 2011, 13, 26-36.	1.8	5
1157	Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments. <i>Current Oncology Reports</i> , 2011, 13, 42-49.	1.8	21
1158	O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. <i>BMC Cancer</i> , 2011, 11, 35.	1.1	41
1159	Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. <i>Molecular Cancer</i> , 2011, 10, 128.	7.9	265
1160	Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?. <i>Radiation Oncology</i> , 2011, 6, 115.	1.2	99
1161	Current concepts and management of glioblastoma. <i>Annals of Neurology</i> , 2011, 70, 9-21.	2.8	380
1162	Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. <i>NMR in Biomedicine</i> , 2011, 24, 734-749.	1.6	81

#	ARTICLE	IF	CITATIONS
1163	The hunt for the epiallele. <i>Environmental and Molecular Mutagenesis</i> , 2011, 52, 1-11.	0.9	28
1164	Treatment of pituitary neoplasms with temozolomide. <i>Cancer</i> , 2011, 117, 454-462.	2.0	94
1165	Benefits of interferon- $\beta$ and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter. <i>Cancer</i> , 2011, 117, 1721-1730.	2.0	85
1166	Alpha-interneuron expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. <i>Cancer</i> , 2011, 117, 3014-3026.	2.0	32
1167	Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. <i>Cancer</i> , 2011, 117, 4617-4622.	2.0	233
1168	STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: A potential for targeted therapy?. <i>International Journal of Cancer</i> , 2011, 128, 826-838.	2.3	94
1169	Promoter methylation and expression of <i>MGMT</i> and the DNA mismatch repair genes <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> and <i>PMS2</i> in paired primary and recurrent glioblastomas. <i>International Journal of Cancer</i> , 2011, 129, 659-670.	2.3	247
1170	Prognostic Value of Early [18F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 176-184.	0.4	132
1171	Favorable Prognosis in Patients With High-Grade Glioma With Radiation Necrosis: The University of Colorado Reoperation Series. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 211-217.	0.4	37
1172	Treatment of Glioblastoma Multiforme with Radiotherapy and Concomitant and Adjuvant Temozolomide: Translation of Randomised Controlled Trial Evidence into Routine Clinical Practice. <i>Clinical Oncology</i> , 2011, 23, 372-373.	0.6	8
1173	The Unexpected Burden of Hypomagnesaemia in Gynaecology Chemotherapy Clinics. <i>Clinical Oncology</i> , 2011, 23, 373-374.	0.6	2
1174	Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. <i>Neurology</i> , 2011, 76, 1126-1134.	1.5	97
1175	Motexafin gadolinium: a promising radiation sensitizer in brain metastasis. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 195-203.	2.5	16
1176	Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. <i>Journal of Neurosurgery</i> , 2011, 114, 587-594.	0.9	156
1177	Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. <i>Journal of Neurosurgery</i> , 2011, 115, 220-229.	0.9	40
1178	Editorial: Low-grade gliomas. <i>Journal of Neurosurgery</i> , 2011, 115, 945-947.	0.9	4
1179	Neuro-oncology: a selected review of ASCO 2011 abstracts. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1371-1377.	1.4	1
1180	Treatment advances for glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1343-1345.	1.4	5

#	ARTICLE	IF	CITATIONS
1181	Intra-Arterial Chemotherapy for Malignant Gliomas: A Critical Analysis. <i>Interventional Neuroradiology</i> , 2011, 17, 286-295.	0.7	34
1182	Discovering neurosurgery: new frontiers. <i>Journal of Neurosurgery</i> , 2011, 115, 1053-1066.	0.9	1
1183	Epigenetic mechanisms regulating neural development and pediatric brain tumor formation. <i>Journal of Neurosurgery: Pediatrics</i> , 2011, 8, 119-132.	0.8	12
1184	Editorial: Epigenetics. <i>Journal of Neurosurgery: Pediatrics</i> , 2011, 8, 117.	0.8	0
1185	Evidence for Sequenced Molecular Evolution of <i>IDH1</i> Mutant Glioblastoma From a Distinct Cell of Origin. <i>Journal of Clinical Oncology</i> , 2011, 29, 4482-4490.	0.8	420
1187	Association of the CC genotype of the regulatory BCL2 promoter polymorphism ( $\sim 938C>A$ ) with better 2-year survival in patients with glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2011, 114, 1631-1639.	0.9	14
1188	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 324-333.	0.6	306
1189	DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma. <i>Journal of the National Cancer Institute</i> , 2011, 103, 143-153.	3.0	224
1190	Patients' and staff's experiences of multidisciplinary follow-up for high-grade glioma after radical radiotherapy. <i>Psychology, Health and Medicine</i> , 2011, 16, 357-365.	1.3	6
1191	Epigenetic Regulation of Gene Expression in Physiological and Pathological Brain Processes. <i>Physiological Reviews</i> , 2011, 91, 603-649.	13.1	315
1192	Oligodendroglioma Arising in the Region of the Pineal Gland. <i>Neurosurgery Quarterly</i> , 2011, 21, 226-230.	0.1	1
1193	Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. <i>Neuro-Oncology</i> , 2011, 13, 1244-1251.	0.6	85
1194	Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3611-3619.	0.8	135
1195	A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas. <i>Clinical Cancer Research</i> , 2011, 17, 317-327.	3.2	73
1196	Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. <i>Neuro-Oncology</i> , 2011, 13, 974-982.	0.6	154
1197	Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. <i>Neuro-Oncology</i> , 2011, 13, 487-499.	0.6	79
1198	How Fine a Slice: Treatment of Newly Diagnosed Glioblastoma With an Epidermal Growth Factor Receptor Variant III Peptide Vaccine. <i>Journal of Clinical Oncology</i> , 2011, 29, e517-e518.	0.8	4
1199	<i>NFKBIA</i> Deletion in Glioblastomas. <i>New England Journal of Medicine</i> , 2011, 364, 627-637.	13.9	220

#	ARTICLE	IF	CITATIONS
1201	Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3050-3055.	0.8	196
1202	A new frontier in personalized cancer therapy: mapping molecular changes. <i>Future Oncology</i> , 2011, 7, 873-894.	1.1	12
1203	The paradoxical effect of bevacizumab in the therapy of malignant gliomas. <i>Neurology</i> , 2011, 76, 87-93.	1.5	97
1204	The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. <i>Neuro-Oncology</i> , 2011, 13, 736-747.	0.6	92
1205	Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/S�azary Syndrome: Correlation with 6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins. <i>Clinical Cancer Research</i> , 2011, 17, 5748-5754.	3.2	29
1206	Next Generation Radiologic-Pathologic Correlation in Oncology: Rad-Path 2.0. <i>American Journal of Roentgenology</i> , 2011, 197, 990-997.	1.0	29
1207	Hot spots in dynamic 18F-FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. <i>Neuro-Oncology</i> , 2011, 13, 307-316.	0.6	215
1208	Epigenetic changes of DNA repair genes in cancer. <i>Journal of Molecular Cell Biology</i> , 2011, 3, 51-58.	1.5	168
1209	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. <i>Neuro-Oncology</i> , 2011, 13, 235-241.	0.6	60
1210	Essential Gene Pathways for Glioblastoma Stem Cells: Clinical Implications for Prevention of Tumor Recurrence. <i>Cancers</i> , 2011, 3, 1975-1995.	1.7	16
1211	Recent progress and clinical importance on pharmacogenetics in cancer therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1621-32.	1.4	10
1212	Achievement of Three Year Remission with Bevacizumab and Irinotecan in Recurrent Glioblastoma Multiforme: A case Report. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S6525.	0.6	5
1213	Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S7685.	0.6	34
1214	Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells. <i>International Journal of Radiation Biology</i> , 2011, 87, 192-201.	1.0	3
1215	Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma. <i>American Journal of Neuroradiology</i> , 2011, 32, 882-889.	1.2	167
1216	Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. <i>Neuro-Oncology</i> , 2011, 13, 84-98.	0.6	115
1217	Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres. <i>Clinical Cancer Research</i> , 2011, 17, 255-266.	3.2	75
1218	N-methylpurine DNA glycosylase and DNA polymerase $\beta$ modulate BER inhibitor potentiation of glioma cells to temozolomide. <i>Neuro-Oncology</i> , 2011, 13, 471-486.	0.6	100



#	ARTICLE	IF	CITATIONS
1219	Cilengitide: A Prototypic Integrin Inhibitor for the Treatment of Glioblastoma and Other Malignancies. <i>Genes and Cancer</i> , 2011, 2, 1159-1165.	0.6	63
1220	A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. <i>Journal of Experimental Medicine</i> , 2011, 208, 689-702.	4.2	77
1221	Targeting ErbB Receptors in High-Grade Glioma. <i>Current Pharmaceutical Design</i> , 2011, 17, 2468-2487.	0.9	36
1222	The changing face of brain tumours. <i>British Journal of Radiology</i> , 2011, 84, S79-S81.	1.0	0
1223	Towards Tailored Therapy of Glioblastoma Multiforme. <i>Journal of Chemotherapy</i> , 2011, 23, 187-199.	0.7	19
1224	Î2-catenin and Gli1 are prognostic markers in glioblastoma. <i>Cancer Biology and Therapy</i> , 2011, 11, 753-761.	1.5	107
1225	Oncogenic EGFR Signaling Activates an mTORC2â€“NF-Î®B Pathway That Promotes Chemotherapy Resistance. <i>Cancer Discovery</i> , 2011, 1, 524-538.	7.7	275
1226	A Combined Epigenetic Therapy Equals the Efficacy of Conventional Chemotherapy in Refractory Advanced Nonâ€“Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2011, 1, 557-559.	7.7	17
1227	DNA methylation in personalized medicine. <i>Personalized Medicine</i> , 2011, 8, 35-43.	0.8	4
1228	Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2011, 29, 142-148.	0.8	418
1229	Diagnostic Dilemma of Pseudoprogression in the Treatment of Newly Diagnosed Glioblastomas: The Role of Assessing Relative Cerebral Blood Flow Volume and Oxygen-6-Methylguanine-DNA Methyltransferase Promoter Methylation Status. <i>American Journal of Neuroradiology</i> , 2011, 32, 382-387.	1.2	178
1230	Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. <i>Neurology</i> , 2011, 77, 1156-1164.	1.5	267
1231	WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe. <i>Clinical Cancer Research</i> , 2011, 17, 4200-4207.	3.2	209
1232	Drug approval challenges in the age of personalized cancer treatment. <i>Personalized Medicine</i> , 2011, 8, 633-640.	0.8	4
1233	Recurrent high-grade glioma: a diagnostic and therapeutic challenge. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 509-518.	1.4	20
1234	Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. <i>British Journal of Cancer</i> , 2011, 105, 773-777.	2.9	34
1235	Advances in malignant glioma drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 739-753.	2.5	16
1236	Integrating Collection of Biospecimens in Clinical Trials: The Approach of the European Organization for Research and Treatment of Cancer. <i>Biopreservation and Biobanking</i> , 2011, 9, 181-186.	0.5	9

#	ARTICLE	IF	CITATIONS
1237	Novel ways to target brain tumour metabolism. Expert Opinion on Therapeutic Targets, 2011, 15, 1227-1239.	1.5	13
1238	Brief Report: Phase II Multicenter Study of Temozolomide in Patients with Cisplatin-Resistant Germ Cell Tumors. Oncology, 2011, 80, 219-222.	0.9	8
1239	A Hypermethylated Phenotype Is a Better Predictor of Survival than <i>MGMT</i> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951. Clinical Cancer Research, 2011, 17, 7148-7155.	3.2	107
1240	A promising cancer vaccine. Future Oncology, 2011, 7, 331-334.	1.1	1
1241	Genetic Alterations in Glioma. Cancers, 2011, 3, 1129-1140.	1.7	24
1242	The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma. Japanese Journal of Clinical Oncology, 2011, 41, 190-196.	0.6	11
1243	Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro-Oncology, 2011, 13, 317-323.	0.6	316
1244	Brain Cancer Stem Cells: Current Status on Glioblastoma Multiforme. Cancers, 2011, 3, 1777-1797.	1.7	75
1245	O <sup>6</sup> -methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: A review of current status. Neurology India, 2011, 59, 229.	0.2	17
1246	Neural Stem/Progenitors and Glioma Stem-Like Cells Have Differential Sensitivity to Chemotherapy. Neurology, 2011, 77, e135; author reply e135-6.	1.5	39
1247	NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neuro-Oncology, 2011, 13, 830-845.	0.6	60
1248	Innovative Therapies against Human Glioblastoma Multiforme. ISRN Oncology, 2011, 2011, 1-12.	2.1	11
1249	A review of PARP inhibitors: from bench to bedside. Annals of Oncology, 2011, 22, 268-279.	0.6	198
1250	Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Neuro-Oncology, 2011, 13, 546-557.	0.6	40
1251	Les tumeurs gliales malignes de l'adulte. , 2011, , 591-612.		0
1252	Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro-Oncology, 2012, 14, 109-116.	0.6	36
1253	O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions. International Journal of Molecular Sciences, 2012, 13, 6983-6994.	1.8	47
1254	Enhancement of the radiation response of EMT-6 tumours by a copper octabromotetracarboranylphenylporphyrin. British Journal of Radiology, 2012, 85, 443-450.	1.0	8

#	ARTICLE	IF	CITATIONS
1255	What to do when there is no standard of care: A brief review of treatment options for glioblastoma in children. <i>Journal of Neurosciences in Rural Practice</i> , 2012, 03, 113-114.	0.3	0
1256	Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide. <i>Frontiers in Oncology</i> , 2012, 2, 99.	1.3	3
1257	Case 17-2012. <i>New England Journal of Medicine</i> , 2012, 366, 2112-2120.	13.9	3
1258	Status of O <sup>6</sup> -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India. <i>Neurology India</i> , 2012, 60, 481.	0.2	10
1259	The strategy for enhancing temozolomide against malignant glioma. <i>Frontiers in Oncology</i> , 2012, 2, 98.	1.3	48
1260	Integrins and p53 pathways in glioblastoma resistance to temozolomide. <i>Frontiers in Oncology</i> , 2012, 2, 157.	1.3	30
1261	MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma. <i>Clinical Cancer Research</i> , 2012, 18, 3030-3041.	3.2	46
1262	Molecular biology of brain tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 23-34.	1.0	11
1263	Molecularly targeted therapy in neuro-oncology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 255-278.	1.0	9
1264	Complications of chemotherapy in neuro-oncology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 873-885.	1.0	9
1265	Ataxia resulting from posterior fossa tumors of childhood and other mass lesions. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 103, 161-173.	1.0	4
1266	Multiple oligodendroglioma with pseudoprogression. <i>Journal of Neurosciences in Rural Practice</i> , 2012, 03, 379-382.	0.3	0
1267	Cellular-Based Immunotherapies for Patients with Glioblastoma Multiforme. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-15.	3.3	17
1268	Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide. <i>Frontiers in Oncology</i> , 2012, 2, 176.	1.3	43
1269	A phase I/II trial of vandetanib for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2012, 14, 1519-1526.	0.6	80
1270	Novel Therapies in Glioblastoma. <i>Neurology Research International</i> , 2012, 2012, 1-14.	0.5	46
1271	DNA Methylation As a Clinical Marker in Oncology. <i>Journal of Clinical Oncology</i> , 2012, 30, 2566-2568.	0.8	48
1272	Management of brain tumors in the pediatric patient. , 2012, , 329-346.		2

#	ARTICLE	IF	CITATIONS
1273	<i>BRCA1</i> epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. <i>Epigenetics</i> , 2012, 7, 1225-1229.	1.3	113
1274	Key concepts in glioblastoma therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 753-760.	0.9	69
1275	Assessment of Treatment Response in Patients with Glioblastoma Using $^{18}\text{F}$ -Fluoroethyl-L-Tyrosine PET in Comparison to MRI. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1048-1057.	2.8	184
1276	La formalisation de la GRH dans une PME comme enjeu d'une certification RSE. <i>Revue De Gestion Des Ressources Humaines</i> , 2012, N° 83, 20-30.	0.1	8
1277	Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. <i>Neuro-Oncology</i> , 2012, 14, 351-359.	0.6	76
1278	STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1289-1299.	1.9	159
1279	A clinical review of treatment outcomes in glioblastoma multiforme—the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?. <i>British Journal of Radiology</i> , 2012, 85, e729-e733.	1.0	144
1280	Gene and Viral Therapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 82-88.	1.0	38
1281	Treatment Outcome of Elderly Patients With Glioblastoma who Received Combination Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 486-489.	0.6	4
1282	Prime time for molecular marker diagnostics in neuro-oncology. <i>Current Opinion in Neurology</i> , 2012, 25, 743-744.	1.8	2
1283	Management of Malignant Gliomas and Primary CNS Lymphoma. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2012, 18, 406-415.	0.4	10
1284	Molecular predictors of outcome in low-grade glioma. <i>Current Opinion in Neurology</i> , 2012, 25, 767-773.	1.8	54
1285	Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 12-19.	1.0	60
1286	Individualized Targeted Therapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 40-44.	1.0	64
1287	Temozolomide plus radiotherapy for glioblastoma in a Canadian province: Efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 229-238.	0.5	15
1288	Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). <i>Neuro-Oncology</i> , 2012, 14, 798-807.	0.6	26
1289	Chemotherapy with cytotoxic and cytostatic agents in brain cancer. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012, 104, 229-254.	1.0	9
1290	Recent Surgical Management of Gliomas. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 12-25.	0.8	57

#	ARTICLE	IF	CITATIONS
1291	Chemotherapy for Brain Tumors. , 2012, , 94-104.		0
1292	Surgical management of high-grade glioma: a standard of care. CNS Oncology, 2012, 1, 181-192.	1.2	7
1293	Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro. Cell Cycle, 2012, 11, 2660-2671.	1.3	64
1294	Therapeutic Kinase Inhibitors. Current Topics in Microbiology and Immunology, 2012, , .	0.7	1
1295	Glioblastomaâ€™community adjusts to new standard of care. Nature Reviews Neurology, 2012, 8, 244-246.	4.9	3
1296	Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT. Current Medicinal Chemistry, 2012, 19, 3886-3892.	1.2	29
1297	Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy. Current Molecular Medicine, 2012, 12, 788-803.	0.6	5
1298	Image guidance in malignant gliomas: a focused strategy. CNS Oncology, 2012, 1, 131-136.	1.2	0
1299	Targeted Therapy for Brain Tumours: Role of PARP Inhibitors. Current Cancer Drug Targets, 2012, 12, 218-236.	0.8	23
1300	Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas. Current Cancer Drug Targets, 2012, 12, 1016-1031.	0.8	19
1301	Treating glioblastoma in the elderly. CNS Oncology, 2012, 1, 193-201.	1.2	6
1302	Supportive follow-up in patients treated with radical intent for high-grade glioma. CNS Oncology, 2012, 1, 39-48.	1.2	9
1303	Biomarkers usher in era of personalized care for malignant glioma patients. CNS Oncology, 2012, 1, 3-6.	1.2	1
1304	Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis. Journal of Neurosurgery, 2012, 117, 476-485.	0.9	9
1305	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 2012, 14, iv100-iv108.	0.6	154
1306	Enhancing Diagnosis, Prognosis, and Therapeutic Outcome Prediction of Gliomas Using Genomics. OMICS A Journal of Integrative Biology, 2012, 16, 113-122.	1.0	27
1307	Anaplastic astrocytomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 451-466.	1.0	1
1308	Anaplastic oligodendroglial tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 467-484.	1.0	4

#	ARTICLE	IF	CITATIONS
1309	Treatment-Related Change Versus Tumor Recurrence in High-Grade Gliomas: A Diagnostic Conundrum—Use of Dynamic Susceptibility Contrast-Enhanced (DSC) Perfusion MRI. <i>American Journal of Roentgenology</i> , 2012, 198, 19-26.	1.0	131
1310	Personalized Cancer Medicine. , 2012, , 257-282.		2
1311	HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2012, 14, i56-i68.	0.6	2
1312	The potential of PARP inhibitors in neuro-oncology. <i>CNS Oncology</i> , 2012, 1, 85-97.	1.2	12
1313	Methylation profile of triple-negative breast carcinomas. <i>Oncogenesis</i> , 2012, 1, e17-e17.	2.1	50
1314	Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. <i>Oncogene</i> , 2012, 31, 1995-2006.	2.6	42
1315	Methylation-sensitive high-resolution melting in the context of legislative requirements for validation of analytical procedures for diagnostic applications. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 39-47.	1.5	19
1317	Increased Immune Gene Expression and Immune Cell Infiltration in High-Grade Astrocytoma Distinguish Long-Term from Short-Term Survivors. <i>Journal of Immunology</i> , 2012, 189, 1920-1927.	0.4	62
1318	Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker. <i>Clinical Cancer Research</i> , 2012, 18, 1138-1145.	3.2	151
1319	Pushing the Limits of Glioma Resection Using Electrophysiologic Brain Mapping. <i>Journal of Clinical Oncology</i> , 2012, 30, 2437-2440.	0.8	3
1320	Deletion or Epigenetic Silencing of <i>AJAP1</i> on 1p36 in Glioblastoma. <i>Molecular Cancer Research</i> , 2012, 10, 208-217.	1.5	34
1321	State of the art and perspectives in the treatment of glioblastoma. <i>CNS Oncology</i> , 2012, 1, 49-70.	1.2	5
1322	Hedgehog signaling in glioblastoma multiforme. <i>Cancer Biology and Therapy</i> , 2012, 13, 487-495.	1.5	36
1323	Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 808-816.	0.6	96
1324	miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. <i>Neuro-Oncology</i> , 2012, 14, 712-719.	0.6	167
1325	A High Frequency of MSH6 G268A Polymorphism and Survival Association in Glioblastoma. <i>International Journal of Neuroscience</i> , 2012, 123, 114-120.	0.8	9
1326	Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. <i>Neuro-Oncology</i> , 2012, 14, 518-525.	0.6	61
1329	Moving toward molecular classification of diffuse gliomas in adults. <i>Neurology</i> , 2012, 79, 1917-1926.	1.5	70

#	ARTICLE	IF	CITATIONS
1330	Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-9.	3.0	90
1331	Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events. <i>Journal of Signal Transduction</i> , 2012, 2012, 1-9.	2.0	13
1332	Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	100
1333	The Role of Radiotherapy and Chemotherapy in the Treatment of Primary Adult High Grade Gliomas: Assessment of Patients for These Treatment Approaches and the Common Immediate Side Effects. <i>ISRN Oncology</i> , 2012, 2012, 1-6.	2.1	9
1334	Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. <i>Frontiers in Oncology</i> , 2012, 2, 186.	1.3	88
1335	Treatment of Progressive Brain Stem Glioma With Bevacizumab: Radiological, Metabolic and Histopathological Aspects. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2012, 73, 187-191.	0.4	0
1336	Studying a Complex Tumor. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 107-114.	1.0	26
1337	Randomized Phase II Trial Designs With Biomarkers. <i>Journal of Clinical Oncology</i> , 2012, 30, 3304-3309.	0.8	86
1339	Anti-VEGF Strategies “ from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer. <i>Current Pharmaceutical Design</i> , 2012, 18, 2680-2701.	0.9	20
1340	Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF- $\kappa$ B-dependent pathway. <i>Oncology Reports</i> , 2012, 27, 2050-6.	1.2	67
1341	Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab. <i>Experimental and Therapeutic Medicine</i> , 2012, 4, 151-157.	0.8	35
1344	Resistance to Hypoxia-Induced, BNIP3-Mediated Cell Death Contributes to an Increase in a CD133-Positive Cell Population in Human Glioblastomas In Vitro. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 1086-1099.	0.9	21
1345	A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 796-802.	0.7	32
1346	Coplanar versus noncoplanar intensityâ€modulated radiation therapy (IMRT) and volumetricâ€modulated arc therapy (VMAT) treatment planning for frontoâ€temporal highâ€grade glioma. <i>Journal of Applied Clinical Medical Physics</i> , 2012, 13, 44-53.	0.8	44
1347	Effectiveness of Maximal Safe Resection for Glioblastoma Including Elderly and Low Karnofsky Performance Status Patients: Retrospective Review at a Single Institute. <i>Neurologia Medico-Chirurgica</i> , 2012, 52, 570-576.	1.0	18
1348	LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation. <i>Oncology Reports</i> , 2012, 28, 2271-2277.	1.2	7
1349	Surgical Resection and Glioblastoma: Molecular Profiling and Safety. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 561-562.	0.3	3
1350	Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. <i>Oncology Reports</i> , 2012, 28, 654-658.	1.2	29

#	ARTICLE	IF	CITATIONS
1353	Primary brain tumours in adults. <i>Lancet, The</i> , 2012, 379, 1984-1996.	6.3	723
1354	DNA repair dysregulation from cancer driver to therapeutic target. <i>Nature Reviews Cancer</i> , 2012, 12, 801-817.	12.8	851
1355	DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 231-241.	2.1	20
1356	Atypical Teratoid Rhabdoid Tumors (ATRTs): The British Columbia's Children's Hospital's Experience, 1986-2006. <i>Brain Pathology</i> , 2012, 22, 625-635.	2.1	29
1357	Recent Medical Management of Glioblastoma. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 26-40.	0.8	20
1358	Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1458-1469.	3.0	56
1359	FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene <i>Rad51</i> . <i>Clinical Cancer Research</i> , 2012, 18, 5961-5971.	3.2	92
1360	Aldehyde dehydrogenase 1A1 is a new mediator of resistance to temozolomide in glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 1452-1464.	0.6	80
1361	MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1789-1797.	1.2	23
1362	Transfection of a human glioblastoma cell line with liver-type glutaminase ( <i>LGA</i> ) downregulates the expression of DNA repair gene <i>MGMT</i> and sensitizes the cells to alkylating agents. <i>Journal of Neurochemistry</i> , 2012, 123, 428-436.	2.1	26
1363	Prospective, high-throughput molecular profiling of human gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 89-98.	1.4	47
1364	Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1391-1415.	1.9	63
1365	Gene therapy for brain tumors: Basic developments and clinical implementation. <i>Neuroscience Letters</i> , 2012, 527, 71-77.	1.0	53
1366	Anti-angiogenic gene therapy in the treatment of malignant gliomas. <i>Neuroscience Letters</i> , 2012, 527, 62-70.	1.0	53
1367	Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2033-2044.	2.0	136
1368	Galectins as Novel Targets for the Treatment of Malignant Gliomas. <i>ACS Symposium Series</i> , 2012, , 171-180.	0.5	0
1369	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2012, 13, 916-926.	5.1	1,075
1370	Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. <i>Cancer</i> , 2012, 118, 5595-5600.	2.0	95



#	ARTICLE	IF	CITATIONS
1371	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 707-715.	5.1	980
1372	Pathology: Commonly Monitored Glioblastoma Markers: EGFR, EGFRvIII, PTEN, and MGMT. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 237-246.	0.8	24
1373	Unique biology of gliomas: challenges and opportunities. <i>Trends in Neurosciences</i> , 2012, 35, 546-556.	4.2	67
1374	Magnetic Resonance Imaging and Computed Tomography Findings in Pediatric Giant Cell Glioblastoma. <i>Clinical Neuroradiology</i> , 2012, 22, 359-363.	1.0	6
1375	Molecular markers of glioma: an update on recent progress and perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1971-1981.	1.2	51
1376	Pathological findings and prognostic factors in recurrent glioblastomas. <i>Brain Tumor Pathology</i> , 2012, 29, 192-200.	1.1	22
1377	Weekly low-dose Semustine in a patient with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) coupled with subcutaneous involvement and positive O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. <i>Chinese-German Journal of Clinical Oncology</i> , 2012, 11, 544-547.	0.1	0
1378	Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 109, 391-397.	1.4	58
1379	Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. <i>Journal of Neuro-Oncology</i> , 2012, 109, 467-475.	1.4	37
1380	Nuclear karyopherin $\alpha 2$ : a novel biomarker for infiltrative astrocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 545-553.	1.4	49
1381	Chemosensitized radiosurgery for recurrent brain metastases. <i>Journal of Neuro-Oncology</i> , 2012, 110, 265-270.	1.4	2
1382	Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 279-285.	1.4	29
1383	The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 325-333.	1.4	69
1384	ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. <i>Journal of Neuro-Oncology</i> , 2012, 110, 349-357.	1.4	54
1385	Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. <i>Pituitary</i> , 2012, 15, 276-287.	1.6	54
1386	Retrospective Comparison of Chemoradiotherapy Followed by Adjuvant Chemotherapy, With or Without Prior Gliadel Implantation (Carmustine) After Initial Surgery in Patients With Newly Diagnosed High-Grade Gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 749-755.	0.4	65
1387	Phase II Study of Short-Course Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Elderly Patients With Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 93-99.	0.4	129
1388	MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated With Temozolomide-Based Chemoradiotherapy: A Single-Institution Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 661-667.	0.4	51

#	ARTICLE	IF	CITATIONS
1389	Gamma Knife Surgery versus Reoperation for Recurrent Glioblastoma Multiforme. World Neurosurgery, 2012, 78, 658-669.	0.7	98
1390	Terapie molecolari mirate e antiangiogeniche nel trattamento dei glioblastomi. EMC - Neurologia, 2012, 12, 1-14.	0.0	0
1391	Clinical Management of Pituitary Carcinomas. Neurosurgery Clinics of North America, 2012, 23, 595-606.	0.8	13
1392	Management of Large Aggressive Nonfunctional Pituitary Tumors. Neurosurgery Clinics of North America, 2012, 23, 587-594.	0.8	5
1393	Hallazgos neurorradiológicos en la fase inicial del desarrollo de astrocitomas corticales de alto grado de malignidad. Radiologia, 2012, 54, 424-431.	0.3	3
1394	Plasmacytoid Dendritic Cells in the Tumor Microenvironment: Immune Targets for Glioma Therapeutics. Neoplasia, 2012, 14, 757-IN26.	2.3	46
1395	Recent developments on immunotherapy for brain cancer. Expert Opinion on Emerging Drugs, 2012, 17, 181-202.	1.0	56
1396	Pharmacogene regulatory elements: from discovery to applications. Genome Medicine, 2012, 4, 45.	3.6	18
1397	Epidemiology of primary central nervous system tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 3-22.	1.0	18
1398	O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme. Molecular Cancer Therapeutics, 2012, 11, 2440-2450.	1.9	21
1399	Chemoprotection in glioblastoma therapy: reality or a dream?. CNS Oncology, 2012, 1, 11-14.	1.2	0
1400	Clinical trials in neuro-oncology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 417-434.	1.0	1
1401	Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. Expert Review of Clinical Pharmacology, 2012, 5, 173-186.	1.3	114
1402	Brain Tumors in Children. Current Problems in Pediatric and Adolescent Health Care, 2012, 42, 80-103.	0.8	53
1403	DNA methylation profiling in the clinic: applications and challenges. Nature Reviews Genetics, 2012, 13, 679-692.	7.7	675
1404	Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Journal of Neurochemistry, 2012, 122, 444-455.	2.1	120
1405	Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Review of Anticancer Therapy, 2012, 12, 635-642.	1.1	109
1406	Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?. Journal of Hepatology, 2012, 56, 686-695.	1.8	161

#	ARTICLE	IF	CITATIONS
1407	Novel Therapeutic Approaches for Small Cell Lung Cancer: The Future has Arrived. <i>Current Problems in Cancer</i> , 2012, 36, 156-173.	1.0	6
1408	Glioblastoma: Clinical characteristics, prognostic factors and survival in 492 patients. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 840-845.	0.6	133
1409	Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 299-306.	0.6	17
1410	Folate supplementation limits the tumourigenesis in rodent models of gliomagenesis. <i>European Journal of Cancer</i> , 2012, 48, 2431-2441.	1.3	22
1411	New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. <i>European Journal of Cancer</i> , 2012, 48, 1176-1184.	1.3	161
1412	Glioma Revisited: From Neurogenesis and Cancer Stem Cells to the Epigenetic Regulation of the Niche. <i>Journal of Oncology</i> , 2012, 2012, 1-20.	0.6	40
1413	Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1247-1266.	1.9	50
1414	Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 307-322.	0.8	66
1415	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. <i>Acta Neuropathologica</i> , 2012, 124, 547-560.	3.9	274
1416	LRpath analysis reveals common pathways dysregulated via DNA methylation across cancer types. <i>BMC Genomics</i> , 2012, 13, 526.	1.2	65
1417	MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma. <i>BMC Cancer</i> , 2012, 12, 218.	1.1	60
1418	Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. <i>Molecular Cancer</i> , 2012, 11, 20.	7.9	34
1419	MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. <i>Journal of Translational Medicine</i> , 2012, 10, 250.	1.8	68
1420	A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. <i>Journal of Translational Medicine</i> , 2012, 10, 90.	1.8	12
1421	MGMT. , 2012, , 17-28.		3
1422	The emerging role of DNA methylation in epileptogenesis. <i>Epilepsia</i> , 2012, 53, 11-20.	2.6	82
1423	Genetics of adult glioma. <i>Cancer Genetics</i> , 2012, 205, 613-621.	0.2	737
1424	Epigenetic Epidemiology of Cancer. , 2012, , 225-267.		0

#	ARTICLE	IF	CITATIONS
1425	Epigenetic Alterations in Glioblastoma Multiforme. , 2012, , 71-90.		1
1426	Radiopeptide Therapy of Brain Tumors. Medical Radiology, 2012, , 199-205.	0.0	0
1427	Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). Experimental and Therapeutic Medicine, 2012, 3, 9-14.	0.8	72
1428	Topoisomerase I Inhibitors: Current Use and Prospects. Cancer Drug Discovery and Development, 2012, , 245-277.	0.2	2
1429	Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China. PLoS ONE, 2012, 7, e30339.	1.1	114
1430	A Simplified Approach for the Molecular Classification of Glioblastomas. PLoS ONE, 2012, 7, e45475.	1.1	52
1431	Overview of Primary Brain Tumors. Hematology/Oncology Clinics of North America, 2012, 26, 715-732.	0.9	29
1432	Glioblastoma biomarkers from bench to bedside: advances and challenges. British Journal of Neurosurgery, 2012, 26, 189-194.	0.4	22
1433	A novel treatment for glioblastoma: integrin inhibition. Expert Review of Neurotherapeutics, 2012, 12, 421-435.	1.4	34
1434	Methylation in Malignant Astrocytomas. , 2012, , 3-12.		0
1435	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. European Journal of Cancer, Supplement, 2012, 10, 20-26.	2.2	0
1436	EORTC-related new drug discovery and development activities: role of the Pharmacology and Molecular Mechanisms Group. European Journal of Cancer, Supplement, 2012, 10, 128-140.	2.2	1
1437	EORTC Radiation Oncology Group: 50 years of continuous accomplishments. European Journal of Cancer, Supplement, 2012, 10, 150-159.	2.2	3
1438	Elderly people with glioblastoma. Lancet Oncology, The, 2012, 13, e328-e329.	5.1	0
1439	DNA methylation based biomarkers: Practical considerations and applications. Biochimie, 2012, 94, 2314-2337.	1.3	139
1440	Recent developments in the treatment of high-grade gliomas. Community Oncology, 2012, 9, 307-314.	0.2	0
1441	Treatment of elderly patients with glioblastoma: From clinical evidence to molecular highlights. Cancer Treatment Reviews, 2012, 38, 988-995.	3.4	24
1442	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. NeuroImage, 2012, 59, 908-916.	2.1	128

#	ARTICLE	IF	CITATIONS
1443	Neuroimaging findings in the initial phase of development of high grade cortical astrocytomas. <i>Radiologia</i> , 2012, 54, 424-431.	0.3	1
1444	Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: From bedside to bench. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1568-1572.	0.8	32
1446	Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients – yes, but how?., 2012, 31, 405-408.		19
1447	Pseudoprogression and Treatment Effect. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 277-287.	0.8	27
1448	Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients. <i>Journal of Neurosurgery</i> , 2012, 117, 204-211.	0.9	48
1449	Malignancies of the Spinal Cord. <i>Advances in Experimental Medicine and Biology</i> , 2012, 760, 101-113.	0.8	8
1450	Streptozocin-based chemotherapy is not history in neuroendocrine tumours. <i>Targeted Oncology</i> , 2012, 7, 161-168.	1.7	22
1451	The Spectrum of Vaccine Therapies for Patients With Glioblastoma Multiforme. <i>Current Treatment Options in Oncology</i> , 2012, 13, 437-450.	1.3	20
1452	Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas. <i>Current Treatment Options in Oncology</i> , 2012, 13, 417-436.	1.3	25
1453	Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. <i>Medical Oncology</i> , 2012, 29, 3478-3483.	1.2	44
1454	Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas. <i>Cell Stress and Chaperones</i> , 2012, 17, 779-790.	1.2	7
1455	Quality of Life and Outcomes in Glioblastoma Management. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 507-513.	0.8	5
1456	Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro. <i>Oncogene</i> , 2012, 31, 3409-3418.	2.6	38
1461	Antitumour imidazotetrazines. Synthesis and chemistry of 4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide (nor-temozolomide): an intermediate for the preparation of the antitumour drug temozolomide and analogues, avoiding the use of isocyanates. <i>MedChemComm</i> , 2012, 3, 1419.	3.5	10
1464	<i>In Vitro</i> Evaluation of Combined Temozolomide and Radiotherapy Using X-rays and High-Linear Energy Transfer Radiation for Glioblastoma. <i>Radiation Research</i> , 2012, 177, 651-662.	0.7	32
1465	Management of Multifocal and Multicentric Gliomas. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 343-350.	0.8	22
1466	Stem Cells and Cancer Stem Cells, Volume 3. , 2012, , .		2
1467	Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index. <i>Radiation Oncology</i> , 2012, 7, 104.	1.2	17

#	ARTICLE	IF	CITATIONS
1468	Relationship Between Molecular Oncology and Radiotherapy in Malignant Gliomas (An Overview). , 2012, , 103-110.		0
1469	Alternative Chemotherapeutic Agents: Nitrosoureas, Cisplatin, Irinotecan. Neurosurgery Clinics of North America, 2012, 23, 297-306.	0.8	16
1471	Malignant Astrocytomas of the Spinal Cord: Clinicopathologic Parameters. , 2012, , 35-41.		0
1472	Potential Usefulness of Radiosensitizers in Glioblastoma. Neurosurgery Clinics of North America, 2012, 23, 429-437.	0.8	6
1473	Glioblastoma and malignant astrocytoma. , 2012, , 384-407.		3
1474	The Role of Adjuvant Radiation Therapy in the Management of High-Grade Gliomas. Neurosurgery Clinics of North America, 2012, 23, 247-258.	0.8	8
1475	O6-methylguanine-DNA methyltransferase (MGMT) Promoter methylation is a rare event in soft tissue sarcoma. Radiation Oncology, 2012, 7, 180.	1.2	5
1476	Expression Signature of IFN/STAT1 Signaling Genes Predicts Poor Survival Outcome in Glioblastoma Multiforme in a Subtype-Specific Manner. PLoS ONE, 2012, 7, e29653.	1.1	118
1477	Use of a Deformable Atlas to Identify Cryptic Critical Structures in the Treatment of Glioblastoma Multiforme. PLoS ONE, 2012, 7, e32098.	1.1	4
1478	Subgroup Economic Analysis for Glioblastoma in a Health Resource-Limited Setting. PLoS ONE, 2012, 7, e34588.	1.1	29
1479	Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event. PLoS ONE, 2012, 7, e41298.	1.1	43
1480	A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature. PLoS ONE, 2012, 7, e41522.	1.1	82
1481	Expression of Eukaryotic Initiation Factor 5A and Hypusine Forming Enzymes in Glioblastoma Patient Samples: Implications for New Targeted Therapies. PLoS ONE, 2012, 7, e43468.	1.1	53
1482	Fasting Enhances the Response of Glioma to Chemo- and Radiotherapy. PLoS ONE, 2012, 7, e44603.	1.1	169
1483	MIR-328 Expression Is Decreased in High-Grade Gliomas and Is Associated with Worse Survival in Primary Glioblastoma. PLoS ONE, 2012, 7, e47270.	1.1	53
1484	Clinical trials and chemotherapy. , 2012, , 306-315.		0
1485	Whole Brain Radiation-Induced Cognitive Impairment: Pathophysiological Mechanisms and Therapeutic Targets. Biomolecules and Therapeutics, 2012, 20, 357-370.	1.1	68
1486	Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas. Journal of Oncology, 2012, 2012, 1-12.	0.6	12

#	ARTICLE	IF	CITATIONS
1487	The Limitations of Locus Specific Methylation Qualification and Quantification in Clinical Material. <i>Frontiers in Genetics</i> , 2012, 3, 21.	1.1	10
1488	Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. <i>Folia Neuropathologica</i> , 2012, 4, 301-321.	0.5	80
1489	DNA Methylation in the Pathogenesis of Head and Neck Cancer. , 0, , .		3
1490	Gliomas: marcadores tumorais e prognóstico. <i>Brazilian Neurosurgery</i> , 2012, 31, 91-94.	0.0	1
1491	Glioblastoma: Biology, Genetics, and Behavior. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 102-107.	1.8	11
1492	Establishing the Standard of Care for Patients with Newly Diagnosed and Recurrent Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 112-117.	1.8	0
1493	Current Concepts in Brain Tumor Imaging. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 119-124.	1.8	3
1494	Future Directions in Glioblastoma Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 108-111.	1.8	2
1495	Glioblastoma: approach to treat elderly patients. <i>Einstein (Sao Paulo, Brazil)</i> , 2012, 10, 512-518.	0.3	7
1496	Does Neurologic Deterioration Help to Differentiate between Pseudoprogression and True Disease Progression in Newly Diagnosed Glioblastoma Multiforme?. <i>Current Oncology</i> , 2012, 19, 295-298.	0.9	6
1497	Genomic instability of surgical sample and cancer-initiating cell lines from human glioblastoma. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 1469.	3.0	10
1498	Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 1.	0.8	36
1499	The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma. <i>Oncology Letters</i> , 2012, 4, 551-555.	0.8	6
1500	Survival in Patients with Newly Diagnosed Conventional Glioblastoma: A Modified Prognostic Score Based on a Single-Institution Series. <i>Tumori</i> , 2012, 98, 756-761.	0.6	4
1501	Temozolomide in aggressive pituitary adenomas and carcinomas. <i>Clinics</i> , 2012, 67, 119-123.	0.6	42
1502	Molecular biomarkers of glioblastoma: current targets and clinical implications. <i>Current Biomarker Findings</i> , 0, , 63.	0.4	4
1503	Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF- $\kappa$ B/MMP-9 pathway. <i>Journal of Pathology</i> , 2012, 226, 534-543.	2.1	33
1504	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. <i>Nature</i> , 2012, 483, 479-483.	13.7	1,668

#	ARTICLE	IF	CITATIONS
1505	The Epigenetics of Brain Tumors. <i>Methods in Molecular Biology</i> , 2012, 863, 139-153.	0.4	38
1506	DNA methylation biomarkers in cancer: progress towards clinical implementation. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 473-487.	1.5	146
1507	DNA methylation testing and marker validation using PCR: diagnostic applications. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 75-92.	1.5	24
1508	Genetics and Epigenetics of the Skin Meet Deep Sequence. <i>Journal of Investigative Dermatology</i> , 2012, 132, 923-932.	0.3	15
1509	Clinically useful biomarkers in neurooncology. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 201-204.	0.3	1
1510	A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. <i>Epigenetics</i> , 2012, 7, 772-780.	1.3	64
1511	Molecular Biology of Glioma. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 2-11.	0.8	58
1512	Emerging insights into the molecular and cellular basis of glioblastoma. <i>Genes and Development</i> , 2012, 26, 756-784.	2.7	463
1513	Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1036-1044.	0.9	17
1514	Frequent epigenetic inactivation of the chaperone <i>SGNE1</i> in human gliomas. <i>International Journal of Cancer</i> , 2012, 131, 612-622.	2.3	8
1515	<i>MGMT</i> CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with <i>IDH1</i> or <i>IDH2</i> mutations. <i>International Journal of Cancer</i> , 2012, 131, 1104-1113.	2.3	78
1516	Predictive impact of <i>MGMT</i> promoter methylation in glioblastoma of the elderly. <i>International Journal of Cancer</i> , 2012, 131, 1342-1350.	2.3	220
1517	Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors. <i>International Journal of Cancer</i> , 2012, 131, 1577-1590.	2.3	133
1518	Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. <i>Future Oncology</i> , 2012, 8, 549-558.	1.1	18
1519	Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to <i>MGMT</i> Upregulation in Glioblastoma Xenografts. <i>Clinical Cancer Research</i> , 2012, 18, 4070-4079.	3.2	127
1520	Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight,) Tj ETQq1 1 0.784314 rgBT /Over O6-methylguanine-DNA-methyltransferase in a series of 100 glioblastoma patients. <i>Cancer</i> , 2012, 118, 4201-4211.	2.0	172
1521	O6-methylguanine-DNA methyltransferase ( <i>MGMT</i> ) promoter methylation and low <i>MGMT</i> -encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. <i>Cancer</i> , 2012, 118, 4545-4554.	2.0	79
1522	A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). <i>Cancer</i> , 2012, 118, 5601-5607.	2.0	112



#	ARTICLE	IF	CITATIONS
1523	Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. <i>Neuro-Oncology</i> , 2012, 14, 132-144.	0.6	185
1524	Glioblastoma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 485-506.	1.0	18
1525	Glioma Stem Cells and their Therapy Resistance. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2012, 01, .	0.3	4
1526	Neuronal stem cells in the central nervous system and in human diseases. <i>Protein and Cell</i> , 2012, 3, 262-270.	4.8	11
1527	Targeting DNA repair and the cell cycle in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 107, 463-477.	1.4	32
1528	MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. <i>Journal of Neuro-Oncology</i> , 2012, 107, 617-631.	1.4	52
1529	Clinicopathologic and genomic features of gliosarcomas. <i>Journal of Neuro-Oncology</i> , 2012, 107, 643-650.	1.4	48
1530	Recent advances in the molecular understanding of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 108, 11-27.	1.4	358
1531	Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. <i>Journal of Neuro-Oncology</i> , 2012, 108, 89-97.	1.4	120
1532	Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2012, 108, 173-177.	1.4	60
1533	Dose dense 1Âweek on/1Âweek off temozolomide in recurrent glioma: a retrospective study. <i>Journal of Neuro-Oncology</i> , 2012, 108, 195-200.	1.4	34
1534	Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. <i>Journal of Neuro-Oncology</i> , 2012, 109, 45-52.	1.4	41
1535	Temozolomide for Pediatric High-Grade Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 111-113.	2.0	1
1536	Temozolomide Dosing Regimens for Glioma Patients. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 286-293.	2.0	34
1537	Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 302-307.	2.0	21
1538	Anaplastic Glioma. <i>Current Treatment Options in Neurology</i> , 2012, 14, 381-390.	0.7	14
1539	Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. <i>Medical Oncology</i> , 2012, 29, 1292-1296.	1.2	28
1540	Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. <i>Neuroradiology</i> , 2012, 54, 555-563.	1.1	111

#	ARTICLE	IF	CITATIONS
1541	Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. <i>Neuroradiology</i> , 2012, 54, 641-643.	1.1	21
1542	Prognostic significance of MRP5 immunohistochemical expression in glioblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1387-1391.	1.1	18
1543	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. <i>Acta Neuropathologica</i> , 2012, 123, 841-852.	3.9	77
1544	Temozolomide and radiotherapy in newly diagnosed glioblastoma patients: O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and Ki-67 as biomarkers for survival and response to treatment. <i>Chinese-German Journal of Clinical Oncology</i> , 2012, 11, 168-176.	0.1	4
1545	Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 131-137.	1.1	35
1546	Challenges in drug delivery to tumors of the central nervous system: An overview of pharmacological and surgical considerations. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 590-597.	6.6	95
1547	Balancing repair and tolerance of DNA damage caused by alkylating agents. <i>Nature Reviews Cancer</i> , 2012, 12, 104-120.	12.8	740
1548	The Concepts, Diagnosis and Management of Early Imaging Changes after Therapy for Glioblastomas. <i>Clinical Oncology</i> , 2012, 24, 216-227.	0.6	31
1549	Treatment of Glioblastoma Multiforme – The Oxford Cancer Centre Experience. <i>Clinical Oncology</i> , 2012, 24, 149-150.	0.6	1
1550	Radiotherapy and Cervix Cancer – University Hospitals Birmingham Experience with Patients Not Suitable for Concurrent Chemoradiotherapy with Cisplatin. <i>Clinical Oncology</i> , 2012, 24, 150-151.	0.6	0
1551	Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic Markers. <i>European Urology</i> , 2012, 61, 1245-1256.	0.9	92
1552	O6-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 71-82.	3.3	71
1553	Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. <i>Biomaterials</i> , 2012, 33, 5115-5123.	5.7	247
1554	Clinical Applications of Epigenetic Markers and Epigenetic Profiling in Myeloid Malignancies. <i>Seminars in Oncology</i> , 2012, 39, 109-122.	0.8	45
1555	Mutated <i>IDH1</i> is a Favorable Prognostic Factor for Type 2 Gliomatosis Cerebri. <i>Brain Pathology</i> , 2012, 22, 307-317.	2.1	23
1556	<i>IDH</i> mutations predict longer survival and response to temozolomide in secondary glioblastoma. <i>Cancer Science</i> , 2012, 103, 269-273.	1.7	239
1557	Significance of <i>IDH</i> mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. <i>Cancer Science</i> , 2012, 103, 587-592.	1.7	87
1558	Temozolomide in the management of dopamine agonist-resistant prolactinomas. <i>Clinical Endocrinology</i> , 2012, 76, 877-886.	1.2	78

#	ARTICLE	IF	CITATIONS
1559	Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. <i>Clinical Endocrinology</i> , 2012, 76, 769-775.	1.2	125
1560	Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 271-291.	1.8	97
1561	A study of clinicopathological parameters and O <sup>6</sup> -methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. <i>Neuropathology</i> , 2012, 32, 534-542.	0.7	31
1562	MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. <i>Journal of Translational Medicine</i> , 2012, 10, 36.	1.8	91
1563	The hypermethylation of the O <sup>6</sup> -methylguanine-DNA methyltransferase gene promoter in gliomas correlation with array comparative genome hybridization results and IDH1 mutation. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 20-29.	1.5	13
1564	Bevacizumab and daily temozolomide for recurrent glioblastoma. <i>Cancer</i> , 2012, 118, 1302-1312.	2.0	132
1565	Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-activated nitric oxide donor PABA/NO in malignant gliomas. <i>International Journal of Cancer</i> , 2012, 130, 1184-1194.	2.3	44
1566	Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6-methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen. <i>Cell Biochemistry and Biophysics</i> , 2012, 62, 185-191.	0.9	34
1567	Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma. <i>Medical Oncology</i> , 2012, 29, 301-303.	1.2	13
1568	Methylation status of O6-methylguanine-DNA-methyl transferase promoter region in non-small-cell lung cancer patients with brain metastasis. <i>Clinical and Translational Oncology</i> , 2012, 14, 31-35.	1.2	15
1569	Correlation between quantified promoter methylation and enzymatic activity of O 6-methylguanine-DNA methyltransferase in glioblastomas. <i>Tumor Biology</i> , 2012, 33, 373-381.	0.8	15
1570	The Promoter Hypermethylation Status of GATA6, MGMT, and FHIT in Glioblastoma. <i>Cellular and Molecular Neurobiology</i> , 2012, 32, 237-244.	1.7	21
1571	Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. <i>Journal of Neuro-Oncology</i> , 2012, 106, 155-160.	1.4	37
1572	O6-methylguanine-DNA-methyltransferase promoter methylation assessment by microdissection-assisted methylation-specific PCR and high resolution melting analysis in patients with glioblastomas. <i>Journal of Neuro-Oncology</i> , 2012, 106, 243-250.	1.4	11
1573	Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology. <i>Journal of Neuro-Oncology</i> , 2012, 106, 619-626.	1.4	17
1574	O 6-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. <i>Journal of Neuro-Oncology</i> , 2012, 107, 147-153.	1.4	30
1575	Valproic acid sensitizes human glioma cells for temozolomide and <sup>13</sup> I-radiation. <i>Journal of Neuro-Oncology</i> , 2012, 107, 61-67.	1.4	92
1576	Glioblastoma survival in the United States before and during the temozolomide era. <i>Journal of Neuro-Oncology</i> , 2012, 107, 359-364.	1.4	632

#	ARTICLE	IF	CITATIONS
1577	Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis. <i>Journal of Neuro-Oncology</i> , 2012, 107, 281-288.	1.4	45
1578	Radiation necrosis following treatment of high grade glioma—a review of the literature and current understanding. <i>Acta Neurochirurgica</i> , 2012, 154, 191-201.	0.9	116
1579	Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 35-47.	1.2	37
1580	IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. <i>Brain Tumor Pathology</i> , 2013, 30, 67-72.	1.1	41
1581	Lipidized glioblastoma: Pathological and molecular characteristics. <i>Neuropathology</i> , 2013, 33, 87-92.	0.7	5
1582	The efficacy of temozolomide for recurrent glioblastoma multiforme. <i>European Journal of Neurology</i> , 2013, 20, 223-230.	1.7	46
1583	Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. <i>Radiation Oncology</i> , 2013, 8, 65.	1.2	81
1584	Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2013, 60, 783-790.	0.8	13
1585	Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 29.	0.4	8
1586	Correlation between Rho-kinase pathway gene expressions and development and progression of glioblastoma multiforme. <i>Tumor Biology</i> , 2013, 34, 1139-1144.	0.8	12
1587	Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. <i>Journal of Applied Genetics</i> , 2013, 54, 335-344.	1.0	58
1588	O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2013, 114, 135-140.	1.4	13
1589	Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 467-477.	1.4	28
1590	Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients. <i>Journal of Neuro-Oncology</i> , 2013, 113, 251-258.	1.4	32
1591	A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. <i>Journal of Neuro-Oncology</i> , 2013, 113, 127-134.	1.4	9
1592	Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. <i>Journal of Neuro-Oncology</i> , 2013, 112, 439-448.	1.4	19
1593	“One week on”/“one week off” efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. <i>Journal of Neuro-Oncology</i> , 2013, 112, 209-215.	1.4	12
1594	Gliomatosis cerebri: clinical characteristics, management, and outcomes. <i>Journal of Neuro-Oncology</i> , 2013, 112, 267-275.	1.4	61

#	ARTICLE	IF	CITATIONS
1595	The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 112, 277-283.	1.4	21
1596	Assessment of genetic markers and glioblastoma stem-like cells in activation of dendritic cells. <i>Human Cell</i> , 2013, 26, 105-113.	1.2	6
1597	Epigenetics Primer: Why the Clinician Should Care About Epigenetics. <i>Pharmacotherapy</i> , 2013, 33, 1362-1368.	1.2	16
1598	Invasion as target for therapy of glioblastoma multiforme. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1836, 236-244.	3.3	81
1599	Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 823-833.	5.1	192
1600	Progress on molecular biomarkers and classification of malignant gliomas. <i>Frontiers of Medicine</i> , 2013, 7, 150-156.	1.5	21
1601	Glioblastoma: bridging the gap with gene therapy. <i>Lancet Oncology</i> , The, 2013, 14, 789-790.	5.1	6
1603	Current treatment options for hyperprolactinemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1611-1625.	0.9	13
1604	Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. <i>BMC Cancer</i> , 2013, 13, 299.	1.1	61
1605	Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells. <i>BMC Cancer</i> , 2013, 13, 147.	1.1	99
1606	Primary Intracranial Neoplasms. , 2013, , 649-657.		0
1607	Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis. <i>Cancer</i> , 2013, 119, 3489-3495.	2.0	95
1608	Impact of Genetic Targets on Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, v-vi.	0.8	1
1609	A long non-coding RNA signature in glioblastoma multiforme predicts survival. <i>Neurobiology of Disease</i> , 2013, 58, 123-131.	2.1	196
1610	Effect of temozolomide on male gametes: an epigenetic risk to the offspring?. <i>Journal of Assisted Reproduction and Genetics</i> , 2013, 30, 827-833.	1.2	19
1611	The Adolescent and Young Adult with Cancer: State of the Art"Brain Tumor. <i>Current Oncology Reports</i> , 2013, 15, 308-316.	1.8	8
1612	Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. <i>Cancer Letters</i> , 2013, 331, 68-75.	3.2	25
1613	ID1 affects the efficacy of radiotherapy in glioblastoma through inhibition of DNA repair pathways. <i>Medical Oncology</i> , 2013, 30, 325.	1.2	16

#	ARTICLE	IF	CITATIONS
1614	Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation. <i>Brain Tumor Pathology</i> , 2013, 30, 175-179.	1.1	8
1615	Primary Tumors of the Nervous System. , 2013, , 1-22.		0
1616	Bioinformatics analysis reveals potential candidate drugs for different subtypes of glioma. <i>Neurological Sciences</i> , 2013, 34, 1139-1143.	0.9	10
1617	Molecular neuro-oncology in clinical practice: a new horizon. <i>Lancet Oncology</i> , The, 2013, 14, e370-e379.	5.1	167
1618	Emerging Concepts in Neuro-Oncology. , 2013, , .		0
1619	Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis. <i>Acta Neurochirurgica</i> , 2013, 155, 429-435.	0.9	12
1621	Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma. <i>Targeted Oncology</i> , 2013, 8, 153-155.	1.7	10
1622	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotential. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1191-1199.	1.1	164
1623	Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. <i>Acta Neuropathologica</i> , 2013, 126, 277-289.	3.9	49
1624	In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. <i>Acta Neuropathologica</i> , 2013, 125, 671-681.	3.9	73
1625	DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. <i>Acta Neuropathologica</i> , 2013, 125, 359-371.	3.9	133
1626	Glioblastoma management in the temozolomide era: have we improved outcome?. <i>Journal of Neuro-Oncology</i> , 2013, 115, 303-310.	1.4	27
1627	Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases. <i>Acta Neurochirurgica</i> , 2013, 155, 1277-1286.	0.9	124
1628	Genetic and epigenetic markers of gliomas. <i>Cell and Tissue Biology</i> , 2013, 7, 303-313.	0.2	3
1629	The treatment of glioblastomas: A systematic update on clinical Phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 265-282.	2.0	32
1630	Age-Dependent Association between Protein Expression of the Embryonic Stem Cell Marker Cripto-1 and Survival of Glioblastoma Patients. <i>Translational Oncology</i> , 2013, 6, 732-IN33.	1.7	24
1631	DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases. <i>Translational Oncology</i> , 2013, 6, 133-142.	1.7	10
1632	Esami citologico, istologico, immunoistochimico e genetico dei tumori del sistema nervoso centrale. <i>EMC - Neurologia</i> , 2013, 13, 1-26.	0.0	0

#	ARTICLE	IF	CITATIONS
1633	Oncology Scanâ€™High-Grade Gliomas. International Journal of Radiation Oncology Biology Physics, 2013, 85, 283-285.	0.4	7
1634	The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro-Oncology, 2013, 15, 1151-1159.	0.6	46
1635	Clinical trial participation and outcome for patients with glioblastoma: Multivariate analysis from a comprehensive dataset. Journal of Clinical Neuroscience, 2013, 20, 783-789.	0.8	46
1636	Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1480-9.	3.3	37
1637	The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells. Neuro-Oncology, 2013, 15, 269-278.	0.6	79
1639	Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology, 2013, 6, 742-IN34.	1.7	31
1640	Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids. Neuroendocrinology, 2013, 98, 151-155.	1.2	79
1641	Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death and Differentiation, 2013, 20, 396-407.	5.0	53
1642	Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines â€™ does scheduling matter?. International Journal of Radiation Biology, 2013, 89, 692-697.	1.0	15
1643	Surgical outcomes in recurrent glioma. Journal of Neurosurgery, 2013, 118, 1224-1231.	0.9	57
1644	Molecular pathways and potential therapeutic targets in glioblastoma multiforme. Expert Review of Anticancer Therapy, 2013, 13, 1307-1318.	1.1	5
1645	Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Annals of Oncology, 2013, 24, 3117-3123.	0.6	166
1646	Glioblastoma and Other Malignant Gliomas. JAMA - Journal of the American Medical Association, 2013, 310, 1842.	3.8	1,779
1647	Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology, 2013, 31, 4085-4091.	0.8	820
1648	Cancer Development, Progression, and Therapy: An Epigenetic Overview. International Journal of Molecular Sciences, 2013, 14, 21087-21113.	1.8	257
1649	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
1650	HDAC1â€™mSin3aâ€™NCOR1, Dnmt3bâ€™HDAC1â€™Egr1 and Dnmt1â€™PCNAâ€™UHRF1â€™G9a regulate the <i>ESQ1</i> gene expression. Molecular Oncology, 2013, 7, 452-463.	2.1	42
1651	Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro-Oncology, 2013, 15, 1635-1643.	0.6	19

#	ARTICLE	IF	CITATIONS
1652	Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951. <i>Journal of Clinical Oncology</i> , 2013, 31, 328-336.	0.8	99
1653	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. <i>Journal of Clinical Oncology</i> , 2013, 31, 337-343.	0.8	968
1654	Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. <i>Neuro-Oncology</i> , 2013, 15, 1469-1478.	0.6	19
1655	Update in the Treatment of High-grade Gliomas. <i>Neurologic Clinics</i> , 2013, 31, 847-867.	0.8	9
1656	Epigenetic Alterations in Oncogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, v-vii.	0.8	10
1657	Optimal management of elderly patients with glioblastoma. <i>Cancer Treatment Reviews</i> , 2013, 39, 350-357.	3.4	131
1658	Developing epigenetic diagnostics and therapeutics for brain disorders. <i>Trends in Molecular Medicine</i> , 2013, 19, 732-741.	3.5	21
1659	Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1677-1683.	3.0	118
1660	The T genotype of the MGMT C&gt;T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. <i>European Journal of Cancer</i> , 2013, 49, 360-368.	1.3	55
1662	Gene markers in brain tumors: What the epileptologist should know. <i>Epilepsia</i> , 2013, 54, 25-29.	2.6	18
1663	Current status of local therapy in malignant gliomas " A clinical review of three selected approaches. , 2013, 139, 341-358.		125
1664	Chemotherapy and immunotherapy of brain tumors: What the epileptologist must know. <i>Epilepsia</i> , 2013, 54, 105-108.	2.6	8
1665	cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. <i>Journal of Neuro-Oncology</i> , 2013, 115, 249-259.	1.4	28
1666	YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. <i>Journal of Translational Medicine</i> , 2013, 11, 216.	1.8	45
1667	Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. <i>BMC Cancer</i> , 2013, 13, 402.	1.1	68
1668	Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. <i>BMC Cancer</i> , 2013, 13, 617.	1.1	43
1669	Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. <i>Cancer and Metastasis Reviews</i> , 2013, 33, 161-71.	2.7	30
1670	Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time?. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 993-995.	1.0	11



#	ARTICLE	IF	CITATIONS
1671	Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. <i>World Journal of Surgical Oncology</i> , 2013, 11, 284.	0.8	22
1672	Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study. <i>International Journal of Cancer</i> , 2013, 133, 1204-1213.	2.3	132
1673	Mesenchymal Differentiation Mediated by NF- $\kappa$ B Promotes Radiation Resistance in Glioblastoma. <i>Cancer Cell</i> , 2013, 24, 331-346.	7.7	856
1674	Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. <i>Journal of Neuroimmunology</i> , 2013, 264, 71-83.	1.1	330
1675	Pharmacotherapeutic Management of Pediatric Gliomas. <i>Paediatric Drugs</i> , 2013, 15, 29-42.	1.3	10
1676	The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma - a single centre retrospective study. <i>British Journal of Neurosurgery</i> , 2013, 27, 430-435.	0.4	5
1677	The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. <i>EMBO Molecular Medicine</i> , 2013, 5, 1196-1212.	3.3	337
1678	Tumor blood flow from arterial spin labeling perfusion MRI: A key parameter in distinguishing high-grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high-grade gliomas. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 852-860.	1.9	40
1679	Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. <i>Genome Medicine</i> , 2013, 5, 66.	3.6	23
1680	Current and future directions for Phase II trials in high-grade glioma. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 369-387.	1.4	4
1681	Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. <i>Journal of Neurosurgery</i> , 2013, 119, 1415-1423.	0.9	53
1682	Bevacizumab for the treatment of glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 937-949.	1.4	21
1683	The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress. <i>Cancer Research</i> , 2013, 73, 3225-3234.	0.4	126
1684	Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 663-676.	1.3	11
1685	DNA Repair Mechanisms in Glioblastoma Cancer Stem Cells. , 2013, , 89-103.		0
1686	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 14-26.	12.5	281
1687	Patient-Specific Orthotopic Glioblastoma Xenograft Models Recapitulate the Histopathology and Biology of Human Glioblastomas In Situ. <i>Cell Reports</i> , 2013, 3, 260-273.	2.9	186
1688	Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2013, 61, 25-41.	1.0	191

#	ARTICLE	IF	CITATIONS
1689	Genetics and pharmacogenomics of diffuse gliomas. , 2013, 137, 78-88.		7
1690	Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. <i>European Radiology</i> , 2013, 23, 513-520.	2.3	86
1691	Clinicopathological features of human brainstem gliomas. <i>Brain Tumor Pathology</i> , 2013, 30, 1-7.	1.1	20
1692	Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. <i>Journal of Neuro-Oncology</i> , 2013, 111, 97-102.	1.4	55
1693	Development of a new application of the comet assay to assess levels of O6-methylguanine in genomic DNA (CoMeth). <i>Free Radical Biology and Medicine</i> , 2013, 60, 41-48.	1.3	10
1694	Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. <i>Cancer Letters</i> , 2013, 331, 139-146.	3.2	228
1695	IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. <i>Neuro-Oncology</i> , 2013, 15, 469-479.	0.6	158
1696	Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MSâ€MLPA in patients with glioblastoma multiforme. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 351-358.	1.9	42
1697	The Role of MGMT Testing in Clinical Practice. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 539-555.	1.2	57
1698	Pulsed Versus Conventional Radiation Therapy in Combination With Temozolomide in a Murine Orthotopic Model of Glioblastoma Multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 978-985.	0.4	24
1699	In Reply to Healy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 630-631.	0.4	0
1700	In Regard to Lee etâ€Al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 631.	0.4	4
1701	Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: Explorative hypothesis-generating retrospective analysis. <i>Radiotherapy and Oncology</i> , 2013, 108, 132-135.	0.3	42
1702	Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. <i>Journal of Clinical Virology</i> , 2013, 57, 36-42.	1.6	116
1703	Î±vÎ²3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2013, 49, 2161-2169.	1.3	47
1704	Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutation. <i>Neurology</i> , 2013, 81, 1515-1522.	1.5	211
1706	Restricted Calorie Ketogenic Diet for the Treatment of Glioblastoma Multiforme. <i>Journal of Child Neurology</i> , 2013, 28, 1002-1008.	0.7	23
1707	Clinicopathological characteristics and treatment of rhabdoid glioblastoma. <i>Journal of Neurosurgery</i> , 2013, 119, 412-419.	0.9	22

#	ARTICLE	IF	CITATIONS
1708	Inhibition of the mitochondrial Hsp90 chaperone network: A novel, efficient treatment strategy for cancer?. <i>Cancer Letters</i> , 2013, 333, 133-146.	3.2	50
1709	Pituitary adenomas: Surgery and radiotherapy in the age of molecular diagnostics and pathology. <i>Current Problems in Cancer</i> , 2013, 37, 6-37.	1.0	14
1710	Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors. <i>Seminars in Oncology</i> , 2013, 40, 75-83.	0.8	10
1711	The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. <i>Journal of Neuroimmunology</i> , 2013, 260, 99-106.	1.1	88
1712	Genetic expression profiles of adult and pediatric ependymomas: Molecular pathways, prognostic indicators, and therapeutic targets. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 388-399.	0.6	16
1713	Chemotherapy in the management of advanced cutaneous malignant melanoma. <i>Clinics in Dermatology</i> , 2013, 31, 290-297.	0.8	80
1714	Oncology Scanâ€”Low-Grade Gliomas: Predicting and Changing Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 234-236.	0.4	4
1715	Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas. <i>Medical Journal Armed Forces India</i> , 2013, 69, 228-236.	0.3	1
1716	In Reply to Sharma et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 631-632.	0.4	0
1717	Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials. <i>Current Oncology Reports</i> , 2013, 15, 56-63.	1.8	32
1718	Success at Last: A Molecular Factor That Informs Treatment. <i>Current Oncology Reports</i> , 2013, 15, 47-55.	1.8	6
1719	Tumor Prognostic Factors and the Challenge of Developing Predictive Factors. <i>Current Oncology Reports</i> , 2013, 15, 33-46.	1.8	1
1720	Telomere Profiling: Toward Glioblastoma Personalized Medicine. <i>Molecular Neurobiology</i> , 2013, 47, 64-76.	1.9	31
1721	New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology. <i>Science Translational Medicine</i> , 2013, 5, 173sr2.	5.8	197
1722	Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. <i>Cancer Letters</i> , 2013, 331, 131-138.	3.2	188
1723	Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: Design, synthesis and biological screening. <i>European Journal of Medicinal Chemistry</i> , 2013, 63, 589-602.	2.6	73
1724	Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 511-521.	1.1	25
1725	Surgical resection of malignant gliomasâ€”role in optimizing patient outcome. <i>Nature Reviews Neurology</i> , 2013, 9, 141-151.	4.9	133

#	ARTICLE	IF	CITATIONS
1726	Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas. <i>European Journal of Cancer</i> , 2013, 49, 2243-2252.	1.3	18
1727	Impact of Genetic Targets on Primary Brain Tumor Therapy: What's Ready for Prime Time?. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 267-289.	0.8	11
1728	Classification of Gliomas. , 2013, , 3-20.		2
1729	The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. <i>Familial Cancer</i> , 2013, 12, 449-458.	0.9	94
1730	Research on DNA methylation of human osteosarcoma cell MGMT and its relationship with cell resistance to alkylating agents. <i>Biochemistry and Cell Biology</i> , 2013, 91, 209-213.	0.9	8
1731	Assessing the MGMT status in glioblastoma: one step forward, two steps back?. <i>Neuro-Oncology</i> , 2013, 15, 253-254.	0.6	12
1732	Epigenetics and Brain Cancer. , 2013, , 21-40.		0
1733	Stem Cells and Brain Cancer. , 2013, , 61-71.		0
1734	How Molecular Testing Can Help (and Hurt) in the Workup of Gliomas. <i>American Journal of Clinical Pathology</i> , 2013, 139, 275-288.	0.4	6
1735	Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. <i>Oncogene</i> , 2013, 32, 1539-1548.	2.6	55
1736	Interplay between the Cancer Genome and Epigenome. <i>Cell</i> , 2013, 153, 38-55.	13.5	733
1737	Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model. <i>International Journal of Oncology</i> , 2013, 42, 1501-1515.	1.4	88
1738	Targeting apoptosis pathways in glioblastoma. <i>Cancer Letters</i> , 2013, 332, 335-345.	3.2	60
1739	Differential Expression of MicroRNAs in Patients with Glioblastoma after Concomitant Chemoradiotherapy. <i>OMICS A Journal of Integrative Biology</i> , 2013, 17, 259-268.	1.0	14
1740	What do we know about IDH1/2 mutations so far, and how do we use it?. <i>Acta Neuropathologica</i> , 2013, 125, 621-636.	3.9	133
1741	Anaplastic Astrocytoma. <i>Current Treatment Options in Neurology</i> , 2013, 15, 302-315.	0.7	8
1742	Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. <i>Cancer Gene Therapy</i> , 2013, 20, 211-221.	2.2	58
1743	Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. <i>OncoTargets and Therapy</i> , 2013, 6, 223.	1.0	38

#	ARTICLE	IF	CITATIONS
1744	Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. <i>Journal of Neuro-Oncology</i> , 2013, 111, 229-236.	1.4	72
1745	Human Low-Grade Glioma Cultures. , 2013, , 137-163.		3
1746	PKC signaling in glioblastoma. <i>Cancer Biology and Therapy</i> , 2013, 14, 287-294.	1.5	54
1747	Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 545-555.	1.4	75
1748	MGMT Promoter Methylation and Glioblastoma Prognosis: A Systematic Review and Meta-analysis. <i>Archives of Medical Research</i> , 2013, 44, 281-290.	1.5	49
1749	Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 479-492.	2.7	46
1750	The methylation hypothesis of pharmacoresistance in epilepsy. <i>Epilepsia</i> , 2013, 54, 41-47.	2.6	81
1751	Posttreatment Evaluation of Central Nervous System Gliomas. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2013, 21, 241-268.	0.6	11
1752	Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. <i>Acta Neuropathologica</i> , 2013, 126, 21-37.	3.9	16
1754	Diagnostic and prognostic markers in gliomas “ an update. <i>British Journal of Neurosurgery</i> , 2013, 27, 311-315.	0.4	12
1755	A pilot study of glioblastoma multiforme in elderly patients: Treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1375-1378.	0.6	28
1756	Epigenetic profiling joins personalized cancer medicine. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 473-479.	1.5	32
1757	Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma. <i>NeuroMolecular Medicine</i> , 2013, 15, 420-434.	1.8	34
1758	Current Progress for the Use of miRNAs in Glioblastoma Treatment. <i>Molecular Neurobiology</i> , 2013, 48, 757-768.	1.9	38
1759	Glioblastoma cancer stem cells “ From concept to clinical application. <i>Cancer Letters</i> , 2013, 338, 32-40.	3.2	67
1760	Optimizing Glioblastoma Temozolomide Chemotherapy Employing Lentiviral-based Anti-MGMT shRNA Technology. <i>Molecular Therapy</i> , 2013, 21, 570-579.	3.7	29
1761	The Evolving Landscape of Neuroendocrine Tumors. <i>Seminars in Oncology</i> , 2013, 40, 4-22.	0.8	25
1762	Circulating biomarkers of CNS tumors: an update. <i>Biomarkers in Medicine</i> , 2013, 7, 267-285.	0.6	16

#	ARTICLE	IF	CITATIONS
1763	Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opinion on Emerging Drugs, 2013, 18, 137-153.	1.0	29
1764	The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. Journal of Neuro-Oncology, 2013, 113, 163-174.	1.4	49
1766	Predictive value of tumor recurrence using urinary vascular endothelial factor levels in patients receiving radiation therapy for Glioblastoma Multiforme (GBM). Biomarker Research, 2013, 1, 29.	2.8	3
1767	Pseudoprogression after glioma therapy: a comprehensive review. Expert Review of Neurotherapeutics, 2013, 13, 389-403.	1.4	92
1768	Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 2013, 31, 344-350.	0.8	1,003
1769	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European Journal of Cancer, 2013, 49, 3477-3485.	1.3	51
1770	Methylation of the <i>hTERT</i> Promoter: A Novel Cancer Biomarker for Leptomeningeal Metastasis Detection in Cerebrospinal Fluids. Clinical Cancer Research, 2013, 19, 2216-2223.	3.2	36
1771	Future of Clinical Genomics in Pediatric Oncology. Journal of Clinical Oncology, 2013, 31, 1893-1903.	0.8	40
1772	Defining pseudoprogression in glioblastoma multiforme. European Journal of Neurology, 2013, 20, 1335-1341.	1.7	48
1773	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 2013, 15, 1017-1026.	0.6	78
1774	Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress. Neuro-Oncology, 2013, 15, 1186-1199.	0.6	63
1775	Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O6-methylguanine DNA-methyltransferase. Neurological Sciences, 2013, 34, 1421-1428.	0.9	40
1776	DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. International Journal of Oncology, 2013, 42, 127-133.	1.4	63
1777	Longitudinal Expression Analysis of $\beta$ Integrins in Human Gliomas Reveals Upregulation of Integrin $\beta$ 23 as a Negative Prognostic Factor. Journal of Neuropathology and Experimental Neurology, 2013, 72, 194-210.	0.9	46
1778	Advances in personalized therapy for lung cancer. Expert Opinion on Medical Diagnostics, 2013, 7, 475-485.	1.6	9
1779	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology, 2013, 15, 1405-1412.	0.6	53
1780	Vaccine-based immunotherapy for glioblastoma. CNS Oncology, 2013, 2, 331-349.	1.2	11
1781	Neuroendocrine tumours: cracking the epigenetic code. Endocrine-Related Cancer, 2013, 20, R65-R82.	1.6	50

#	ARTICLE	IF	CITATIONS
1782	Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer. <i>Epigenomics</i> , 2013, 5, 595-598.	1.0	8
1783	Multiple resections for patients with glioblastoma: prolonging survival. <i>Journal of Neurosurgery</i> , 2013, 118, 812-820.	0.9	166
1784	DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1130-1136.	1.8	100
1786	Relationship between cognitive function and prognosis in glioblastoma. <i>CNS Oncology</i> , 2013, 2, 195-201.	1.2	24
1787	Subependymal spread of recurrent glioblastoma detected with the intraoperative use of 5-aminolevulinic acid. <i>Journal of Neurosurgery</i> , 2013, 118, 1220-1223.	0.9	18
1788	<i>MGMT</i> -STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951. <i>Clinical Cancer Research</i> , 2013, 19, 5513-5522.	3.2	106
1789	Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2013, 15, 930-935.	0.6	77
1790	O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. <i>Journal of Carcinogenesis</i> , 2013, 12, 20.	2.5	13
1792	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. <i>Neuro-Oncology</i> , 2013, 15, 370-381.	0.6	97
1793	Cerebrotendinous Xanthomatosis: Report of two cases and a novel genetic mutation in an Indian patient. <i>Journal of Neurosciences in Rural Practice</i> , 2013, 04, S87-S90.	0.3	4
1794	Glioblastoma multiforme: A bigger challenge in resource-limited countries. <i>Journal of Neurosciences in Rural Practice</i> , 2013, 04, S3-S4.	0.3	0
1795	Article Commentary: Dealing with Diversity in Computational Cancer Modeling. <i>Cancer Informatics</i> , 2013, 12, CIN.S11583.	0.9	15
1796	Transcriptional expression of glioma chemotherapy drugs associated marker molecules in gliomas and normal brain tissues. <i>Cancer Biomarkers</i> , 2013, 13, 59-66.	0.8	2
1797	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. <i>Annals of Oncology</i> , 2013, 24, 3123-3128.	0.6	32
1798	Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT. <i>Frontiers in Oncology</i> , 2013, 3, 266.	1.3	16
1799	Risk factors for gliomas. An extensive review. <i>Romanian Neurosurgery</i> , 2013, 20, 5-21.	1.0	12
1800	Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas. <i>ISRN Oncology</i> , 2013, 2013, 1-13.	2.1	20
1801	Brain Tumors and Gliomas. , 2013, , 749-764.		0

#	ARTICLE	IF	CITATIONS
1802	The molecular landscape of diffuse glioma and prospects for biomarker development. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 573-587.	1.6	9
1803	Molecular insights into brain tumors. <i>Current Opinion in Neurology</i> , 2013, 26, 678-680.	1.8	1
1804	Predictive biomarkers in adult gliomas. <i>Current Opinion in Oncology</i> , 2013, 25, 689-694.	1.1	34
1805	PTEN suppresses SPARC-induced pMAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma. <i>Neuro-Oncology</i> , 2013, 15, 451-461.	0.6	28
1806	Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. <i>Scientific Reports</i> , 2013, 3, 2789.	1.6	30
1807	Probabilistic Radiographic Atlas of Glioblastoma Phenotypes. <i>American Journal of Neuroradiology</i> , 2013, 34, 533-540.	1.2	192
1808	Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. <i>Neuro-Oncology</i> , 2013, 15, 670-681.	0.6	96
1809	Hydroxymethylation- and methylation-sensitive tag sequencing: how will this technology change clinical applications of DNA methylation profiling?. <i>Epigenomics</i> , 2013, 5, 355-357.	1.0	4
1810	Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme. <i>Neuro-Oncology</i> , 2013, 15, 1366-1378.	0.6	44
1811	Molecular prognostic factors in glioblastoma: state of the art and future challenges. <i>CNS Oncology</i> , 2013, 2, 495-510.	1.2	9
1812	On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. <i>Neuro-Oncology</i> , 2013, 15, 198-207.	0.6	87
1813	Glioblastoma – Current Concepts, Prognostic Markers And Molecular Classification. <i>Acta Chirurgica Latviensis</i> , 2013, 13, 58-64.	0.2	0
1814	Urinary Metabolomic Profiling of Patients with Glioblastoma Multiforme. <i>Journal of Proteomics and Bioinformatics</i> , 2013, 01, .	0.4	6
1815	Glycogen synthase kinase 3 $\beta$ inhibition sensitizes human glioblastoma cells to temozolomide by affecting O <sup>6</sup> -methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. <i>Carcinogenesis</i> , 2013, 34, 2206-2217.	1.3	63
1816	Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 365-368.	0.5	11
1817	<i>BRAF</i> V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults. <i>Journal of Clinical Oncology</i> , 2013, 31, e233-e236.	0.8	67
1818	Anticancer Effects of Niclosamide in Human Glioblastoma. <i>Clinical Cancer Research</i> , 2013, 19, 4124-4136.	3.2	135
1819	DNA Damage-Inducible Gene, Reprimo Functions as a Tumor Suppressor and Is Suppressed by Promoter Methylation in Gastric Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 1362-1374.	1.5	40



#	ARTICLE	IF	CITATIONS
1820	Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. <i>Neuro-Oncology</i> , 2013, 15, 972-978.	0.6	37
1821	Controversies and challenges regarding the impact of radiation therapy on survival. <i>Annals of Oncology</i> , 2013, 24, 38-46.	0.6	39
1822	Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. <i>Neuro-Oncology</i> , 2013, 15, 562-577.	0.6	72
1823	Systematic use of computational methods allows stratification of treatment responders in glioblastoma multiforme. <i>Systems Biomedicine (Austin, Tex )</i> , 2013, 1, 130-136.	0.7	1
1824	DNA Methylation Pattern as Important Epigenetic Criterion in Cancer. <i>Genetics Research International</i> , 2013, 2013, 1-9.	2.0	74
1825	Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. <i>Neuro-Oncology</i> , 2013, 15, 423-432.	0.6	60
1826	Temozolomide-Related Hematologic Toxicity. <i>Onkologie</i> , 2013, 36, 444-449.	1.1	25
1827	Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy. <i>International Journal of Clinical Practice</i> , 2013, 67, 1225-1227.	0.8	12
1828	Differential gene hypermethylation in genital lichen sclerosis and cancer: a comparative study. <i>Histopathology</i> , 2013, 63, 659-669.	1.6	22
1829	Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. <i>Oncogene</i> , 2013, 32, 5315-5330.	2.6	44
1830	Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach. <i>Cell Death and Disease</i> , 2013, 4, e629-e629.	2.7	43
1831	Three different brain tumours evolving from a common origin. <i>Oncogenesis</i> , 2013, 2, e41-e41.	2.1	9
1832	Clinical application of the CpG island methylator phenotype to prognostic diagnosis in neuroblastomas. <i>Journal of Human Genetics</i> , 2013, 58, 428-433.	1.1	20
1833	Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. <i>Cancer Gene Therapy</i> , 2013, 20, 544-551.	2.2	48
1834	Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. <i>CNS Oncology</i> , 2013, 2, 351-358.	1.2	10
1835	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2013, 15, 242-250.	0.6	83
1836	Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2265-2272.	3.2	96
1837	A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O <sup>6</sup> -Methylguanine-DNA Methyltransferase Promoter. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 809-818.	1.9	48

#	ARTICLE	IF	CITATIONS
1838	Standards of care for treatment of recurrent glioblastoma—are we there yet?. <i>Neuro-Oncology</i> , 2013, 15, 4-27.	0.6	592
1839	A model for the regulation of T-type Ca <sup>2+</sup> channels in proliferation: roles in stem cells and cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 589-595.	1.1	13
1840	DNA Methylation in Cancer: A Gene Silencing Mechanism and the Clinical Potential of Its Biomarkers. <i>Tohoku Journal of Experimental Medicine</i> , 2013, 229, 173-185.	0.5	72
1841	Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients. <i>International Journal of Oncology</i> , 2013, 42, 929-934.	1.4	65
1842	Update on the current management of glioblastoma. <i>Clinical Practice (London, England)</i> , 2013, 10, 157-165.	0.1	0
1843	Current Status of Immunotherapy and Gene Therapy for High-Grade Gliomas. <i>Cancer Control</i> , 2013, 20, 43-48.	0.7	27
1844	Controversies in the Treatment of Elderly Patients With Newly Diagnosed Glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1165-1173.	2.3	23
1845	Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma. <i>Scientific Reports</i> , 2013, 3, 1160.	1.6	20
1847	Glioma Spheroids Obtained via Ultrasonic Aspiration Are Viable and Express Stem Cell Markers. <i>Neurosurgery</i> , 2013, 73, 868-886.	0.6	21
1848	Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma. <i>Current Pharmaceutical Design</i> , 2013, 19, 951-957.	0.9	26
1849	Exclusion of Histiocytes/Endothelial Cells and Using Endothelial Cells as Internal Reference Are Crucial for Interpretation of MGMT Immunohistochemistry in Glioblastoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 264-271.	2.1	21
1850	Glioma-amplified sequence KUB3 influences double-strand break repair after ionizing radiation. <i>International Journal of Oncology</i> , 2013, 43, 50-56.	1.4	8
1851	Surgical Management of Adult Intrinsic Brainstem Tumors. <i>Neurosurgery</i> , 2013, 60, 131-138.	0.6	12
1852	Increased xCT Expression Correlates With Tumor Invasion and Outcome in Patients With Glioblastomas. <i>Neurosurgery</i> , 2013, 72, 33-41.	0.6	102
1853	Efficacy of Temozolomide in a Central Nervous System Relapse of Neuroblastoma With O <sup>6</sup> -Methylguanine Methyltransferase (MGMT) Promoter Methylation. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, e38-e41.	0.3	5
1854	Imaging Genomic Mapping in Glioblastoma. <i>Neurosurgery</i> , 2013, 60, 126-130.	0.6	27
1856	Antitumor Activity of (2E,5Z)-5-(2-Hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a Novel Microtubule-Depolymerizing Agent, in U87MG Human Glioblastoma Cells and Corresponding Mouse Xenograft Model. <i>Journal of Pharmacological Sciences</i> , 2013, 122, 223-231.	1.1	13
1857	Anti-cancer Therapies in High Grade Gliomas. <i>Current Proteomics</i> , 2013, 10, 246-260.	0.1	28

#	ARTICLE	IF	CITATIONS
1858	Abundance of Flt3 and its ligand in astrocytic tumors. <i>OncoTargets and Therapy</i> , 2013, 6, 555.	1.0	7
1859	High-grade glioma in elderly patients: can the oncogeriatrician help?. <i>Clinical Interventions in Aging</i> , 2013, 8, 1617.	1.3	6
1860	Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights. , 2013, , .		0
1861	Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. <i>OncoTargets and Therapy</i> , 2013, 6, 371.	1.0	26
1862	Recent Advances in Glioblastoma Treatment. <i>Journal of the Nihon University Medical Association</i> , 2013, 72, 43-51.	0.0	0
1863	The prognostic impact of MGMT expression on low-grade gangliogliomas: a clinicopathological and immunohistochemical study. <i>Folia Neuropathologica</i> , 2013, 4, 275-282.	0.5	7
1864	The Role of Temozolomide in the Treatment of a Patient With a Pure Silent Pituitary Somatotroph Carcinoma. <i>Endocrine Practice</i> , 2013, 19, e145-e149.	1.1	21
1866	Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma. <i>Tumori</i> , 2013, 99, 480-487.	0.6	10
1867	IDH1-Associated Primary Glioblastoma in Young Adults Displays Differential Patterns of Tumour and Vascular Morphology. <i>PLoS ONE</i> , 2013, 8, e56328.	1.1	27
1868	Quality Evaluation of Methyl Binding Domain Based Kits for Enrichment DNA-Methylation Sequencing. <i>PLoS ONE</i> , 2013, 8, e59068.	1.1	50
1869	Circulating Endothelial Cells and Procoagulant Microparticles in Patients with Glioblastoma: Prognostic Value. <i>PLoS ONE</i> , 2013, 8, e69034.	1.1	30
1870	Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in Glioblastoma. <i>PLoS ONE</i> , 2013, 8, e71777.	1.1	21
1871	Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e74242.	1.1	55
1872	Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results. <i>PLoS ONE</i> , 2013, 8, e78943.	1.1	72
1873	microRNA-100 Targets SMRT/NCOR2, Reduces Proliferation, and Improves Survival in Glioblastoma Animal Models. <i>PLoS ONE</i> , 2013, 8, e80865.	1.1	47
1874	Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities. <i>OncoTargets and Therapy</i> , 2013, 6, 931.	1.0	16
1875	Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. <i>Frontiers in Oncology</i> , 2013, 3, 28.	1.3	11
1876	Recent therapeutic advances and insights of recurrent glioblastoma multiforme. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 676.	3.0	17

#	ARTICLE	IF	CITATIONS
1877	Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors. <i>Brain Tumor Research and Treatment</i> , 2013, 1, 2.	0.4	15
1878	Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. <i>OncoTargets and Therapy</i> , 2013, 6, 1363.	1.0	127
1879	Emerging Biomarkers in Glioblastoma. <i>Cancers</i> , 2013, 5, 1103-1119.	1.7	80
1880	Impact of MTHFR polymorphisms on methylation of MGMT in glioma patients from Northeast China with different folate levels. <i>Genetics and Molecular Research</i> , 2013, 12, 5160-5171.	0.3	7
1881	Pharmacological Treatment for Pituitary Adenomas. <i>Japanese Journal of Neurosurgery</i> , 2013, 22, 101-108.	0.0	0
1882	DNA methylation. , 0, , 37-45.		1
1883	Laboratory Testing for Prognostic and Predictive Markers in Gliomas. , 0, , .		0
1884	Chemotherapeutic Agent for Glioma. , 2013, , .		1
1885	Genetic Profiling: Searching for Novel Genetic Aberrations in Glioblastoma. , 0, , .		0
1886	Evolution of microRNAs as Therapeutic Targets for Malignant Gliomas. , 0, , .		1
1887	Topoisomerase Therapy in the Treatment of Brain Tumors. , 0, , .		1
1888	DNA Repair and Resistance to Cancer Therapy. , 0, , .		2
1889	Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. <i>Cancer Management and Research</i> , 2014, 6, 149.	0.9	149
1890	Surgical delivery of drug releasing poly(lactic-co-glycolic acid)/poly(ethylene glycol) paste with in vivo effects against glioblastoma. <i>Annals of the Royal College of Surgeons of England</i> , 2014, 96, 495-501.	0.3	11
1891	The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e85102.	1.1	38
1892	Visualizing Molecular Profiles of Glioblastoma with GBM-BioDP. <i>PLoS ONE</i> , 2014, 9, e101239.	1.1	52
1893	Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC. <i>PLoS ONE</i> , 2014, 9, e107124.	1.1	21
1894	MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study. <i>PLoS ONE</i> , 2014, 9, e107558.	1.1	27

#	ARTICLE	IF	CITATIONS
1895	Surprisal Analysis of Glioblastoma Multiform (GBM) MicroRNA Dynamics Unveils Tumor Specific Phenotype. PLoS ONE, 2014, 9, e108171.	1.1	13
1896	Antineoplastic Effect of Decoy Oligonucleotide Derived from MGMT Enhancer. PLoS ONE, 2014, 9, e113854.	1.1	3
1897	Treatment options and outcomes for glioblastoma in the elderly patient. Clinical Interventions in Aging, 2014, 9, 357.	1.3	92
1898	Molecular, histopathological, and genomic variants of glioblastoma. Frontiers in Bioscience - Landmark, 2014, 19, 1065.	3.0	17
1899	Most frequent molecular and immunohistochemical markers present in selected types of brain tumors. General Physiology and Biophysics, 2014, 33, 259-279.	0.4	8
1900	Review Glioblastoma multiforme – an overview. Wspolczesna Onkologia, 2014, 5, 307-312.	0.7	171
1901	Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment. Frontiers in Oncology, 2014, 4, 47.	1.3	36
1902	Orphan drugs in glioblastoma multiforme: a review. Orphan Drugs: Research and Reviews, 0, , 83.	0.6	6
1903	The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Management and Research, 2014, 6, 373.	0.9	32
1904	Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study. OncoTargets and Therapy, 2014, 7, 485.	1.0	46
1905	Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Oncotarget, 2014, 5, 10901-10915.	0.8	34
1906	Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response. ImmunoTargets and Therapy, 2014, 3, 55.	2.7	5
1907	Co-deletion of 1p/19q is Strongly Correlated with a High Level of MGMT Promoter Methylation in High Grade Gliomas as Revealed by Pyrosequencing. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2014, 09, .	0.1	0
1908	High Grade Glioma – Standard Approach, Obstacles and Future Directions. , 0, , .		0
1909	Vasculogenic mimicry: a novel target for glioma therapy. Chinese Journal of Cancer, 2014, 33, 74-79.	4.9	81
1911	The Role of Adjuvant Therapy in Newly Diagnosed High-Grade Astrocytomas. , 2014, , .		0
1912	A Comprehensive Approach to Patient-individual Glioblastoma Multiforme Model Establishment. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	1
1913	Targeting glioblastoma cancer stem cells: the next great hope?. Neurosurgical Focus, 2014, 37, E7.	1.0	13

#	ARTICLE	IF	CITATIONS
1914	Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray. <i>Epigenetics</i> , 2014, 9, 829-833.	1.3	62
1915	Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. <i>CNS Oncology</i> , 2014, 3, 389-400.	1.2	38
1916	Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O <sup>6</sup> -methylguanine DNA methyltransferase expression. <i>British Journal of Haematology</i> , 2014, 167, 664-670.	1.2	14
1917	A novel approach to the discovery of survival biomarkers in glioblastoma using a joint analysis of DNA methylation and gene expression. <i>Epigenetics</i> , 2014, 9, 873-883.	1.3	27
1918	Personalized Cancer Therapy. , 2014, , 671-824.		1
1919	Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature. <i>Cancer Biology and Therapy</i> , 2014, 15, 862-877.	1.5	9
1921	Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 439-452.	1.5	69
1922	Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2047-2061.	0.9	19
1923	Expression of Different Neurokinin-1 Receptor (NK1R) Isoforms in Glioblastoma Multiforme: Potential Implications for Targeted Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 221-226.	0.7	13
1924	The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?. <i>Journal of Neuro-Oncology</i> , 2014, 120, 625-634.	1.4	101
1925	NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2004-2017.	1.9	52
1926	Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region. <i>BMC Cancer</i> , 2014, 14, 641.	1.1	20
1927	A phase II study of surgical excision, temozolomide, radiotherapy, and anti-EGFR radioimmunotherapy (EXTRA) as adjuvant therapy in high-grade gliomas. <i>Journal of Radiation Oncology</i> , 2014, 3, 347-353.	0.7	1
1928	The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy. <i>Cancers</i> , 2014, 6, 1953-1985.	1.7	62
1929	Potential new gene therapy option with sitimagene ceradenovec for newly diagnosed patients with glioblastoma multiforme. <i>Cancer Biology and Therapy</i> , 2014, 15, 263-265.	1.5	3
1930	Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. <i>BMC Genomics</i> , 2014, 15, 1079.	1.2	45
1931	Epigenetic deregulation in pediatric acute lymphoblastic leukemia. <i>Epigenetics</i> , 2014, 9, 459-467.	1.3	51
1932	A Phase I Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. <i>Molecular Therapy</i> , 2014, 22, 1048-1055.	3.7	233

#	ARTICLE	IF	CITATIONS
1933	The Prognosis of MGMT Promoter Methylation in Glioblastoma Patients of Different Race: A Meta-analysis. <i>Neurochemical Research</i> , 2014, 39, 2277-2287.	1.6	17
1934	Progression of O6-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research. <i>Molecular Biology Reports</i> , 2014, 41, 6659-6665.	1.0	18
1935	Hippocampal EUD in primarily irradiated glioblastoma patients. <i>Radiation Oncology</i> , 2014, 9, 276.	1.2	9
1936	Molecular characteristics of pediatric high-grade gliomas. <i>CNS Oncology</i> , 2014, 3, 433-443.	1.2	26
1937	Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation. <i>Oncogenesis</i> , 2014, 3, e108-e108.	2.1	82
1938	Rindopemimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. <i>Immunotherapy</i> , 2014, 6, 679-690.	1.0	88
1939	Strategies for validation and testing of DNA methylation biomarkers. <i>Epigenomics</i> , 2014, 6, 603-622.	1.0	28
1940	Initial care and outcome of glioblastoma multiforme patients in 2 diverse health care scenarios in Brazil: does public versus private health care matter?. <i>Neuro-Oncology</i> , 2014, 16, 999-1005.	0.6	13
1941	Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. <i>Cell Death and Disease</i> , 2014, 5, e1223-e1223.	2.7	57
1942	A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy. <i>Oncology Letters</i> , 2014, 8, 2000-2006.	0.8	86
1943	Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review. <i>Diagnostic Pathology</i> , 2014, 9, 17.	0.9	27
1944	Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. <i>Neurosurgical Focus</i> , 2014, 37, E4.	1.0	60
1945	Brain Tumors; Clinical Aspects. , 2014, , 527-531.		0
1946	Brain Tumor Genomics. , 2014, , 321-338.		0
1947	Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme. <i>Neurology Research International</i> , 2014, 2014, 1-5.	0.5	9
1948	Carbon-Ion Radiotherapy. , 2014, , .		55
1949	Are we done with dose-intense temozolomide in recurrent glioblastoma?. <i>Neuro-Oncology</i> , 2014, 16, 1161-1163.	0.6	11
1951	Emerging Insights into Barriers to Effective Brain Tumor Therapeutics. <i>Frontiers in Oncology</i> , 2014, 4, 126.	1.3	127

#	ARTICLE	IF	CITATIONS
1952	Cytotoxic Autophagy in Cancer Therapy. International Journal of Molecular Sciences, 2014, 15, 10034-10051.	1.8	120
1953	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. Oncologist, 2014, 19, 845-850.	1.9	48
1954	Glioblastoma multiforme: State of the art and future therapeutics. , 2014, 5, 64.		223
1955	Case comparison and literature review of glioblastoma: A tale of two tumors. , 2014, 5, 121.		4
1956	Drug Resistance in Cancer: An Overview. Cancers, 2014, 6, 1769-1792.	1.7	1,810
1957	ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents. Cancer Discovery, 2014, 4, 1198-1213.	7.7	55
1958	Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling. Oncology Reports, 2014, 32, 1610-1616.	1.2	65
1959	Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line. International Journal of Oncology, 2014, 45, 411-418.	1.4	37
1960	Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls. CNS Oncology, 2014, 3, 287-298.	1.2	10
1961	An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. Journal of Neurosurgery, 2014, 120, 846-853.	0.9	217
1963	Genomic landscape of glioblastoma and the potential clinical utility. CNS Oncology, 2014, 3, 169-172.	1.2	0
1965	Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature. Experimental Hematology and Oncology, 2014, 3, 29.	2.0	3
1966	Culturally and linguistically diverse patient participation in glioma research. Neuro-Oncology Practice, 2014, 1, 101-105.	1.0	11
1968	Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging. Journal of Neurosurgery, 2014, 121, 367-373.	0.9	77
1969	Metronomic Chemotherapy. , 2014, , .		3
1970	Epigenomics – Understanding the Epigenetic Landscape of Cells. , 2014, , .		0
1971	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 2014, 16, 1630-1638.	0.6	77
1972	Epigenetic Therapy of Cancer. , 2014, , .		1



#	ARTICLE	IF	CITATIONS
1973	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). <i>Neuro-Oncology</i> , 2014, 16, 92-102.	0.6	57
1974	Glioblastoma: Background, Standard Treatment Paradigms, and Supportive Care Considerations. <i>Journal of Law, Medicine and Ethics</i> , 2014, 42, 171-182.	0.4	71
1976	<i>SDHB</i> mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. <i>International Journal of Cancer</i> , 2014, 135, 2711-2720.	2.3	155
1977	In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4542-4547.	3.3	168
1978	Comparison between poor and long-term survivors with glioblastoma: Review of an Australian dataset. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 153-161.	0.7	26
1979	High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii93-iii101.	0.6	532
1980	Emerging drugs for acromegaly. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 79-97.	1.0	9
1981	Meningeal hemangiopericytomas: A clinicopathological study with emphasis on <i>MGMT</i> ( <i>OM6</i> methylguanine- <i>8</i> DNA methyltransferase) promoter methylation status. <i>Neuropathology</i> , 2014, 34, 333-342.	0.7	2
1982	Management of high-grade gliomas in the pediatric patient: Past, present, and future. <i>Neuro-Oncology Practice</i> , 2014, 1, 145-157.	1.0	31
1983	Stereotactic Radiosurgery for Recurrent High-Grade Gliomas. <i>World Neurosurgery</i> , 2014, 82, e593-e595.	0.7	6
1984	Use of High-Resolution Volumetric MR Spectroscopic Imaging in Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor. <i>American Journal of Roentgenology</i> , 2014, 203, W158-W165.	1.0	13
1985	Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. <i>Neurosurgical Focus</i> , 2014, 37, E12.	1.0	136
1986	Deletion of the <i>MGMT</i> gene in familial melanoma. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 703-711.	1.5	4
1987	Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells <i>In Vitro</i> and <i>In Vivo</i> and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival. <i>Clinical Cancer Research</i> , 2014, 20, 5756-5767.	3.2	46
1988	Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. <i>International Journal of Cancer</i> , 2014, 134, 2437-2447.	2.3	100
1989	Increased Expression of <i>Capn4</i> is Associated with the Malignancy of Human Glioma. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 521-527.	1.9	20
1990	Underutilization of radiation therapy in patients with glioblastoma. <i>Cancer</i> , 2014, 120, 238-243.	2.0	30
1991	Glioblastoma stem-like cells: approaches for isolation and characterization. <i>Journal of Cancer Stem Cell Research</i> , 2014, 1, 1.	1.1	12

#	ARTICLE	IF	CITATIONS
1992	Hospitalization burden and survival among older glioblastoma patients. <i>Neuro-Oncology</i> , 2014, 16, 1530-1540.	0.6	31
1993	Beating the odds: extreme long-term survival with glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1159-1160.	0.6	63
1994	DNA Methylation as a Biomarker in Cancer. , 2014, , 1-22.		0
1995	Assessment and treatment relevance in elderly glioblastoma patients. <i>Neuro-Oncology</i> , 2014, 16, 1459-1468.	0.6	34
1996	Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. <i>BMC Cancer</i> , 2014, 14, 17.	1.1	106
1997	Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. <i>Clinical Epigenetics</i> , 2014, 6, 22.	1.8	19
1998	Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. <i>Acta Neuropathologica Communications</i> , 2014, 2, 68.	2.4	29
1999	Feasibility and Outcomes of Hypofractionated Simultaneous Integrated Boost-Intensity Modulated Radiotherapy for Malignant Gliomas: A Preliminary Report. <i>Yonsei Medical Journal</i> , 2014, 55, 70.	0.9	2
2000	Treatment of glioblastoma in elderly patients. <i>CNS Oncology</i> , 2014, 3, 159-167.	1.2	3
2001	Molecular Genetics of Gliomas. <i>Cancer Journal (Sudbury, Mass )</i> , 2014, 20, 66-72.	1.0	93
2002	Paclitaxel Poliglumex, Temozolomide, and Radiation for Newly Diagnosed High-grade Glioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 444-449.	0.6	43
2003	Limited Margins Using Modern Radiotherapy Techniques Does Not Increase Marginal Failure Rate of Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 177-181.	0.6	69
2004	A Randomized Clinical Trial of Vascular Endothelial Growth Factor Inhibition in the Treatment of Glioblastoma Multiforme. <i>Neurosurgery</i> , 2014, 74, N14-N17.	0.6	0
2005	Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas?. <i>Anti-Cancer Drugs</i> , 2014, 25, 375-384.	0.7	5
2006	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 409-414.	3.3	152
2007	Multiplex mapping of chromatin accessibility and DNA methylation within targeted single molecules identifies epigenetic heterogeneity in neural stem cells and glioblastoma. <i>Genome Research</i> , 2014, 24, 329-339.	2.4	51
2009	DNA Methylation Abnormalities in Hematopoietic Disorders: Biological Significance and Methodological Approaches. , 2014, , 107-120.		0
2010	Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2014, 120, 155-161.	1.4	19

#	ARTICLE	IF	CITATIONS
2011	Clinical Trials Using LV-P140K-MGMT for Gliomas. , 2014, , 379-391.		4
2012	RNA Interference Therapeutics for Tumor Therapy. , 2014, , 393-408.		4
2013	Emerging Therapies for Glioblastoma. JAMA Neurology, 2014, 71, 1437.	4.5	148
2014	Prognostic Impact of MGMT Promoter Methylation in Glioblastoma - A Systematic Review. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	2
2015	Discordant <i>In Vitro</i> and <i>In Vivo</i> Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts. Clinical Cancer Research, 2014, 20, 3730-3741.	3.2	64
2016	Evidence of association of human papillomavirus with prognosis worsening in glioblastoma multiforme. Neuro-Oncology, 2014, 16, 298-302.	0.6	34
2017	Epigenetic inactivation of DNA repair in breast cancer. Cancer Letters, 2014, 342, 213-222.	3.2	27
2018	Phase 2 Trial of Hypofractionated High-Dose Intensity Modulated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2014, 88, 793-800.	0.4	87
2019	Inter-individual variation in DNA repair capacity: A need for multi-pathway functional assays to promote translational DNA repair research. DNA Repair, 2014, 19, 199-213.	1.3	75
2020	How Much Is Enough? The Question of Extent of Resection in Glioblastoma Multiforme. World Neurosurgery, 2014, 82, e109-e110.	0.7	15
2021	Brain tumor stem cells: Molecular characteristics and their impact on therapy. Molecular Aspects of Medicine, 2014, 39, 82-101.	2.7	164
2022	Promoter hypermethylation of <i>CDKN2A</i> , <i>MGMT</i> , <i>MLH1</i> , and <i>DAPK</i> genes in laryngeal squamous cell carcinoma and their associations with clinical profiles of the patients. Head and Neck, 2014, 36, 1103-1108.	0.9	42
2023	Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma. Medical Molecular Morphology, 2014, 47, 8-13.	0.4	2
2024	Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. International Journal of Cancer, 2014, 134, 1300-1310.	2.3	27
2025	Brain and Spinal Cord. , 2014, , 1384-1426.		0
2026	Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. Clinical and Translational Oncology, 2014, 16, 273-279.	1.2	13
2027	Tumor-associated mutations in <i>O<sup>6</sup></i> -methylguanine DNA-methyltransferase (MGMT) reduce DNA repair functionality. Molecular Carcinogenesis, 2014, 53, 201-210.	1.3	11
2028	Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. Journal of Neuro-Oncology, 2014, 116, 357-363.	1.4	39

#	ARTICLE	IF	CITATIONS
2029	Methylation-specific multiplex ligation-dependent probe amplification and its impact on clinical findings in medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 116, 213-220.	1.4	8
2030	Prognostic and Predictive Biomarkers: Tools in Personalized Oncology. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 273-284.	1.6	132
2031	Systematic Review of Protein Biomarkers of Invasive Behavior in Glioblastoma. <i>Molecular Neurobiology</i> , 2014, 49, 1212-1244.	1.9	28
2032	Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide. <i>Annals of Surgical Oncology</i> , 2014, 21, 1337-1344.	0.7	80
2033	Hypoxia upregulates aldehyde dehydrogenase isoform 1 (ALDH1) expression and induces functional stem cell characteristics in human glioblastoma cells. <i>Brain Tumor Pathology</i> , 2014, 31, 247-256.	1.1	20
2034	Clinical radiobiology of glioblastoma multiforme. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 925-932.	1.0	45
2035	Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. <i>Neuro-Oncology</i> , 2014, 16, 1067-1077.	0.6	23
2036	Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. <i>Neuro-Oncology</i> , 2014, 16, 123-130.	0.6	23
2037	Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study. <i>Journal of Clinical Pathology</i> , 2014, 67, 550-555.	1.0	19
2038	H3F3A K27M mutations in thalamic gliomas from young adult patients. <i>Neuro-Oncology</i> , 2014, 16, 140-146.	0.6	151
2039	MicroRNA as potential modulators in chemoresistant high-grade gliomas. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 395-400.	0.8	39
2040	Transcriptional diversity of long-term glioblastoma survivors. <i>Neuro-Oncology</i> , 2014, 16, 1186-1195.	0.6	69
2041	Glioblastoma cancer stem cells: Biomarker and therapeutic advances. <i>Neurochemistry International</i> , 2014, 71, 1-7.	1.9	62
2042	Current concepts in clinical radiation oncology. <i>Radiation and Environmental Biophysics</i> , 2014, 53, 1-29.	0.6	143
2043	Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation. <i>Journal of Neuro-Oncology</i> , 2014, 117, 77-84.	1.4	20
2044	NDRG1 prognosticates the natural course of disease in WHO grade II glioma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 25-32.	1.4	19
2045	Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 85-92.	1.4	11
2046	Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 243-251.	1.4	12

#	ARTICLE	IF	CITATIONS
2047	Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. <i>International Journal of Clinical Oncology</i> , 2014, 19, 16-23.	1.0	15
2048	Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. <i>Neurosurgical Review</i> , 2014, 37, 415-424.	1.2	37
2049	MGMT promoter methylation in plasma of glioma patients receiving temozolomide. <i>Journal of Neuro-Oncology</i> , 2014, 117, 347-357.	1.4	43
2050	Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme. <i>Radiation Oncology</i> , 2014, 9, 20.	1.2	14
2051	Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2014, 116, 487-496.	1.4	56
2052	Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. <i>Journal of Hematology and Oncology</i> , 2014, 7, 4.	6.9	21
2053	Brain tumor senescence might be mediated by downregulation of S-phase kinase-associated protein 2 via butylidenephthalide leading to decreased cell viability. <i>Tumor Biology</i> , 2014, 35, 4875-4884.	0.8	24
2054	Polymersomes conjugated with des-octanoyl ghrelin and folate as a BBB-penetrating cancer cell-targeting delivery system. <i>Biomaterials</i> , 2014, 35, 4066-4081.	5.7	73
2055	Tumors of the Central Nervous System, Volume 12. <i>Tumors of the Central Nervous System</i> , 2014, , .	0.1	0
2056	Current management of choroid plexus carcinomas. <i>Neurosurgical Review</i> , 2014, 37, 179-192.	1.2	56
2057	Ex vivo cultures of glioblastoma in three-dimensional hydrogel maintain the original tumor growth behavior and are suitable for preclinical drug and radiation sensitivity screening. <i>Experimental Cell Research</i> , 2014, 321, 99-108.	1.2	57
2058	Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1823-32.	3.3	114
2059	Epigenetics and Oncology. <i>Pharmacotherapy</i> , 2014, 34, 495-505.	1.2	47
2060	Using the molecular classification of glioblastoma to inform personalized treatment. <i>Journal of Pathology</i> , 2014, 232, 165-177.	2.1	214
2061	Molecular Testing in Cancer. , 2014, , .		2
2062	Inhibition of DNA Repair as a Therapeutic Target. , 2014, , 193-237.		0
2063	Update on Anti-angiogenic Treatment for Malignant Gliomas. <i>Current Oncology Reports</i> , 2014, 16, 380.	1.8	19
2064	Key determinants of short-term and long-term glioblastoma survival: A 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital. <i>Clinical Neurology and Neurosurgery</i> , 2014, 120, 103-112.	0.6	42

#	ARTICLE	IF	CITATIONS
2065	<i>miR-218</i> opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 291-296.	3.3	101
2066	A mesenchymal glioma stem cell profile is related to clinical outcome. <i>Oncogenesis</i> , 2014, 3, e91-e91.	2.1	54
2067	The epidemiology of glioma in adults: a "state of the science" review. <i>Neuro-Oncology</i> , 2014, 16, 896-913.	0.6	1,586
2068	Inhibition of EGFR Induces a c-MET-Driven Stem Cell Population in Glioblastoma. <i>Stem Cells</i> , 2014, 32, 338-348.	1.4	52
2069	MALDI imaging and in-source decay for top-down characterization of glioblastoma. <i>Proteomics</i> , 2014, 14, 1290-1301.	1.3	27
2070	Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. <i>Acta Neurochirurgica</i> , 2014, 156, 1427-1440.	0.9	51
2071	Pathology of Gliomas and Developments in Molecular Testing. <i>Clinical Oncology</i> , 2014, 26, 377-384.	0.6	5
2072	Current and Investigational Drug Strategies for Glioblastoma. <i>Clinical Oncology</i> , 2014, 26, 419-430.	0.6	31
2073	Long-term survival of children less than six years of age enrolled on the CCG945 phase III trial for newly diagnosed high-grade glioma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 151-157.	0.8	19
2074	Glioblastomas are composed of genetically divergent clones with distinct tumorigenic potential and variable stem cell-associated phenotypes. <i>Acta Neuropathologica</i> , 2014, 127, 203-219.	3.9	97
2075	Nanotherapeutic approaches for brain cancer management. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, e905-e919.	1.7	87
2076	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. <i>Nature Reviews Cancer</i> , 2014, 14, 92-107.	12.8	469
2077	Mining cancer methylomes: prospects and challenges. <i>Trends in Genetics</i> , 2014, 30, 75-84.	2.9	180
2078	Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. <i>Neuro-Oncology</i> , 2014, 16, 719-727.	0.6	68
2079	Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 45-51.	1.2	57
2080	The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection. <i>Journal of Neuro-Oncology</i> , 2014, 116, 25-30.	1.4	15
2081	Tumors of the Central Nervous System, Volume 13. <i>Tumors of the Central Nervous System</i> , 2014, , .	0.1	3
2083	Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium. <i>Photodiagnosis and Photodynamic Therapy</i> , 2014, 11, 556-564.	1.3	5

#	ARTICLE	IF	CITATIONS
2084	Confounding Factors in Diagnostics of <i>MGMT</i> ; Promoter Methylation Status in Glioblastomas in Stereotactic Biopsies. <i>Stereotactic and Functional Neurosurgery</i> , 2014, 92, 129-139.	0.8	13
2085	Compendium of aberrant DNA methylation and histone modifications in cancer. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 3-9.	1.0	58
2086	Epigenetic Changes in Gliomas. , 2014, , 23-45.		0
2087	The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma. <i>Clinical Cancer Research</i> , 2014, 20, 5601-5611.	3.2	53
2088	Glioma Cell Biology. , 2014, , .		3
2089	<i>4E-BP1</i> regulates the sensitivity of human glioma cells to chemotherapy through <i>PI3K/Akt/mTOR</i> -independent pathway. <i>Neuropathology</i> , 2014, 34, 227-235.	0.7	5
2090	Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians. <i>CNS Drugs</i> , 2014, 28, 1127-1137.	2.7	10
2092	Development of barcode and proteome profiling of glioblastoma. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2014, 8, 243-251.	0.2	6
2093	Temozolomide Induces the Production of Epidermal Growth Factor to Regulate <i>MDR1</i> Expression in Glioblastoma Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2399-2411.	1.9	72
2094	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	3.2	89
2095	Spinal metastasis of gliosarcoma: Array-based comparative genomic hybridization for confirmation of metastatic spread. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1945-1950.	0.8	8
2096	<sup>11</sup> C-methinine uptake correlates with <i>MGMT</i> promoter methylation in nonenhancing gliomas. <i>Clinical Neurology and Neurosurgery</i> , 2014, 125, 212-216.	0.6	39
2097	DNA methylation and personalized medicine. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 621-627.	0.7	32
2098	Evaluating the sensitivity of hybridization-based epigenotyping using a methyl binding domain protein. <i>The Analyst</i> , 2014, 139, 3695-3701.	1.7	23
2099	Phase II trial of 7 days on/7 days off temozolomide for recurrent high-grade glioma. <i>Neuro-Oncology</i> , 2014, 16, 1255-1262.	0.6	44
2100	Pan-cancer patterns of DNA methylation. <i>Genome Medicine</i> , 2014, 6, 66.	3.6	149
2102	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014, 32, 1634-1635.	0.8	2
2103	Targeting adaptive glioblastoma: an overview of proliferation and invasion. <i>Neuro-Oncology</i> , 2014, 16, 1575-1584.	0.6	206

#	ARTICLE	IF	CITATIONS
2104	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108.	5.1	800
2105	Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. <i>CNS Oncology</i> , 2014, 3, 257-265.	1.2	6
2106	Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective. <i>Journal of Neuro-Oncology</i> , 2014, 119, 481-490.	1.4	20
2107	Diagnostic and prognostic value of preoperative combined GFAP, IGFBP $\alpha$ 2, and YKL $\alpha$ 40 plasma levels in patients with glioblastoma. <i>Cancer</i> , 2014, 120, 3972-3980.	2.0	69
2108	Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies. <i>Seminars in Oncology</i> , 2014, 41, 511-522.	0.8	21
2109	Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma. <i>Cancer Research</i> , 2014, 74, 1752-1765.	0.4	129
2110	Genetic Markers in Adult High-Grade Gliomas. <i>Seminars in Radiation Oncology</i> , 2014, 24, 235-239.	1.0	2
2111	Section III: Molecular diagnostics in neuro-oncology. <i>Current Problems in Cancer</i> , 2014, 38, 175-179.	1.0	6
2112	Novel <i>MSH6</i> Mutations in Treatment-Na $\tilde{v}$ e Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of <i>MGMT</i> Promoter Methylation. <i>Clinical Cancer Research</i> , 2014, 20, 4894-4903.	3.2	51
2113	The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. <i>Neuro-Oncology</i> , 2014, 16, 1263-1273.	0.6	159
2114	DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 43-57.	1.0	139
2116	Radiation Therapy Dose Escalation for Glioblastoma Multiforme in the Era of Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 877-885.	0.4	49
2117	The Impact of Adjuvant Radiation Therapy for High-Grade Gliomas by Histology in the United States Population. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 894-902.	0.4	23
2118	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology</i> , The, 2014, 15, e395-e403.	5.1	647
2119	Cancer stem cells and radioresistance. <i>International Journal of Radiation Biology</i> , 2014, 90, 615-621.	1.0	214
2120	MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 579-586.	1.4	12
2121	Glioma di alto grado: astrocitoma anaplastico e glioblastoma. <i>EMC - Neurologia</i> , 2014, 14, 1-10.	0.0	0
2122	Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma. <i>Nanoscale</i> , 2014, 6, 10865-10873.	2.8	111



#	ARTICLE	IF	CITATIONS
2123	Epidemiologic and Molecular Prognostic Review of Glioblastoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1985-1996.	1.1	933
2124	Post-Treatment Imaging Changes in Primary Brain Tumors. <i>Current Oncology Reports</i> , 2014, 16, 397.	1.8	31
2125	Epigenetic epidemiology of cancer. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 70-83.	1.0	88
2126	Is the absolute value of O6-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?. <i>Journal of Neurosurgery</i> , 2014, 121, 818-826.	0.9	10
2127	Molecular profiling of childhood cancer: Biomarkers and novel therapies. <i>BBA Clinical</i> , 2014, 1, 59-77.	4.1	34
2128	Changing incidence and improved survival of gliomas. <i>European Journal of Cancer</i> , 2014, 50, 2309-2318.	1.3	176
2129	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. <i>Lancet Oncology</i> , 2014, 15, 943-953.	5.1	639
2130	Interferon- $\gamma$ Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 948-961.	1.9	47
2131	Immunohistochemical evaluation of O <sup>6</sup> -methylguanine-DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma. <i>Neuropathology</i> , 2014, 34, 268-276.	0.7	18
2132	Case 8-2014. <i>New England Journal of Medicine</i> , 2014, 370, 1049-1059.	13.9	2
2133	miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. <i>Cell Death and Disease</i> , 2014, 5, e1279-e1279.	2.7	70
2134	Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models. <i>Clinical Cancer Research</i> , 2014, 20, 1555-1565.	3.2	32
2135	Towards developing biomarkers for glioblastoma multiforme: a proteomics view. <i>Expert Review of Proteomics</i> , 2014, 11, 621-639.	1.3	33
2136	Poised epigenetic states and acquired drug resistance in cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 747-753.	12.8	252
2137	Predictive biomarkers investigated in glioblastoma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 883-893.	1.5	16
2138	Molecular Neuro-oncology and the Challenge of the Blood-Brain Barrier. <i>Seminars in Oncology</i> , 2014, 41, 438-445.	0.8	12
2139	Molecular and genetic pathways in gliomas: the future of personalized therapeutics. <i>CNS Oncology</i> , 2014, 3, 123-136.	1.2	22
2140	CNS macrophages and peripheral myeloid cells in brain tumours. <i>Acta Neuropathologica</i> , 2014, 128, 347-362.	3.9	129

#	ARTICLE	IF	CITATIONS
2141	A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors. <i>Acta Neuropathologica</i> , 2014, 128, 39-54.	3.9	139
2142	Cancer genomics identifies disrupted epigenetic genes. <i>Human Genetics</i> , 2014, 133, 713-725.	1.8	47
2143	Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. <i>Medical Molecular Morphology</i> , 2014, 47, 1-7.	0.4	18
2144	Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. <i>Neurosurgical Review</i> , 2014, 37, 73-78.	1.2	21
2145	microRNA Expression Pattern Modulates Temozolomide Response in GBM Tumors with Cancer Stem Cells. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 679-692.	1.7	36
2146	Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. <i>Investigational New Drugs</i> , 2014, 32, 604-617.	1.2	58
2147	MGMT promoter methylation status in clival chordoma. <i>Journal of Neuro-Oncology</i> , 2014, 118, 271-276.	1.4	18
2148	Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors. <i>Journal of Neuro-Oncology</i> , 2014, 119, 177-185.	1.4	35
2149	The proteomic response in glioblastoma in young patients. <i>Journal of Neuro-Oncology</i> , 2014, 119, 79-89.	1.4	14
2150	Biological significance of the CpG island methylator phenotype. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 35-42.	1.0	86
2151	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , 2014, 25, 404-408.	0.6	67
2152	An Epigenetic Biomarker Panel for Glioblastoma Multiforme Personalized Medicine through DNA Methylation Analysis of Human Embryonic Stem Cell-like Signature. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 310-323.	1.0	23
2153	Medical therapy of gliomas. <i>Journal of Neuro-Oncology</i> , 2014, 119, 503-512.	1.4	15
2154	Combination Treatment with Theranostic Nanoparticles for Glioblastoma Sensitization to TMZ. <i>Molecular Imaging and Biology</i> , 2014, 16, 680-689.	1.3	37
2155	Role of Surgical Resection in Low- and High-Grade Gliomas. <i>Current Treatment Options in Neurology</i> , 2014, 16, 284.	0.7	134
2156	Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. <i>Medical Oncology</i> , 2014, 31, 985.	1.2	89
2157	MicroRNA Expression Signatures Determine Prognosis and Survival in Glioblastoma Multiforme—a Systematic Overview. <i>Molecular Neurobiology</i> , 2014, 50, 896-913.	1.9	53
2158	Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. <i>BMC Cancer</i> , 2014, 14, 151.	1.1	64

#	ARTICLE	IF	CITATIONS
2159	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of <i>IDH1</i> . <i>Journal of Clinical Oncology</i> , 2014, 32, 783-790.	0.8	356
2160	Principles of Surgery for Malignant Astrocytomas. <i>Seminars in Oncology</i> , 2014, 41, 523-531.	0.8	4
2161	Validation of DNA Methylation Biomarkers for Diagnosis of Acute Lymphoblastic Leukemia. <i>Clinical Chemistry</i> , 2014, 60, 995-1003.	1.5	20
2162	High-Throughput Screening (HTS) of Anticancer Drug Efficacy on a Micropillar/Microwell Chip Platform. <i>Analytical Chemistry</i> , 2014, 86, 535-542.	3.2	90
2163	Case presentation “A five-year survival of the patient with glioblastoma brain tumor. <i>Reports of Practical Oncology and Radiotherapy</i> , 2014, 19, 347-351.	0.3	5
2164	Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype. <i>Neuro-Oncology</i> , 2014, 16, 361-371.	0.6	42
2165	Polyunsaturated fatty acids and gliomas: A critical review of experimental, clinical, and epidemiologic data. <i>Nutrition</i> , 2014, 30, 1104-1109.	1.1	15
2166	Implications of MGMT methylation status in pituitary adenoma. <i>Pathology Research and Practice</i> , 2014, 210, 407-411.	1.0	8
2167	Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells. <i>Leukemia Research</i> , 2014, 38, 138-143.	0.4	26
2168	A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. <i>Lancet Oncology</i> , The, 2014, 15, e184-e193.	5.1	30
2169	When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved?. <i>World Neurosurgery</i> , 2014, 82, e257-e265.	0.7	140
2170	A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival. <i>ACS Nano</i> , 2014, 8, 5494-5514.	7.3	130
2171	MGMT testing—the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , 2014, 10, 372-385.	4.9	454
2172	IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. <i>Journal of Neuro-Oncology</i> , 2014, 118, 377-383.	1.4	53
2173	Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 832-838.	2.8	79
2174	Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models. <i>Journal of Controlled Release</i> , 2014, 187, 74-82.	4.8	94
2175	The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 326-341.	3.3	118
2176	Epigenetics in radiotherapy: Where are we heading?. <i>Radiotherapy and Oncology</i> , 2014, 111, 168-177.	0.3	43

#	ARTICLE	IF	CITATIONS
2177	Current Concepts in the Surgical Management of Glioma Patients. <i>Clinical Oncology</i> , 2014, 26, 385-394.	0.6	29
2178	Management of Central Nervous System Tumours in The Elderly. <i>Clinical Oncology</i> , 2014, 26, 431-437.	0.6	11
2179	Epigenetics in human gliomas. <i>Cancer Letters</i> , 2014, 342, 185-192.	3.2	48
2180	Treatment of Pituitary Carcinomas and Atypical Pituitary Adenomas: A Review. <i>Neurologia Medico-Chirurgica</i> , 2014, 54, 966-973.	1.0	12
2181	Emerging treatment strategies for glioblastoma multiforme. <i>EMBO Molecular Medicine</i> , 2014, 6, 1359-1370.	3.3	280
2182	Harnessing the potential of epigenetic therapy to target solid tumors. <i>Journal of Clinical Investigation</i> , 2014, 124, 56-63.	3.9	130
2183	DNA Methylation Biomarkers: Cancer and Beyond. <i>Genes</i> , 2014, 5, 821-864.	1.0	236
2185	Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients. <i>Oncology Reports</i> , 2014, 31, 1683-1690.	1.2	24
2186	Establishment and genetic characterization of ANGM-CSS, a novel, immortal cell line derived from a human glioblastoma multiforme. <i>International Journal of Oncology</i> , 2014, 44, 717-724.	1.4	7
2189	The Comprehensive Neuro-Oncology Data Repository (CONDR). <i>Neurosurgery</i> , 2014, 74, 88-98.	0.6	8
2190	The Continuing Evolution: Biology and Treatment of Brain Tumors. <i>Neurosurgery</i> , 2014, 61, 100-104.	0.6	6
2191	Evolution of Malignant Glioma Treatment. <i>Neurosurgery</i> , 2014, 61, 74-83.	0.6	18
2192	YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. <i>Oncology Reports</i> , 2014, 32, 159-166.	1.2	32
2194	Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma. <i>Clinical Neurology and Neurosurgery</i> , 2015, 138, 37-44.	0.6	30
2195	Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors. <i>Molecular Pharmaceutics</i> , 2015, 12, 3924-3934.	2.3	18
2196	Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. <i>Journal of Medical Radiation Sciences</i> , 2015, 62, 92-98.	0.8	35
2197	PALM-IST: Pathway Assembly from Literature Mining - an Information Search Tool. <i>Scientific Reports</i> , 2015, 5, 10021.	1.6	21
2198	Glioma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15017.	18.1	718

#	ARTICLE	IF	CITATIONS
2199	Leukemia cells are sensitized to temozolomide, carmustine and melphalan by the inhibition of O6-methylguanine-DNA methyltransferase. <i>Oncology Letters</i> , 2015, 10, 845-849.	0.8	8
2201	A Surveillance, Epidemiology and End Results-Medicare data analysis of elderly patients with glioblastoma multiforme: Treatment patterns, outcomes and cost. <i>Molecular and Clinical Oncology</i> , 2015, 3, 971-978.	0.4	27
2203	Dose-dense Temozolomide: Is It Still Promising?. <i>Neurologia Medico-Chirurgica</i> , 2015, 55, 38-49.	1.0	15
2205	Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison. <i>Scientific Reports</i> , 2015, 5, 15375.	1.6	17
2206	PCMDB: Pancreatic Cancer Methylation Database. <i>Scientific Reports</i> , 2014, 4, 4197.	1.6	28
2207	Interferon- $\beta$ and temozolomide combination therapy for temozolomide monotherapy-refractory malignant gliomas. <i>Molecular and Clinical Oncology</i> , 2015, 3, 909-913.	0.4	15
2208	Effect of temozolomide on the viability of musculoskeletal sarcoma cells. <i>Oncology Letters</i> , 2015, 10, 2511-2518.	0.8	4
2209	Expression profiling of O6 methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases. <i>BMC Cancer</i> , 2015, 15, 644.	1.1	8
2210	PO69THE IMPACT OF MGMT METHYLATION AND IDH-1 MUTATION ON LONG TERM OUTCOME FOR GLIOBLASTOMA TREATED WITH CHEMORADIOTHERAPY. <i>Neuro-Oncology</i> , 2015, 17, viii12.5-viii12.	0.6	0
2211	Extracranial metastasis of glioblastoma: Three illustrative cases and current review of the molecular pathology and management strategies. <i>Molecular and Clinical Oncology</i> , 2015, 3, 479-486.	0.4	55
2212	Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. <i>Molecular Cancer</i> , 2015, 14, 189.	7.9	38
2213	Quantitative analysis of DNA methylation in the promoter region of the methylguanine-O <sup>6</sup> -DNA-methyltransferase gene by COBRA and subsequent native capillary gel electrophoresis. <i>Electrophoresis</i> , 2015, 36, 2939-2950.	1.3	3
2214	Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival. <i>BMC Cancer</i> , 2015, 15, 839.	1.1	55
2215	TMEM140 is associated with the prognosis of glioma by promoting cell viability and invasion. <i>Journal of Hematology and Oncology</i> , 2015, 8, 89.	6.9	30
2216	Review of the development of DNA methylation as a marker of response to neoadjuvant therapy and outcomes in rectal cancer. <i>Clinical Epigenetics</i> , 2015, 7, 70.	1.8	17
2217	Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma. <i>Clinical Epigenetics</i> , 2015, 7, 107.	1.8	21
2218	Frequency of O <sup>6</sup> -methylguanine-DNA-methyltransferase promoter methylation in cytological samples from small cell lung cancer. <i>Diagnostic Cytopathology</i> , 2015, 43, 947-952.	0.5	13
2219	Outcomes in Reoperated Low-Grade Gliomas. <i>Neurosurgery</i> , 2015, 77, 175-184.	0.6	54

#	ARTICLE	IF	CITATIONS
2220	Imaging Genomics in Gliomas. Cancer Journal (Sudbury, Mass ), 2015, 21, 225-234.	1.0	22
2221	Immunohistochemical profiles of $\Delta$ 1, MGMT and P53: Practical significance for prognostication of patients with diffuse gliomas. Neuropathology, 2015, 35, 324-335.	0.7	52
2222	Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice. Cancer, 2015, 121, 3428-3434.	2.0	38
2223	Imaging of the Posttherapeutic Brain. Topics in Magnetic Resonance Imaging, 2015, 24, 147-154.	0.7	9
2224	Management of diffusely infiltrating glioma in the elderly. Current Opinion in Oncology, 2015, 27, 502-509.	1.1	8
2225	Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 514-519.	0.6	50
2226	Imaging Genomics of Glioblastoma. Topics in Magnetic Resonance Imaging, 2015, 24, 155-163.	0.7	14
2228	Targeted Therapy for Glioblastoma: Lessons Learned and Future Directions. Current Cancer Therapy Reviews, 2015, 11, 44-58.	0.2	0
2229	Pathology and Molecular Classification. , 2015, , .		0
2230	34. Supratentorial Hemispheric Gliomas. , 2015, , .		0
2231	Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation. Oncology Letters, 2015, 9, 2063-2067.	0.8	16
2232	Epigenetics of Glioblastoma Multiforme. Journal of Clinical Research & Bioethics, 2015, 06, .	0.2	1
2233	Recent Molecular Advances in Our Understanding of Glioma. Cureus, 2015, 7, e287.	0.2	10
2234	Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. Journal of Cancer, 2015, 6, 832-842.	1.2	27
2235	BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo. OncoTargets and Therapy, 2015, 8, 689.	1.0	13
2236	Autophagy in Human Brain Cancer. , 2015, , 105-120.		1
2237	DNA Repair and Chemotherapy. , 0, , .		1
2238	DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes. Epigenetic Diagnosis & Therapy, 2015, 1, 37-48.	0.1	8

#	ARTICLE	IF	CITATIONS
2239	Personalized Medicine in Cancer. Journal of Bangladesh College of Physicians & Surgeons, 2015, 32, 153-163.	0.0	0
2240	Histone H3 Phosphorylation in GBM: a New Rational to Guide the Use of Kinase Inhibitors in anti-GBM Therapy. Theranostics, 2015, 5, 12-22.	4.6	33
2241	Direct Reversal Repair in Mammalian Cells. , 0, , .		3
2242	Modern Brain Tumor Imaging. Brain Tumor Research and Treatment, 2015, 3, 8.	0.4	157
2243	Metabolomic Screening of Tumor Tissue and Serum in Glioma Patients Reveals Diagnostic and Prognostic Information. Metabolites, 2015, 5, 502-520.	1.3	63
2244	Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. Frontiers in Oncology, 2015, 5, 147.	1.3	91
2245	Targeting Aggressive Cancer Stem Cells in Glioblastoma. Frontiers in Oncology, 2015, 5, 159.	1.3	107
2246	Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence. Frontiers in Oncology, 2015, 5, 251.	1.3	77
2247	Combined Epidermal Growth Factor Receptor and Beclin1 Autophagic Protein Expression Analysis Identifies Different Clinical Presentations, Responses to Chemo- and Radiotherapy, and Prognosis in Glioblastoma. BioMed Research International, 2015, 2015, 1-13.	0.9	18
2248	MGMT Promoter Methylation and Glioblastoma: A Comparison of Analytical Methods and of Tumor Specimens. International Journal of Biological Markers, 2015, 30, 208-216.	0.7	18
2249	Comprehensive Glycomics of a Multistep Human Brain Tumor Model Reveals Specific Glycosylation Patterns Related to Malignancy. PLoS ONE, 2015, 10, e0128300.	1.1	28
2250	IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLoS ONE, 2015, 10, e0130596.	1.1	54
2251	A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells. PLoS ONE, 2015, 10, e0136669.	1.1	69
2252	Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance. PLoS ONE, 2015, 10, e0140528.	1.1	38
2253	Nonsurgical Treatment of Recurrent Glioblastoma. Current Oncology, 2015, 22, 273-281.	0.9	228
2254	Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. BioMed Research International, 2015, 2015, 1-10.	0.9	50
2255	The Oncofetal Protein IMP3: A Novel Grading Tool and Predictor of Poor Clinical Outcome in Human Gliomas. BioMed Research International, 2015, 2015, 1-10.	0.9	12
2256	Molecular Markers in the Diagnosis and Treatment of Cancer. BioMed Research International, 2015, 2015, 1-2.	0.9	2

#	ARTICLE	IF	CITATIONS
2257	Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-5.	0.2	4
2258	Epigenetics of Meningiomas. <i>BioMed Research International</i> , 2015, 2015, 1-6.	0.9	25
2259	The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma. <i>Disease Markers</i> , 2015, 2015, 1-6.	0.6	14
2260	A Role of Boron Neutron Capture Therapy in the Multimodal Treatment for Malignant Glioma. <i>Radioisotopes</i> , 2015, 64, 79-91.	0.1	0
2261	Targeting DNA Repair Mechanisms to Treat Glioblastoma. , 0, , .		6
2263	Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets. <i>Oncotarget</i> , 2015, 6, 12234-12247.	0.8	104
2266	Can Elderly Patients With Newly Diagnosed Glioblastoma be Enrolled in Radiochemotherapy Trials?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 23-27.	0.6	29
2267	Anti-tumoral Effects of miR-3189-3p in Glioblastoma. <i>Journal of Biological Chemistry</i> , 2015, 290, 8067-8080.	1.6	28
2269	Potential of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells. <i>Purinergic Signalling</i> , 2015, 11, 331-346.	1.1	27
2270	Personalized Epigenetics. , 2015, , 123-150.		0
2271	Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1219-1226.	0.8	41
2272	Brain Tumor Imaging. <i>Medical Radiology</i> , 2015, , 1-9.	0.0	1
2273	Photochemical internalization of bleomycin and temozolomide “ in vitro studies on the glioma cell line F98. <i>Photochemical and Photobiological Sciences</i> , 2015, 14, 1357-1366.	1.6	8
2274	Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy. <i>Oncolytic Virotherapy</i> , 2015, 4, 33.	6.0	11
2275	Malignant Glioma: Viewpoint“Chemotherapy. , 2015, , 279-293.		0
2276	Genomic Applications in Brain Tumors. , 2015, , 321-339.		0
2277	The <i>MGMT</i> promoter SNP rs16906252 is a risk factor for <i>MGMT</i> methylation in glioblastoma and is predictive of response to temozolomide. <i>Neuro-Oncology</i> , 2015, 17, 1589-1598.	0.6	57
2278	Epigenomic Biomarkers for the Advance of Personalized Medicine. <i>Translational Bioinformatics</i> , 2015, , 187-217.	0.0	0



#	ARTICLE	IF	CITATIONS
2279	Oligodendroglioma: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015, 129, 809-827.	3.9	162
2280	Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1131-1137.	1.2	30
2281	CXCR7 and CXCR4 Expressions in Infiltrative Astrocytomas and Their Interactions with HIF1 $\alpha$ Expression and IDH1 Mutation. <i>Pathology and Oncology Research</i> , 2015, 21, 229-240.	0.9	13
2282	Shared Mechanisms of Disease. , 2015, , 407-443.		0
2283	Extracranial growth of glioblastoma multiforme. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1521-1523.	0.8	25
2284	Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 231-238.	0.3	5
2285	Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. <i>Cancer Research</i> , 2015, 75, 3127-3138.	0.4	96
2286	Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM. <i>Scientific Reports</i> , 2015, 5, 7915.	1.6	15
2287	Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). <i>International Journal of Oncology</i> , 2015, 47, 417-428.	1.4	103
2288	AvancÃ©es dans les tumeurs cÃ©rÃ©brales primitives malignes de l'adulte : quels patients transfÃ©rer en rÃ©animation mÃ©dicale?. <i>Reanimation: Journal De La Societe De Reanimation De Langue Francaise</i> , 2015, 24, 424-432.	0.1	1
2289	The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 741-752.	1.4	221
2290	Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma. <i>Tumor Biology</i> , 2015, 36, 8439-8446.	0.8	24
2292	Neuroendocrine Tumours. , 2015, , .		6
2294	Biomarker-driven diagnosis of diffuse gliomas. <i>Molecular Aspects of Medicine</i> , 2015, 45, 87-96.	2.7	71
2295	Adult brainstem gliomas: Correlation of clinical and molecular features. <i>Journal of the Neurological Sciences</i> , 2015, 353, 92-97.	0.3	44
2296	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 694-720.	1.8	83
2297	Mir-21 $\alpha$ Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. <i>Journal of Neuroscience</i> , 2015, 35, 15097-15112.	1.7	53
2298	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2535.	3.8	982

#	ARTICLE	IF	CITATIONS
2299	Oligodendrogliomas: a short history of clinical developments. <i>CNS Oncology</i> , 2015, 4, 281-285.	1.2	4
2300	Advances in the treatment of newly diagnosed glioblastoma. <i>BMC Medicine</i> , 2015, 13, 293.	2.3	36
2301	A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 743-750.	1.2	12
2303	Î²BÎ¶, an atypical member of the inhibitor of nuclear factor kappa B family, is induced by Î³-irradiation in glioma cells, regulating cytokine secretion and associated with poor prognosis. <i>International Journal of Oncology</i> , 2015, 47, 1971-1980.	1.4	17
2304	Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-Î³-lyase function. <i>Oncology Reports</i> , 2015, 33, 1465-1474.	1.2	196
2305	Interferon-Î±/Î² enhances temozolomide activity against MGMT-positive glioma stem-like cells. <i>Oncology Reports</i> , 2015, 34, 2715-2721.	1.2	32
2306	Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells. <i>International Journal of Molecular Medicine</i> , 2015, 36, 1159-1164.	1.8	21
2307	Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. <i>Neuroendocrinology</i> , 2015, 101, 274-288.	1.2	72
2308	Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 722-732.	1.1	33
2309	Repair mechanisms help glioblastoma resist treatment. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 14-20.	0.8	48
2310	Treatment Considerations for MGMT-Unmethylated Glioblastoma. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 507.	2.0	45
2311	Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 506.	2.0	114
2312	Low-Grade Glioma. <i>Cancer Treatment and Research</i> , 2015, 163, 75-87.	0.2	61
2313	Epigenetic DNA Methylation in Radiation Biology: On the Field or on the Sidelines?. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 212-217.	1.2	26
2314	Phase 2 Study of Temozolomide-Based Chemoradiation Therapy for High-Risk Low-Grade Gliomas: Preliminary Results of Radiation Therapy Oncology Group 0424. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 497-504.	0.4	134
2315	Lâ€™Ã©pilepsie associÃ©e aux tumeurs cÃ©rÃ©brales. <i>Pratique Neurologique - FMC</i> , 2015, 6, 19-33.	0.1	0
2316	Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1689-1698.	1.8	142
2317	MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. <i>International Journal of Cancer</i> , 2015, 136, 2844-2853.	2.3	45

#	ARTICLE	IF	CITATIONS
2318	Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastoma. <i>CNS Oncology</i> , 2015, 4, 47-52.	1.2	24
2319	Oligodendroglial Tumors. <i>Molecular Pathology Library</i> , 2015, , 105-120.	0.1	0
2321	The potential for epigenetic analysis of paediatric CNS tumours to improve diagnosis, treatment and prognosis. <i>Annals of Oncology</i> , 2015, 26, 1314-1324.	0.6	10
2322	Glioblastoma in England: 2007–2011. <i>European Journal of Cancer</i> , 2015, 51, 533-542.	1.3	164
2323	Impact on prognosis of the regional distribution of <i>MGMT</i> methylation with respect to the CpG island methylator phenotype and age in glioma patients. <i>Journal of Neuro-Oncology</i> , 2015, 122, 441-450.	1.4	41
2324	Glioblastoma. , 2015, , 909-917.		6
2325	Emulsion PCR Significantly Improves Nonequilibrium Capillary Electrophoresis of Equilibrium Mixtures-Based Aptamer Selection: Allowing for Efficient and Rapid Selection of Aptamer to Unmodified ABH2 Protein. <i>Analytical Chemistry</i> , 2015, 87, 1411-1419.	3.2	64
2326	Radiation Therapy of Glioblastoma. <i>Cancer Treatment and Research</i> , 2015, 163, 49-73.	0.2	80
2327	Prognosis of glioblastoma with faint <i>MGMT</i> methylation-specific PCR product. <i>Journal of Neuro-Oncology</i> , 2015, 122, 179-188.	1.4	24
2328	Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. <i>Neuro-Oncology</i> , 2015, 17, 1148-1156.	0.6	108
2329	Cantharidin induces DNA damage and inhibits DNA repair-associated protein levels in NCI-H460 human lung cancer cells. <i>Environmental Toxicology</i> , 2015, 30, 1135-1143.	2.1	22
2330	Survival and low-grade glioma: the emergence of genetic information. <i>Neurosurgical Focus</i> , 2015, 38, E6.	1.0	358
2331	TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway. <i>Oncogene</i> , 2015, 34, 600-610.	2.6	118
2332	FGF2 as a potential prognostic biomarker for proneural glioma patients. <i>Acta Oncologica</i> , 2015, 54, 385-394.	0.8	22
2333	Clinical impact of molecular biomarkers in gliomas. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 437-444.	0.8	57
2334	Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. <i>Cell Death and Disease</i> , 2015, 6, e1601-e1601.	2.7	202
2335	ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 453-463.	1.2	21
2336	Prognostic Significance of Dynamic <sup>18</sup> F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 9-15.	2.8	144

#	ARTICLE	IF	CITATIONS
2337	The methylation of a panel of genes differentiates low-grade from high-grade gliomas. <i>Tumor Biology</i> , 2015, 36, 3831-3841.	0.8	23
2338	O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. <i>British Journal of Cancer</i> , 2015, 112, 523-531.	2.9	111
2339	A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. <i>International Journal of Clinical Oncology</i> , 2015, 20, 650-658.	1.0	49
2340	Principles of Epigenetic Treatment. , 2015, , 443-465.		0
2341	Keratinocyte Differentiation and Epigenetics. , 2015, , 37-52.		2
2342	Robustness of Equations that Define Molecular Subtypes of Glioblastoma Tumors Based on Five Transcripts Measured by RT-PCR. <i>OMICS A Journal of Integrative Biology</i> , 2015, 19, 41-51.	1.0	2
2343	Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. <i>Drug Discovery Today</i> , 2015, 20, 899-905.	3.2	199
2344	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. <i>Genome Biology</i> , 2015, 16, 16.	3.8	82
2345	Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. <i>Journal of Neuro-Oncology</i> , 2015, 122, 111-119.	1.4	22
2346	Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. <i>Journal of Neuro-Oncology</i> , 2015, 122, 11-20.	1.4	81
2347	Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 685-695.	3.3	216
2348	Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. <i>Journal of Neuro-Oncology</i> , 2015, 121, 573-581.	1.4	30
2349	Liquid biopsies in patients with diffuse glioma. <i>Acta Neuropathologica</i> , 2015, 129, 849-865.	3.9	81
2350	The Cancer Genomics Resource List 2014. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 989-1008.	1.2	18
2351	Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. <i>Acta Neuropathologica</i> , 2015, 129, 597-607.	3.9	143
2352	Incorporation of biomarkers in phase II studies of recurrent glioblastoma. <i>Tumor Biology</i> , 2015, 36, 153-162.	0.8	3
2353	Biomarkers for glioma immunotherapy: the next generation. <i>Journal of Neuro-Oncology</i> , 2015, 123, 359-372.	1.4	23
2354	Histone deacetylases inhibition by SAHA/Morinostat normalizes the glioma microenvironment via xCT equilibration. <i>Scientific Reports</i> , 2014, 4, 6226.	1.6	20

#	ARTICLE	IF	CITATIONS
2355	EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	39
2356	Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. <i>Neurosurgical Focus</i> , 2015, 38, E2.	1.0	42
2357	The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. <i>Journal of Neuro-Oncology</i> , 2015, 122, 263-271.	1.4	44
2358	Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. <i>Cancer</i> , 2015, 121, 1456-1462.	2.0	34
2359	Current evidence of temozolomide and bevacizumab in treatment of gliomas. <i>Neurological Research</i> , 2015, 37, 167-183.	0.6	45
2360	Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy. <i>Clinical Neurology and Neurosurgery</i> , 2015, 132, 1-8.	0.6	17
2361	CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models. <i>Neuro-Oncology</i> , 2015, 17, 1453-1462.	0.6	52
2362	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
2363	Personalized Medicine for Gliomas. , 2015, 6, 89.		31
2364	Molecularly based management of gliomas in clinical practice. <i>Neurological Sciences</i> , 2015, 36, 1551-1557.	0.9	7
2365	DNA-hybrid-gated functional mesoporous silica for sensitive DNA methyltransferase SERS detection. <i>Chemical Communications</i> , 2015, 51, 13983-13985.	2.2	28
2366	Oncostatin-M Differentially Regulates Mesenchymal and Proneural Signature Genes in Gliomas via STAT3 Signaling. <i>Neoplasia</i> , 2015, 17, 225-237.	2.3	44
2367	Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?. <i>Clinical Neurology and Neurosurgery</i> , 2015, 135, 46-53.	0.6	8
2368	Surgical treatment of cervical disc protrusion causing intracranial hypotension following chiropractic manipulation. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1523-1525.	0.8	8
2369	Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK -positive NSCLC: Implications for disease assessment and management. <i>Lung Cancer</i> , 2015, 88, 355-359.	0.9	31
2370	Input of molecular analysis in medical management of primary brain tumor patients. <i>Revue Neurologique</i> , 2015, 171, 457-465.	0.6	2
2371	Progress in the application of molecular biomarkers in gliomas. <i>Biochemical and Biophysical Research Communications</i> , 2015, 465, 1-4.	1.0	50
2372	Identification of Global DNA Methylation Signatures in Glioblastoma-Derived Cancer Stem Cells. <i>Journal of Genetics and Genomics</i> , 2015, 42, 355-371.	1.7	47

#	ARTICLE	IF	CITATIONS
2373	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2735-2744.	0.8	244
2374	P53 stratification reveals the prognostic utility of matrix metalloproteinase-9 protein expression in glioblastoma. <i>Neurology India</i> , 2015, 63, 399.	0.2	4
2375	Personalized Therapyâ€™Epigenetic Profiling as Predictors of Prognosis and Response. , 2015, , 677-698.		1
2376	Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1425-1429.	0.8	4
2377	Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas. <i>Therapeutic Delivery</i> , 2015, 6, 353-369.	1.2	67
2378	Chemoresistance and Chemotherapy Targeting Stem-Like Cells in Malignant Glioma. <i>Advances in Experimental Medicine and Biology</i> , 2015, 853, 111-138.	0.8	43
2379	The influence of different classification standards of age groups on prognosis in high-grade hemispheric glioma patients. <i>Journal of the Neurological Sciences</i> , 2015, 356, 148-152.	0.3	16
2380	Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. <i>Journal of Neuro-Oncology</i> , 2015, 124, 137-146.	1.4	12
2381	Novel Surgical Approaches to High-Grade Gliomas. <i>Current Treatment Options in Neurology</i> , 2015, 17, 369.	0.7	6
2382	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015, 124, 119-126.	1.4	67
2383	Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery. <i>Neuro-Oncology</i> , 2015, 17, 1560-1567.	0.6	50
2384	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	3.2	79
2385	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1994-1999.	0.6	105
2386	Applicable advances in the molecular pathology of glioblastoma. <i>Brain Tumor Pathology</i> , 2015, 32, 153-162.	1.1	12
2387	Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?. <i>Seminars in Radiation Oncology</i> , 2015, 25, 203-209.	1.0	12
2388	Isocitrate Dehydrogenase (IDH) Mutation in Gliomas. , 2015, , 441-458.		0
2389	Molecular profiling of gliomas: potential therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 955-962.	1.1	22
2390	Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications. <i>Frontiers in Oncology</i> , 2015, 5, 55.	1.3	186

#	ARTICLE	IF	CITATIONS
2391	Toward precision medicine in glioblastoma: the promise and the challenges. <i>Neuro-Oncology</i> , 2015, 17, 1051-1063.	0.6	178
2392	Economics of Malignant Gliomas: A Critical Review. <i>Journal of Oncology Practice</i> , 2015, 11, e59-e65.	2.5	46
2393	Polymeric drug delivery for the treatment of glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, ii9-ii23.	0.6	65
2394	Using bioluminescence imaging in glioma research. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 779-784.	0.8	16
2395	Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma. <i>Neurological Research</i> , 2015, 37, 95-105.	0.6	25
2396	A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 785-799.	0.8	33
2397	Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. <i>Genes and Diseases</i> , 2015, 2, 152-163.	1.5	176
2398	Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1093-1105.	3.3	23
2400	HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation. <i>Journal of Neuro-Oncology</i> , 2015, 122, 303-312.	1.4	36
2401	Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 122, 549-558.	1.4	30
2402	Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. <i>Journal of Neuro-Oncology</i> , 2015, 122, 595-605.	1.4	11
2403	Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2015, 123, 179-188.	1.4	21
2404	Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 647-664.	1.5	40
2405	ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. <i>Journal of Translational Medicine</i> , 2015, 13, 74.	1.8	26
2406	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. <i>Journal of Hematology and Oncology</i> , 2015, 8, 16.	6.9	80
2407	Cell Cycle Checkpoint and DNA Damage Response Defects as Anticancer Targets: From Molecular Mechanisms to Therapeutic Opportunities. , 2015, , 29-49.		6
2409	Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. <i>Nature Communications</i> , 2015, 6, 6999.	5.8	484
2410	MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors. <i>Future Oncology</i> , 2015, 11, 1201-1209.	1.1	15

#	ARTICLE	IF	CITATIONS
2411	EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9.	3.3	86
2413	Anaplastic glioma: current treatment and management. Expert Review of Neurotherapeutics, 2015, 15, 601-620.	1.4	21
2414	LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2. Brain Research, 2015, 1611, 93-100.	1.1	22
2415	Pediatric Neuro-oncology. , 2015, , .		2
2416	How Treatment Monitoring Is Influencing Treatment Decisions in Glioblastomas. Current Treatment Options in Neurology, 2015, 17, 343.	0.7	13
2417	Phase 1/2 Trials of Temozolomide, Motexafin Gadolinium, and 60-Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: Final Results of RTOG 0513. International Journal of Radiation Oncology Biology Physics, 2015, 91, 961-967.	0.4	27
2418	Oct-3/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1197-1205.	1.1	16
2419	Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. Trends in Pharmacological Sciences, 2015, 36, 236-252.	4.0	44
2420	The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment. International Journal of Oncology, 2015, 46, 2299-2308.	1.4	44
2421	Molecular targets in glioblastoma. Future Oncology, 2015, 11, 1407-1420.	1.1	32
2422	Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 829-848.	3.9	503
2423	Bevacizumab in Recurrent Glioblastoma: Five Informative Patient Scenarios. Canadian Journal of Neurological Sciences, 2015, 42, 149-156.	0.3	3
2424	The role of metabolic therapy in treating glioblastoma multiforme. , 2015, 6, 61.		35
2425	Chemotherapy in glioma. CNS Oncology, 2015, 4, 179-192.	1.2	58
2426	Glioblastoma multiforme: Pathogenesis and treatment. , 2015, 152, 63-82.		588
2427	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
2428	SAT1 and glioblastoma multiforme: Disarming the resistance. Molecular and Cellular Oncology, 2015, 2, e983393.	0.3	2
2429	Feedback circuitry between <i>miR-218</i> repression and RTK activation in glioblastoma. Science Signaling, 2015, 8, ra42.	1.6	19



#	ARTICLE	IF	CITATIONS
2430	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 1943-1950.	0.8	21
2431	Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide. <i>Cancer Research</i> , 2015, 75, 2039-2048.	0.4	15
2432	Kaempferol Induces DNA Damage and Inhibits DNA Repair Associated Protein Expressions in Human Promyelocytic Leukemia HL-60 Cells. <i>The American Journal of Chinese Medicine</i> , 2015, 43, 365-382.	1.5	39
2433	In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma. <i>RSC Advances</i> , 2015, 5, 28219-28227.	1.7	29
2434	Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis. <i>Advances in Anatomic Pathology</i> , 2015, 22, 50-58.	2.4	78
2435	Manejo de los tumores hipofisarios agresivos. , 2015, , 171-198.		0
2436	Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast. <i>Tumor Biology</i> , 2015, 36, 6485-6496.	0.8	20
2437	<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2057-2064.	3.2	264
2438	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. <i>Neuro-Oncology</i> , 2015, 17, 708-717.	0.6	191
2439	Steric-Dependent Label-Free and Washing-Free Enzyme Amplified Protein Detection with Dual-Functional Synthetic Probes. <i>Analytical Chemistry</i> , 2015, 87, 4231-4236.	3.2	16
2440	Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma?. <i>Seminars in Radiation Oncology</i> , 2015, 25, 197-202.	1.0	19
2441	Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. <i>Melanoma Research</i> , 2015, 25, 138-148.	0.6	53
2442	Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas. <i>Anti-Cancer Drugs</i> , 2015, 26, 293-300.	0.7	32
2443	A practical review of prognostic correlations of molecular biomarkers in glioblastoma. <i>Neurosurgical Focus</i> , 2015, 38, E4.	1.0	88
2444	Antitumor Activity of a Polypyridyl Chelating Ligand: In Vitro and In Vivo Inhibition of Glioma. <i>ASN Neuro</i> , 2015, 7, 175909141557236.	1.5	4
2445	Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays. <i>Laboratory Investigation</i> , 2015, 95, 833-842.	1.7	40
2446	The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas. <i>Neoplasia</i> , 2015, 17, 239-255.	2.3	114
2448	Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. <i>Journal of Neurological Surgery Reports</i> , 2015, 76, e43-e47.	0.3	0

#	ARTICLE	IF	CITATIONS
2450	The roles of CD147 in the progression of gliomas. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1351-1359.	1.1	10
2451	Emerging circulating biomarkers in glioblastoma: promises and challenges. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1311-1323.	1.5	60
2452	Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit. <i>Cancer Cell</i> , 2015, 28, 456-471.	7.7	160
2453	Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. <i>Science Translational Medicine</i> , 2015, 7, 303ra138.	5.8	227
2454	Early cognitive function tests predict early progression in glioblastoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 137-143.	1.0	14
2455	Therapeutic management of gliosarcoma in the temozolomide era. <i>CNS Oncology</i> , 2015, 4, 171-178.	1.2	16
2456	Synthesis of oligonucleotides carrying fluorescently labelled O6-alkylguanine for measuring hAGT activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5208-5211.	1.0	5
2457	The role of neuropathology in the management of patients with diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 531-549.	1.4	120
2459	Targeting cancer epigenetics: Linking basic biology to clinical medicine. <i>Advanced Drug Delivery Reviews</i> , 2015, 95, 56-64.	6.6	34
2460	The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 327-337.	0.8	13
2461	Case-Based Review: newly diagnosed glioblastoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 106-121.	1.0	13
2462	Characterization and directed evolution of a methyl-binding domain protein for high-sensitivity DNA methylation analysis. <i>Protein Engineering, Design and Selection</i> , 2015, 28, 543-551.	1.0	11
2463	Radioactive 125I seeds inhibit cell growth and epithelial-mesenchymal transition in human glioblastoma multiforme via a ROS-mediated signaling pathway. <i>BMC Cancer</i> , 2015, 15, 1.	1.1	314
2464	Ribozyme- <i>Spherical Nucleic Acids</i> . <i>Journal of the American Chemical Society</i> , 2015, 137, 10528-10531.	6.6	58
2465	Withholding temozolomide in glioblastoma patients with unmethylated <i>MGMT</i> promoter—still a dilemma?: Table 1.. <i>Neuro-Oncology</i> , 2015, 17, 1425-1427.	0.6	78
2466	A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. <i>Journal of Controlled Release</i> , 2015, 218, 29-35.	4.8	51
2467	Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression. <i>Journal of Neuro-Oncology</i> , 2015, 124, 385-392.	1.4	6
2468	Brain Cancer: The New Frontiers. , 2015, , 231-246.		0

#	ARTICLE	IF	CITATIONS
2469	Epigenetics and Epilepsy. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a022731.	2.9	68
2470	Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. Journal of Neuro-Oncology, 2015, 125, 183-190.	1.4	106
2472	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular Cancer Therapeutics, 2015, 14, 2735-2743.	1.9	75
2474	Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide. Child's Nervous System, 2015, 31, 2341-2344.	0.6	10
2475	Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. Neuro-Oncology, 2015, 17, 1525-1537.	0.6	75
2476	Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. Journal of Neuro-Oncology, 2015, 125, 123-131.	1.4	8
2477	Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma. Clinical Radiology, 2015, 70, 1299-1312.	0.5	41
2478	Novel chemotherapeutics and other therapies for treating high-grade glioma. Expert Opinion on Investigational Drugs, 2015, 24, 1361-1379.	1.9	23
2479	MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Journal of Clinical Neuroscience, 2015, 22, 1938-1942.	0.8	21
2480	Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). European Journal of Medicinal Chemistry, 2015, 103, 210-222.	2.6	21
2481	LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biology and Therapy, 2015, 16, 821-833.	1.5	83
2482	DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell, 2015, 28, 307-317.	7.7	221
2483	Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell, 2015, 28, 318-328.	7.7	242
2484	The Amazing and Deadly Glioma Race. Cancer Cell, 2015, 28, 275-277.	7.7	11
2485	Circulating biomarkers for gliomas. Nature Reviews Neurology, 2015, 11, 556-566.	4.9	154
2486	Evaluating the role of admixture in cancer therapy via <i>in vitro</i> drug response and multivariate genome-wide associations. Pharmacogenomics, 2015, 16, 1451-1463.	0.6	8
2487	Central Nervous System Tumors. , 2015, , 537-565.		0
2488	The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival. American Journal of Neuroradiology, 2015, 36, 2235-2241.	1.2	36

#	ARTICLE	IF	CITATIONS
2489	The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis. <i>Journal of Neuro-Oncology</i> , 2015, 125, 339-349.	1.4	24
2490	Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv369.	3.0	102
2491	The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. <i>Cell Cycle</i> , 2015, 14, 3418-3429.	1.3	104
2492	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. <i>CNS Oncology</i> , 2015, 4, 287-294.	1.2	48
2493	What next for newly diagnosed glioblastoma?. <i>Future Oncology</i> , 2015, 11, 3273-3283.	1.1	22
2494	New insights into acquired temozolomide resistance in glioblastoma?. <i>Brain</i> , 2015, 138, 3468-3470.	3.7	5
2495	Wnt/ $\beta$ -catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. <i>Nature Communications</i> , 2015, 6, 8904.	5.8	177
2496	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 1087-1093.	1.2	13
2497	Advances in Cancer Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, , .	0.8	14
2498	Molecular diagnostics: techniques and recommendations for 1p/19q assessment. <i>CNS Oncology</i> , 2015, 4, 295-306.	1.2	37
2500	Neuroimaging and Genetic Influence in Treating Brain Neoplasms. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 121-140.	0.5	5
2501	Glioma Biology and Molecular Markers. <i>Cancer Treatment and Research</i> , 2015, 163, 15-30.	0.2	161
2502	MGMT promoter methylation in non-neoplastic brain. <i>Journal of Neuro-Oncology</i> , 2015, 121, 459-467.	1.4	3
2503	ZEB1 Promotes Invasion in Human Fetal Neural Stem Cells and Hypoxic Glioma Neurospheres. <i>Brain Pathology</i> , 2015, 25, 724-732.	2.1	59
2504	The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy. <i>Annual Review of Medicine</i> , 2015, 66, 129-143.	5.0	403
2505	Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. <i>Carcinogenesis</i> , 2015, 36, 177-185.	1.3	184
2506	Current Medical Treatment of Glioblastoma. <i>Cancer Treatment and Research</i> , 2015, 163, 103-115.	0.2	66
2507	Genomics of Brain Tumor Imaging. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 105-119.	0.5	33

#	ARTICLE	IF	CITATIONS
2508	Contemporary murine models in preclinical astrocytoma drug development. <i>Neuro-Oncology</i> , 2015, 17, 12-28.	0.6	23
2509	Imaging Genomics of Glioblastoma. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 141-153.	0.5	37
2510	Current Understanding and Treatment of Gliomas. <i>Cancer Treatment and Research</i> , 2015, , .	0.2	11
2511	Stem cell signature in glioblastoma: therapeutic development for a moving target. <i>Journal of Neurosurgery</i> , 2015, 122, 324-330.	0.9	81
2512	Understanding Genetics in Neuroimaging. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 1-16.	0.5	1
2513	O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma. <i>BBA Clinical</i> , 2015, 3, 1-10.	4.1	16
2514	A DNA-based nano-immunoassay for the label-free detection of glial fibrillary acidic protein in multicell lysates. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 293-300.	1.7	19
2515	A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 301-311.	1.7	91
2516	Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. <i>Scientific Reports</i> , 2014, 4, 5260.	1.6	35
2517	MGMT methylation in glioblastoma: tale of the tail. <i>Neuro-Oncology</i> , 2015, 17, 167-168.	0.6	8
2518	Molecular Mechanisms of Fenofibrate-Induced Metabolic Catastrophe and Glioblastoma Cell Death. <i>Molecular and Cellular Biology</i> , 2015, 35, 182-198.	1.1	80
2519	IDH1/2 mutation detection in gliomas. <i>Brain Tumor Pathology</i> , 2015, 32, 79-89.	1.1	44
2520	Gene Therapies for Cancer: Strategies, Challenges and Successes. <i>Journal of Cellular Physiology</i> , 2015, 230, 259-271.	2.0	179
2521	A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. <i>Scientific Reports</i> , 2014, 4, 4186.	1.6	37
2522	TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. <i>Neuro-Oncology</i> , 2015, 17, 45-52.	0.6	172
2523	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	0.6	28
2525	DNA Repair Pathways and Human Cancer. , 2015, , 47-66.e2.		6
2526	Epigenetics and Cancer. , 2015, , 67-78.e3.		0

#	ARTICLE	IF	CITATIONS
2527	We are all individualsâ€¦ bioinformatics in the personalized medicine era. Cellular Oncology (Dordrecht), 2015, 38, 29-37.	2.1	5
2528	Genomic Applications in Pathology. , 2015, , .		1
2529	Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric Cancer, 2015, 18, 280-287.	2.7	63
2530	The Importance of Mutational Drivers in GBM. Critical Reviews in Eukaryotic Gene Expression, 2016, 26, 19-26.	0.4	6
2531	Molecular Advances in Glioblastoma Neuropathology. , 0, , .		3
2532	MGMTâ€¦a critical DNA repair gene target for chemotherapy resistance. , 2016, , 55-82.		2
2533	Predicting and Monitoring Responses to Epigenetic Drugs. , 2016, , 373-406.		2
2534	Brain Tumors: Epidemiology and Current Trends in Treatment. Journal of Brain Tumors & Neurooncology, 2016, 01, .	0.1	6
2535	p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment. Biochemistry & Physiology, 2016, 05, .	0.2	4
2536	Positive expression of KIF20A indicates poor prognosis of glioma patients. OncoTargets and Therapy, 2016, Volume 9, 6741-6749.	1.0	51
2537	Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. OncoTargets and Therapy, 2016, 9, 1115.	1.0	14
2538	Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy. Patient Preference and Adherence, 2016, Volume 10, 2397-2406.	0.8	23
2539	Prognostic Epigenetics. , 2016, , 177-195.		0
2540	TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT. Tropical Journal of Obstetrics and Gynaecology, 2016, 13, 1-4.	0.3	2
2541	Use of Chromatin Changes as Biomarkers. , 2016, , 403-421.		0
2542	The Molecular Pathogenesis of Glioblastoma. , 2016, , 21-31.		3
2543	Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. Oncotarget, 2016, 7, 56713-56725.	0.8	36
2544	&beta;-Elemene treatment of glioblastoma: a single-center retrospective study. OncoTargets and Therapy, 2016, Volume 9, 7521-7526.	1.0	23

#	ARTICLE	IF	CITATIONS
2545	Radioresistance of Brain Tumors. <i>Cancers</i> , 2016, 8, 42.	1.7	35
2546	Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2881-2897.	2.0	14
2547	Relationships between <em>MGMT</em> promoter methylation and gastric cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6049-6057.	1.0	5
2548	Presentation of Two Cases with Early Extracranial Metastases from Glioblastoma and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.2	14
2549	Proteomic Profiling of High-grade Glioblastoma Using Virtual experimental 2DE. <i>Journal of Proteomics and Bioinformatics</i> , 2016, 09, .	0.4	13
2550	Seeking New Approaches to Patients With Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e477-e482.	1.8	2
2551	Principles and Tenets of Radiation Treatment in Glioblastoma. , 2016, , 105-132.		0
2552	Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 804-818.	0.6	9
2553	A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. <i>Oncotarget</i> , 2016, 7, 69991-69999.	0.8	37
2554	A three-dimensional collagen scaffold cell culture system for screening anti-glioma therapeutics. <i>Oncotarget</i> , 2016, 7, 56904-56914.	0.8	64
2555	The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells. <i>Oncotarget</i> , 2016, 7, 20890-20901.	0.8	49
2556	Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. <i>Oncotarget</i> , 2016, 7, 59360-59376.	0.8	34
2557	Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma. <i>Sarcoma</i> , 2016, 2016, 1-7.	0.7	3
2558	Glioma Stem Cells: Signaling, Microenvironment, and Therapy. <i>Stem Cells International</i> , 2016, 2016, 1-10.	1.2	140
2559	Hallmarks of glioblastoma: a systematic review. <i>ESMO Open</i> , 2016, 1, e000144.	2.0	122
2560	Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway. <i>BioMed Research International</i> , 2016, 2016, 1-11.	0.9	39
2561	Tumor Mesenchymal Stem-Like Cell as a Prognostic Marker in Primary Glioblastoma. <i>Stem Cells International</i> , 2016, 2016, 1-7.	1.2	20
2562	DNA methylation at enhancer regions Novel avenues for epigenetic biomarker development. <i>Frontiers in Bioscience - Landmark</i> , 2016, 21, 430-446.	3.0	17

#	ARTICLE	IF	CITATIONS
2563	17 Tumor genomicsGenomicsOn the Horizon: Tumor Genomics. , 2016, , .		0
2564	5 Deep-Seated Brain Tumors. , 2016, , .		0
2565	Delineation of radiation therapy target volumes for patients with postoperative glioblastoma: a review. OncoTargets and Therapy, 2016, 9, 3197.	1.0	20
2566	High-Grade Glioma Management and Response Assessmentâ€”Recent Advances and Current Challenges. Current Oncology, 2016, 23, 383-391.	0.9	33
2567	MicroRNAs as efficient biomarkers in high-grade gliomas. Folia Neuropathologica, 2016, 4, 369-374.	0.5	36
2568	Immunological Biomarkers for Patient Stratification. , 2016, , 327-361.		0
2569	High expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas. Experimental and Therapeutic Medicine, 2016, 11, 571-576.	0.8	8
2570	A Systematic Review on the Characteristics, Treatments and Outcomes of the Patients with Primary Spinal Glioblastomas or Gliosarcomas Reported in Literature until March 2015. PLoS ONE, 2016, 11, e0148312.	1.1	20
2571	Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma. PLoS ONE, 2016, 11, e0162929.	1.1	7
2572	Platform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral Decomposition. PLoS ONE, 2016, 11, e0164546.	1.1	11
2573	Epigenetics in Brain Tumors: HDACs Take Center Stage. Current Neuropharmacology, 2016, 14, 48-54.	1.4	21
2574	Specific Inhibition of DNMT3A/ISGF3Î³ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth. Theranostics, 2016, 6, 1988-1999.	4.6	17
2575	Evolving Molecular Genetics of Glioblastoma. Chinese Medical Journal, 2016, 129, 464-471.	0.9	41
2576	Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy. Frontiers in Pharmacology, 2016, 7, 477.	1.6	93
2577	Biomarker Development in Targeting Cancer Epigenetic. , 2016, , 123-142.		0
2578	Biomarkers towards Ovarian Cancer Diagnostics: Present and Future Prospects. Brazilian Archives of Biology and Technology, 2016, 59, .	0.5	19
2579	Chemotherapy for gliomas. , 0, , 76-90.		0
2580	Prognostic factors for glioblastoma patients - a clinical population-based study. Acta Neurologica Scandinavica, 2016, 133, 434-441.	1.0	25



#	ARTICLE	IF	CITATIONS
2581	MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2016, 23, 625-633.	1.6	78
2582	Glioblastoma care in the elderly. <i>Cancer</i> , 2016, 122, 189-197.	2.0	53
2583	<i>LOC283731</i> promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. <i>International Journal of Cancer</i> , 2016, 139, 424-432.	2.3	18
2584	Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now141.	0.6	41
2585	Environment-sensitive Fluorescent Turn-on Chemical Probe for the Specific Detection of O <sup>6</sup> -Methylguanine-DNA Methyltransferase (MGMT) in Living Cells. <i>Journal of the Chinese Chemical Society</i> , 2016, 63, 688-693.	0.8	4
2586	Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. <i>Cancer</i> , 2016, 122, 2206-2215.	2.0	77
2587	Monitoring the Glutathione Redox Reaction in Living Human Cells by Combining Metabolic Labeling with Heteronuclear NMR. <i>Angewandte Chemie</i> , 2016, 128, 8071-8074.	1.6	7
2588	Monitoring the Glutathione Redox Reaction in Living Human Cells by Combining Metabolic Labeling with Heteronuclear NMR. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 7939-7942.	7.2	30
2589	Downregulation of <i>GLS2</i> in glioblastoma cells is related to DNA hypermethylation but not to the p53 status. <i>Molecular Carcinogenesis</i> , 2016, 55, 1309-1316.	1.3	21
2590	Current status of biomarker research in neurology. <i>EPMA Journal</i> , 2016, 7, 14.	3.3	36
2591	Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma. <i>Molecular Cancer Research</i> , 2016, 14, 928-940.	1.5	53
2592	Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. <i>Anti-Cancer Drugs</i> , 2016, 27, 133-137.	0.7	12
2593	Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1155-1167.	1.5	8
2594	Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant <i>IDH</i> glioma patients. <i>Neuro-Oncology</i> , 2016, 18, now100.	0.6	30
2595	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. <i>Neuro-Oncology</i> , 2016, 18, 1357-1366.	0.6	116
2596	Valproic Acid Promotes Human Glioma U87 Cells Apoptosis and Inhibits Glycogen Synthase Kinase-3 <sup>β</sup> Through ERK/Akt Signaling. <i>Cellular Physiology and Biochemistry</i> , 2016, 39, 2173-2185.	1.1	55
2597	Drug Repurposing to Circumvent Chemotherapy Resistance in Brain Tumours. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 107-144.	0.1	3
2599	Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis. <i>Journal of Neuro-Oncology</i> , 2016, 129, 525-532.	1.4	19

#	ARTICLE	IF	CITATIONS
2600	Resistance to Targeted Therapies Against Adult Brain Cancers. Resistance To Targeted Anti-cancer Therapeutics, 2016, , .	0.1	4
2601	Improved survival for elderly married glioblastoma patients. Strahlentherapie Und Onkologie, 2016, 192, 797-805.	1.0	14
2602	Adult Diffuse Astrocytoma in the Medulla Oblongata: Molecular Biological Analyses Including H3F3A Mutation of Histone H3.3. NMC Case Report Journal, 2016, 3, 29-33.	0.2	2
2603	Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Scientific Reports, 2016, 6, 22477.	1.6	129
2604	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology, 2017, 19, now257.	0.6	80
2605	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
2606	Genome-wide epigenomic profiling for biomarker discovery. Clinical Epigenetics, 2016, 8, 122.	1.8	67
2607	Copy Number Profiling of Brazilian Astrocytomas. G3: Genes, Genomes, Genetics, 2016, 6, 1867-1878.	0.8	12
2608	A novel NFIA-NFÎB feed-forward loop contributes to glioblastoma cell survival. Neuro-Oncology, 2017, 19, now233.	0.6	15
2609	Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro-Oncology, 2017, 19, now239.	0.6	39
2610	Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. American Journal of Neuroradiology, 2016, 37, 2201-2208.	1.2	59
2611	Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition. Cell Reports, 2016, 17, 2994-3009.	2.9	169
2612	Current management of low-grade gliomas. Current Opinion in Neurology, 2016, 29, 782-788.	1.8	26
2613	Laser Ablation of Newly Diagnosed Malignant Gliomas. Neurosurgery, 2016, 79, S17-S23.	0.6	56
2614	Central Nervous System: Notable Developments in the Management of Primary and Recurrent Gliomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 681-684.	2.3	8
2615	Genetics of glioma. , 0, , 1-23.		1
2616	Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World Journal of Surgical Oncology, 2016, 14, 225.	0.8	134
2617	Analysis of DNA Methylation in Clinical Samples: Methods and Applications. , 2016, , 261-277.		1

#	ARTICLE	IF	CITATIONS
2618	Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity. <i>Oncology Reports</i> , 2016, 35, 2811-2824.	1.2	22
2619	Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 333-339.	1.4	52
2621	Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. <i>Neuro-Oncology</i> , 2016, 18, 1442-1450.	0.6	111
2622	Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2016, 6, 217-225.	1.1	162
2623	The Age Factor in the Treatment of Glioblastoma. <i>JAMA Neurology</i> , 2016, 73, 783.	4.5	1
2624	Constraint based temporal event sequence mining for Glioblastoma survival prediction. <i>Journal of Biomedical Informatics</i> , 2016, 61, 267-275.	2.5	21
2625	Therapeutic innovations in endocrine diseases – part 3: temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. <i>Presse Medicale</i> , 2016, 45, e211-e216.	0.8	9
2626	Further understanding of the pathology of glioma: implications for the clinic. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1055-1065.	1.4	32
2627	Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma. <i>Radiology</i> , 2016, 281, 175-184.	3.6	51
2628	Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 289-295.	0.4	8
2629	Investigational new drugs for brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 937-956.	1.9	16
2630	Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era. <i>JAMA Neurology</i> , 2016, 73, 821.	4.5	46
2631	DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. <i>Cancer Treatment Reviews</i> , 2016, 44, 1-9.	3.4	14
2632	Epigenetic Advancements in Cancer. , 2016, , .		1
2633	Epigenetic Determinants of Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2016, 8, a019505.	2.3	834
2634	Methods for genome-wide DNA methylation analysis in human cancer. <i>Briefings in Functional Genomics</i> , 2016, 15, elw010.	1.3	18
2635	Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. <i>Journal of Neuro-Oncology</i> , 2016, 127, 505-514.	1.4	42
2636	Infiltrating spinal cord astrocytomas: Epidemiology, diagnosis, treatments and future directions. <i>Journal of Clinical Neuroscience</i> , 2016, 29, 15-20.	0.8	28

#	ARTICLE	IF	CITATIONS
2637	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagnostic Pathology, 2016, 11, 13.	0.9	10
2638	DNA Methylation and Cancer. , 2016, , 103-134.		4
2639	Intratumoral Heterogeneity of the Epigenome. Cancer Cell, 2016, 29, 440-451.	7.7	172
2640	Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results. Journal of Clinical Oncology, 2016, 34, 1567-1569.	0.8	21
2641	Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives. Expert Opinion on Pharmacotherapy, 2016, 17, 1259-1270.	0.9	24
2642	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro-Oncology, 2016, 18, 1304-1312.	0.6	71
2643	Epigenetic Post transcriptional Mutation in Neuro-Oncology. , 2016, , 177-205.		1
2644	Chordoma: The Quest for Better Treatment Options. Oncology and Therapy, 2016, 4, 35-51.	1.0	34
2645	Protein Markers Predict Survival in Glioma Patients. Molecular and Cellular Proteomics, 2016, 15, 2356-2365.	2.5	26
2646	Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clinical Cancer Research, 2016, 22, 3860-3875.	3.2	142
2647	Phase II Study of Radiotherapy and Temozolomide versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	3.2	105
2648	Is there a role for early chemotherapy in the management of pituitary adenomas?. Neuro-Oncology, 2016, 18, 1350-1356.	0.6	19
2650	CCCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2016, 375, 263-273.	3.2	448
2651	Big data visualization identifies the multidimensional molecular landscape of human gliomas. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5394-5399.	3.3	45
2652	Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. Journal of Neuro-Oncology, 2016, 127, 221-232.	1.4	13
2653	Molecular classification of gliomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 97-120.	1.0	90
2654	Developing a Novel Embryo-Larval Zebrafish Xenograft Assay to Prioritize Human Glioblastoma Therapeutics. Zebrafish, 2016, 13, 317-329.	0.5	33
2655	MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Clinical Epigenetics, 2016, 8, 49.	1.8	59

#	ARTICLE	IF	CITATIONS
2656	Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. <i>Radiology and Oncology</i> , 2016, 50, 394-401.	0.6	46
2657	Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 128-132.	0.8	32
2658	Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches. <i>Oncology Letters</i> , 2016, 12, 2283-2288.	0.8	75
2659	Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 620-634.	1.2	42
2660	The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , 2016, 149, 15-21.	0.6	16
2661	Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4574-4584.	1.8	18
2662	Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. <i>Clinical Epigenetics</i> , 2016, 8, 95.	1.8	47
2663	The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. <i>Journal of Clinical Neuroscience</i> , 2016, 31, 67-71.	0.8	7
2664	Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review. <i>Journal of Oncological Science</i> , 2016, 2, 87-94.	0.1	7
2665	Radiomics in Brain Tumors. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 719-729.	0.6	73
2666	Imaging Genomics in Glioblastoma Multiforme. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 731-740.	0.6	7
2667	Biomarkers in NOA-04: another piece to the puzzle. <i>Neuro-Oncology</i> , 2016, 18, 1467-1469.	0.6	4
2668	Actionable Molecular Biomarkers in Primary Brain Tumors. <i>Trends in Cancer</i> , 2016, 2, 338-349.	3.8	41
2669	High-Grade Gliomas. , 2016, , 469-482.e4.		1
2670	Antitumor imidazo[5,1-d]-1,2,3,5-tetrazines: compounds modified at the 3-position overcome resistance in human glioblastoma cell lines. <i>MedChemComm</i> , 2016, 7, 2332-2343.	3.5	15
2671	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Neuro-Oncology</i> , 2017, 19, now208.	0.6	109
2672	Mapping genetic factors in high-grade glioma patients. <i>Clinical Neurology and Neurosurgery</i> , 2016, 150, 159-163.	0.6	3
2673	The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines. <i>Experimental Cell Research</i> , 2016, 348, 177-183.	1.2	11

#	ARTICLE	IF	CITATIONS
2674	Viral Oncolysis of Glioblastoma. , 2016, , 481-517.		0
2675	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications, 2016, 4, 79.	2.4	189
2676	Gamma Knife Radiosurgery in Recurrent Glioblastoma. Stereotactic and Functional Neurosurgery, 2016, 94, 265-272.	0.8	27
2677	Molecular and histologic characteristics of pseudoprogression in diffuse gliomas. Journal of Neuro-Oncology, 2016, 130, 529-533.	1.4	26
2678	DNA Methylation of the TERT Gene in Breast Cancer Revisited: Diagnostic and Clinical Implications. Laboratory Medicine, 2016, 47, 293-299.	0.8	4
2679	Nano-structures mediated co-delivery of therapeutic agents for glioblastoma treatment: A review. Materials Science and Engineering C, 2016, 69, 1092-1102.	3.8	59
2680	Astrocytic gliomas WHO grades II and III. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 345-360.	1.0	11
2681	Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study. Cancer, 2016, 122, 3157-3165.	2.0	52
2682	Genetics and epigenetics in small intestinal neuroendocrine tumours. Journal of Internal Medicine, 2016, 280, 584-594.	2.7	31
2683	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. Current Treatment Options in Oncology, 2016, 17, 51.	1.3	32
2684	The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma. Journal of Clinical Neuroscience, 2016, 34, 145-150.	0.8	1
2685	Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. Asia-Pacific Journal of Clinical Oncology, 2016, 12, e23-9.	0.7	28
2687	Precision medicine in pheochromocytoma and paraganglioma: current and future concepts. Journal of Internal Medicine, 2016, 280, 559-573.	2.7	49
2688	Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression. Pediatric Blood and Cancer, 2016, 63, 152-155.	0.8	5
2689	Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. Acta Neurologica Scandinavica, 2016, 133, 4-16.	1.0	28
2690	Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. Tumor Biology, 2016, 37, 13571-13579.	0.8	10
2691	Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncology, The, 2016, 17, 1386-1395.	5.1	357
2692	Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India. Translational Oncology, 2016, 9, 371-376.	1.7	11

#	ARTICLE	IF	CITATIONS
2693	Fractional Anisotropy Correlates with Overall Survival in Glioblastoma. <i>World Neurosurgery</i> , 2016, 95, 525-534.e1.	0.7	6
2694	Human <i>TERT</i> promoter mutation enables survival advantage from <i>MGMT</i> promoter methylation in <i>IDH1</i> wild-type primary glioblastoma treated by standard chemoradiotherapy. <i>Neuro-Oncology</i> , 2017, 19, now189.	0.6	65
2695	The role of CD44 in glioblastoma multiforme. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 1-5.	0.8	112
2696	The role of gender in glioblastoma: does it matter?. <i>Future Neurology</i> , 2016, 11, 197-199.	0.9	1
2697	<i>Neurologic Disease.</i> , 2016, , .		5
2698	Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2016, 23, 759-767.	1.6	131
2699	The role of DNA methylation in ST6Gal1 expression in gliomas. <i>Glycobiology</i> , 2016, 26, 1271-1283.	1.3	17
2700	Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas. <i>Chemical Research in Toxicology</i> , 2016, 29, 1369-1380.	1.7	11
2701	Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood. <i>Surgical Pathology Clinics</i> , 2016, 9, 379-390.	0.7	4
2702	The impact of <i>MGMT</i> methylation and <i>IDH-1</i> mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. <i>Acta Neurochirurgica</i> , 2016, 158, 1943-1953.	0.9	37
2703	An Evolutionary Genetic Perspective on Cancer Biology. <i>Annual Review of Ecology, Evolution, and Systematics</i> , 2016, 47, 25-49.	3.8	10
2704	Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2016, 130, 211-219.	1.4	35
2705	5-Hydroxymethylcytosine localizes to enhancer elements and is associated with survival in glioblastoma patients. <i>Nature Communications</i> , 2016, 7, 13177.	5.8	102
2706	Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. <i>Radiology</i> , 2016, 281, 907-918.	3.6	236
2707	Caring for Patients with Newly Diagnosed High-Grade Gliomas. <i>Seminars in Neurology</i> , 2016, 36, 324-329.	0.5	0
2708	The Clinical Implications of Inconsistently Methylated Results from Glioblastoma <i>MGMT</i> Testing by Replicate Methylation-Specific PCR. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 864-871.	1.2	14
2709	Efficacy of Combined Epigenetic Therapies. , 2016, , 347-371.		0
2710	Genomic Landscape of Brain Tumors. , 2016, , 653-663.		0

#	ARTICLE	IF	CITATIONS
2711	Regulation of TAZ in cancer. <i>Protein and Cell</i> , 2016, 7, 548-561.	4.8	41
2712	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). <i>Journal of Neuro-Oncology</i> , 2016, 130, 31-42.	1.4	35
2713	Glioblastoma Multiforme (GBM) in the Elderly: Initial Treatment Strategy and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E87-E88.	0.4	1
2714	Low-grade epilepsy-associated neuroepithelial tumours - the 2016 WHO classification. <i>Nature Reviews Neurology</i> , 2016, 12, 732-740.	4.9	113
2715	BIRC3 is a novel driver of therapeutic resistance in Glioblastoma. <i>Scientific Reports</i> , 2016, 6, 21710.	1.6	71
2716	Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1289-1296.	1.1	42
2717	The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2016, 14, 261.	0.8	54
2718	Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. <i>Cancer Discovery</i> , 2016, 6, 1215-1229.	7.7	81
2719	Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide. <i>Scientific Reports</i> , 2016, 6, 28948.	1.6	18
2720	Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression. <i>Scientific Reports</i> , 2016, 6, 32972.	1.6	53
2721	A Simple Automated Method for Detecting Recurrence in High-Grade Glioma. <i>American Journal of Neuroradiology</i> , 2016, 37, 2019-2025.	1.2	6
2722	Emerging targeted therapies for glioma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 441-452.	1.0	45
2723	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	5.8	158
2724	Translational Biomedical Informatics. <i>Advances in Experimental Medicine and Biology</i> , 2016, , .	0.8	1
2725	Medical Imaging Informatics. <i>Advances in Experimental Medicine and Biology</i> , 2016, 939, 167-224.	0.8	9
2726	Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma. <i>BMC Cancer</i> , 2016, 16, 611.	1.1	58
2727	Targeted Therapy for Malignant Brain Tumors. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2016, , 433-450.	0.4	0
2728	Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas. <i>Scientific Reports</i> , 2016, 6, 21141.	1.6	29



#	ARTICLE	IF	CITATIONS
2729	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. <i>Neuro-Oncology</i> , 2016, 18, v1-v75.	0.6	995
2731	Imaging Biomarkers in Immunotherapy. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31805.	3.6	31
2732	Epidemiology of Glioblastoma and Trends in Glioblastoma Survivorship. , 2016, , 11-19.		3
2733	Laser Ablation vs Open Resection for Deep-Seated Tumors: The Case for Open Resection. <i>Neurosurgery</i> , 2016, 63, 10-14.	0.6	3
2734	Compliance with reporting guidelines by Australian pathologists: an audit of the quality of histopathology reporting in high-grade glioma. <i>Neuro-Oncology Practice</i> , 2016, 3, 97-104.	1.0	0
2735	Molecular imaging of 1p/19q deletion in oligodendroglial tumours with <sup>11</sup> C-methionine positron emission tomography. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1016-1021.	0.9	32
2736	Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit. <i>Neurosurgery</i> , 2016, 79, 678-689.	0.6	48
2741	Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. <i>Cancer Cell International</i> , 2016, 16, 88.	1.8	16
2743	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naïve human glioblastoma. <i>Cancer</i> , 2016, 122, 1718-1727.	2.0	47
2744	Chemoproteomics-Enabled Discovery of a Potent and Selective Inhibitor of the DNA Repair Protein MGMT. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 2911-2915.	7.2	42
2745	Concurrent chemoradiotherapy versus radiotherapy alone for biopsy-only glioblastoma multiforme. <i>Cancer</i> , 2016, 122, 2364-2370.	2.0	24
2746	Intracranial Mass Lesions. , 2016, , 399-411.		2
2747	Evaluation of variability in target volume delineation for newly diagnosed glioblastoma: a multi-institutional study from the Korean Radiation Oncology Group. <i>Radiation Oncology</i> , 2016, 10, 137.	1.2	20
2748	Clonal evolution of glioblastoma under therapy. <i>Nature Genetics</i> , 2016, 48, 768-776.	9.4	591
2749	Advanced interstitial chemotherapy for treating malignant glioma. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1533-1544.	2.4	21
2750	Radiobiology of Glioblastoma. <i>Current Clinical Pathology</i> , 2016, , .	0.0	2
2751	Glioblastoma in the elderly: making sense of the evidence. <i>Neuro-Oncology Practice</i> , 2016, 3, 77-86.	1.0	17
2752	Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3892-900.	3.3	87

#	ARTICLE	IF	CITATIONS
2753	Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 347-353.	1.4	11
2755	Cell Death Pathways, with Special Regard to Ionizing Radiation and Temozolomide. <i>Current Clinical Pathology</i> , 2016, , 209-224.	0.0	0
2756	The "Radioresistance" of Glioblastoma in the Clinical Setting, and the Present Therapeutic Options. <i>Current Clinical Pathology</i> , 2016, , 15-27.	0.0	0
2757	MethylMeter <sup>®</sup> : bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples. <i>Epigenomics</i> , 2016, 8, 747-765.	1.0	5
2758	DNA repair mechanisms and their clinical impact in glioblastoma. <i>Mutation Research - Reviews in Mutation Research</i> , 2016, 769, 19-35.	2.4	128
2759	Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. <i>Nature Biotechnology</i> , 2016, 34, 726-737.	9.4	270
2760	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	0.6	217
2761	Therapies in the pipeline for small-cell lung cancer: Table 1. <i>British Medical Bulletin</i> , 2016, 119, 37-48.	2.7	11
2762	PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. <i>Cancer Research</i> , 2016, 76, 4708-4719.	0.4	107
2763	Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. <i>Public Health Genomics</i> , 2016, 19, 170-177.	0.6	2
2765	Anaplastic astrocytoma. <i>CNS Oncology</i> , 2016, 5, 145-157.	1.2	51
2766	Pediatric Brain Tumors: An Update. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2016, 46, 242-250.	0.8	29
2767	Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children. <i>Neuro-Oncology Practice</i> , 2016, 3, 39-47.	1.0	6
2768	Investigating therapies in ependymoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 761-773.	0.5	0
2769	Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. <i>BMC Cancer</i> , 2016, 16, 81.	1.1	51
2770	Diffusion Magnetic Resonance Imaging in Brain Tumors. , 2016, , 273-300.		0
2771	Interaction of Chemotherapy and Radiation. , 2016, , 63-79.e4.		4
2772	A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 129, 139-146.	1.4	36

#	ARTICLE	IF	CITATIONS
2773	Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. <i>Cancer Cell</i> , 2016, 29, 859-873.	7.7	169
2774	DNA methylation in adult diffuse gliomas. <i>Briefings in Functional Genomics</i> , 2016, 15, elw019.	1.3	11
2775	SNP rs16906252C&gt;T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing <i>MGMT</i>-Methylated Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6266-6277.	3.2	22
2776	Chemoradiotherapy: Radiation Total Dose and Fractionation. <i>Current Clinical Pathology</i> , 2016, , 41-62.	0.0	0
2777	Chemoproteomikâ€vermittelte Entdeckung eines potenten und selektiven Inhibitors des DNAâ€Reparaturproteins MGMT. <i>Angewandte Chemie</i> , 2016, 128, 2964-2968.	1.6	7
2778	Rethinking pheochromocytomas and paragangliomas from a genomic perspective. <i>Oncogene</i> , 2016, 35, 1080-1089.	2.6	50
2779	Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical value. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1038424.	0.3	24
2780	Therapeutic options in recurrent glioblastomaâ€”An update. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 389-408.	2.0	161
2781	External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 347-358.	1.1	25
2782	Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the â€integratedâ€™ diagnosis approach. <i>Journal of Clinical Pathology</i> , 2016, 69, 686-694.	1.0	19
2783	Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients. <i>Radiotherapy and Oncology</i> , 2016, 118, 9-15.	0.3	34
2784	IDH mutation is associated with higher risk of malignant transformation in low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2016, 127, 363-372.	1.4	48
2785	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. <i>Cancer Research</i> , 2016, 76, 525-534.	0.4	93
2786	Pharmacological inhibition of lipid droplet formation enhances the effectiveness of curcumin in glioblastoma. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 100, 66-76.	2.0	44
2787	Re-do Craniotomy for Recurrent Grade IV Glioblastomas: Impact and Outcomes from the National Neuroscience Institute Singapore. <i>World Neurosurgery</i> , 2016, 87, 439-445.	0.7	24
2788	Has the survival of patients with glioblastoma changed over the years?. <i>British Journal of Cancer</i> , 2016, 114, 146-150.	2.9	54
2789	Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide. <i>Journal of the Egyptian National Cancer Institute</i> , 2016, 28, 23-30.	0.6	8
2790	Pseudoprogression in glioblastoma patients: the impact of extent of resection. <i>Journal of Neuro-Oncology</i> , 2016, 126, 559-566.	1.4	14

#	ARTICLE	IF	CITATIONS
2791	MGMT testing allows for personalised therapy in the temozolomide era. <i>Tumor Biology</i> , 2016, 37, 87-96.	0.8	27
2792	Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean) Tj ETQq1 1 0.78431 4 rgBT4/Overlo	0.78431	4
2793	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O <sup>6</sup> -Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1611-1619.	0.8	151
2794	Glioblastoma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 381-397.	1.0	289
2795	Detection of O6-methylguanine-DNA methyltransferase gene promoter region methylation pattern using pyrosequencing and the effect of methylation pattern on survival, recurrence, and chemotherapy sensitivity in patients with laryngeal cancer. <i>Pathology Research and Practice</i> , 2016, 212, 456-462.	1.0	5
2796	ExRNA in Biofluids as Biomarkers for Brain Tumors. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 353-360.	1.7	20
2797	MGMT in colorectal cancer: a promising component of personalized treatment. <i>Tumor Biology</i> , 2016, 37, 11443-11456.	0.8	11
2798	Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 199-209.	1.1	35
2799	Genotyping low-grade gliomas among Hispanics. <i>Neuro-Oncology Practice</i> , 2016, 3, 164-172.	1.0	4
2800	Adverse prognosis and distinct progression patterns after concurrent chemoradiotherapy for glioblastoma with synchronous subventricular zone and corpus callosum invasion. <i>Radiotherapy and Oncology</i> , 2016, 118, 16-23.	0.3	32
2801	Expression of DNA methyltransferases 1 and 3B correlates with EZH2 and this 3-marker epigenetic signature predicts outcome in glioblastomas. <i>Experimental and Molecular Pathology</i> , 2016, 100, 312-320.	0.9	23
2802	The challenges associated with molecular targeted therapies for glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 127, 427-434.	1.4	58
2803	Clinical trials for personalized glioblastoma radiotherapy: Markers for efficacy and late toxicity but often delayed treatment "Does that matter?". <i>Radiotherapy and Oncology</i> , 2016, 118, 211-213.	0.3	3
2804	A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3361-3371.	3.2	113
2805	Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma. <i>Journal of Neuro-Oncology</i> , 2016, 127, 483-492.	1.4	29
2806	Second surgery for recurrent glioblastoma: A concise overview of the current literature. <i>Clinical Neurology and Neurosurgery</i> , 2016, 142, 60-64.	0.6	64
2807	Craniospinal irradiation with concomitant and adjuvant temozolomide—a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. <i>Journal of Neuro-Oncology</i> , 2016, 127, 295-302.	1.4	8
2808	How I treat glioblastoma in older patients. <i>Journal of Geriatric Oncology</i> , 2016, 7, 1-6.	0.5	6

#	ARTICLE	IF	CITATIONS
2809	Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. <i>Neuro-Oncology</i> , 2016, 18, 962-973.	0.6	38
2810	Gambogic acid induces apoptotic cell death in T98G glioma cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1097-1101.	1.0	27
2811	Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria. <i>Neuro-Oncology Practice</i> , 2016, 3, 59-67.	1.0	24
2812	Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. <i>Cell Reports</i> , 2016, 14, 2587-2598.	2.9	58
2813	TTFields: where does all the skepticism come from?. <i>Neuro-Oncology</i> , 2016, 18, 303-305.	0.6	55
2814	Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models. <i>Neuro-Oncology</i> , 2016, 18, 1120-1128.	0.6	36
2815	High-mobility group AT-hook protein 2 expression and its prognostic significance in MGMT methylated and unmethylated glioblastoma. <i>International Journal of Oncology</i> , 2016, 48, 1485-1492.	1.4	6
2816	Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2016, 22, 2885-2896.	3.2	45
2817	Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. <i>Journal of Neuro-Oncology</i> , 2016, 128, 157-162.	1.4	23
2819	Epidemiology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 3-18.	1.0	15
2820	Surgical approaches for the gliomas. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 51-69.	1.0	31
2821	Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 350-361.	1.2	90
2822	Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 246-255.	0.9	33
2823	Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. <i>Neuro-Oncology</i> , 2016, 18, 1109-1119.	0.6	42
2824	Biomarkers Applied to Specific Tumor Types. , 2016, , 59-98.		0
2825	Survival in glioblastoma: a review on the impact of treatment modalities. <i>Clinical and Translational Oncology</i> , 2016, 18, 1062-1071.	1.2	476
2826	Breaking the DNA damage response to improve cervical cancer treatment. <i>Cancer Treatment Reviews</i> , 2016, 42, 30-40.	3.4	54
2827	The impact of next-generation sequencing on the DNA methylation-based translational cancer research. <i>Translational Research</i> , 2016, 169, 1-18.e1.	2.2	58

#	ARTICLE	IF	CITATIONS
2828	Epigenetic alternations and cancer chemotherapy response. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 673-684.	1.1	34
2829	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016, 11, 337-343.	1.7	23
2830	Expression and prognostic value of the WEE1 kinase in gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 127, 381-389.	1.4	48
2831	ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma (retracted). <i>CNS Oncology</i> , 2016, 5, 11-26.	1.2	21
2832	A prospective study on neurocognitive effects after primary radiotherapy in high-grade glioma patients. <i>International Journal of Clinical Oncology</i> , 2016, 21, 642-650.	1.0	21
2833	The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients'™ survival. <i>Carcinogenesis</i> , 2016, 37, 169-176.	1.3	14
2834	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 4-18.	0.9	81
2835	Update on Brain Tumors: New Developments in Neuro'™oncologic Diagnosis and Treatment, and Impact on Rehabilitation Strategies. <i>PM and R</i> , 2016, 8, 678-689.	0.9	14
2836	TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. <i>Journal of Neuro-Oncology</i> , 2016, 126, 441-446.	1.4	30
2837	Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. <i>Journal of Neurosurgery</i> , 2016, 125, 7-16.	0.9	20
2838	Advances and Technical Standards in Neurosurgery. <i>Advances and Technical Standards in Neurosurgery</i> , 2016, , .	0.2	2
2839	Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas. <i>Advances and Technical Standards in Neurosurgery</i> , 2016, , 91-108.	0.2	37
2840	Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis. <i>Neuro-Oncology Practice</i> , 2016, 3, 29-38.	1.0	22
2841	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. <i>Clinical Cancer Research</i> , 2016, 22, 1632-1641.	3.2	127
2842	A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. <i>Journal of Neuro-Oncology</i> , 2016, 126, 309-316.	1.4	57
2843	5-Aminolevulinic Acid'™Protoporphyrin IX Fluorescence-Guided Surgery of High-Grade Gliomas: A Systematic Review. <i>Advances and Technical Standards in Neurosurgery</i> , 2016, , 61-90.	0.2	30
2844	Strategies to target drugs to gliomas and CNS metastases of solid tumors. <i>Journal of Neurology</i> , 2016, 263, 428-440.	1.8	14
2845	Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. <i>Neuro-Oncology</i> , 2016, 18, 261-268.	0.6	36

#	ARTICLE	IF	CITATIONS
2846	Protein sensing in living cells by molecular rotor-based fluorescence-switchable chemical probes. <i>Chemical Science</i> , 2016, 7, 301-307.	3.7	76
2847	A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. <i>Journal of Neuro-Oncology</i> , 2016, 126, 185-192.	1.4	63
2848	Malignant gliomas: old and new systemic treatment approaches. <i>Radiology and Oncology</i> , 2016, 50, 129-138.	0.6	25
2849	Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme. <i>Neurological Sciences</i> , 2016, 37, 23-29.	0.9	20
2850	Current status and future directions of anti-angiogenic therapy for gliomas. <i>Neuro-Oncology</i> , 2016, 18, 315-328.	0.6	61
2851	The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. <i>Oncogene</i> , 2016, 35, 2145-2155.	2.6	58
2852	The use of cannabinoids as anticancer agents. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 259-266.	2.5	130
2853	MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment. <i>Cellular and Molecular Immunology</i> , 2016, 13, 658-668.	4.8	8
2854	Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors. <i>Neuro-Oncology</i> , 2016, 18, 350-360.	0.6	45
2855	Isocitrate dehydrogenase mutations in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 16-26.	0.6	221
2856	Hypoxia in astrocytic tumors and implications for therapy. <i>Neurobiology of Disease</i> , 2016, 85, 227-233.	2.1	34
2857	HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme. <i>Molecular Neurobiology</i> , 2016, 53, 1802-1807.	1.9	0
2858	CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF- $\kappa$ B pathway in multidrug-resistant glioblastoma cells in vitro. <i>Oncogene</i> , 2016, 35, 241-250.	2.6	61
2859	Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 497-504.	0.6	16
2860	ACTC1 as an invasion and prognosis marker in glioma. <i>Journal of Neurosurgery</i> , 2017, 126, 467-475.	0.9	40
2861	Current and future strategies for treatment of glioma. <i>Neurosurgical Review</i> , 2017, 40, 1-14.	1.2	416
2862	Integrative functional genomic analysis identifies epigenetically regulated fibromodulin as an essential gene for glioma cell migration. <i>Oncogene</i> , 2017, 36, 71-83.	2.6	48
2863	Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter. <i>Journal of Neurosurgery</i> , 2017, 126, 1461-1471.	0.9	9

#	ARTICLE	IF	CITATIONS
2864	<i>In vitro</i> anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 1445-1454.	0.8	25
2865	Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era. <i>JAMA Oncology</i> , 2017, 3, 784.	3.4	83
2866	The new WHO 2016 classification of brain tumors—what neurosurgeons need to know. <i>Acta Neurochirurgica</i> , 2017, 159, 403-418.	0.9	85
2867	Stem Cell-Based Approaches for Treatment of Glioblastoma. <i>Stem Cells in Clinical Applications</i> , 2017, , 65-82.	0.4	0
2868	Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. <i>Journal of Neurosurgery</i> , 2017, 127, 1219-1230.	0.9	29
2869	Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma. <i>Computer Methods and Programs in Biomedicine</i> , 2017, 140, 249-257.	2.6	75
2870	Durable, exceptional response to temozolomide in a patient with extensive-stage small cell lung cancer (ES-SCLC) metastatic to brain. <i>Cancer Treatment and Research Communications</i> , 2017, 10, 17-20.	0.7	5
2871	Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study. <i>Journal of Neuro-Oncology</i> , 2017, 132, 55-62.	1.4	26
2872	Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide. <i>Journal of Neuro-Oncology</i> , 2017, 132, 287-294.	1.4	12
2873	The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines. <i>Neuroscience</i> , 2017, 346, 298-308.	1.1	36
2874	Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 351-358.	1.4	34
2875	Antiangiogenic Therapy for Malignant Gliomas. , 2017, , 163-175.		0
2876	Radiation Therapy for Malignant Gliomas: Current Options. , 2017, , 217-231.		3
2878	Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted). , 2017, , 251-263.		0
2879	Glioblastoma. , 2017, , 265-288.		11
2880	Molecular Neuropathology and the Ontogeny of Malignant Gliomas. , 2017, , 15-29.		0
2881	Current Standard Treatment Options for Malignant Glioma. , 2017, , 123-131.		1
2882	New Directions in Anti-Angiogenic Therapy for Glioblastoma. <i>Neurotherapeutics</i> , 2017, 14, 321-332.	2.1	91



#	ARTICLE	IF	CITATIONS
2883	Honokiol Inhibits DNA Polymerases $\beta$ and $\delta$ and Increases Bleomycin Sensitivity of Human Cancer Cells. <i>Chemical Research in Toxicology</i> , 2017, 30, 715-725.	1.7	15
2884	The role of epigenomics in personalized medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 33-45.	0.4	61
2885	DNA Methylation-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2017, 35, 793-795.	0.8	7
2886	Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 29-39.	3.3	43
2887	1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 561-570.	2.8	12
2888	Molecular markers in glioma. <i>Journal of Neuro-Oncology</i> , 2017, 134, 505-512.	1.4	279
2889	On glioblastoma and the search for a cure: where do we stand?. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2451-2466.	2.4	56
2890	A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications. <i>Mathematical Biosciences</i> , 2017, 288, 1-13.	0.9	24
2891	Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. <i>Journal of Controlled Release</i> , 2017, 263, 112-119.	4.8	90
2892	Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma. <i>Cell Cycle</i> , 2017, 16, 765-775.	1.3	15
2893	Role of <i>MGMT</i> Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. <i>Oncologist</i> , 2017, 22, 432-437.	1.9	61
2894	Glioma Subclassifications and Their Clinical Significance. <i>Neurotherapeutics</i> , 2017, 14, 284-297.	2.1	471
2895	$^{18}\text{F}$ -FET PET prior to recurrent high-grade glioma re-irradiation: additional prognostic value of dynamic time-to-peak analysis and early static summation images?. <i>Journal of Neuro-Oncology</i> , 2017, 132, 277-286.	1.4	21
2896	Temozolomide in the Era of Precision Medicine. <i>Cancer Research</i> , 2017, 77, 823-826.	0.4	91
2897	Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. <i>Immunological Reviews</i> , 2017, 276, 9-25.	2.8	13
2898	Microtubule actin cross-linking factor 1, a novel target in glioblastoma. <i>International Journal of Oncology</i> , 2017, 50, 310-316.	1.4	31
2899	Brain Gliomas in the Elderly. , 2017, , 119-140.		0
2900	DNA-Targeted Inhibition of MGMT. <i>ChemBioChem</i> , 2017, 18, 894-898.	1.3	5

#	ARTICLE	IF	CITATIONS
2901	High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma. <i>Clinical Oncology</i> , 2017, 29, 335-343.	0.6	8
2902	The Survival Advantage of "Supratotal" Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique. <i>Neurosurgery</i> , 2017, 81, 275-288.	0.6	96
2903	DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. <i>Clinical Epigenetics</i> , 2017, 9, 32.	1.8	22
2904	Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. <i>Clinical Epigenetics</i> , 2017, 9, 34.	1.8	129
2905	Genomic Analysis in the Practice of Surgical Neuropathology: The Emory Experience. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 355-365.	1.2	2
2906	Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 247-261.	2.1	44
2908	Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma Treated with FOLFIRINOX. <i>Clinical Drug Investigation</i> , 2017, 37, 669-677.	1.1	8
2909	A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. <i>British Journal of Cancer</i> , 2017, 116, 1279-1286.	2.9	37
2910	Biological activity of tumor-treating fields in preclinical glioma models. <i>Cell Death and Disease</i> , 2017, 8, e2753-e2753.	2.7	79
2911	Expression and function of ABCG2 and XIAP in glioblastomas. <i>Journal of Neuro-Oncology</i> , 2017, 133, 47-57.	1.4	43
2912	EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest. <i>Cell Cycle</i> , 2017, 16, 1085-1092.	1.3	12
2913	Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. <i>Annals of Oncology</i> , 2017, 28, 1448-1456.	0.6	283
2914	Temozolomide does not influence the transcription or activity of matrix metalloproteinases 9 and 2 in glioma cell lines. <i>Journal of Clinical Neuroscience</i> , 2017, 41, 144-149.	0.8	6
2916	A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study. <i>World Neurosurgery</i> , 2017, 104, 581-588.	0.7	19
2917	Tumor microtubules convey resistance to surgical lesions and chemotherapy in gliomas. <i>Neuro-Oncology</i> , 2017, 19, 1316-1326.	0.6	190
2919	Enhancement of temozolomide stability by loading in chitosan-carboxylated polylactide-based nanoparticles. <i>Journal of Nanoparticle Research</i> , 2017, 19, 71.	0.8	29
2920	Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma. <i>Investigative Radiology</i> , 2017, 52, 360-366.	3.5	96
2921	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329.	5.1	816

#	ARTICLE	IF	CITATIONS
2922	Structural and functional intratumor heterogeneities in glioblastoma: a spacetime odyssey at single-cell level. <i>Annals of Oncology</i> , 2017, 28, 1415-1417.	0.6	3
2923	Prediction of therapy response in ovarian cancer: Where are we now?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 233-266.	2.7	28
2924	Angiogenesis inhibitors in tackling recurrent glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 507-515.	1.1	28
2925	Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database. <i>Cancer Medicine</i> , 2017, 6, 1192-1200.	1.3	24
2927	DNA methylation: an epigenetic mark of cellular memory. <i>Experimental and Molecular Medicine</i> , 2017, 49, e322-e322.	3.2	286
2928	Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 17-27.	1.0	8
2929	<i>EGFR</i> -Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1. <i>Stem Cells Translational Medicine</i> , 2017, 6, 830-839.	1.6	31
2930	FREQUENT SUBGRAPH MINING OF PERSONALIZED SIGNALING PATHWAY NETWORKS GROUPS PATIENTS WITH FREQUENTLY DYSREGULATED DISEASE PATHWAYS AND PREDICTS PROGNOSIS. , 2017, 22, 402-413.		1
2931	From K-space to Nucleotide. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 33-41.	0.7	2
2932	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i> -Mutant Cancers and Potentiates NAD <sup>+</sup> Depletion-Mediated Cytotoxicity. <i>Cancer Research</i> , 2017, 77, 4102-4115.	0.4	74
2933	Update on Radiotherapy for Central Nervous System Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 347-355.	0.6	3
2934	Glioblastoma-derived cells <i>in vitro</i> unveil the spectrum of drug resistance capability – comparative study of tumour chemosensitivity in different culture systems. <i>Bioscience Reports</i> , 2017, 37, .	1.1	8
2935	Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival. <i>Journal of Neuro-Oncology</i> , 2017, 134, 107-118.	1.4	25
2936	Glioblastoma Multiforme: an Advanced Analysis of 153 Patients and Review of the Literature. <i>Brazilian Neurosurgery</i> , 2017, 36, 080-090.	0.0	2
2937	DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discovery</i> , 2017, 7, 675-693.	7.7	519
2938	Citation classics in neuro-oncology: assessment of historical trends and scientific progress. <i>Neuro-Oncology</i> , 2017, 19, 1158-1172.	0.6	24
2939	Cancer subtypes in aetiological research. <i>European Journal of Epidemiology</i> , 2017, 32, 353-361.	2.5	15
2940	A Comprehensive Review of Genomics and Noncoding RNA in Gliomas. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 3-14.	0.7	18

#	ARTICLE	IF	CITATIONS
2941	Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. <i>International Journal of Cancer</i> , 2017, 141, 1671-1681.	2.3	26
2942	Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era. <i>Mayo Clinic Proceedings</i> , 2017, 92, 995-1004.	1.4	15
2943	MGMT promoter methylation status: time for a frank discussion. <i>Journal of Neuro-Oncology</i> , 2017, 133, 667-668.	1.4	0
2944	NEUROPATOLOGÃA: DIAGNÃ“STICO CON BIOLOGÃA MOLECULAR. <i>Revista MÃ©dica ClÃnica Las Condes</i> , 2017, 28, 352-359.	0.2	0
2945	O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, 758-763.	0.5	28
2946	Primary Spinal Cord Glioblastoma Multiforme: A Retrospective Study of Patients at a Single Institution. <i>World Neurosurgery</i> , 2017, 106, 113-119.	0.7	15
2947	Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients. <i>Neuro-Oncology</i> , 2017, 19, 736-738.	0.6	20
2948	Milestones of the last 10Ãyears. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 18-21.	0.3	8
2949	Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 826-830.	0.8	24
2950	Î²-Asarone promotes Temozolomideâ€™s entry into glioma cells and decreases the expression of P-glycoprotein and MDR1. <i>Biomedicine and Pharmacotherapy</i> , 2017, 90, 368-374.	2.5	17
2951	Prognostic and predictive biomarkers in neuroendocrine tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 268-282.	2.0	42
2952	Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma. <i>Radiology</i> , 2017, 284, 180-190.	3.6	48
2953	Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma. <i>Journal of Translational Medicine</i> , 2017, 15, 61.	1.8	34
2954	Expression signatures of DNA repair genes correlate with survival prognosis of astrocytoma patients. <i>Tumor Biology</i> , 2017, 39, 101042831769455.	0.8	33
2955	Central nervous system gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 213-234.	2.0	109
2956	Drug Resistance in Cancer. , 2017, , 449-473.		2
2957	Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. <i>Journal of Neuro-Oncology</i> , 2017, 134, 541-549.	1.4	109
2958	O 2 â€¦.â” and H 2 O 2 -Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. <i>Cancer Cell</i> , 2017, 31, 487-500.e8.	7.7	316

#	ARTICLE	IF	CITATIONS
2959	Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. <i>British Journal of Cancer</i> , 2017, 116, 1287-1293.	2.9	22
2960	DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. <i>Epigenetics</i> , 2017, 12, 416-432.	1.3	98
2961	Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. <i>Radiotherapy and Oncology</i> , 2017, 123, 106-111.	0.3	32
2963	Molecular mechanisms and therapeutic targets in pediatric brain tumors. <i>Science Signaling</i> , 2017, 10, .	1.6	53
2964	Methylation-sensitive enrichment of minor DNA alleles using a double-strand DNA-specific nuclease. <i>Nucleic Acids Research</i> , 2017, 45, e39-e39.	6.5	22
2965	Does Pretreatment Tumor Growth Hold Prognostic Information for Patients with Glioblastoma?. <i>World Neurosurgery</i> , 2017, 101, 686-694.e4.	0.7	11
2966	The Effect of Molecular Diagnostics on the Treatment of Glioma. <i>Current Oncology Reports</i> , 2017, 19, 26.	1.8	40
2967	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. , 2017, , .		13
2968	Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. <i>Journal of Neurology</i> , 2017, 264, 350-358.	1.8	27
2969	<i>GPX3</i> promoter methylation predicts platinum sensitivity in colorectal cancer. <i>Epigenetics</i> , 2017, 12, 540-550.	1.3	43
2970	The NCI-60 Methylome and Its Integration into CellMiner. <i>Cancer Research</i> , 2017, 77, 601-612.	0.4	48
2971	Pathogenesis and Treatment of Aggressive Corticotroph Pituitary Tumors. , 2017, , 93-110.		1
2972	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017, 71, 43-50.	1.3	27
2973	Bioelectrochemistry of nucleic acids for early cancer diagnostics – analysis of DNA methylation and detection of microRNAs. <i>Reviews in Analytical Chemistry</i> , 2017, 36, .	1.5	7
2974	Glioblastoma in the elderly: treatment patterns and survival. <i>CNS Oncology</i> , 2017, 6, 19-28.	1.2	18
2975	Advances in the molecular genetics of gliomas – implications for classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 434-452.	12.5	497
2976	Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. <i>Cancer Research</i> , 2017, 77, 960-970.	0.4	78
2977	Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 347-358.	1.0	24

#	ARTICLE	IF	CITATIONS
2978	Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice. <i>Neuro-Oncology Practice</i> , 2017, 4, 209-219.	1.0	17
2979	Personalized Medicine Through Advanced Genomics. , 2017, , 31-48.		1
2980	Toward Personalized Targeted Therapeutics: An Overview. <i>Neurotherapeutics</i> , 2017, 14, 256-264.	2.1	22
2981	Treatment of Glioblastoma in Older Adults. <i>Current Oncology Reports</i> , 2017, 19, 81.	1.8	45
2982	Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 925-934.	0.6	8
2983	A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma. <i>Journal of Genetics and Genomics</i> , 2017, 44, 519-530.	1.7	29
2984	The extent of edema and tumor synchronous invasion into the subventricular zone and corpus callosum classify outcomes and radiotherapy strategies of glioblastomas. <i>Radiotherapy and Oncology</i> , 2017, 125, 248-257.	0.3	16
2985	A comparison between oral chemotherapy combined with radiotherapy and radiotherapy for newly diagnosed glioblastoma. <i>Medicine (United States)</i> , 2017, 96, e8444.	0.4	9
2986	A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth. <i>Biochemical and Biophysical Research Communications</i> , 2017, 494, 477-483.	1.0	22
2987	Prognosis of patients with primary malignant brain tumors admitted to the intensive care unit: a two-decade experience. <i>Journal of Neurology</i> , 2017, 264, 2303-2312.	1.8	12
2988	Screening critical genes associated with malignant glioma using bioinformatics analysis. <i>Molecular Medicine Reports</i> , 2017, 16, 6580-6589.	1.1	10
2989	Microtubule actin cross-linking factor 1, a novel potential target in cancer. <i>Cancer Science</i> , 2017, 108, 1953-1958.	1.7	52
2990	Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2735-2746.	1.9	58
2991	Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. <i>Cancer Cell</i> , 2017, 32, 411-426.e11.	7.7	161
2992	Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 917-926.	1.5	8
2993	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. <i>Radiographics</i> , 2017, 37, 2164-2180.	1.4	105
2994	Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy related intracranial effects. <i>British Journal of Radiology</i> , 2018, 91, 20170553.	1.0	3
2995	Long noncoding RNA eosinophil granule ontogeny transcript inhibits cell proliferation and migration and promotes cell apoptosis in human glioma. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 3817-3823.	0.8	14

#	ARTICLE	IF	CITATIONS
2996	Of mice and men: patient-derived xenografts in cancer medicine. <i>Annals of Oncology</i> , 2017, 28, 2330-2331.	0.6	3
2997	Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas. <i>Glia</i> , 2017, 65, 1914-1926.	2.5	50
2998	High-Definition Medicine. <i>Cell</i> , 2017, 170, 828-843.	13.5	168
2999	Power estimation in biomarker studies where events are already observed. <i>Clinical Trials</i> , 2017, 14, 621-628.	0.7	3
3000	Cholera Toxin Subunit B Enabled Multifunctional Glioma-Targeted Drug Delivery. <i>Advanced Healthcare Materials</i> , 2017, 6, 1700709.	3.9	27
3001	Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 429-439.	1.0	15
3002	Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche. <i>Cancer Microenvironment</i> , 2017, 10, 57-68.	3.1	17
3003	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1373-1385.	5.1	776
3004	Sensitivity to <i>BUB1B</i> Inhibition Defines an Alternative Classification of Glioblastoma. <i>Cancer Research</i> , 2017, 77, 5518-5529.	0.4	38
3005	Future Perspective of DNA and Histone Methylation as Cancer Targets. <i>Cancer Drug Discovery and Development</i> , 2017, , 607-622.	0.2	0
3006	Association of O <sup>6</sup> -Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. <i>JAMA Surgery</i> , 2017, 152, e173120.	2.2	22
3007	Molecular Pathology of Glioblastoma- An Update. <i>Current Cancer Research</i> , 2017, , 19-55.	0.2	0
3008	Pseudoprogression after glioma therapy: an update. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1109-1115.	1.4	40
3009	GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. <i>Scientific Reports</i> , 2017, 7, 8814.	1.6	20
3010	Tumor-homing Stem Cell Therapy for Brain Cancer. <i>Current Surgery Reports</i> , 2017, 5, 1.	0.4	7
3011	Mapping and elucidating the function of modified bases in DNA. <i>Nature Reviews Chemistry</i> , 2017, 1, .	13.8	73
3012	DNA and Histone Methylation in Colon Cancer. <i>Cancer Drug Discovery and Development</i> , 2017, , 461-487.	0.2	0
3013	Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. <i>Oncology Letters</i> , 2017, 14, 1141-1146.	0.8	58

#	ARTICLE	IF	CITATIONS
3014	Imaging Correlates of Adult Glioma Genotypes. <i>Radiology</i> , 2017, 284, 316-331.	3.6	160
3015	The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. <i>Immunology Letters</i> , 2017, 190, 20-25.	1.1	26
3016	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. <i>Journal of Neuro-Oncology</i> , 2017, 135, 183-192.	1.4	138
3017	MicroRNAs as Multifaceted Players in Glioblastoma Multiforme. <i>International Review of Cell and Molecular Biology</i> , 2017, 333, 269-323.	1.6	21
3018	Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas. <i>Journal of Neuro-Oncology</i> , 2017, 133, 399-407.	1.4	5
3019	<i>Olea europaea</i> Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma. <i>Nutrition and Cancer</i> , 2017, 69, 873-880.	0.9	12
3020	The cost and value of glioblastoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 657-659.	1.1	10
3022	CLINICAL RELEVANCE OF MOLECULAR MARKERS IN GLIOMAS. <i>Revista Médica Clínica Las Condes</i> , 2017, 28, 343-351.	0.2	6
3023	Current Therapies and Future Directions in Treatment of Glioblastoma. <i>Current Cancer Research</i> , 2017, , 57-89.	0.2	1
3024	Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. <i>Clinical Cancer Research</i> , 2017, 23, 6650-6660.	3.2	141
3025	Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors. <i>Cancer Gene Therapy</i> , 2017, 24, 348-357.	2.2	5
3026	BET inhibitors: a novel epigenetic approach. <i>Annals of Oncology</i> , 2017, 28, 1776-1787.	0.6	276
3027	Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches. <i>International Journal of Pharmaceutics</i> , 2017, 531, 372-388.	2.6	54
3028	Global DNA Methylation Analysis Identifies Two Discrete clusters of Pheochromocytoma with Distinct Genomic and Genetic Alterations. <i>Scientific Reports</i> , 2017, 7, 44943.	1.6	13
3029	The proline rich domain of p53 is dispensable for MGMT-dependent DNA repair and cell survival following alkylation damage. <i>Cell Death and Differentiation</i> , 2017, 24, 1925-1936.	5.0	10
3030	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	16
3031	Management of glioblastoma in elderly patients. <i>Journal of the Neurological Sciences</i> , 2017, 380, 250-255.	0.3	40
3032	Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer. <i>Medicine (United States)</i> , 2017, 96, e6708.	0.4	10



#	ARTICLE	IF	CITATIONS
3033	Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients. <i>Medicine (United States)</i> , 2017, 96, e7422.	0.4	39
3034	Cell Signaling Pathways in Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 15-26.	0.7	5
3035	A Dexamethasone-regulated Gene Signature Is Prognostic for Poor Survival in Glioblastoma Patients. <i>Journal of Neurosurgical Anesthesiology</i> , 2017, 29, 46-58.	0.6	28
3036	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017, 390, 1645-1653.	6.3	307
3037	Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming. <i>Scientific Reports</i> , 2017, 7, 7425.	1.6	28
3038	Identification of potential key genes associated with glioblastoma based on the gene expression profile. <i>Oncology Letters</i> , 2017, 14, 2045-2052.	0.8	12
3039	Challenges to Treating Older Glioblastoma Patients: the Influence of Clinical and Tumour Characteristics on Survival Outcomes. <i>Clinical Oncology</i> , 2017, 29, 739-747.	0.6	29
3041	Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1043-1046.	1.1	4
3042	PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma. <i>Scientific Reports</i> , 2017, 7, 7391.	1.6	8
3043	Glioblastoma entities express subtle differences in molecular composition and response to treatment. <i>Oncology Reports</i> , 2017, 38, 1341-1352.	1.2	24
3044	Nanoformulations for Therapeutics. , 2017, , 79-95.		0
3045	Prognostic and predictive factors in high-grade gliomas. Experience at our institution. <i>NeurocirugÃa (English Edition)</i> , 2017, 28, 276-283.	0.1	3
3047	Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 1591-1605.	1.1	22
3048	From bench to clinical trials the EORTC experience in biology-based clinical cancer research. <i>Journal of the Egyptian National Cancer Institute</i> , 2017, 29, 171-176.	0.6	0
3049	Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition. <i>Cell Cycle</i> , 2017, 16, 2355-2365.	1.3	28
3050	Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis. <i>BMI Open</i> , 2017, 7, e017387.	0.8	30
3051	ATP7B expression in human glioblastoma is related to temozolomide resistance. <i>Oncology Letters</i> , 2017, 14, 7777-7782.	0.8	1
3053	Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas. <i>Pathology Research and Practice</i> , 2017, 213, 1489-1493.	1.0	24

#	ARTICLE	IF	CITATIONS
3054	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. <i>Journal of Neuro-Oncology</i> , 2017, 134, 331-338.	1.4	21
3055	Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 389-399.	2.1	9
3057	Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume. <i>Journal of Neuro-Oncology</i> , 2017, 134, 377-385.	1.4	16
3058	Role of epigenome in tumorigenesis and drug resistance. <i>Food and Chemical Toxicology</i> , 2017, 109, 663-668.	1.8	19
3059	Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner. <i>Oncology Letters</i> , 2017, 14, 322-328.	0.8	33
3060	Recent developments in predictive biomarkers of pediatric glioma. <i>Oncology Letters</i> , 2017, 14, 497-500.	0.8	1
3061	Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6239-6253.	3.2	93
3062	Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 682-694.	12.5	86
3063	Characterization of gliomas: from morphology to molecules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 257-269.	1.4	86
3064	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. <i>CNS Drugs</i> , 2017, 31, 675-684.	2.7	24
3065	Exosomes: New players in cancer. <i>Oncology Reports</i> , 2017, 38, 665-675.	1.2	122
3066	Pediatric High Grade Glioma. <i>Current Cancer Research</i> , 2017, , 241-266.	0.2	1
3067	Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort. <i>World Neurosurgery</i> , 2017, 106, 165-173.	0.7	28
3069	Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, 341-347.	0.7	24
3070	Subventricular zones: new key targets for glioblastoma treatment. <i>Radiation Oncology</i> , 2017, 12, 67.	1.2	35
3071	Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy. <i>Molecular Cytogenetics</i> , 2017, 10, 16.	0.4	9
3072	Liposomal temozolomide drug delivery using convection enhanced delivery. <i>Journal of Controlled Release</i> , 2017, 261, 138-146.	4.8	63
3074	Pathology of Pituitary Tumors Update. <i>AJSP Review and Reports</i> , 2017, 22, 189-195.	0.0	2

#	ARTICLE	IF	CITATIONS
3075	DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. <i>Cancer Research</i> , 2017, 77, 198-206.	0.4	96
3076	FDG PET/MR Imaging Coregistration Helps Predict Survival in Patients with Glioblastoma and Radiologic Progression after Standard of Care Treatment. <i>Radiology</i> , 2017, 283, 508-514.	3.6	22
3077	Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. <i>Journal of Neurosurgery</i> , 2017, 127, 132-138.	0.9	25
3078	Epigenetic Mechanisms in Cancer Development. , 2017, , 263-275.		3
3080	Epigenetic Basis of Human Cancer. , 2017, , 83-102.		1
3081	Reverse phase protein arrays enable glioblastoma molecular subtyping. <i>Journal of Neuro-Oncology</i> , 2017, 131, 437-448.	1.4	9
3082	Microglia and brain macrophages: An update. <i>Neuropathology</i> , 2017, 37, 452-464.	0.7	68
3083	Impact of DNA repair on the dose-response of colorectal cancer formation induced by dietary carcinogens. <i>Food and Chemical Toxicology</i> , 2017, 106, 583-594.	1.8	28
3084	Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 301-311.	1.4	13
3085	Regulation of DNA Alkylation Damage Repair: Lessons and Therapeutic Opportunities. <i>Trends in Biochemical Sciences</i> , 2017, 42, 206-218.	3.7	81
3086	O 6 -Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?. <i>Lung Cancer</i> , 2017, 107, 91-99.	0.9	19
3087	Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 562-574.	3.2	60
3088	Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention. <i>Oncogene</i> , 2017, 36, 877-884.	2.6	117
3089	The Unexpected Roles of Aurora A Kinase in Glioblastoma Recurrences. <i>Targeted Oncology</i> , 2017, 12, 11-18.	1.7	12
3090	Brain Tumors-Epidemiology. , 2017, , 279-290.		1
3091	In vivo molecular profiling of human glioma using diffusion kurtosis imaging. <i>Journal of Neuro-Oncology</i> , 2017, 131, 93-101.	1.4	56
3093	Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. <i>Molecular Neurobiology</i> , 2017, 54, 5780-5797.	1.9	52
3094	Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide. <i>World Neurosurgery</i> , 2017, 97, 21-26.	0.7	5

#	ARTICLE	IF	CITATIONS
3095	High-Grade Gliomas. <i>Pediatric Oncology</i> , 2017, , 37-50.	0.5	0
3096	Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Boxâ€œBehnken design. <i>Pharmaceutical Development and Technology</i> , 2017, 22, 370-382.	1.1	45
3097	Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma. <i>Journal of Drug Targeting</i> , 2017, 25, 156-162.	2.1	8
3098	PARP Inhibitor Activity Correlates with <i>SLFN11</i> Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 523-535.	3.2	252
3099	The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. <i>Journal of Clinical Neuroscience</i> , 2017, 36, 120-124.	0.8	32
3100	A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 487-494.	0.4	40
3101	Pathology and Molecular Pathology of Brain Cancer. , 2017, , 291-311.		2
3102	Prognostic Role of the Expression of Invasion-Related Molecules in Glioblastoma. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2017, 78, 12-19.	0.4	14
3103	Administration of Non-Torsadogenic human Ether-Ã-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERGâ€œExpressing Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2017, 23, 73-80.	3.2	40
3104	Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG 2000 -transferrin in treatment of brain glioma. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 129-140.	1.9	67
3105	Effect of O6â€œmethylguanineâ€œDNA methyltransferase methylation in medulloblastoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1107-1111.	0.4	2
3107	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	3.8	1,619
3108	Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. <i>Oncolimmunology</i> , 2017, 6, e1336272.	2.1	17
3109	Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. <i>Oncology Reports</i> , 2018, 39, 537-544.	1.2	9
3110	Identification of expression quantitative trait loci of MTOR associated with the progression of glioma. <i>Oncology Letters</i> , 2017, 15, 665-671.	0.8	1
3111	CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010â€œ2014. <i>Neuro-Oncology</i> , 2017, 19, v1-v88.	0.6	1,236
3112	Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma. <i>Oncology Letters</i> , 2018, 15, 1263-1270.	0.8	38
3113	Meningeal seeding from glioblastoma multiforme treated with radiotherapy andÂtemozolomide. <i>Asian Journal of Surgery</i> , 2017, 40, 61-65.	0.2	14

#	ARTICLE	IF	CITATIONS
3114	<i>BICD1</i> expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas. <i>Oncotarget</i> , 2017, 8, 113766-113791.	0.8	9
3115	Advances in epigenetic glioblastoma therapy. <i>Oncotarget</i> , 2017, 8, 18577-18589.	0.8	75
3116	Subcutaneous Dissemination in Highly Aggressive Intracranial Glioblastoma: Case Report and Literature Review. <i>Brazilian Neurosurgery</i> , 2017, 36, 47-53.	0.0	0
3117	Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 193-203.	1.3	26
3118	Beyond Alkylating Agents for Gliomas: <i>Quo Vadimus</i> ?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 175-186.	1.8	6
3119	Managing CNS Tumors: The Nanomedicine Approach. , 2017, , .		2
3120	The Response to Chemo Radiation Therapy in Unresectable Glioblastoma Multiforme Patients in Relation to MGMT Promoter Methylation Status: A Study from a Single Saudi Center. <i>Journal of Clinical Epigenetics</i> , 2017, 03, .	0.3	0
3122	Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 99-113.	0.7	63
3123	Immune Checkpoint in Glioblastoma: Promising and Challenging. <i>Frontiers in Pharmacology</i> , 2017, 8, 242.	1.6	133
3124	The Role of Epigenetics in Autoimmune Disorders. , 2017, , 535-551.		0
3125	Molecular mechanisms underlying the $\beta$ -catenin-directed apoptosis in human malignant glioblastoma cell lines A172 and U87MG. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 6183-6192.	0.8	4
3126	MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	24
3127	Immunotherapy Clinical Trials in Neuro-Oncology. , 2017, , 181-210.		0
3128	Epigenetic Biomarkers. , 2017, , 277-292.		0
3129	The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2452.	1.8	45
3130	Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2732.	1.8	26
3131	Mitochondrial Deficiencies in the Predisposition to Paraganglioma. <i>Metabolites</i> , 2017, 7, 17.	1.3	21
3132	Molecular Techniques for DNA Methylation Studies. , 2017, , 103-139.		5

#	ARTICLE	IF	CITATIONS
3133	The Role of Hypoxia in Glioblastoma Invasion. <i>Cells</i> , 2017, 6, 45.	1.8	224
3134	IQGAP1 in Podosomes/Invadosomes Is Involved in the Progression of Glioblastoma Multiforme Depending on the Tumor Status. <i>International Journal of Molecular Sciences</i> , 2017, 18, 150.	1.8	12
3135	n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 372.	1.8	21
3136	Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 735.	1.8	23
3137	Molecular Markers of Gliomas. <i>Molecular Genetics, Microbiology and Virology</i> , 2017, 32, 180-190.	0.0	2
3138	Difference in the Inhibitory Effect of Temozolomide on TJ905 Glioma Cells and Stem Cells. <i>Frontiers in Neurology</i> , 2017, 8, 474.	1.1	3
3139	Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma. <i>Frontiers in Oncology</i> , 2017, 7, 45.	1.3	45
3140	Extracellular Vesicles As Modulators of Tumor Microenvironment and Disease Progression in Glioma. <i>Frontiers in Oncology</i> , 2017, 7, 144.	1.3	47
3141	Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma. <i>Frontiers in Oncology</i> , 2017, 7, 178.	1.3	9
3142	MicroRNA in Glioblastoma: An Overview. <i>International Journal of Genomics</i> , 2017, 2017, 1-16.	0.8	114
3143	Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	239
3144	Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	9
3145	Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma. <i>Cancers</i> , 2017, 9, 57.	1.7	61
3146	Effect of temozolomide on survival in elderly patients with glioblastoma and impaired performance status: a propensity score&ndash;matching analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4029-4035.	1.0	7
3147	4.30 Nanomaterials for Drug Delivery to the Brain. , 2017, , 549-570.		0
3148	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Practical Approach for Gliomas, Part 1. <i>Basic Tumor Genetics. Neurographics</i> , 2017, 7, 334-343.	0.2	7
3149	The rs16906252:C&gt;T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort. <i>PLoS ONE</i> , 2017, 12, e0178842.	1.1	2
3150	Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma. <i>Cancer Cell International</i> , 2017, 17, 117.	1.8	45

#	ARTICLE	IF	CITATIONS
3151	Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant. <i>Acta Neuropathologica Communications</i> , 2017, 5, 98.	2.4	35
3152	Anaplastic pleomorphic xanthoastrocytoma with disseminated growth pattern at the time of diagnosis as well as after treatment: case report and review of literature. <i>Chinese Neurosurgical Journal</i> , 2017, 3, .	0.3	2
3154	Brain tumor initiating cells: with great technology will come greater understanding. <i>Future Neurology</i> , 2017, 12, 223-236.	0.9	1
3155	MGMT promoter methylation as a potential prognostic marker for acute leukemia. <i>Archives of Medical Science</i> , 2017, 6, 1433-1441.	0.4	9
3156	Brain Tumor Treatment: 2017 Update. <i>Cancer and Clinical Oncology</i> , 2017, 7, 30.	0.2	0
3157	The role of p53 in cancer drug resistance and targeted chemotherapy. <i>Oncotarget</i> , 2017, 8, 8921-8946.	0.8	407
3159	Treatment and Outcomes for Glioblastoma in Elderly Compared with Non-elderly Patients: A Population-Based Study. <i>Current Oncology</i> , 2017, 24, 92-98.	0.9	48
3160	Cerium Oxide Nanoparticles as Novel Tool in Glioma Treatment: An In vitro Study. <i>Journal of Nanomedicine &amp; Nanotechnology</i> , 2017, 08, .	1.1	9
3161	Patterns of diagnostic marker assessment in adult diffuse glioma: a survey of the European Confederation of Neuropathological Societies (Euro-CNS). , 2017, 36, 5-14.		6
3162	Advances in the Treatment of Primary Brain Tumors: The Realm of Immunotherapy. , 0, , .		0
3163	Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 83-92.	1.0	31
3164	Is the prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis. <i>Cancer Management and Research</i> , 2017, Volume 9, 411-425.	0.9	14
3165	Treatment of Glioblastoma. <i>Journal of Oncology Practice</i> , 2017, 13, 629-638.	2.5	94
3166	Clinical trial endpoints for patients with gliomas. <i>Neuro-Oncology Practice</i> , 2017, 4, 201-208.	1.0	7
3167	Adult Glioblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2402-2409.	0.8	561
3169	New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 753-763.	1.8	9
3170	Nanotechnology in neurosurgical oncology. , 2017, , 139-170.		2
3171	Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. <i>Oncotarget</i> , 2017, 8, 44015-44031.	0.8	69

#	ARTICLE	IF	CITATIONS
3172	Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 71-80.	1.1	19
3173	Genetic and Epigenetic Heterogeneity in Normal Liver Homeostasis and Its Implications for Liver Disease and Hepatocellular Cancer. <i>Seminars in Liver Disease</i> , 2018, 38, 041-050.	1.8	25
3174	Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer. <i>Oncology Letters</i> , 2018, 15, 3586-3593.	0.8	15
3175	Temozolomide perillyl alcohol conjugate downregulates O6-methylguanine DNA methyltransferase via inducing ubiquitination-dependent proteolysis in non-small cell lung cancer. <i>Cell Death and Disease</i> , 2018, 9, 202.	2.7	5
3176	Targeting metabotropic glutamate receptors in the treatment of primary brain tumors. <i>Current Opinion in Pharmacology</i> , 2018, 38, 59-64.	1.7	4
3177	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491875907.	0.6	4
3178	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. <i>Advances in Anatomic Pathology</i> , 2018, 25, 143-171.	2.4	31
3179	Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775359.	1.5	5
3180	Transcriptional control of O <sup>6</sup> -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. <i>Journal of Neurochemistry</i> , 2018, 144, 780-790.	2.1	24
3181	Deep learning with convolutional neural network in radiology. <i>Japanese Journal of Radiology</i> , 2018, 36, 257-272.	1.0	243
3182	The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis. <i>Journal of Clinical Neuroscience</i> , 2018, 51, 85-90.	0.8	16
3183	Current Challenges and Opportunities in Treating Glioblastoma. <i>Pharmacological Reviews</i> , 2018, 70, 412-445.	7.1	571
3184	A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location. <i>World Neurosurgery</i> , 2018, 115, e375-e385.	0.7	17
3185	ARTE and craft of bevacizumab in elderly patients with glioblastoma. <i>Annals of Oncology</i> , 2018, 29, 1346-1347.	0.6	0
3186	Medicinal Plants as Novel Promising Therapeutics for Neuroprotection and Neuroregeneration. , 2018, , 437-453.		4
3187	Premature Mortality Due to Malignancies of the Central Nervous System in Canada, 1980-2010. <i>Neuroepidemiology</i> , 2018, 50, 195-200.	1.1	11
3188	New Age Herbals. , 2018, , .		7
3189	Analysis of DNA methylation in cancer: location revisited. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 459-466.	12.5	486



#	ARTICLE	IF	CITATIONS
3190	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. <i>Nature Communications</i> , 2018, 9, 1474.	5.8	106
3191	Sequencing the next generation of glioblastomas. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 264-282.	2.7	27
3192	Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study. <i>Journal of Neuro-Oncology</i> , 2018, 139, 373-381.	1.4	14
3193	Long noncoding RNA LINC00152 is a potential prognostic biomarker in patients with high-grade glioma. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 957-966.	1.9	20
3194	Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. , 2018, 188, 168-175.		40
3195	Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. <i>Scientific Reports</i> , 2018, 8, 5087.	1.6	124
3196	Treatment of glioblastoma with herbal medicines. <i>World Journal of Surgical Oncology</i> , 2018, 16, 28.	0.8	9
3197	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 422-442.	12.5	873
3198	Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. <i>Journal of Experimental Medicine</i> , 2018, 215, 963-983.	4.2	36
3199	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. <i>Neuro-Oncology</i> , 2018, 20, 546-556.	0.6	93
3200	Pediatric high-grade glioma: a review of biology, prognosis, and treatment. <i>Journal of Radiation Oncology</i> , 2018, 7, 7-15.	0.7	6
3201	Brain Tumors. <i>American Journal of Medicine</i> , 2018, 131, 874-882.	0.6	121
3202	The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. <i>World Neurosurgery</i> , 2018, 112, e342-e347.	0.7	36
3203	Pathology and Genetics of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 31, 1-37.	1.3	19
3204	Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. <i>Progress in Neurological Surgery</i> , 2018, 31, 168-179.	1.3	2
3205	Chemotherapy of High-Grade Astrocytomas in Adults. <i>Progress in Neurological Surgery</i> , 2018, 31, 116-144.	1.3	5
3206	Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?. <i>Clinical Neurology and Neurosurgery</i> , 2018, 167, 6-10.	0.6	11
3207	Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence. <i>Neuro-Oncology</i> , 2018, 20, 942-953.	0.6	31

#	ARTICLE	IF	CITATIONS
3208	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	0.6	130
3209	Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002444.	0.5	16
3210	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018, 135, 601-615.	3.9	76
3211	Where does O <sup>6</sup> -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?. <i>Cancer</i> , 2018, 124, 1316-1318.	2.0	9
3212	New aspects of glioblastoma multiforme revealed by similarities between neural and glioblastoma stem cells. <i>Cell Biology and Toxicology</i> , 2018, 34, 425-440.	2.4	29
3213	Universitätsspital Zürich: 80 years of neurosurgical patient care in Switzerland. <i>Acta Neurochirurgica</i> , 2018, 160, 3-22.	0.9	18
3214	From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence. <i>Clinical and Translational Oncology</i> , 2018, 20, 989-1003.	1.2	9
3215	Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 809-819.	1.2	17
3216	Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. <i>Cell Death and Disease</i> , 2018, 9, 190.	2.7	22
3217	Synthesis and growth-inhibitory activities of imidazo[5,1- <i>d</i> ]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position. <i>MedChemComm</i> , 2018, 9, 545-553.	3.5	6
3218	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation in the NCT Neuro Master Match (N2M2) pilot study. <i>Neuro-Oncology</i> , 2018, 20, 826-837.	0.6	32
3219	Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. <i>European Radiology</i> , 2018, 28, 2115-2123.	2.3	49
3220	MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. <i>Epigenomics</i> , 2018, 10, 277-288.	1.0	381
3221	PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. <i>Clinical and Translational Radiation Oncology</i> , 2018, 8, 12-16.	0.9	51
3222	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1195-1203.	0.4	45
3223	Apparent diffusion coefficient histogram analysis for prediction of prognosis in glioblastoma. <i>Journal of Neuroradiology</i> , 2018, 45, 236-241.	0.6	18
3224	Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab. <i>World Neurosurgery</i> , 2018, 110, e727-e737.	0.7	14
3225	Large Scale Identification of Variant Proteins in Glioma Stem Cells. <i>ACS Chemical Neuroscience</i> , 2018, 9, 73-79.	1.7	12

#	ARTICLE	IF	CITATIONS
3226	Management and Outcomes in the Oldest-Old Population with Glioblastoma. Canadian Journal of Neurological Sciences, 2018, 45, 199-205.	0.3	10
3227	Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma. Journal of Neurosurgery, 2018, 129, 1446-1455.	0.9	22
3228	Molecular Basis of Diseases of the Nervous System. , 2018, , 651-690.		3
3229	Current and Future Initiatives for Radiation Oncology at the National Cancer Institute in the Era of Precision Medicine. International Journal of Radiation Oncology Biology Physics, 2018, 102, 18-25.	0.4	12
3230	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	1.9	196
3231	Computational modeling in glioblastoma: from the prediction of blood-brain barrier permeability to the simulation of tumor behavior. Future Medicinal Chemistry, 2018, 10, 121-131.	1.1	16
3232	Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. Journal of Neuro-Oncology, 2018, 137, 533-542.	1.4	19
3233	Rationale and design of the 500-patient, 3-year, and prospective Vigilant Observation of Glioblastoma Wafer Implants registry. CNS Oncology, 2018, 7, CNS08.	1.2	12
3234	Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 472-483.	0.6	42
3235	Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma. Journal of Neuro-Oncology, 2018, 137, 395-407.	1.4	42
3236	Recent advances in intradural spinal tumors. Neuro-Oncology, 2018, 20, 729-742.	0.6	36
3237	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro-Oncology, 2018, 20, 1162-1172.	0.6	92
3238	Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro-Oncology, 2018, 20, 642-654.	0.6	39
3239	Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). Scientific Reports, 2018, 8, 6704.	1.6	51
3240	A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer. BMC Cancer, 2018, 18, 377.	1.1	27
3241	Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma. World Neurosurgery, 2018, 116, e147-e161.	0.7	8
3242	Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. Clinical Medicine Insights: Oncology, 2018, 12, 117955491876336.	0.6	27
3243	Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. BMC Cancer, 2018, 18, 215.	1.1	63

#	ARTICLE	IF	CITATIONS
3244	Distinct demographic profile and molecular markers of primary CNS tumor in 1873 adolescent and young adult patient population. <i>Child's Nervous System</i> , 2018, 34, 1489-1495.	0.6	3
3245	Assessing the predictability of <i>IDH</i> mutation and <i>MGMT</i> methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. <i>Neuro-Oncology</i> , 2018, 20, 1661-1671.	0.6	119
3246	Temozolomide for immunomodulation in the treatment of glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1566-1572.	0.6	166
3247	Brain tumors â€“ other treatment modalities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.0	2
3248	Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI. <i>Journal of Neuro-Oncology</i> , 2018, 139, 455-460.	1.4	19
3249	Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis. <i>Acta Neurochirurgica</i> , 2018, 160, 1167-1174.	0.9	10
3250	CpG Islands in Cancer: Heads, Tails, and Sides. <i>Methods in Molecular Biology</i> , 2018, 1766, 49-80.	0.4	19
3251	Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor $l\pm 1$ and $l\pm 2$ gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2018, 136, 463-474.	1.4	47
3252	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. <i>Lancet Neurology</i> , The, 2018, 17, 423-433.	4.9	342
3253	Reprint of: A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth. <i>Biochemical and Biophysical Research Communications</i> , 2018, 499, 136-142.	1.0	5
3254	An Examination of the Role of Supramaximal Resection of Temporal Lobe Glioblastoma Multiforme. <i>World Neurosurgery</i> , 2018, 114, e747-e755.	0.7	32
3255	Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study. <i>European Radiology</i> , 2018, 28, 3640-3650.	2.3	131
3256	JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon $\beta$ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 627-636.	1.4	49
3257	Multi-Label Nonlinear Matrix Completion With Transductive Multi-Task Feature Selection for Joint MGMT and IDH1 Status Prediction of Patient With High-Grade Gliomas. <i>IEEE Transactions on Medical Imaging</i> , 2018, 37, 1775-1787.	5.4	25
3258	Anti-Angiogenics: Their Role in the Treatment of Glioblastoma. <i>Oncology Research and Treatment</i> , 2018, 41, 181-186.	0.8	28
3259	XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair. <i>Cancer Letters</i> , 2018, 424, 119-126.	3.2	34
3260	Current Clinical State of Advanced Magnetic Resonance Imaging for Brain Tumor Diagnosis and Follow Up. <i>Seminars in Roentgenology</i> , 2018, 53, 45-61.	0.2	10
3261	New Directions in the Treatment of Glioblastoma. <i>Seminars in Neurology</i> , 2018, 38, 050-061.	0.5	33

#	ARTICLE	IF	CITATIONS
3262	Retrospective Analysis of Radiological Recurrence Patterns in Glioblastoma, Their Prognostic Value And Association to Postoperative Infarct Volume. <i>Scientific Reports</i> , 2018, 8, 4561.	1.6	48
3263	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
3264	MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. <i>Future Oncology</i> , 2018, 14, 699-707.	1.1	29
3265	Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients. <i>American Journal of Clinical Pathology</i> , 2018, 149, 412-417.	0.4	29
3266	PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 159-162.	0.6	15
3267	Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide. <i>Journal of Neurosurgery</i> , 2018, 128, 679-684.	0.9	29
3268	The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. <i>Journal of Cellular Physiology</i> , 2018, 233, 378-386.	2.0	238
3269	Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma. <i>Neurosurgery</i> , 2018, 82, 24-34.	0.6	54
3270	Epigenetics of pheochromocytoma and paraganglioma. <i>Molecular and Cellular Endocrinology</i> , 2018, 469, 92-97.	1.6	12
3271	Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. <i>Neuro-Oncology Practice</i> , 2018, 5, 64-68.	1.0	10
3272	Prognostic value of O <sup>6</sup> -methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 172-184.	1.8	34
3273	Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 90-101.	0.8	35
3274	DNA methylation profiles in cancer diagnosis and therapeutics. <i>Clinical and Experimental Medicine</i> , 2018, 18, 1-14.	1.9	276
3275	Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes. <i>Neurosurgery</i> , 2018, 83, 76-85.	0.6	31
3276	Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26861.	0.8	29
3277	European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. <i>European Journal of Endocrinology</i> , 2018, 178, G1-G24.	1.9	387
3278	Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. <i>Neuro-Oncology</i> , 2018, 20, 608-620.	0.6	194
3279	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 848-857.	0.6	170

#	ARTICLE	IF	CITATIONS
3280	Combating malignant astrocytes: Strategies mitigating tumor invasion. <i>Neuroscience Research</i> , 2018, 126, 22-30.	1.0	11
3281	Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2018, 20, 557-566.	0.6	24
3282	Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance. <i>International Journal of Cancer</i> , 2018, 142, 1266-1276.	2.3	27
3283	Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics. <i>Methods in Molecular Biology</i> , 2018, 1699, 3-21.	0.4	14
3284	Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival. <i>Journal of Neuro-Oncology</i> , 2018, 136, 307-315.	1.4	21
3285	H2â€P, a honokiol derivative, exerts anti-angiogenesis effects via c-MYC signaling pathway in glioblastoma. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3142-3148.	1.2	7
3286	Clinical implications of in silico mathematical modeling for glioblastoma: a critical review. <i>Journal of Neuro-Oncology</i> , 2018, 136, 1-11.	1.4	14
3287	Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma. <i>World Neurosurgery</i> , 2018, 109, e67-e74.	0.7	60
3288	Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy. <i>Investigational New Drugs</i> , 2018, 36, 340-345.	1.2	6
3289	Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO). <i>Clinical Cancer Research</i> , 2018, 24, 52-61.	3.2	162
3290	Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. <i>Neurosurgical Review</i> , 2018, 41, 621-628.	1.2	22
3291	Pharmacoeugenetics and Toxicoeugenetics: Novel Mechanistic Insights and Therapeutic Opportunities. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 161-185.	4.2	45
3292	Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. <i>American Journal of Roentgenology</i> , 2018, 210, 30-38.	1.0	52
3293	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , 2018, 20, 367-379.	0.6	79
3294	Tumor location and patient age predict biological signatures of high-grade gliomas. <i>Neurosurgical Review</i> , 2018, 41, 599-604.	1.2	28
3295	Biomarkers and therapeutic advances in glioblastoma multiforme. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 40-51.	0.7	120
3296	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. <i>Clinical Cancer Research</i> , 2018, 24, 737-743.	3.2	154
3297	Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide-based combination chemotherapy. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26750.	0.8	7

#	ARTICLE	IF	CITATIONS
3298	Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine. <i>Clinical and Translational Oncology</i> , 2018, 20, 508-516.	1.2	36
3299	Lung cancer epigenetics: From knowledge to applications. <i>Seminars in Cancer Biology</i> , 2018, 51, 116-128.	4.3	202
3300	Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1380-1387.	1.9	107
3301	Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 1-9.	1.1	12
3302	Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide. <i>World Neurosurgery</i> , 2018, 109, e662-e668.	0.7	9
3303	Repair gene O <sup>6</sup> -methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation. <i>Journal of Neurochemistry</i> , 2018, 144, 139-151.	2.1	41
3304	Bioinformatic analysis of gene expression and methylation regulation in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 495-503.	1.4	38
3305	Glioma epigenetics: From subclassification to novel treatment options. <i>Seminars in Cancer Biology</i> , 2018, 51, 50-58.	4.3	377
3306	Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection. <i>Annals of Surgical Oncology</i> , 2018, 25, 558-564.	0.7	33
3307	MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks. , 2018, , .		42
3308	A Summary of the Biological Processes, Disease-Associated Changes, and Clinical Applications of DNA Methylation. <i>Methods in Molecular Biology</i> , 2018, 1708, 3-30.	0.4	32
3309	Integrating Molecular Diagnostics With Surgical Neuropathology. , 2018, , 71-89.		3
3310	Astrocytic and Oligodendroglial Tumors. , 2018, , 91-123.		1
3311	Contemporary management of high-grade gliomas. <i>CNS Oncology</i> , 2018, 7, 51-65.	1.2	32
3312	Surgical Resection of Anterior and Posterior Butterfly Glioblastoma. <i>World Neurosurgery</i> , 2018, 110, e612-e620.	0.7	33
3313	SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 22-28.	1.2	56
3314	Treatment of a glioblastoma multiforme dural metastasis with stereotactic radiosurgery: A case report and select review of the literature. <i>Journal of Clinical Neuroscience</i> , 2018, 48, 118-121.	0.8	4
3315	Precision Medicine in Pediatric Neurooncology: A Review. <i>ACS Chemical Neuroscience</i> , 2018, 9, 11-28.	1.7	12

#	ARTICLE	IF	CITATIONS
3316	MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication. American Journal of Neuroradiology, 2018, 39, 252-259.	1.2	26
3317	Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. Anti-Cancer Drugs, 2018, 29, 102-105.	0.7	17
3318	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002329.	0.5	30
3319	Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. Journal of Neurochemistry, 2018, 144, 93-104.	2.1	111
3320	Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomarkers, 2018, 21, 323-334.	0.8	37
3321	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine, 2018, 60, 490-498.	1.1	59
3322	Prognostic and Predictive Value of O6-methylguanine Methyltransferase for Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. Annals of Surgical Oncology, 2018, 25, 342-348.	0.7	4
3323	Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. , 2018, 184, 13-41.		230
3324	Clinical neuropathology of brain tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 477-534.	1.0	6
3325	O 6 -methylguanine-DNA-methyltransferase immunostaining intensity in glioblastoma. Neurologia I Neurochirurgia Polska, 2018, 52, 116-119.	0.6	0
3326	Resveratrol inhibited cell growth and promoted autophagy via P53/Bcl-2/Bcl-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells. Journal of Cellular Physiology, 2018, 233, 2434-2443.	2.0	55
3327	Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Neuro-Oncology, 2018, 20, 236-248.	0.6	103
3328	Applying Precision Oncology Principles in Radiation Oncology. JCO Precision Oncology, 2018, 2, 1-23.	1.5	12
3329	Glioblastoma: new therapeutic strategies to address cellular and genomic complexity. Oncotarget, 2018, 9, 9540-9554.	0.8	60
3330	Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment. Anti-Cancer Drugs, 2018, 29, 924-928.	0.7	2
3331	Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 158-167.	1.8	5
3332	Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 292-299.	1.8	9
3333	Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. JCO Precision Oncology, 2018, 2, 1-6.	1.5	2



#	ARTICLE	IF	CITATIONS
3334	Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. <i>Oncotarget</i> , 2018, 9, 28772-28783.	0.8	63
3335	Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 951-958.	0.8	95
3336	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 148-157.	1.8	2
3337	G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future. <i>Cancer Biology and Medicine</i> , 2018, 15, 354.	1.4	19
3338	Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma <i>in vitro</i> . <i>Oncotarget</i> , 2018, 9, 22703-22716.	0.8	50
3339	Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma. <i>Radiation Oncology</i> , 2018, 13, 251.	1.2	13
3340	Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme. <i>G3: Genes, Genomes, Genetics</i> , 2018, 8, 3627-3636.	0.8	12
3341	Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	30
3342	Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?. <i>Radiology and Oncology</i> , 2018, 52, 121-128.	0.6	42
3343	Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature. <i>Molecular and Clinical Oncology</i> , 2019, 10, 58-66.	0.4	10
3344	Survivorship in Neuro-Oncology: Improving Care by Advancing Science. <i>Neuro-Oncology</i> , 2018, 20, NP-NP.	0.6	0
3345	Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	1
3346	Apoptotic Effects of Temozolomide and Naturopathic Agents upon Glioblastoma Cells. <i>Journal of Oncology Translational Research</i> , 2018, 04, .	0.2	0
3347	Current Trends in Glioblastoma Treatment. , 0, , .		4
3348	Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-6.	0.4	141
3349	Updates in prognostic markers for gliomas. <i>Neuro-Oncology</i> , 2018, 20, vii17-vii26.	0.6	78
3350	Surgery and Evidence-based Treatments in Patients with Newly Diagnosed High-grade Glioma. <i>Seminars in Oncology Nursing</i> , 2018, 34, 443-453.	0.7	13
3351	Antitumor effect of ergosterol and cisplatin-loaded liposomes modified with cyclic arginine-glycine-aspartic acid and octa-arginine peptides. <i>Medicine (United States)</i> , 2018, 97, e11916.	0.4	18

#	ARTICLE	IF	CITATIONS
3352	Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma. International Journal of Molecular Sciences, 2018, 19, 3773.	1.8	71
3353	Potential Epigenetic-Based Therapeutic Targets for Glioma. Frontiers in Molecular Neuroscience, 2018, 11, 408.	1.4	64
3355	The clinical use of IDH1 and IDH2 mutations in gliomas. Expert Review of Molecular Diagnostics, 2018, 18, 1041-1051.	1.5	34
3356	Tumor Treating Fields: Adjuvant Treatment for High-grade Gliomas. Seminars in Oncology Nursing, 2018, 34, 454-464.	0.7	16
3357	Epidemiology and Overview of Gliomas. Seminars in Oncology Nursing, 2018, 34, 420-429.	0.7	163
3358	Glioblastoma: Biology, Diagnosis, and Treatment. , 2018, , 154-154.		0
3359	Epigallocatechin Gallate Preferentially Inhibits O <sup>6</sup> -Methylguanine DNA-Methyltransferase Expression in Glioblastoma Cells Rather than in Nontumor Glial Cells. Nutrition and Cancer, 2018, 70, 1339-1347.	0.9	20
3360	Current Options and Future Directions in Immune Therapy for Glioblastoma. Frontiers in Oncology, 2018, 8, 578.	1.3	21
3361	EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence. BMC Cancer, 2018, 18, 1215.	1.1	13
3362	Use of statins or NSAIDs and survival of patients with high-grade glioma. PLoS ONE, 2018, 13, e0207858.	1.1	22
3363	MGMT promoter methylation in Peruvian patients with glioblastoma. Ecancermedicalsecience, 2018, 12, 812.	0.6	1
3364	Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule. Cell Death Discovery, 2018, 4, 41.	2.0	30
3365	Evidence-based Therapy and Problem of Glioblastoma. Japanese Journal of Neurosurgery, 2018, 27, 91-98.	0.0	0
3366	The potential for remodelling the tumour vasculature in glioblastoma. Advanced Drug Delivery Reviews, 2018, 136-137, 49-61.	6.6	15
3367	Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier. International Journal of Molecular Sciences, 2018, 19, 2879.	1.8	151
3368	Juniperus Communis Extract Exerts Antitumor Effects in Human Glioblastomas Through Blood-Brain Barrier. Cellular Physiology and Biochemistry, 2018, 49, 2443-2462.	1.1	9
3369	Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk. Frontiers in Oncology, 2018, 8, 373.	1.3	2
3370	Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. Scientific Reports, 2018, 8, 14429.	1.6	22

#	ARTICLE	IF	CITATIONS
3371	HOXA10â€™AS: A novel oncogenic long nonâ€™coding RNA in glioma. <i>Oncology Reports</i> , 2018, 40, 2573-2583.	1.2	21
3372	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011â€™2015. <i>Neuro-Oncology</i> , 2018, 20, iv1-iv86.	0.6	1,624
3373	Epigenetic Targeting of Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 448.	1.3	82
3374	High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma. , 2018, , 193-221.		0
3375	Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma. <i>Oncotarget</i> , 2018, 9, 27728-27735.	0.8	15
3376	Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. <i>Endocrine</i> , 2018, 62, 737-739.	1.1	21
3377	MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP. <i>Nucleic Acids Research</i> , 2018, 46, 10888-10904.	6.5	13
3378	Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics. <i>Current Treatment Options in Oncology</i> , 2018, 19, 61.	1.3	5
3379	Management of diffuse glioma. <i>Presse Medicale</i> , 2018, 47, e199-e212.	0.8	11
3380	Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism. <i>Cell Death and Disease</i> , 2018, 9, 1112.	2.7	13
3381	Methylation dependent down-regulation of GOS2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma. <i>PLoS ONE</i> , 2018, 13, e0206552.	1.1	8
3382	<i>MGMT</i> Gene Promoter Methylation Status â€™ Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 437-446.	1.0	44
3383	Primary cilium and glioblastoma. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880116.	1.4	23
3384	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018, 10, 372.	1.7	67
3385	An intronic genetic variation of <em>MGMT</em> affects enhancer activity and is associated with glioma susceptibility. <i>Cancer Management and Research</i> , 2018, Volume 10, 3995-4003.	0.9	3
3386	Stereotactic imageâ€™based histological analysis reveals a correlation between 11Câ€™methionine uptake and MGMT promoter methylation in nonâ€™enhancing gliomas. <i>Oncology Letters</i> , 2018, 16, 1924-1930.	0.8	4
3387	Bevacizumab: Is the lower the better for glioblastoma patients in progression?. <i>Bulletin Du Cancer</i> , 2018, 105, 1135-1146.	0.6	3
3388	Epigenetic biomarkers of promoter <scp>DNA</scp> methylation in the new era of cancer treatment. <i>Cancer Science</i> , 2018, 109, 3695-3706.	1.7	68

#	ARTICLE	IF	CITATIONS
3389	Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3353.	1.8	25
3390	WINDOW consortium: A path towards increased therapy efficacy against glioblastoma. <i>Drug Resistance Updates</i> , 2018, 40, 17-24.	6.5	15
3391	Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. <i>Scientific Reports</i> , 2018, 8, 15383.	1.6	11
3392	Combination therapy to checkmate Glioblastoma: clinical challenges and advances. <i>Clinical and Translational Medicine</i> , 2018, 7, 33.	1.7	148
3393	Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population. <i>Frontiers in Oncology</i> , 2018, 8, 426.	1.3	10
3394	Prognostic Evaluation of Neurological Assessment of the Neuro-Oncology Scale in Glioblastoma Patients. <i>Brain Tumor Research and Treatment</i> , 2018, 6, 22.	0.4	29
3395	Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. <i>Radiotherapy and Oncology</i> , 2018, 129, 347-351.	0.3	18
3396	Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma. <i>NeuroMolecular Medicine</i> , 2018, 20, 452-474.	1.8	18
3397	A translational perspective on epigenetics in allergic diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 715-726.	1.5	51
3398	Configurational and Conformational Equilibria of N6-(2-Deoxy-d-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5-N-methylformamidopyrimidine (MeFapy-dG) Lesion in DNA. <i>Chemical Research in Toxicology</i> , 2018, 31, 924-935.	1.7	2
3399	Persistent Disparities in Survival for Patients with Glioblastoma. <i>World Neurosurgery</i> , 2018, 120, e511-e516.	0.7	26
3400	Drug Repurposing of Metabolic Agents in Malignant Glioma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2768.	1.8	27
3401	NF- $\kappa$ B, Mesenchymal Differentiation and Glioblastoma. <i>Cells</i> , 2018, 7, 125.	1.8	44
3402	Using genomics to guide treatment for glioblastoma. <i>Pharmacogenomics</i> , 2018, 19, 1217-1229.	0.6	10
3403	Re-purposing Chloroquine for Glioblastoma: Potential Merits and Confounding Variables. <i>Frontiers in Oncology</i> , 2018, 8, 335.	1.3	59
3404	Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes. <i>Brain Research</i> , 2018, 1700, 199-210.	1.1	25
3405	Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. <i>Medical Oncology</i> , 2018, 35, 136.	1.2	5
3406	A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 293.	0.7	27

#	ARTICLE	IF	CITATIONS
3407	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS ONE, 2018, 13, e0202860.	1.1	28
3408	Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment. Frontiers in Oncology, 2018, 8, 314.	1.3	43
3409	Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma. Clinical Neurology and Neurosurgery, 2018, 170, 127-131.	0.6	8
3410	Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Current Opinion in Pharmacology, 2018, 41, 79-88.	1.7	50
3411	Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas. Cellular Physiology and Biochemistry, 2018, 47, 428-439.	1.1	100
3412	FM19G11 inhibits O6 -methylguanine DNA-methyltransferase expression under both hypoxic and normoxic conditions. Cancer Medicine, 2018, 7, 3292-3300.	1.3	9
3413	Microvascular fractal dimension predicts prognosis and response to chemotherapy in glioblastoma: an automatic image analysis study. Laboratory Investigation, 2018, 98, 924-934.	1.7	23
3414	A new method of identifying glioblastoma subtypes and creation of corresponding animal models. Oncogene, 2018, 37, 4781-4791.	2.6	6
3415	Down-regulation of MDR1 by Ad-DKK3 via Akt/NF $\kappa$ B pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model. Journal of Neuro-Oncology, 2018, 139, 323-332.	1.4	7
3416	Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics. Archives of Pathology and Laboratory Medicine, 2018, 142, 804-814.	1.2	22
3417	The prognostic value of DAPK1 hypermethylation in gliomas: A site-specific analysis. Pathology Research and Practice, 2018, 214, 940-948.	1.0	5
3418	Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. Science Translational Medicine, 2018, 10, .	5.8	112
3419	Emergence of exosomal DNA in molecular neuropathology. Laboratoriums Medizin, 2018, 42, 9-22.	0.1	3
3420	Extracranial glioblastoma diagnosed by examination of pleural effusion using the cell block technique: case report. Neurosurgical Focus, 2018, 44, E8.	1.0	4
3421	Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 642-645.	2.3	9
3422	The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review. Clinical Neurology and Neurosurgery, 2018, 170, 120-126.	0.6	26
3423	Long noncoding RNA $\text{miR-185}$ overexpression deleteriously affects the growth of glioblastoma cells through $\text{miR-185}/\text{KrÄ¼ppel-like factor 16}$ axis. Journal of Cellular Biochemistry, 2018, 119, 9081-9089.	1.2	20
3424	Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU. Oncology Letters, 2018, 15, 9877-9883.	0.8	7

#	ARTICLE	IF	CITATIONS
3425	Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response. <i>Disease Markers</i> , 2018, 2018, 1-11.	0.6	34
3426	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. <i>Future Oncology</i> , 2018, 14, 1559-1567.	1.1	17
3427	Association of <i>MGMT</i> Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide. <i>JAMA Oncology</i> , 2018, 4, 1405.	3.4	141
3428	C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma. <i>Molecular Oncology</i> , 2018, 12, 1464-1479.	2.1	17
3429	Chemotherapy Resistance. , 2018, , 87-104.		0
3430	Interstitial Chemotherapy and Polymer Drug Delivery. , 2018, , 155-165.		0
3431	An Overview of Molecular Genetics of Brain Tumors. , 2018, , 249-255.		1
3432	The Use of Temozolomide for Chemoradiation and Adjuvant Therapy of High-Grade Gliomas. , 2018, , 411-417.		0
3433	Chemotherapy of Pediatric High-Grade Gliomas. , 2018, , 557-568.		0
3434	Apoptosis Pathways and Chemotherapy in Brain Tumors. , 2018, , 291-303.		0
3435	Predictive Value of Epigenetic Signatures. , 2018, , 275-311.		0
3436	Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 141-147.	1.1	13
3437	Chemotherapy of Brainstem Gliomas. , 2018, , 585-596.		3
3438	Molecular physiology of contrast enhancement in glioblastomas: An analysis of The Cancer Imaging Archive (TCIA). <i>Journal of Clinical Neuroscience</i> , 2018, 55, 86-92.	0.8	14
3439	The Treatment of Gliomas in Adulthood. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2018, 115, 356-364.	0.6	20
3440	Molecular Pathogenesis and Emerging Treatment for Glioblastoma. <i>World Neurosurgery</i> , 2018, 116, 495-504.	0.7	13
3441	Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. <i>Neurologic Clinics</i> , 2018, 36, 421-437.	0.8	9
3442	PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways. <i>Theranostics</i> , 2018, 8, 1527-1539.	4.6	33

#	ARTICLE	IF	CITATIONS
3443	Clinical significance of FBXO17 gene expression in high-grade glioma. <i>BMC Cancer</i> , 2018, 18, 773.	1.1	9
3444	Bright Future for Novel Viral Glioblastoma Multiforme Therapy. <i>World Neurosurgery</i> , 2018, 117, 463.	0.7	2
3445	β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species. <i>Cancer Letters</i> , 2018, 435, 66-79.	3.2	34
3446	Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 454.	1.6	7
3447	Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy. <i>Frontiers in Physiology</i> , 2018, 9, 170.	1.3	110
3448	Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 5392-5406.	3.2	67
3449	The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3513-3520.	1.0	13
3450	A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. <i>Nature Communications</i> , 2018, 9, 2949.	5.8	183
3451	A Coclinal Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. <i>Clinical Cancer Research</i> , 2018, 24, 6288-6299.	3.2	74
3452	Coaxial extrusion bioprinted shell-core hydrogel microfibers mimic glioma microenvironment and enhance the drug resistance of cancer cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 171, 291-299.	2.5	83
3453	Treatment of Glioblastoma in the Elderly. <i>Drugs and Aging</i> , 2018, 35, 707-718.	1.3	11
3454	Inherent and toxicant-provoked reduction in DNA repair capacity: A key mechanism for personalized risk assessment, cancer prevention and intervention, and response to therapy. <i>International Journal of Hygiene and Environmental Health</i> , 2018, 221, 993-1006.	2.1	13
3455	CAT <sup>3</sup> , a prodrug of 13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine, circumvents temozolomide-resistant glioblastoma via the Hedgehog signaling pathway, independently of O <sup>6</sup> -methylguanine DNA methyltransferase expression. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3671-3684.	1.0	14
3456	Primary brain tumours in adults. <i>Lancet, The</i> , 2018, 392, 432-446.	6.3	882
3457	One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?. <i>Journal of Neuro-Oncology</i> , 2018, 140, 385-391.	1.4	31
3458	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 82.	1.4	61
3459	Epstein-Barr Virus in Gliomas: Cause, Association, or Artifact?. <i>Frontiers in Oncology</i> , 2018, 8, 123.	1.3	43
3460	Clinically Relevant Imaging Features for MGMT Promoter Methylation in Multiple Glioblastoma Studies: A Systematic Review and Meta-Analysis. <i>American Journal of Neuroradiology</i> , 2018, 39, 1439-1445.	1.2	24

#	ARTICLE	IF	CITATIONS
3461	Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. <i>Brain Sciences</i> , 2018, 8, 15.	1.1	104
3462	Predicting O6-Methylguanine-DNA Methyltransferase Protein Expression in Primary Low- and High-Grade Gliomas Using Certain Qualitative Characteristics of Amide Proton Transfer-Weighted Magnetic Resonance Imaging. <i>World Neurosurgery</i> , 2018, 116, e814-e823.	0.7	9
3463	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. <i>Cancer Cell</i> , 2018, 34, 163-177.e7.	7.7	145
3464	Coordinated autophagy modulation overcomes glioblastoma chemoresistance through disruption of mitochondrial bioenergetics. <i>Scientific Reports</i> , 2018, 8, 10348.	1.6	27
3465	The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 395.	1.8	9
3466	Impact of DNA and RNA Methylation on Radiobiology and Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 555.	1.8	26
3467	DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 679.	1.8	19
3468	Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1765.	1.8	44
3469	Proton and Carbon Ion Therapy of Intracranial Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 32, 57-65.	1.3	7
3470	Differential Characterization of Temozolomide-Resistant Human Glioma Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 127.	1.8	28
3471	Brain Targeting by Liposome-Encapsulated Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells. <i>ACS Chemical Neuroscience</i> , 2018, 9, 3166-3174.	1.7	53
3472	Brain tumor related-epilepsy. <i>Neurologia i Neurochirurgia Polska</i> , 2018, 52, 436-447.	0.6	29
3473	Clinical and immunological correlates of long term survival in glioblastoma. <i>Wspolczesna Onkologia</i> , 2018, 2018, 81-85.	0.7	15
3474	Î²-asarone induces cell apoptosis, inhibits cell proliferation and decreases migration and invasion of glioma cells. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 655-664.	2.5	13
3475	Hybrid Gd <sup>3+</sup> /cisplatin cross-linked polymer nanoparticles enhance platinum accumulation and formation of DNA adducts in glioblastoma cell lines. <i>Biomaterials Science</i> , 2018, 6, 2386-2409.	2.6	28
3476	Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum. <i>Cancers</i> , 2018, 10, 101.	1.7	53
3477	Comparison of glioblastoma (GBM) molecular classification methods. <i>Seminars in Cancer Biology</i> , 2018, 53, 201-211.	4.3	125
3478	Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. <i>Oncotarget</i> , 2018, 9, 20134-20155.	0.8	46



#	ARTICLE	IF	CITATIONS
3479	The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 32.	6.9	24
3480	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. <i>Future Oncology</i> , 2018, 14, 1063-1069.	1.1	11
3481	Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. <i>BMC Cancer</i> , 2018, 18, 105.	1.1	32
3482	Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer. <i>Clinical Epigenetics</i> , 2018, 10, 15.	1.8	32
3484	An anatomic transcriptional atlas of human glioblastoma. <i>Science</i> , 2018, 360, 660-663.	6.0	384
3485	Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma. <i>Pathology Research and Practice</i> , 2018, 214, 840-847.	1.0	8
3486	Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas. <i>American Journal of Neuroradiology</i> , 2018, 39, 1201-1207.	1.2	323
3488	MicroRNA-142-3p is involved in regulation of &em&gt;MGMT&lt;/em&gt; expression in glioblastoma cells. <i>Cancer Management and Research</i> , 2018, Volume 10, 775-785.	0.9	17
3489	The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. <i>Nature Communications</i> , 2018, 9, 3292.	5.8	153
3490	Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?. <i>Neuroradiology</i> , 2018, 60, 1043-1051.	1.1	15
3492	Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells. <i>Cancer Gene Therapy</i> , 2018, 25, 309-316.	2.2	16
3493	Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications. <i>Genes</i> , 2018, 9, 429.	1.0	108
3494	The role of interleukin&#x2013;6&#x2013;STAT3 signalling in glioblastoma (Review). <i>Oncology Letters</i> , 2018, 16, 4095-4104.	0.8	61
3495	Dendritic cell vaccines for high-grade gliomas. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1299-1313.	0.9	42
3496	Current Chemotherapy Use in Neuroendocrine Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 603-614.	1.2	12
3497	Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2018, 140, 559-568.	1.4	9
3498	Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 81.	2.4	22
3499	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	0.6	32

#	ARTICLE	IF	CITATIONS
3500	Under explored epigenetic modulators: role in glioma chemotherapy. <i>European Journal of Pharmacology</i> , 2018, 833, 201-209.	1.7	4
3501	Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. <i>Neoplasia</i> , 2018, 20, 710-720.	2.3	84
3502	Specifically Targeted Electromagnetic Fields Arrest Proliferation of Glioblastoma Multiforme U-87 Cells in Culture. <i>Anticancer Research</i> , 2018, 38, 3255-3266.	0.5	2
3503	Cell-Cycle Regulation. , 2018, , 257-269.		3
3504	miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP- $\beta$ in glioblastoma. <i>Oncology Letters</i> , 2018, 15, 7563-7570.	0.8	15
3505	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. <i>Neurologia Medico-Chirurgica</i> , 2018, 58, 290-295.	1.0	29
3506	Liposome-Based Drug Delivery for Brain Tumor Theranostics. , 2018, , 245-266.		3
3507	Epigenetics and MicroRNAs in Pharmacogenetics. <i>Advances in Pharmacology</i> , 2018, 83, 33-64.	1.2	15
3508	Nanocarriers for the delivery of temozolomide in the treatment of glioblastoma. , 2018, , 687-722.		10
3509	Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 59-70.	0.6	60
3510	A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication. <i>European Radiology</i> , 2019, 29, 877-888.	2.3	81
3511	MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation. <i>Neurosurgery</i> , 2019, 85, 147-155.	0.6	10
3512	Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 314-322.	1.9	42
3513	Hypermethylated gene ANKDD1A is a candidate tumor suppressor that interacts with FIH1 and decreases HIF1 $\beta$ stability to inhibit cell autophagy in the glioblastoma multiforme hypoxia microenvironment. <i>Oncogene</i> , 2019, 38, 103-119.	2.6	37
3514	Use of metformin and survival of patients with high-grade glioma. <i>International Journal of Cancer</i> , 2019, 144, 273-280.	2.3	48
3515	Retrochiasmal Disorders. , 2019, , 293-339.		1
3516	A comprehensive methylation signature identifies lymph node metastasis in esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 1160-1169.	2.3	10
3519	Prognostic significance of MGMT promoter methylation in diffuse glioma patients. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 639-644.	0.5	4

#	ARTICLE	IF	CITATIONS
3520	The pivotal role of sampling recurrent tumors in the precision care of patients with tumors of the central nervous system. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004143.	0.5	4
3521	Molecular profile of long-term survivors of glioblastoma: A scoping review of the literature. <i>Journal of Clinical Neuroscience</i> , 2019, 68, 1-8.	0.8	14
3522	Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. <i>Cells</i> , 2019, 8, 863.	1.8	156
3523	Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. <i>British Journal of Cancer</i> , 2019, 121, 545-555.	2.9	49
3524	Kinins in Glioblastoma Microenvironment. <i>Cancer Microenvironment</i> , 2019, 12, 77-94.	3.1	12
3525	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	170
3526	Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. <i>Scientific Reports</i> , 2019, 9, 11125.	1.6	25
3527	The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 787-797.	1.9	22
3528	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 663-677.	1.4	3
3529	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. <i>Acta Neuropathologica</i> , 2019, 138, 1053-1074.	3.9	106
3530	<sup>18</sup> F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma. <i>Cancer Imaging</i> , 2019, 19, 58.	1.2	32
3531	Global DNA Methylation Patterns in Human Gliomas and Their Interplay with Other Epigenetic Modifications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3478.	1.8	35
3532	Analysis of peritumoral hyperintensity on pre-operative T2-weighted MR images in glioblastoma: Additive prognostic value of Minkowski functionals. <i>PLoS ONE</i> , 2019, 14, e0217785.	1.1	7
3533	Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor. <i>Frontiers in Oncology</i> , 2019, 9, 307.	1.3	19
3534	Modeling clinical and molecular covariates of mutational process activity in cancer. <i>Bioinformatics</i> , 2019, 35, i492-i500.	1.8	15
3535	Knockdown ATG4C inhibits gliomas progression and promotes temozolomide chemosensitivity by suppressing autophagic flux. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 298.	3.5	45
3536	How we treat glioblastoma. <i>ESMO Open</i> , 2019, 4, e000520.	2.0	62
3538	Progress Toward Long-Term Survivors of Glioblastoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1278-1286.	1.4	72

#	ARTICLE	IF	CITATIONS
3539	QKI deficiency maintains glioma stem cell stemness by activating the SHH/GLI1 signaling pathway. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 801-813.	2.1	21
3540	Mechanism of methylation and acetylation of high GDNF transcription in glioma cells: A review. <i>Heliyon</i> , 2019, 5, e01951.	1.4	12
3541	Development of dual drug loaded PLGA based mesoporous silica nanoparticles and their conjugation with Angiopep-2 to treat glioma. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 53, 101157.	1.4	12
3542	Combined Use of 5-Aminolevulinic Acid and Intraoperative Low-Field Magnetic Resonance Imaging in High-Grade Glioma Surgery. <i>World Neurosurgery</i> , 2019, 130, e206-e212.	0.7	8
3543	Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?. <i>Clinical Neurology and Neurosurgery</i> , 2019, 184, 105445.	0.6	3
3544	Quantitative proteomics reveals reduction of endocytic machinery components in gliomas. <i>EBioMedicine</i> , 2019, 46, 32-41.	2.7	26
3545	Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma. <i>Scientific Reports</i> , 2019, 9, 10555.	1.6	26
3546	Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. <i>Cancer Science</i> , 2019, 110, 2247-2257.	1.7	42
3547	Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study. <i>Oncotarget</i> , 2019, 10, 4397-4406.	0.8	27
3548	Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. <i>Brain</i> , 2019, 142, 2352-2366.	3.7	98
3549	Defining Protein Pattern Differences Among Molecular Subtypes of Diffuse Gliomas Using Mass Spectrometry*[S]. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 2029-2043.	2.5	19
3550	Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1529-1539.	0.6	21
3551	Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. <i>Cancers</i> , 2019, 11, 1072.	1.7	16
3552	Glioblastoma Unique Features Drive the Ways for Innovative Therapies in the Trunk-branch Era. <i>Folia Medica</i> , 2019, 61, 7-25.	0.2	2
3553	Primary central nervous system tumor treatment and survival in the United States, 2004–2015. <i>Journal of Neuro-Oncology</i> , 2019, 144, 179-191.	1.4	28
3554	Basic principles of brain tumor chemotherapy. , 2019, , 309-330.		0
3555	Hypofractionated stereotactic radiotherapy combined with chemotherapy or not in the management of recurrent malignant gliomas: A systematic review and meta-analysis. <i>Clinical Neurology and Neurosurgery</i> , 2019, 183, 105401.	0.6	1
3556	Volumetric assessment of glioblastoma and its predictive value for survival. <i>Acta Neurochirurgica</i> , 2019, 161, 1723-1732.	0.9	18

#	ARTICLE	IF	CITATIONS
3557	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	0.6	49
3558	Discovery of predictive biomarkers in malignant gliomas. <i>Neuro-Oncology</i> , 2019, 21, 1089-1090.	0.6	1
3559	Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors. <i>Cancer Research</i> , 2019, 79, 4331-4338.	0.4	44
3560	Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 41935-41945.	4.0	16
3561	A new chance for EGFR inhibition in glioblastoma?. <i>Neuro-Oncology</i> , 2019, 21, 1487-1488.	0.6	0
3562	Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. <i>BMC Cancer</i> , 2019, 19, 968.	1.1	55
3563	Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience. <i>Neuro-Oncology Practice</i> , 2019, 7, 185-195.	1.0	5
3564	A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. <i>Frontiers in Genetics</i> , 2019, 10, 910.	1.1	22
3565	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019, 80, 101896.	3.4	386
3566	Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets. <i>Frontiers in Oncology</i> , 2019, 9, 963.	1.3	207
3567	The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 156.	2.4	47
3568	Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity. <i>PLoS ONE</i> , 2019, 14, e0223555.	1.1	18
3569	Using 3D MRI Anatomic Maps to Determine Prognosis for Glioblastomas. <i>Radiology</i> , 2019, 293, 644-645.	3.6	0
3570	Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial. <i>Journal of Clinical Neuroscience</i> , 2019, 70, 157-163.	0.8	3
3571	Current clinical management of patients with glioblastoma. <i>Cancer Reports</i> , 2019, 2, e1216.	0.6	11
3572	Treatment strategies for glioblastoma in older patients: age is just a number. <i>Journal of Neuro-Oncology</i> , 2019, 145, 357-364.	1.4	12
3573	Aerobic microbial electrochemical technology based on the coexistence and interactions of aerobes and exoelectrogens for synergistic pollutant removal from wastewater. <i>Environmental Science: Water Research and Technology</i> , 2019, 5, 60-69.	1.2	8
3574	Glioblastoma Treatment Modalities besides Surgery. <i>Journal of Cancer</i> , 2019, 10, 4793-4806.	1.2	85

#	ARTICLE	IF	CITATIONS
3575	The role of p-Stat3 Y705 immunohistochemistry in glioblastoma prognosis. <i>Diagnostic Pathology</i> , 2019, 14, 124.	0.9	12
3576	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. <i>Neuro-Oncology</i> , 2019, 21, v1-v100.	0.6	1,735
3577	Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients. <i>Journal of Cancer</i> , 2019, 10, 5536-5548.	1.2	10
3578	Epigenetic biomarkers in personalized medicine. , 2019, , 375-395.		3
3579	The Influence of Distinct Regulatory miRNAs of the p15/p16/RB1/E2F Pathway on the Clinical Progression of Glioblastoma Multiforme. <i>World Neurosurgery</i> , 2019, 132, e900-e908.	0.7	7
3580	Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging. <i>Scientific Reports</i> , 2019, 9, 16613.	1.6	8
3581	SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through downregulation of MGMT. <i>FASEB Journal</i> , 2019, 33, 14171-14184.	0.2	26
3582	Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma. <i>Frontiers in Neuroscience</i> , 2019, 13, 1137.	1.4	1
3583	Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. <i>Molecular Medicine</i> , 2019, 25, 49.	1.9	27
3584	Activation of $\text{LXR}^2$ inhibits tumor respiration and is synthetically lethal with $\text{Bcl}^2$ inhibition. <i>EMBO Molecular Medicine</i> , 2019, 11, e10769.	3.3	32
3585	Imaging Glioblastoma Posttreatment. <i>Radiologic Clinics of North America</i> , 2019, 57, 1199-1216.	0.9	55
3586	Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas. <i>European Journal of Radiology</i> , 2019, 121, 108714.	1.2	39
3587	Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas. <i>Cancers</i> , 2019, 11, 1616.	1.7	17
3588	Management of Glioblastoma, Present and Future. <i>World Neurosurgery</i> , 2019, 131, 328-338.	0.7	39
3589	Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study. <i>Neuro-Oncology Practice</i> , 2019, 7, 164-175.	1.0	3
3590	DNA Methylation Cancer Biomarkers: Translation to the Clinic. <i>Frontiers in Genetics</i> , 2019, 10, 1150.	1.1	301
3591	Microenvironmental Heterogeneity in Brain Malignancies. <i>Frontiers in Immunology</i> , 2019, 10, 2294.	2.2	78
3592	Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres. <i>Biomolecules</i> , 2019, 9, 595.	1.8	22

#	ARTICLE	IF	CITATIONS
3593	SB365, Pulsatilla Saponin D Induces Caspase-Independent Cell Death and Augments the Anticancer Effect of Temozolomide in Glioblastoma Multiforme Cells. <i>Molecules</i> , 2019, 24, 3230.	1.7	10
3594	First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 6590-6597.	3.2	52
3595	Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma. <i>PLoS ONE</i> , 2019, 14, e0221502.	1.1	13
3596	A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients With GBM. <i>Frontiers in Genetics</i> , 2019, 10, 906.	1.1	39
3597	The Relevance of Gender in Tumor-Influencing Epigenetic Traits. <i>Epigenomes</i> , 2019, 3, 6.	0.8	3
3598	Health-related quality of life and neurocognitive functioning with lomustineâ€“temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1444-1453.	5.1	29
3599	A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters. <i>Cell</i> , 2019, 178, 1465-1477.e17.	13.5	144
3600	Highlights in Resistance Mechanism Pathways for Combination Therapy. <i>Cells</i> , 2019, 8, 1013.	1.8	51
3601	Temozolomide has anti-tumor effects through the phosphorylation of cPLA2 on glioblastoma cells. <i>Brain Research</i> , 2019, 1723, 146396.	1.1	12
3603	Receipt of brachytherapy is an independent predictor of survival in glioblastoma in the Surveillance, Epidemiology, and End Results database. <i>Journal of Neuro-Oncology</i> , 2019, 145, 75-83.	1.4	19
3604	Fluorescent probes for bioactive detection and imaging of phase II metabolic enzymes. <i>Coordination Chemistry Reviews</i> , 2019, 399, 213026.	9.5	37
3605	Combination of chemotherapy and radiotherapy: A thirty years evolution. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 662-665.	0.6	20
3606	Feasibility of a Modified Atkins Diet in Glioma Patients During Radiation and Its Effect on Radiation Sensitization. <i>Current Oncology</i> , 2019, 26, 433-438.	0.9	26
3607	miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme. <i>Acta Neurochirurgica</i> , 2019, 161, 2299-2309.	0.9	7
3608	Age-sensitive associations of segmental and suprasegmental perception with sentence-level language skills in Mandarin-speaking children with cochlear implants. <i>Research in Developmental Disabilities</i> , 2019, 93, 103453.	1.2	6
3609	CircFOXO3 promotes glioblastoma progression by acting as a competing endogenous RNA for NFAT5. <i>Neuro-Oncology</i> , 2019, 21, 1284-1296.	0.6	78
3610	Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore. <i>Neuro-Oncology</i> , 2019, 22, 216-228.	0.6	8
3611	Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. <i>Biomedicines</i> , 2019, 7, 69.	1.4	136

#	ARTICLE	IF	CITATIONS
3612	Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide. <i>Clinical Cancer Research</i> , 2019, 25, 7594-7608.	3.2	28
3613	Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111694.	2.6	9
3614	The Need for Multi-Omics Biomarker Signatures in Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4781.	1.8	287
3615	Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma. <i>Scientific Reports</i> , 2019, 9, 14072.	1.6	11
3616	Noninvasive O6 Methylguanine-DNA Methyltransferase Status Prediction in Glioblastoma Multiforme Cancer Using Magnetic Resonance Imaging Radiomics Features: Univariate and Multivariate Radiogenomics Analysis. <i>World Neurosurgery</i> , 2019, 132, e140-e161.	0.7	59
3617	Novel multi-drugs incorporating hybrid-structured nanofibers enhance alkylating agent activity in malignant gliomas. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987555.	1.4	5
3618	Development and Validation of a MRI-Based Radiomics Prognostic Classifier in Patients with Primary Glioblastoma Multiforme. <i>Academic Radiology</i> , 2019, 26, 1292-1300.	1.3	27
3619	Diffusion kurtosis imaging histogram parameter metrics predicting survival in integrated molecular subtypes of diffuse glioma: An observational cohort study. <i>European Journal of Radiology</i> , 2019, 112, 144-152.	1.2	17
3620	Magnetic Resonance Imaging Parameters and Their Impact on Survival of Patients with Glioblastoma: Tumor Perfusion Predicts Survival. <i>World Neurosurgery</i> , 2019, 124, e285-e295.	0.7	1
3621	Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation. <i>Bioengineering</i> , 2019, 6, 11.	1.6	2
3622	Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. <i>Oncolmmunology</i> , 2019, 8, e1561106.	2.1	50
3623	MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF</i> -, <i>NRAS</i> -, and <i>NF1</i> -Mutant Melanomas. <i>Cancer Discovery</i> , 2019, 9, 526-545.	7.7	73
3624	Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. <i>Neuro-Oncology</i> , 2019, 21, 616-627.	0.6	83
3625	A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications. <i>Cancer Research</i> , 2019, 79, 1226-1238.	0.4	26
3626	Functional Blockade of Small GTPase RAN Inhibits Glioblastoma Cell Viability. <i>Frontiers in Oncology</i> , 2018, 8, 662.	1.3	9
3627	Signal transduction pathways and resistance to targeted therapies in glioma. <i>Seminars in Cancer Biology</i> , 2019, 58, 118-129.	4.3	40
3628	Aggressive and Malignant Prolactinomas. <i>Neuroendocrinology</i> , 2019, 109, 57-69.	1.2	16
3629	Predictive markers for MGMT promoter methylation in glioblastomas. <i>Neurosurgical Review</i> , 2019, 42, 867-876.	1.2	14



#	ARTICLE	IF	CITATIONS
3630	Basic Gene Expression Characteristics of Glioma Stem Cells and Human Glioblastoma. <i>Anticancer Research</i> , 2019, 39, 597-607.	0.5	14
3631	Central Nervous System Tumors. , 2019, , 1-41.		0
3632	Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma—a randomised multicentre trial (ASTER trial). An ANOCEF study. <i>European Journal of Cancer</i> , 2019, 109, 129-136.	1.3	13
3633	Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. <i>Journal of Clinical Neuroscience</i> , 2019, 63, 134-141.	0.8	10
3634	Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies. <i>Nanomaterials</i> , 2019, 9, 105.	1.9	88
3635	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.	0.6	17
3636	Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. <i>Science Advances</i> , 2019, 5, eaaw4543.	4.7	98
3637	Clinical chimeric antigen receptor- $\text{T}$ cell therapy: a new and promising treatment modality for glioblastoma. <i>Clinical and Translational Immunology</i> , 2019, 8, e1050.	1.7	33
3638	Clinical and Pathologic Features and Prognostic Factors for Recurrent Gliomas. <i>World Neurosurgery</i> , 2019, 128, e21-e30.	0.7	10
3639	Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response. <i>Cancers</i> , 2019, 11, 825.	1.7	7
3640	Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1497-1505.	1.9	27
3641	Optimizing Neuro-Oncology Imaging: A Review of Deep Learning Approaches for Glioma Imaging. <i>Cancers</i> , 2019, 11, 829.	1.7	75
3642	Truncated TEAD-binding protein of TAZ inhibits glioma survival through the induction of apoptosis and repression of epithelial-mesenchymal transition. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 17337-17344.	1.2	6
3643	Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 4876-4882.	1.6	11
3644	Genetic and molecular epidemiology of adult diffuse glioma. <i>Nature Reviews Neurology</i> , 2019, 15, 405-417.	4.9	437
3645	Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. <i>Acta Neuropathologica Communications</i> , 2019, 7, 99.	2.4	32
3646	Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2294-2301.	1.0	39
3647	Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial. <i>Journal of Cancer</i> , 2019, 10, 3214-3223.	1.2	28

#	ARTICLE	IF	CITATIONS
3648	Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells. <i>Cancers</i> , 2019, 11, 878.	1.7	41
3649	MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 293-301.	1.4	22
3650	Artificial intelligence in oncology, its scope and future prospects with specific reference to radiation oncology. <i>BJR   Open</i> , 2019, 1, 20180031.	0.4	17
3651	Pathology and Classification of Tumors of the Central Nervous System. , 2019, , 3-89.		0
3652	Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study. <i>Journal of Neuro-Oncology</i> , 2019, 144, 127-135.	1.4	12
3653	Epigenetic Mechanisms in the Regulation of Drug Metabolism and Transport. , 2019, , 113-128.		2
3654	Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients. <i>Cancer Control</i> , 2019, 26, 107327481985511.	0.7	13
3655	Etiological and Epidemiological Aspects. , 2019, , 91-109.		0
3656	Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. <i>European Radiology</i> , 2019, 29, 6643-6652.	2.3	45
3657	Oleuropein modulates glioblastoma miRNA pattern different from <i>Olea europaea</i> leaf extract. <i>Human and Experimental Toxicology</i> , 2019, 38, 1102-1110.	1.1	15
3658	Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. <i>Endocrine Journal</i> , 2019, 66, 701-708.	0.7	13
3659	Evolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma. , 2019, , 1-20.		0
3660	Tubastatin A, an inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells. <i>International Journal of Oncology</i> , 2019, 54, 1797-1808.	1.4	22
3662	Integrated analysis of 34 microarray datasets reveals CBX3 as a diagnostic and prognostic biomarker in glioblastoma. <i>Journal of Translational Medicine</i> , 2019, 17, 179.	1.8	36
3663	The Epigenomics of Pituitary Adenoma. <i>Frontiers in Endocrinology</i> , 2019, 10, 290.	1.5	33
3664	Glioblastoma. , 2019, , 237-247.		0
3665	Tumor Biology. , 2019, , 143-152.		0
3666	Prognosis and management of gliosarcoma patients: A review of literature. <i>Clinical Neurology and Neurosurgery</i> , 2019, 182, 98-103.	0.6	11

#	ARTICLE	IF	CITATIONS
3667	Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1107-1120.	2.0	37
3668	The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01. <i>Brain Tumor Research and Treatment</i> , 2019, 7, 1.	0.4	19
3669	The DNA Damaging Revolution: PARP Inhibitors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 185-195.	1.8	144
3670	Tumor. <i>Operative Neurosurgery</i> , 2019, 17, S119-S152.	0.4	3
3671	Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region. <i>Clinical Neurology and Neurosurgery</i> , 2019, 182, 92-97.	0.6	3
3672	The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	9
3674	Comparative Analysis of Subventricular Zone Glioblastoma Contact and Ventricular Entry During Resection in Predicting Dissemination, Hydrocephalus, and Survival. <i>Neurosurgery</i> , 2019, 85, E924-E932.	0.6	34
3675	A Role for NF- $\kappa$ B in Organ Specific Cancer and Cancer Stem Cells. <i>Cancers</i> , 2019, 11, 655.	1.7	84
3676	Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis. <i>Clinical Science</i> , 2019, 133, 1167-1184.	1.8	37
3677	Glioblastoma vs temozolomide: can the red queen race be won?. <i>Cancer Biology and Therapy</i> , 2019, 20, 1083-1090.	1.5	63
3678	<i>Neuro-oncology</i> , 2019, , 391-457.		0
3679	Precision diagnostics based on machine learning-derived imaging signatures. <i>Magnetic Resonance Imaging</i> , 2019, 64, 49-61.	1.0	31
3680	Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2019, 80, 262-268.	0.4	15
3681	Prolactin-Secreting Pituitary Adenomas: Clinical Management. <i>Contemporary Endocrinology</i> , 2019, , 137-159.	0.3	0
3682	Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. <i>Clinical Epigenetics</i> , 2019, 11, 76.	1.8	14
3683	Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifer among Patient Populations. <i>Scientific Reports</i> , 2019, 9, 7442.	1.6	43
3684	Role of multidimensional assessment of frailty in predicting outcomes in older patients with glioblastoma treated with adjuvant concurrent chemo-radiation. <i>Journal of Geriatric Oncology</i> , 2019, 10, 770-778.	0.5	10
3685	Modulating autophagy as a therapeutic strategy for the treatment of paediatric high-grade glioma. <i>Brain Pathology</i> , 2019, 29, 707-725.	2.1	12

#	ARTICLE	IF	CITATIONS
3686	Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. <i>Cells</i> , 2019, 8, 350.	1.8	26
3687	Joint bioinformatics analysis of underlying potential functions of hsa-let-7b-5p and core genes in human glioma. <i>Journal of Translational Medicine</i> , 2019, 17, 129.	1.8	55
3688	&lt;p&gt;The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2215-2224.	1.0	10
3689	DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. <i>DNA Repair</i> , 2019, 78, 128-141.	1.3	89
3690	Transcriptional activation of SIRT6 via FKHL1/FOXO3a inhibits the Warburg effect in glioblastoma cells. <i>Cellular Signalling</i> , 2019, 60, 100-113.	1.7	24
3691	Epilepsy Associated with Glioma. , 2019, , 561-569.		0
3692	Recurrent Metastasized Parathyroid Carcinomaâ€™Longâ€™Term Remission After Combined Treatments With Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide. <i>JBMR Plus</i> , 2019, 3, e10114.	1.3	16
3693	Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 633-640.	0.9	19
3694	Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. <i>Nature Communications</i> , 2019, 10, 2045.	5.8	143
3695	Curcumin Promotes Connexin 43 Degradation and Temozolomide-Induced Apoptosis in Glioblastoma Cells. <i>The American Journal of Chinese Medicine</i> , 2019, 47, 657-674.	1.5	23
3696	c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas. <i>World Neurosurgery</i> , 2019, 126, e1042-e1049.	0.7	8
3697	Engineering Multidimensional Evolutionary Forces to Combat Cancer. <i>Cancer Discovery</i> , 2019, 9, 587-604.	7.7	13
3698	Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue. <i>Cancers</i> , 2019, 11, 469.	1.7	165
3699	Cell lines and immune classification of glioblastoma define patientâ€™s prognosis. <i>British Journal of Cancer</i> , 2019, 120, 806-814.	2.9	16
3700	The Classification of Adult Gliomas. , 2019, , 95-107.		0
3701	Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 537-546.	0.6	61
3702	Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. <i>Cancer Cell</i> , 2019, 35, 347-367.	7.7	533
3703	Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas. <i>Radiotherapy and Oncology</i> , 2019, 132, 135-141.	0.3	25

#	ARTICLE	IF	CITATIONS
3704	Molecular responses to immune checkpoint blockade in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 359-361.	15.2	35
3705	MicroRNAs, Hypoxia and the Stem-Like State as Contributors to Cancer Aggressiveness. <i>Frontiers in Genetics</i> , 2019, 10, 125.	1.1	42
3706	Increased <i>LGALS3</i> expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma. <i>Cancer Medicine</i> , 2019, 8, 2031-2040.	1.3	15
3707	Animal Models of Brain Tumor Surgery. , 2019, , 169-190.		0
3708	Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). <i>Scientific Reports</i> , 2019, 9, 2905.	1.6	34
3709	O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET). <i>Digestive and Liver Disease</i> , 2019, 51, 595-599.	0.4	27
3710	Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells. <i>PLoS ONE</i> , 2019, 14, e0208341.	1.1	15
3711	Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. <i>Cancer Cell</i> , 2019, 35, 692-704.e12.	7.7	172
3712	Clinical management of difficult to treat macroprolactinomas. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 179-192.	1.2	6
3713	A Multi-Cohort and Multi-Omics Meta-Analysis Framework to Identify Network-Based Gene Signatures. <i>Frontiers in Genetics</i> , 2019, 10, 159.	1.1	25
3714	Hyperbaric oxygen increases glioma cell sensitivity to antitumor treatment with a novel isothiourea derivative <i>in vitro</i> . <i>Oncology Reports</i> , 2019, 41, 2703-2716.	1.2	9
3715	5-azacytidine treatment results in nuclear exclusion of DNA methyltransferase 1, as well as reduced proliferation and invasion in human cytomegalovirus-infected glioblastoma cells. <i>Oncology Reports</i> , 2019, 41, 2927-2936.	1.2	4
3716	HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 3602-3616.	3.2	81
3717	Therapy for glioblastoma: is it working?. <i>Drug Discovery Today</i> , 2019, 24, 1193-1201.	3.2	86
3718	Extracranial metastases in glioblastoma—Two case stories. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 289-294.	0.2	6
3719	Correlation of Ki-67 Index with Volumetric Segmentation and its Value as a Prognostic Marker in Glioblastoma. <i>World Neurosurgery</i> , 2019, 125, e1093-e1103.	0.7	21
3720	Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET imaging in glioblastoma multiforme. <i>Radiation Oncology</i> , 2019, 14, 37.	1.2	5
3721	The surgical perspective in precision treatment of diffuse gliomas. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1497-1508.	1.0	18

#	ARTICLE	IF	CITATIONS
3722	The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. <i>Cell Death and Disease</i> , 2019, 10, 246.	2.7	129
3723	Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab. <i>Clinical and Translational Oncology</i> , 2019, 21, 1413-1423.	1.2	7
3724	Divining responder populations from survival data. <i>Annals of Oncology</i> , 2019, 30, 1005-1013.	0.6	9
3725	Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone. <i>Oncotarget</i> , 2019, 10, 660-672.	0.8	35
3726	Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy. <i>Anticancer Research</i> , 2019, 39, 2043-2051.	0.5	15
3727	Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL). <i>Molecular Imaging and Biology</i> , 2019, 21, 1182-1191.	1.3	0
3728	Rethinking Alkylating(-Like) Agents for Solid Tumor Management. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 342-357.	4.0	31
3729	Dose diversification in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 701-702.	0.6	0
3730	Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. <i>Diagnostic Pathology</i> , 2019, 14, 29.	0.9	40
3731	The Impact of Timing of Concurrent Chemoradiation in Patients With High-Grade Glioma in the Era of the Stupp Protocol. <i>Frontiers in Oncology</i> , 2019, 9, 186.	1.3	11
3732	Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2019, 10, 330.	1.6	42
3733	Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. <i>Radiation Oncology</i> , 2019, 14, 51.	1.2	38
3734	Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1562.	1.8	41
3735	Overview of DNA methylation in adult diffuse gliomas. <i>Brain Tumor Pathology</i> , 2019, 36, 84-91.	1.1	45
3736	Temozolomide Treatment Induces lncRNA MALAT1 in an NF- $\kappa$ B and p53 Codependent Manner in Glioblastoma. <i>Cancer Research</i> , 2019, 79, 2536-2548.	0.4	71
3737	Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma. <i>Cancer Discovery</i> , 2019, 9, 469-471.	7.7	27
3738	Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma. <i>Journal of Nanobiotechnology</i> , 2019, 17, 47.	4.2	18
3739	Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1071-1090.	4.2	89

#	ARTICLE	IF	CITATIONS
3740	The landscape of the mesenchymal signature in brain tumours. <i>Brain</i> , 2019, 142, 847-866.	3.7	228
3741	Role of postoperative tumor volume in patients with MGMT-unmethylated glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 529-536.	1.4	10
3742	MGMT Testing in Glioblastomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 117-122.	0.6	17
3743	Comparison of Biomarker Assays for <i>EGFR</i> : Implications for Precision Medicine in Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 3259-3265.	3.2	24
3744	Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial. <i>Cancer Communications</i> , 2019, 39, 1-12.	3.7	28
3745	The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death. <i>Molecular Cancer Research</i> , 2019, 17, 1129-1141.	1.5	40
3746	Imaging in Neuro-Oncology. , 2019, , 53-68.		1
3747	Radiosensitization of Glioblastoma Cells by a Novel DNA Methyltransferase-inhibiting Phthalimido-Alkanamide Derivative. <i>Anticancer Research</i> , 2019, 39, 759-769.	0.5	3
3748	Artificial intelligence in cancer imaging: Clinical challenges and applications. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 127-157.	157.7	965
3749	A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. <i>Scientific Reports</i> , 2019, 9, 1407.	1.6	61
3750	Improved treatment of glioblastoma changes in survival over two decades at a single regional Centre. <i>Acta Oncologica</i> , 2019, 58, 334-341.	0.8	20
3751	Precision dosing of warfarin: open questions and strategies. <i>Pharmacogenomics Journal</i> , 2019, 19, 219-229.	0.9	17
3752	Systemic Therapy for Neuroendocrine Neoplasms. <i>Digestive Disease Interventions</i> , 2019, 03, 063-070.	0.3	0
3753	Biomarkers in tumors of the central nervous system a review. <i>Apmis</i> , 2019, 127, 265-287.	0.9	9
3754	A Simple Three-dimensional Hydrogel Platform Enables <i>Ex Vivo</i> Cell Culture of Patient and PDX Tumors for Assaying Their Response to Clinically Relevant Therapies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 718-725.	1.9	13
3755	Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. <i>European Radiology</i> , 2019, 29, 4957-4967.	2.3	64
3757	Therapeutic implications of germline genetic findings in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 386-396.	12.5	39
3758	Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 878-886.	0.4	10

#	ARTICLE	IF	CITATIONS
3759	The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma. <i>British Journal of Cancer</i> , 2019, 120, 481-487.	2.9	45
3760	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA09): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 678-688.	6.3	384
3761	Improving survival in molecularly selected glioblastoma. <i>Lancet, The</i> , 2019, 393, 615-617.	6.3	32
3762	Glioblastoma Multiforme of the Conus Medullaris Management Strategies and Complications. <i>World Neurosurgery</i> , 2019, 124, 101-109.	0.7	4
3763	How we treat patients with brain tumour during the COVID-19 pandemic. <i>ESMO Open</i> , 2019, 4, e000789.	2.0	16
3764	Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. <i>Clinical and Translational Medicine</i> , 2019, 8, 33.	1.7	20
3765	Concurrent Thermochemoradiotherapy in Glioblastoma Treatment: Preliminary Results. , 0, , .		0
3766	Prediction of the Outcome for Patients with Glioblastoma with lncRNA Expression Profiles. <i>BioMed Research International</i> , 2019, 2019, 1-10.	0.9	5
3767	Epigenetic dysregulation in pituitary tumors. <i>International Journal of Endocrine Oncology</i> , 2019, 6, 11E19.	0.4	3
3768	Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools. <i>Cancer Reports</i> , 2019, 2, e1220.	0.6	12
3770	Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas. <i>Scientific Reports</i> , 2019, 9, 17080.	1.6	15
3771	Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. <i>Biomedicines</i> 2019, 7, 69. <i>Biomedicines</i> , 2019, 7, 90.	1.4	30
3772	System-based approaches as prognostic tools for glioblastoma. <i>BMC Cancer</i> , 2019, 19, 1092.	1.1	9
3773	Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 1134.	1.3	28
3774	Prognostic value of test(s) for O <sup>6</sup> -methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. <i>The Cochrane Library</i> , 0, , .	1.5	2
3775	Laser interstitial thermal therapy for inoperable gliomas. , 2019, , 209-229.		0
3776	Adjuvant therapy and molecular profiling for inoperable gliomas. , 2019, , 193-208.		0
3777	Comorbid Medical Conditions as Predictors of Overall Survival in Glioblastoma Patients. <i>Scientific Reports</i> , 2019, 9, 20018.	1.6	17



#	ARTICLE	IF	CITATIONS
3778	Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989156.	1.4	7
3779	What Neuroradiologists Need to Know About Radiation Treatment for Neural Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2019, 28, 37-47.	0.7	1
3780	Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review. <i>Cancers</i> , 2019, 11, 1837.	1.7	42
3781	ABCC3 Expressed by CD56dim CD16+ NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5886.	1.8	17
3782	Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer. <i>Journal of Cancer</i> , 2019, 10, 6761-6766.	1.2	37
3783	Enhanced Hsa-miR-181d/p-STAT3 and Hsa-miR-181d/p-STAT5A Ratios Mediate the Anticancer Effect of Garcinol in STAT3/5A-Addicted Glioblastoma. <i>Cancers</i> , 2019, 11, 1888.	1.7	25
3786	Brain Tumors of Glial Origin. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1190, 281-297.	0.8	19
3787	Statistical multiscale mapping of IDH1, MGMT, and microvascular proliferation in human brain tumors from multiparametric MR and spatially-registered core biopsy. <i>Scientific Reports</i> , 2019, 9, 17112.	1.6	0
3788	Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. <i>Scientific Reports</i> , 2019, 9, 17794.	1.6	9
3789	Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study. <i>PLoS ONE</i> , 2019, 14, e0225599.	1.1	17
3790	Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-7.	0.2	2
3791	Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 1425.	1.3	30
3792	Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial. <i>Trials</i> , 2019, 20, 641.	0.7	8
3793	Identification of responders to immune checkpoint therapy: which biomarkers have the highest value?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 52-56.	1.3	23
3794	Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. <i>Radiation Oncology</i> , 2019, 14, 227.	1.2	6
3795	Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 62.	7.1	618
3796	Histogram analysis of 11C-methionine integrated PET/MRI may facilitate to determine the O6-methylguanylmethyltransferase methylation status in gliomas. <i>Nuclear Medicine Communications</i> , 2019, 40, 850-856.	0.5	13
3797	Updates in the Neuroimaging and WHO Classification of Primary CNS Gliomas. <i>Topics in Magnetic Resonance Imaging</i> , 2019, 28, 73-84.	0.7	2

#	ARTICLE	IF	CITATIONS
3798	Text-mining clinically relevant cancer biomarkers for curation into the CIVIC database. <i>Genome Medicine</i> , 2019, 11, 78.	3.6	35
3799	Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas. <i>Frontiers in Genetics</i> , 2019, 10, 1143.	1.1	29
3800	Targeting DNA repair in gliomas. <i>Current Opinion in Neurology</i> , 2019, 32, 878-885.	1.8	11
3801	<p>Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10579-10585.	1.0	13
3802	Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions. <i>American Journal of Neuroradiology</i> , 2019, 40, 2052-2058.	1.2	1
3803	Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma. <i>Oncologist</i> , 2019, 24, 1076-1088.	1.9	18
3804	Glioblastoma Recurrence and the Role of O6-Methylguanineâ€œDNA Methyltransferase Promoter Methylation. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	1.0	40
3805	Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma. <i>Oncology Reports</i> , 2019, 41, 3404-3412.	1.2	18
3806	Intratumoral Heterogeneity of Glioblastoma Infiltration Revealed by Joint Histogram Analysis of Diffusion Tensor Imaging. <i>Neurosurgery</i> , 2019, 85, 524-534.	0.6	29
3807	A rare clinical presentation: a pleomorphic xanthoastrocytoma presenting with intracerebral haemorrhage and metastasizing vigorouslyâ€œcase report and review of the literature. <i>Child's Nervous System</i> , 2019, 35, 355-362.	0.6	4
3808	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. <i>Neuro-Oncology</i> , 2019, 21, 167-178.	0.6	173
3809	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019, 107, 164-174.	1.3	9
3810	Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT. <i>Neoplasma</i> , 2019, 66, 288-293.	0.7	6
3811	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019, 565, 234-239.	13.7	956
3812	20(S)-ginsenosideâ€œRg3 reverses temozolomide resistance and restrains epithelialâ€œmesenchymal transition progression in glioblastoma. <i>Cancer Science</i> , 2019, 110, 389-400.	1.7	50
3813	The adaptive potential of RNA editing-mediated miRNA-retargeting in cancer. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2019, 1862, 291-300.	0.9	15
3814	A little piece of mind: best practices for brain tumor intraoperative consultation. <i>Modern Pathology</i> , 2019, 32, 44-57.	2.9	10
3815	Mifepristone Overcomes Tumor Resistance to Temozolomide Associated with DNA Damage Repair and Apoptosis in an Orthotopic Model of Glioblastoma. <i>Cancers</i> , 2019, 11, 16.	1.7	17

#	ARTICLE	IF	CITATIONS
3816	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase- mutant Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 1261-1271.	3.2	50
3817	Clinical epigenetics: seizing opportunities for translation. <i>Nature Reviews Genetics</i> , 2019, 20, 109-127.	7.7	353
3818	Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 337-347.	0.6	25
3819	Significance and Prognostic Value of The Coagulation Profile in Patients with Glioblastoma: Implications for Personalized Therapy. <i>World Neurosurgery</i> , 2019, 121, e621-e629.	0.7	33
3820	Cancer Epigenetics. , 2019, , 65-76.		5
3821	Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. <i>Advances in Radiation Oncology</i> , 2019, 4, 268-282.	0.6	13
3822	Apparent Diffusion Coefficient as a Predictive Biomarker for Survival in Patients with Treatment-Naive Glioblastoma Using Quantitative Multiparametric Magnetic Resonance Profiling. <i>World Neurosurgery</i> , 2019, 122, e812-e820.	0.7	13
3823	Molecular tools for the pathologic diagnosis of central nervous system tumors. <i>Neuro-Oncology Practice</i> , 2019, 6, 4-16.	1.0	8
3824	5-ALA and FDA approval for glioma surgery. <i>Journal of Neuro-Oncology</i> , 2019, 141, 479-486.	1.4	204
3825	Effects of 5-ALA dose on resection of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 523-531.	1.4	29
3826	Optimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era. <i>Neurosurgical Review</i> , 2019, 42, 937-950.	1.2	10
3827	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2019, , 483-503.		0
3828	Circulating tumor stem cells and glioblastoma: A review. <i>Journal of Clinical Neuroscience</i> , 2019, 61, 5-9.	0.8	24
3829	Glioma Surgery. , 2019, , 81-94.		0
3830	Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents. <i>Clinical Epigenetics</i> , 2019, 11, 2.	1.8	15
3831	Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival. <i>Neuro-Oncology</i> , 2019, 21, 264-273.	0.6	36
3832	Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?. <i>Neuro-Oncology</i> , 2019, 21, 14-25.	0.6	69
3833	Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. <i>Journal of Neurochemistry</i> , 2019, 148, 188-203.	2.1	82

#	ARTICLE	IF	CITATIONS
3834	The role of frameless stereotactic biopsy in contemporary neuro-oncology: molecular specifications and diagnostic yield in biopsied glioma patients. <i>Journal of Neuro-Oncology</i> , 2019, 141, 183-194.	1.4	16
3835	Integrated profiling identifies caveolae-associated protein 1 as a prognostic biomarker of malignancy in glioblastoma patients. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 343-354.	1.9	21
3836	Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 43-52.	1.1	12
3837	Novel lncRNA-ZNF281 regulates cell growth, stemness and invasion of glioma stem-like U251s cells. <i>Neoplasma</i> , 2019, 66, 118-127.	0.7	22
3838	Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. <i>Journal of Controlled Release</i> , 2019, 295, 130-139.	4.8	72
3839	Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. <i>Oncogene</i> , 2019, 38, 2706-2721.	2.6	36
3840	MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1809-1816.	3.2	94
3841	Histogram analysis of amide proton transfer-weighted imaging: comparison of glioblastoma and solitary brain metastasis in enhancing tumors and peritumoral regions. <i>European Radiology</i> , 2019, 29, 4133-4140.	2.3	35
3842	MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 57-64.	0.9	8
3843	Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma: the need to further stratify this tumor entity – a meta-analysis. <i>European Journal of Neurology</i> , 2019, 26, 379-387.	1.7	18
3844	Spinal cord astrocytomas: progresses in experimental and clinical investigations for developing recovery neurobiology-based novel therapies. <i>Experimental Neurology</i> , 2019, 311, 135-147.	2.0	16
3845	Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. <i>Oncologist</i> , 2019, 24, 402-413.	1.9	3
3846	MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients. <i>Archives of Medical Science</i> , 2019, 15, 504-512.	0.4	49
3847	Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. <i>Neuroendocrinology</i> , 2019, 108, 7-17.	1.2	19
3848	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 95-105.	0.6	100
3849	Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression. <i>Neuro-Oncology</i> , 2019, 21, 517-526.	0.6	28
3850	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. <i>Clinical Cancer Research</i> , 2019, 25, 253-265.	3.2	42
3851	A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. <i>Modern Pathology</i> , 2019, 32, 4-15.	2.9	41

#	ARTICLE	IF	CITATIONS
3852	Epigenetic regulation of DNA repair genes and implications for tumor therapy. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 780, 15-28.	2.4	59
3853	In Vivo Molecular Profiling of Human Glioma. <i>Clinical Neuroradiology</i> , 2019, 29, 479-491.	1.0	21
3854	A nonmyeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 119-140.	1.8	18
3855	Malignancy Index Using Intraoperative Flow Cytometry is a Valuable Prognostic Factor for Glioblastoma Treated With Radiotherapy and Concomitant Temozolomide. <i>Neurosurgery</i> , 2019, 84, 662-672.	0.6	20
3856	Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas. <i>Neurosurgery</i> , 2019, 84, 190-197.	0.6	59
3857	MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?. <i>Journal of Neurosurgery</i> , 2019, 130, 780-788.	0.9	14
3858	Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 89-110.	1.8	19
3859	Risks and Benefits of Glioblastoma Resection in Older Adults: A Retrospective Austrian Multicenter Study. <i>World Neurosurgery</i> , 2020, 133, e583-e591.	0.7	8
3860	DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas. <i>Clinical Cancer Research</i> , 2020, 26, 93-100.	3.2	34
3861	Synergistic Therapies for Recurrent Malignant Gliomas. <i>World Neurosurgery</i> , 2020, 133, 237-239.	0.7	3
3862	ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. <i>Pharmacogenomics Journal</i> , 2020, 20, 213-219.	0.9	9
3863	Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28011.	0.8	17
3864	Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma. <i>Neuro-Oncology Practice</i> , 2020, 7, 68-76.	1.0	21
3865	The influence of patient sex on clinical approaches to malignant glioma. <i>Cancer Letters</i> , 2020, 468, 41-47.	3.2	20
3866	Longitudinal Characteristics of Glioblastoma in Genome-Wide Studies. <i>Pathology and Oncology Research</i> , 2020, 26, 2035-2047.	0.9	11
3867	Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours. <i>Neuroendocrinology</i> , 2020, 110, 413-421.	1.2	23
3868	Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. <i>European Radiology</i> , 2020, 30, 1202-1211.	2.3	25
3869	Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. <i>Journal of Neuro-Oncology</i> , 2020, 146, 55-62.	1.4	21

#	ARTICLE	IF	CITATIONS
3871	Influence of wide opening of the lateral ventricle on survival for supratentorial glioblastoma patients with radiotherapy and concomitant temozolomide-based chemotherapy. <i>Neurosurgical Review</i> , 2020, 43, 1583-1593.	1.2	11
3872	Role of myeloid cells in the immunosuppressive microenvironment in gliomas. <i>Immunobiology</i> , 2020, 225, 151853.	0.8	50
3873	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. <i>Neuro-Oncology</i> , 2020, 22, 470-479.	0.6	49
3874	The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 176-180.	2.3	21
3875	Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes. <i>FEBS Journal</i> , 2020, 287, 1005-1034.	2.2	84
3876	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. <i>Neuro-Oncology</i> , 2020, 22, 515-523.	0.6	140
3877	Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>CNS Drugs</i> , 2020, 34, 127-145.	2.7	26
3878	Molecular Classification of Diffuse Gliomas. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 464-473.	0.3	5
3879	Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States. <i>Neuro-Oncology Practice</i> , 2020, 7, 299-305.	1.0	3
3880	Is There an Independent Role of TERT and NF1 in High Grade Gliomas?. <i>Translational Oncology</i> , 2020, 13, 346-354.	1.7	11
3881	Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004762.	0.5	8
3882	Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma. <i>Cancers</i> , 2020, 12, 111.	1.7	31
3883	IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 1252-1262.	1.2	21
3884	Survey of treatment recommendations for elderly patients with glioblastoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 1329-1334.	1.2	4
3885	Identification of miRNA signatures in serum exosomes as a potential biomarker after radiotherapy treatment in glioma patients. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151436.	0.6	27
3886	Pangenomic Classification of Pituitary Neuroendocrine Tumors. <i>Cancer Cell</i> , 2020, 37, 123-134.e5.	7.7	186
3887	Supramaximal resection: A systematic review of its safety, efficacy and feasibility in glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 328-334.	0.8	24
3888	Extracellular vesicles and their role in glioblastoma. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 227-252.	2.7	30

#	ARTICLE	IF	CITATIONS
3889	Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. <i>Neuro-Oncology</i> , 2020, 22, 539-549.	0.6	98
3890	Focused Ultrasound Strategies for Brain Tumor Therapy. <i>Operative Neurosurgery</i> , 2020, 19, 9-18.	0.4	55
3891	Twenty Metabolic Genes Based Signature Predicts Survival of Glioma Patients. <i>Journal of Cancer</i> , 2020, 11, 441-449.	1.2	3
3892	Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. <i>Cancer Medicine</i> , 2020, 9, 1955-1965.	1.3	10
3893	Magnetic Resonance Spectroscopy for Prediction of Isocitrate Dehydrogenase Mutation in Glioma. <i>World Neurosurgery</i> , 2020, 134, 187-189.	0.7	3
3894	The prognostic value of peri-operative neurological performance in glioblastoma patients. <i>Acta Neurochirurgica</i> , 2020, 162, 417-425.	0.9	18
3895	Failure to complete standard radiation therapy in glioblastoma patients: Patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 680-687.	0.5	6
3896	Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma. <i>Cancer Medicine</i> , 2020, 9, 469-475.	1.3	14
3897	Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 81-99.	0.8	84
3898	Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair. <i>Clinical Cancer Research</i> , 2020, 26, 1690-1699.	3.2	76
3899	Histone 2A Family Member J Drives Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Multiforme. <i>Cancers</i> , 2020, 12, 98.	1.7	14
3900	Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. <i>Cell Death and Disease</i> , 2020, 11, 19.	2.7	53
3901	A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2020, 2, 100025.	1.3	22
3902	Imaging Gliomas After Treatment. , 2020, , .		0
3903	Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection. <i>Clinical Chemistry</i> , 2020, 66, 105-116.	1.5	26
3904	Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. <i>Journal of Neuro-Oncology</i> , 2020, 146, 163-170.	1.4	21
3905	Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. <i>Cancer Letters</i> , 2020, 472, 108-118.	3.2	8
3906	Epigenetic alterations in salivary gland tumors. <i>Oral Diseases</i> , 2020, 26, 1610-1618.	1.5	11

#	ARTICLE	IF	CITATIONS
3907	Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma. <i>Translational Oncology</i> , 2020, 13, 70-78.	1.7	15
3908	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz051.	0.4	9
3909	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020, 20, 12-25.	12.8	389
3910	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 659-670.	1.2	14
3911	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 82, 101935.	3.4	17
3912	High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. <i>Pathology Research and Practice</i> , 2020, 216, 152728.	1.0	8
3913	Clinical neuro-oncology for the neurologist. <i>Neurology: Clinical Practice</i> , 2020, 10, 458-465.	0.8	5
3914	Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome. <i>JCO Precision Oncology</i> , 2020, 4, 841-847.	1.5	4
3915	Development and Validation of a Novel DNA Methylation-Driven Gene Based Molecular Classification and Predictive Model for Overall Survival and Immunotherapy Response in Patients With Glioblastoma: A Multiomic Analysis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 576996.	1.8	10
3916	Assessment of Pre-operative Measurements of Tumor Size by MRI Methods as Survival Predictors in Wild Type IDH Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 1662.	1.3	12
3917	Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 533000.	1.3	7
3918	Novel Molecular Markers in Glioblastoma—Benefits of Liquid Biopsy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7522.	1.8	40
3919	Non-Coding RNAs in Brain Tumors, the Contribution of lncRNAs, circRNAs, and snoRNAs to Cancer Development—Their Diagnostic and Therapeutic Potential. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7001.	1.8	29
3920	Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7006.	1.8	9
3921	Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. <i>Drug Resistance Updates</i> , 2020, 53, 100720.	6.5	107
3922	Cedrol suppresses glioblastoma progression by triggering DNA damage and blocking nuclear translocation of the androgen receptor. <i>Cancer Letters</i> , 2020, 495, 180-190.	3.2	26
3923	Advances in drug delivery technology for the treatment of glioblastoma multiforme. <i>Journal of Controlled Release</i> , 2020, 328, 350-367.	4.8	58
3924	Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. <i>Scientific Reports</i> , 2020, 10, 15195.	1.6	19



#	ARTICLE	IF	CITATIONS
3925	Updates on Deep Learning and Glioma. <i>Neuroimaging Clinics of North America</i> , 2020, 30, 493-503.	0.5	15
3926	Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 273-279.	0.7	3
3927	Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features. <i>Molecules</i> , 2020, 25, 4641.	1.7	7
3928	Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 6600-6609.	3.2	10
3929	Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7211.	1.8	17
3930	The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7358.	1.8	48
3931	Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis. <i>Neurosurgical Review</i> , 2021, 44, 1943-1955.	1.2	10
3932	Integrin Beta 1 Promotes Glioma Cell Proliferation by Negatively Regulating the Notch Pathway. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	6
3933	Automatic Prediction of MGMT Status in Glioblastoma via Deep Learning-Based MR Image Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	23
3934	A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7304.	1.8	11
3935	<p>Abnormal MGMT Promoter Methylation in Gastrointestinal Stromal Tumors: Genetic Susceptibility and Association with Clinical Outcome</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9941-9952.	0.9	5
3936	A SEMA3 Signaling Pathway-Based Multi-Biomarker for Prediction of Glioma Patient Survival. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7396.	1.8	13
3937	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020, 9, 8373-8385.	1.3	19
3938	Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. <i>Acta Neuropathologica</i> , 2020, 140, 919-949.	3.9	72
3939	Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients. <i>NeuroImage: Clinical</i> , 2020, 28, 102427.	1.4	22
3940	Methylated DNA immunoprecipitation sequencing (MeDIP-seq): Principles and applications. , 2020, , 157-179.		1
3941	MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 855-862.	0.9	9
3942	Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 843-854.	0.9	32

#	ARTICLE	IF	CITATIONS
3943	Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 567-577.	0.6	14
3944	The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients. <i>Cancers</i> , 2020, 12, 1831.	1.7	29
3945	Development of Artificial Plasma Membranes Derived Nanovesicles Suitable for Drugs Encapsulation. <i>Cells</i> , 2020, 9, 1626.	1.8	15
3946	Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme. , 0, , .		0
3947	Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas. <i>EBioMedicine</i> , 2020, 55, 102736.	2.7	35
3948	Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From 18F-DOPA-PET Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1339-1346.	0.4	29
3949	A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas. <i>Scientific Reports</i> , 2020, 10, 11852.	1.6	41
3950	A Ki-67 Index to Predict Treatment Response to the Capecitabine Temozolomide (CAPTEM) Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study. <i>Neuroendocrinology</i> , 2020, 111, 752-763.	1.2	16
3951	The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma. <i>BMC Cancer</i> , 2020, 20, 672.	1.1	12
3952	Dual <i>MGMT</i> inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma. <i>Cancer Medicine</i> , 2020, 9, 6344-6353.	1.3	8
3953	Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. <i>Oncolimmunology</i> , 2020, 9, 1779990.	2.1	28
3954	NORRIN plays a context-dependent role in glioblastoma stem cells. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1758540.	0.3	0
3955	Proteins inform survival-based differences in patients with glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa039.	0.4	3
3956	Voxel-based strain tensors from near-field High Energy Diffraction Microscopy. <i>Current Opinion in Solid State and Materials Science</i> , 2020, 24, 100852.	5.6	15
3957	P.191 The impact of physical activity and fitness on resilience to modern-life stress and the role of brain-derived neurotrophic factor (BDNF). <i>European Neuropsychopharmacology</i> , 2020, 40, S110-S111.	0.3	0
3958	P.467 Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2 / 5-HT7 antagonist, in healthy volunteers. <i>European Neuropsychopharmacology</i> , 2020, 40, S265.	0.3	0
3959	Guided Internet-delivered cognitive behaviour therapy for perfectionism in a non-clinical sample of adolescents: A study protocol for a randomised controlled trial. <i>Internet Interventions</i> , 2020, 21, 100342.	1.4	0
3960	Comparison based on statistical thermodynamics between globule-to-coil transition of poly(N-isopropylacrylamide) and cold denaturation of a protein. <i>Journal of Molecular Liquids</i> , 2020, 317, 114129.	2.3	10

#	ARTICLE	IF	CITATIONS
3963	Post COVID 19 acute acalculous cholecystitis raising the possibility of underlying dysregulated immune response, a case report. <i>Annals of Medicine and Surgery</i> , 2020, 60, 434-437.	0.5	25
3964	479P Open chromatin region (OCR) based model predicts advanced adenoma in plasma cell-free DNA whole-genome bisulfite sequencing data. <i>Annals of Oncology</i> , 2020, 31, S444.	0.6	0
3965	55P MOREL: Multicenter observational study on treatment and PD-L1 testing in patients (pts) with newly diagnosed stage IV NSCLC in Spain. <i>Annals of Oncology</i> , 2020, 31, S1437-S1438.	0.6	0
3966	Assessing mTBI Treatment Protocol for Latent Subgroups. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e129-e130.	0.5	0
3967	Testicular hypertrophy as predictor of contralateral nonpalpable testis among Chinese boys: An 18-year retrospective study. <i>Archives De Pediatrie</i> , 2020, 27, 456-463.	0.4	5
3968	<i>Lactobacillus johnsonii</i> -activated chicken bone marrow-derived dendritic cells exhibit maturation and increased expression of cytokines and chemokines in vitro. <i>Cytokine</i> , 2020, 136, 155269.	1.4	4
3969	$\beta$ -Aminobutyric acid found in fermented foods and beverages: current trends. <i>Heliyon</i> , 2020, 6, e05526.	1.4	51
3970	Influence of the interval length of hydraulic packer systems on thermally-induced pore pressure measurements in rock. <i>International Journal of Rock Mechanics and Minings Sciences</i> , 2020, 135, 104500.	2.6	6
3971	Linearized torsional problem of plastic thin wires. <i>Mechanics Research Communications</i> , 2020, 109, 103598.	1.0	1
3972	Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II. <i>Scientific Reports</i> , 2020, 10, 19758.	1.6	11
3973	Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma. <i>Clinical Epigenetics</i> , 2020, 12, 174.	1.8	3
3974	Blocking MAPK/ERK pathway sensitizes hepatocellular carcinoma cells to temozolomide via downregulating MGMT expression. <i>Annals of Translational Medicine</i> , 2020, 8, 1305-1305.	0.7	15
3975	Natural Compounds That Target DNA Repair Pathways and Their Therapeutic Potential to Counteract Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 598174.	1.3	22
3976	Bright and slip-proof engineered cementitious composites with visible light activated photo-catalysis property for pavement in tunnels. <i>Cement and Concrete Composites</i> , 2020, 114, 103788.	4.6	11
3978	Angelika Amon. <i>Developmental Cell</i> , 2020, 55, 525-528.	3.1	0
3979	Phase states, microstructure and dielectric characteristics of solid solutions $(1-x)\text{NaNbO}_3-x\text{Ca}_2\text{Nb}_2\text{O}_7$ and $(1-x)\text{NaNbO}_3-x\text{Sr}_2\text{Nb}_2\text{O}_7$ . <i>Heliyon</i> , 2020, 6, e05197.	1.4	3
3980	Molecular dynamic study of evaporation in nanoslit: Influence of slit geometry and wettability. <i>International Journal of Heat and Mass Transfer</i> , 2020, 163, 120463.	2.5	6
3981	Deep Markov models of multidimensional random fields. <i>Procedia Computer Science</i> , 2020, 176, 1289-1298.	1.2	3

#	ARTICLE	IF	CITATIONS
3982	Custom optical imaging system for ex-vivo breast cancer detection based on spectral signature. <i>Surgical Oncology</i> , 2020, 35, 547-555.	0.8	14
3983	Tumor Phylogeny Topology Inference via Deep Learning. <i>IScience</i> , 2020, 23, 101655.	1.9	11
3984	Closed-loop optimized nanometal sintering method. <i>Journal of Manufacturing Processes</i> , 2020, 59, 403-410.	2.8	1
3986	Integrating yoga with psychological group-treatment for mixed depression and anxiety in primary healthcare: An explorative pilot study. <i>Complementary Therapies in Clinical Practice</i> , 2020, 41, 101250.	0.7	4
3987	A hybrid fractional optimal control for a novel Coronavirus (2019-nCov) mathematical model. <i>Journal of Advanced Research</i> , 2021, 32, 149-160.	4.4	29
3988	Reconstruction of the glacial history after the Last Glacial Maximum in the Italian Central Alps using Schmidt's hammer R-values and crystallinity ratio indices of soils. <i>Quaternary International</i> , 2020, 558, 19-27.	0.7	5
3990	Is the ALS a motor neuron disease or a hematopoietic stem cell disease?. <i>Progress in Brain Research</i> , 2020, 258, 381-396.	0.9	5
3991	Variation of CD4 count in pregnant women living with HIV. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 962-963.	0.7	1
3992	Shear stress induced activation of von Willebrand factor may facilitate thrombotic events in coronary artery disease in young adults. <i>Atherosclerosis</i> , 2020, 315, e79.	0.4	0
3993	3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3). <i>Atherosclerosis</i> , 2020, 315, e87.	0.4	2
3994	Prognostic power of big endothelin-1 in noncompaction cardiomyopathy. <i>Atherosclerosis</i> , 2020, 315, e260.	0.4	0
3995	Association between added sugar intake and intima media thickness as a marker for atherosclerosis: A cross sectional study in the malmÅr diet and cancer study. <i>Atherosclerosis</i> , 2020, 315, e274.	0.4	0
3996	National OMFS specialty trainee recruitment "does an interview skills course help in preparation?". <i>British Journal of Oral and Maxillofacial Surgery</i> , 2020, 58, e192.	0.4	0
3997	Management of lymphatic malformations of the head and neck region: our 6 year experience. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2020, 58, e192.	0.4	0
3998	Classification of crista galli pneumatization and clinical considerations for anterior skull base surgery. <i>Journal of Clinical Neuroscience</i> , 2020, 82, 225-230.	0.8	4
4005	Fear of negative evaluation and the concealment of their disease by epilepsy patients. <i>Epilepsy and Behavior</i> , 2020, 113, 107539.	0.9	9
4009	The role of oxidative stress on molybdenum enzymes and ischemic reperfusion injury in hyperuricaemic patients. An infrared spectroscopic study. <i>Atherosclerosis</i> , 2020, 315, e60-e61.	0.4	0
4010	Glypican-4 expression is reduced in the inflammatory plaque shoulder in human atherosclerotic lesions. <i>Atherosclerosis</i> , 2020, 315, e63.	0.4	0

#	ARTICLE	IF	CITATIONS
4011	Arterial wall elasticity in Greek soccer athletes with and without family history of cardiovascular disease. <i>Atherosclerosis</i> , 2020, 315, e71.	0.4	0
4012	Percutaneous retrieval of an entrapped rotational atherectomy burr using novel technique of controlled traction and counter traction. <i>Cardiovascular Revascularization Medicine</i> , 2020, 28S, 132-135.	0.3	1
4013	Parametrized Fixed Points and Their Applications to Session Types. <i>Electronic Notes in Theoretical Computer Science</i> , 2020, 352, 149-172.	0.9	0
4016	Recycling for All Solid-State Lithium-Ion Batteries. <i>Matter</i> , 2020, 3, 1845-1861.	5.0	38
4019	Numerical investigation of an optimized plasmonic on-chip refractive index sensor for temperature and blood group detection. <i>Results in Physics</i> , 2020, 19, 103611.	2.0	29
4020	Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance. <i>Advanced Science</i> , 2020, 7, 2002015.	5.6	25
4022	Interventions and Practice Implications for the Management of Endometriosis. <i>Nursing for Women's Health</i> , 2020, 24, 460-467.	0.3	2
4024	Multicenter transperineal MRI-TRUS fusion guided outpatient clinic prostate biopsies under local anesthesia. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 39, 432.e1-432.e7.	0.8	15
4025	14407 The Cancer Risk Among MITF E318K Mutation Carriers. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB23.	0.6	0
4026	15120 Erdheim-Chester disease: Case report with multisystem manifestations. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB30.	0.6	0
4027	15838 Autoimmune comorbidities of psoriasis in US adults and children. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB48.	0.6	0
4028	15174 Risk of ischemic heart disease in patients with hidradenitis suppurativa: Analysis of real-world data within a large, urban, Midwestern US dermatology patient population. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, AB143.	0.6	0
4029	Engineering lytic polysaccharide monoxygenases (LPMOs). <i>Methods in Enzymology</i> , 2020, 644, 1-34.	0.4	12
4030	First-principles study of binary and ternary alloys based on PdCu as oxygen reduction catalysts. <i>Chemical Physics Letters</i> , 2020, 758, 137932.	1.2	0
4031	Targeting the Ubiquitin System in Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 574011.	1.3	21
4032	Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients. <i>Surgical Oncology</i> , 2020, 35, 515-519.	0.8	4
4034	Hernia interna relacionada con la derivación gástrica en Y de Roux: una complicación que representa un reto clínico y diagnóstico. <i>Cirugía Española</i> , 2020, 98, 559.	0.1	0
4035	High-speed video data for settling of dense liquid droplets through liquid media with different viscosities. <i>Data in Brief</i> , 2020, 33, 106428.	0.5	0

#	ARTICLE	IF	CITATIONS
4036	Acidity and Nucleophilicity of Persulfides. <i>Free Radical Biology and Medicine</i> , 2020, 159, S18-S19.	1.3	0
4037	Generation of Glutaredoxin Mutants that Provide Resistance to Oxidative Inactivation and Promote Biological Activity. <i>Free Radical Biology and Medicine</i> , 2020, 159, S88.	1.3	0
4039	Comparison and suggestion of indicators of concentrations associated with CO <sub>2</sub> in seawater considering biological activity. <i>International Journal of Greenhouse Gas Control</i> , 2020, 102, 103152.	2.3	3
4040	Kocuria kristinae infection associated with short bowel syndrome: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 77, 276-278.	0.2	1
4041	A Pilot Longitudinal Study of 3-Dimensional Head and Neck Kinematics During Functional Tasks in Individuals With Chronic Idiopathic Neck Pain Either Wait-Listed for or Receiving Chiropractic Spinal Manipulative Therapy With Exercise. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2020, 43, 490-505.	0.4	3
4042	Infographics Improve Comprehension and Recall at the Orthopaedic Journal Club. <i>Journal of Surgical Education</i> , 2021, 78, 1345-1349.	1.2	12
4043	A neural network based inverse system control strategy to decouple turbine power in multi-reactor and multi-turbine nuclear power plant. <i>Progress in Nuclear Energy</i> , 2020, 129, 103500.	1.3	6
4044	Landing Error Scoring System scores change with knowledge of scoring criteria and prior performance. <i>Physical Therapy in Sport</i> , 2020, 46, 155-161.	0.8	4
4045	Diazoalkane decay kinetics from UVA-active protein labelling molecules: Trifluoromethyl phenyl diazirines. <i>Results in Chemistry</i> , 2020, 2, 100066.	0.9	7
4046	NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 593578.	1.3	26
4047	Comparison of using p-nc-SiOx:H and p-nc-Si:H as window layer in amorphous silicon based solar cells. <i>Optik</i> , 2020, 222, 165444.	1.4	3
4048	Tunneling Nanotubes Mediate Adaptation of Glioblastoma Cells to Temozolomide and Ionizing Radiation Treatment. <i>IScience</i> , 2020, 23, 101450.	1.9	35
4049	Remotely sensed canopy resistance model for analyzing the stomatal behavior of environmentally-stressed winter wheat. <i>ISPRS Journal of Photogrammetry and Remote Sensing</i> , 2020, 168, 197-207.	4.9	11
4050	U-Pb zircon geochronology and geochemistry of metavolcanics and associated iron ores of the magnetite-rich BIF deposits in the Western Kunlun orogenic belt: Constraints on the depositional age, origin and tectonic setting. <i>Ore Geology Reviews</i> , 2020, 126, 103751.	1.1	9
4051	Traitement de la paralysie radiale par transferts tendineux avec r�animation de l�extensor carpi ulnaris: technique et r�ultats. <i>Revue De Chirurgie Orthopedique Et Traumatologique</i> , 2020, 106, 152-156.	0.0	0
4052	Physiological performance in aquaculture: Using physiology to help define optimal conditions for growth and environmental tolerance. <i>Fish Physiology</i> , 2020, , 83-121.	0.2	18
4053	Evidence on the neuroprotective properties of brimonidine in glaucoma. <i>Progress in Brain Research</i> , 2020, 257, 155-166.	0.9	6
4054	Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma. <i>Scientific Reports</i> , 2020, 10, 19542.	1.6	70

#	ARTICLE	IF	CITATIONS
4055	Botulinum toxin injections minimally affect modelled muscle forces during gait in children with cerebral palsy. <i>Gait and Posture</i> , 2020, 82, 54-60.	0.6	9
4056	Microstructure-based approach to the evaluation of welded joints of bainitic rails designed for high-speed railways. <i>Journal of Constructional Steel Research</i> , 2020, 175, 106372.	1.7	12
4057	Descripci3n de la cohorte PROCOAC (PROspective COhort of A CoruAa): Cohorte prospectiva espaAola para el estudio de la osteoartritis. <i>ReumatologAa ClAnica</i> , 2022, 18, 100-104.	0.2	10
4059	A platform for initial testing of multiple camouflage patterns. <i>Defence Technology</i> , 2021, 17, 1833-1839.	2.1	5
4060	Altered hand proprioception following regional anesthesia as a cause of traumatic jersey finger: Report of two cases. <i>Hand Surgery and Rehabilitation</i> , 2020, 39, 582-584.	0.2	2
4061	Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells. <i>Research in Veterinary Science</i> , 2020, 133, 313-317.	0.9	4
4064	Quantitative estimates in reiterated homogenization. <i>Journal of Functional Analysis</i> , 2020, 279, 108759.	0.7	6
4065	Design of Gr/2024Al composite and Ti6Al4V titanium alloy joint brazed using AgCuSnTi filler and Ni/Nb/Ni composite interlayers. <i>Journal of Manufacturing Processes</i> , 2020, 58, 67-74.	2.8	2
4066	Removal of chromium from aqueous solution by porous Bi <sub>2</sub> MoO <sub>6</sub> @BiOCl nanostructure. <i>Journal of Solid State Chemistry</i> , 2020, 292, 121719.	1.4	28
4067	T-cell receptor antibodies expression in benign and malignant cutaneous lymphoid infiltrates in comparison with T-cell receptor gene rearrangement and its diagnostic utility in borderline cases. <i>Pathology Research and Practice</i> , 2020, 216, 153279.	1.0	0
4068	Site-Specific DNA Demethylation as a Potential Target for Cancer Epigenetic Therapy. <i>Epigenetics Insights</i> , 2020, 13, 251686572096480.	0.6	9
4069	Occurrence of Glioma in Pregnant Patients: An Institutional Case Series and Review of the Literature. <i>Anticancer Research</i> , 2020, 40, 3453-3457.	0.5	6
4070	Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5631.	1.8	22
4071	NF- $\kappa$ B inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF- $\kappa$ B(p65) and actin cytoskeleton regulatory pathways. <i>Scientific Reports</i> , 2020, 10, 13352.	1.6	41
4072	Prognostic Nomograms for Primary High-Grade Glioma Patients in Adult: A Retrospective Study Based on the SEER Database. <i>BioMed Research International</i> , 2020, 2020, 1-19.	0.9	9
4073	MGMT Status as a Clinical Biomarker in Glioblastoma. <i>Trends in Cancer</i> , 2020, 6, 380-391.	3.8	131
4074	Nonlinear Dose-Response Modeling of High-Throughput Screening Data Using an Evolutionary Algorithm. <i>Dose-Response</i> , 2020, 18, 155932582092673.	0.7	4
4075	Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis. <i>Frontiers in Genetics</i> , 2020, 11, 775.	1.1	12

#	ARTICLE	IF	CITATIONS
4076	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5297-5303.	3.2	67
4077	Promoter Methylation of DNA Repair Genes Predicts Disease-free Survival of Gastric Adenocarcinoma after Adjuvant Radiotherapy. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 109-117.	2.0	4
4078	Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade. <i>Frontiers in Oncology</i> , 2020, 10, 840.	1.3	41
4079	Release the ballast: Glioblastoma rises above radiation therapy by exporting miR-603 in extracellular vesicles to become treatment-resistant. <i>EBioMedicine</i> , 2020, 56, 102788.	2.7	1
4080	DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. <i>Cancers</i> , 2020, 12, 2098.	1.7	57
4081	MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. <i>Nature Communications</i> , 2020, 11, 3883.	5.8	110
4082	Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2817-2828.	1.2	18
4083	Autophagy as a Potential Therapy for Malignant Glioma. <i>Pharmaceuticals</i> , 2020, 13, 156.	1.7	56
4084	Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 149, 55-64.	1.4	19
4085	Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells. <i>Cell Death and Disease</i> , 2020, 11, 577.	2.7	3
4086	DNA CpG methylation in sequential glioblastoma specimens. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2885-2896.	1.2	5
4087	NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors—Histone Mutated Midline Glioma Workshop Proceedings <sup>®</sup> . <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa007.	0.4	4
4088	DNA methylation analysis with methylation-sensitive high-resolution melting (MS-HRM) reveals gene panel for glioma characteristics. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 1303-1314.	1.9	21
4091	Novel Application for G Protein-Biased Mu Opioid Receptor Agonists in Opioid Relapse Prevention. <i>Biological Psychiatry</i> , 2020, 88, 896-897.	0.7	3
4092	Effect Of Low-Dose Radiotherapy On Abscopal Responses To Hypofractionated Radiotherapy And Anti-PD1 In Mice and NSCLC Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e563.	0.4	3
4093	Phenotypic selection through cell death: stochastic modelling of O-6-methylguanine-DNA methyltransferase dynamics. <i>Royal Society Open Science</i> , 2020, 7, 191243.	1.1	2
4094	<p>&lt;p>End Processing Factor APLF Promotes NHEJ Efficiency and Contributes to TMZ- and Ionizing Radiation-Resistance in Glioblastoma Cells</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10593-10605.	1.0	8
4096	An advanced in silico drug discovery platform, 4HF Data Miner for identifying novel targets for tumors and tumor-stroma. <i>European Journal of Cancer</i> , 2020, 138, S27.	1.3	1



#	ARTICLE	IF	CITATIONS
4097	Fluorescent labeling of extracellular vesicles. <i>Methods in Enzymology</i> , 2020, 645, 15-42.	0.4	13
4098	A single amino acid substitution converts a histidine decarboxylase to an imidazole acetaldehyde synthase. <i>Archives of Biochemistry and Biophysics</i> , 2020, 693, 108551.	1.4	2
4099	Effect of Osteoarthritis on Prefrontal Cortical Activation Patterns During Dual Task Walking in Older Women. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, e63.	0.5	0
4101	Hybrid engineered dental composites by multiscale reinforcements with chitosan-integrated halloysite nanotubes and S-glass fibers. <i>Composites Part B: Engineering</i> , 2020, 202, 108448.	5.9	19
4102	Brief communication: Impact of negative pressure dressing on surgical incisions following caesarean section. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 253, 343-344.	0.5	0
4103	How Sugar Affects Your Body. 2019. <i>Journal of Nutrition Education and Behavior</i> , 2020, 52, 1077-1078.	0.3	0
4104	A sensor framework for combined data streams and in-situ characterization of machining processes. <i>Procedia CIRP</i> , 2020, 93, 868-872.	1.0	2
4105	Spectrum Sensing for Smart Embedded Devices in Cognitive Networks using Machine Learning Algorithms. <i>Procedia Computer Science</i> , 2020, 176, 2404-2413.	1.2	12
4106	The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns. <i>Neuro-Oncology</i> , 2020, 22, 1721-1722.	0.6	1
4107	Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells. <i>Anticancer Research</i> , 2020, 40, 5141-5149.	0.5	0
4108	The effect of temozolomide in combination with doxorubicin in glioblastoma cells <i>in vitro</i> . <i>Journal of Immunoassay and Immunochemistry</i> , 2020, 41, 1033-1043.	0.5	12
4109	Feasibility of removable balloon implant for simultaneous magnetic nanoparticle heating and HDR brachytherapy of brain tumor resection cavities. <i>International Journal of Hyperthermia</i> , 2020, 37, 1189-1201.	1.1	3
4110	Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital. <i>Scientific Reports</i> , 2020, 10, 18445.	1.6	20
4111	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. <i>Neuro-Oncology</i> , 2020, 22, iv1-iv96.	0.6	1,175
4112	Microglia-Centered Combinatorial Strategies Against Glioblastoma. <i>Frontiers in Immunology</i> , 2020, 11, 571951.	2.2	17
4113	Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 157, 108-120.	2.0	39
4114	Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors. <i>Scientific Reports</i> , 2020, 10, 16162.	1.6	12
4115	Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 17768.	1.6	15

#	ARTICLE	IF	CITATIONS
4116	Tailoring precision immunotherapy: coming to a clinic soon?. <i>ESMO Open</i> , 2020, 5, e000631.	2.0	8
4117	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1147-1158.	1.3	8
4118	Pentraxin 3 Promotes Glioblastoma Progression by Negative Regulating Cells Autophagy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 795.	1.8	17
4119	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. <i>PLoS ONE</i> , 2020, 15, e0238238.	1.1	7
4120	Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1031-1037.	0.9	15
4121	Prognostic and Predictive Value of an Immunoscore Signature in Glioblastoma Multiform. <i>Frontiers in Genetics</i> , 2020, 11, 514363.	1.1	8
4122	Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression. <i>Journal of Natural Products</i> , 2020, 83, 3021-3029.	1.5	13
4123	The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. <i>BMC Cancer</i> , 2020, 20, 897.	1.1	26
4124	Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 562798.	1.6	85
4125	MicroRNA miR-100 Decreases Glioblastoma Growth by Targeting SMARCA5 and ErbB3 in Tumor-Initiating Cells. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382096074.	0.8	14
4126	m6A modification in RNA: biogenesis, functions and roles in gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 192.	3.5	94
4127	Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 85.	1.3	43
4128	The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology. <i>International Journal of Hyperthermia</i> , 2020, 37, 27-34.	1.1	16
4129	MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. <i>Neuro-Oncology</i> , 2020, 22, 1553-1554.	0.6	2
4130	Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma. <i>Frontiers in Pharmacology</i> , 2020, 11, 584652.	1.6	10
4131	Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance. <i>Biomedicines</i> , 2020, 8, 339.	1.4	11
4132	Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. <i>Cancers</i> , 2020, 12, 2583.	1.7	6
4133	Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3807-3820.	1.8	16

#	ARTICLE	IF	CITATIONS
4134	Radioresistance in Glioblastoma and the Development of Radiosensitizers. <i>Cancers</i> , 2020, 12, 2511.	1.7	77
4135	Wnt/ $\beta$ -catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. <i>Cell Death and Disease</i> , 2020, 11, 771.	2.7	57
4136	An Experimentally Defined Hypoxia Gene Signature in Glioblastoma and Its Modulation by Metformin. <i>Biology</i> , 2020, 9, 264.	1.3	7
4137	Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1742-1756.	0.6	18
4138	Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa093.	0.4	5
4139	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 14819.	1.6	13
4140	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 785-795.	1.1	23
4141	Utilizing systematic reviews and meta-analyses effectively to evaluate brain tumor biomarkers. <i>Biomarkers in Medicine</i> , 2020, 14, 817-820.	0.6	2
4142	Establishment of age group classification for risk stratification in glioma patients. <i>BMC Neurology</i> , 2020, 20, 310.	0.8	59
4143	The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status. <i>Cell Death and Disease</i> , 2020, 11, 668.	2.7	21
4144	Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. <i>Biomedicines</i> , 2020, 8, 294.	1.4	39
4145	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. <i>Cancers</i> , 2020, 12, 2317.	1.7	37
4146	Viral Vectors as Gene Therapy Agents for Treatment of Glioblastoma. <i>Cancers</i> , 2020, 12, 3724.	1.7	14
4147	A Hematological-Related Prognostic Scoring System for Patients With Newly Diagnosed Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 591352.	1.3	3
4148	Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres. <i>Journal of Translational Medicine</i> , 2020, 18, 482.	1.8	4
4149	The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. <i>Frontiers in Neuroscience</i> , 2020, 14, 603647.	1.4	24
4150	Downregulation of Brain Enriched Type 2 MAGEs Is Associated With Immune Infiltration and Poor Prognosis in Glioma. <i>Frontiers in Oncology</i> , 2020, 10, 573378.	1.3	10
4151	Non-Coding RNAs as Mediators of Epigenetic Changes in Malignancies. <i>Cancers</i> , 2020, 12, 3657.	1.7	64

#	ARTICLE	IF	CITATIONS
4152	Cyclodextrin-Based Nanostructure Efficiently Delivers siRNA to Glioblastoma Cells Preferentially via Macropinocytosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9306.	1.8	9
4153	Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 27, 107815522096861.	0.5	0
4154	Recomendaciones para el tratamiento nutrometabólico especializado del paciente crónico: consecuencias de la desnutrición en el paciente crónico y valoración del estado nutricional. Grupo de Trabajo de Metabolismo y Nutrición de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC). <i>Medicina Intensiva</i> , 2020, 44, 19-23.	0.4	1
4155	Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa082.	0.4	29
4156	Relationship between BRAF V600E and KRAS mutations in stool for identifying colorectal cancer: A cross-sectional study. <i>Annals of Medicine and Surgery</i> , 2020, 60, 121-125.	0.5	2
4157	Cell Biology: An Open Solution for Closed Mitosis. <i>Current Biology</i> , 2020, 30, R942-R944.	1.8	1
4159	White matter structural network disturbances in first-episode, drug-naïve adolescents with generalized anxiety disorder. <i>Journal of Psychiatric Research</i> , 2020, 130, 394-404.	1.5	9
4160	Large Subfoveal Vitelliform Lesions in a Case of Pentosan Polysulfate Maculopathy. <i>Ophthalmology</i> , 2020, 127, 1641.	2.5	7
4162	Follow the evacuation signs or surrounding people during building evacuation, an experimental study. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2020, 560, 125156.	1.2	22
4164	39: Impact of Smoking Status and Pack Year History on Outcomes of Early Stage Non-Small Cell Lung Cancers Treated with Stereotactic Ablative Radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 150, S20.	0.3	0
4165	Application cases of biological transformation in manufacturing technology. <i>CIRP Journal of Manufacturing Science and Technology</i> , 2020, 31, 68-77.	2.3	15
4166	Thyroid function in adults patients undergoing cardiac surgery: A pilot study. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 506-507.	0.5	0
4167	The impact of body composition on mortality in hematopoietic stem cell transplantation. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 544.	0.5	0
4168	Frequency and determinants of malnutrition in hospitalised children with heart diseases. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 577.	0.5	0
4169	Alteration in the profile of fecal bile acids after bypass in Y-Roux (RYGB) in patients with obesity and type 2 diabetes who did not undergo cholecystectomy may be involved with the improvement of postoperative glycemic homeostasis. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 651.	0.5	0
4171	Ectopic pancreas: A rare cause of occult gastrointestinal bleeding. <i>Annals of Medicine and Surgery</i> , 2020, 59, 41-43.	0.5	3
4172	Arrhythmias Involving Variants of Accessory Pathways. <i>Cardiac Electrophysiology Clinics</i> , 2020, 12, 505-518.	0.7	1
4173	An efficient and modular modeling for launch dynamics of tubed rockets on a moving launcher. <i>Defence Technology</i> , 2021, 17, 2011-2026.	2.1	7

#	ARTICLE	IF	CITATIONS
4174	Succession mechanism of microbial community with high species diversity in nutrient-deficient environments with low-dose ionizing radiation. <i>Ecological Modelling</i> , 2020, 435, 109270.	1.2	5
4175	Risk factors for stunting among children in Banggai Regency, Indonesia. <i>EnfermerÃa ClÃnica</i> , 2020, 30, 149-152.	0.1	1
4176	Association of personal exposure to power-frequency magnetic fields with pregnancy outcomes among women seeking fertility treatment in a longitudinal cohort study. <i>Fertility and Sterility</i> , 2020, 114, 1058-1066.	0.5	2
4178	Maladaptation: When Adaptation to Climate Change Goes Very Wrong. <i>One Earth</i> , 2020, 3, 409-414.	3.6	166
4179	Blended Ag nanofluids with optimized optical properties to regulate the performance of PV/T systems. <i>Solar Energy</i> , 2020, 208, 623-636.	2.9	24
4180	Greenhouse gas emissions from high-speed rail infrastructure construction in Korea. <i>Transportation Research, Part D: Transport and Environment</i> , 2020, 87, 102514.	3.2	19
4181	Effect of moringa leaves during pregnancy on growth and morbidity in 0â€“5 months. <i>EnfermerÃa ClÃnica</i> , 2020, 30, 61-65.	0.1	1
4182	Rerouting Europe's gas transit landscape - Effects of Russian natural gas infrastructure strategy on the V4. <i>Energy Policy</i> , 2020, 146, 111748.	4.2	12
4183	Coreâ€“shell Au@Se nanoparticles embedded in cellulose acetate/polyvinylidene fluoride scaffold for wound healing. <i>Journal of Materials Research and Technology</i> , 2020, 9, 15045-15056.	2.6	38
4186	Evaluating the properties of zinc production wastes as filler and their effects on asphalt mastic. <i>Construction and Building Materials</i> , 2020, 265, 120748.	3.2	14
4187	Snapshot of Equine Dentistry: Past, Present, and Future. <i>Veterinary Clinics of North America Equine Practice</i> , 2020, 36, xi-xiii.	0.3	0
4192	Why Racial Justice Matters in Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2020, 5, 7-14.	0.6	0
4193	The Practice of Anti-racist Science Requires an Internationalist Perspective. <i>American Journal of Human Genetics</i> , 2020, 107, 793-796.	2.6	5
4194	A Roadmap to Success â€“ One Workgroup's Approach to Improving Internal Hand Hygiene Compliance in an Acute Care Medical Center. <i>American Journal of Infection Control</i> , 2020, 48, S10-S11.	1.1	0
4195	19 Factors Associated with County-Level SARS-CoV-2 Testing Volume in Nine States. <i>Annals of Emergency Medicine</i> , 2020, 76, S7-S8.	0.3	0
4196	303 Assessing Resident Communication With Faculty from Multiple Specialties in Pediatric Simulation Designed to Provide Multi-Source Feedback. <i>Annals of Emergency Medicine</i> , 2020, 76, S116-S117.	0.3	0
4197	343 Motivational Factors That Influence Adoption of Innovations. <i>Annals of Emergency Medicine</i> , 2020, 76, S132.	0.3	0
4199	Facile synthesis of three-dimensional porous graphene nanostructures from coordination complexes for supercapacitor electrode. <i>Advanced Powder Technology</i> , 2020, 31, 4157-4165.	2.0	4

#	ARTICLE	IF	CITATIONS
4200	The Legacy of Hermann Staudinger: Covalently Linked Macromolecules. <i>CheM</i> , 2020, 6, 2855-2861.	5.8	11
4201	Learning rules. <i>Current Biology</i> , 2020, 30, R1289-R1290.	1.8	0
4202	Green tea ( <i>Camellia sinensis</i> ) extract inhibits biofilm formation in acyl homoserine lactone-producing, antibiotic-resistant <i>Morganella morganii</i> isolated from Pasig River, Philippines. <i>Heliyon</i> , 2020, 6, e05284.	1.4	7
4203	Using an extended Technology Acceptance Model to understand students' use of e-learning during Covid-19: Indonesian sport science education context. <i>Heliyon</i> , 2020, 6, e05410.	1.4	157
4204	A Softer Approach to Quantitative Blood Loss Measurement. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S24.	0.2	0
4205	Innovative Approach to Improving Efficiency Through an Early-Induction Unit. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S36.	0.2	0
4206	A Comparison Study of Patient Characteristics and Outcomes for Use of Nitrous Oxide During Labor. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S51.	0.2	0
4207	Challenging the Status Quo to Innovate the Future of Nurse Productivity and Benchmarking. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2020, 49, S82.	0.2	1
4211	Is enough, enough? SEND data processing considerations when changing the logging rate. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020, 105, 106840.	0.3	0
4212	Effect of remote ischaemic conditioning on coagulation function as measured by rotational thromboelastometry and whole blood impedance aggregometry in off-pump coronary artery bypass surgery: a randomised controlled trial. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, S14-S15.	0.6	0
4213	Resolution of strain abnormalities during extracorporeal rewarming from accidental hypothermic cardiac arrest: a case report. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, S49-S50.	0.6	0
4214	Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics. <i>Neuro-Oncology</i> , 2020, 22, 1713-1714.	0.6	0
4216	Infective endocarditis following transcatheter aortic valve implantation. <i>Annales De Cardiologie Et D'Angeiologie</i> , 2020, 69, 204-206.	0.3	0
4217	Impulsivity facets and cognitive distortions associated with problem gambling: Differences between ADHD and non-ADHD gamblers. <i>Revue Europeenne De Psychologie Appliquee</i> , 2020, 70, 100559.	0.4	5
4218	Ex vivo ultrasonic samples of human brain tumors in the molecular era. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa014.	0.4	2
4219	The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme. <i>Cancers</i> , 2020, 12, 1099.	1.7	26
4220	Improved 3-year survival rates for glioblastoma multiforme are associated with trends in treatment: analysis of the national cancer database from 2004 to 2013. <i>Journal of Neuro-Oncology</i> , 2020, 148, 69-79.	1.4	14
4221	Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas. <i>Neuro-Oncology</i> , 2020, 22, 928-935.	0.6	62

#	ARTICLE	IF	CITATIONS
4222	Genomics models in radiotherapy: From mechanistic to machine learning. <i>Medical Physics</i> , 2020, 47, e203-e217.	1.6	17
4223	Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 716-724.	0.4	7
4224	Past, Present and Future of Epigenetics in Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 1218.	1.7	21
4225	Development of a peptide-based delivery platform for targeting malignant brain tumors. <i>Biomaterials</i> , 2020, 252, 120105.	5.7	15
4226	Role of molecular biomarkers in glioma resection: a systematic review. <i>Chinese Neurosurgical Journal</i> , 2020, 6, 18.	0.3	9
4227	Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2020, 26, 4031-4039.	3.2	27
4228	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1003.	3.4	805
4229	Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. <i>Journal of Neuro-Oncology</i> , 2020, 148, 17-27.	1.4	5
4230	NF-kappa B interacting long noncoding RNA enhances the Warburg effect and angiogenesis and is associated with decreased survival of patients with gliomas. <i>Cell Death and Disease</i> , 2020, 11, 323.	2.7	18
4231	RNA modifications in brain tumorigenesis. <i>Acta Neuropathologica Communications</i> , 2020, 8, 64.	2.4	15
4232	Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition. <i>Journal of the Royal Society Interface</i> , 2020, 17, 20190722.	1.5	16
4233	A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression. <i>RSC Advances</i> , 2020, 10, 17561-17570.	1.7	3
4234	Management of glioblastoma: State of the art and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 299-312.	157.7	969
4235	Anticancer Activity of Amb4269951, a Choline Transporter-Like Protein 1 Inhibitor, in Human Glioma Cells. <i>Pharmaceuticals</i> , 2020, 13, 104.	1.7	12
4236	Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas. <i>Advanced Biology</i> , 2020, 4, 2000029.	3.0	12
4237	Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation. <i>Frontiers in Oncology</i> , 2020, 10, 596.	1.3	13
4238	The clinical characteristics and prognostic factors of multiple lesions in glioblastomas. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 105891.	0.6	8
4239	Applications of radiomics and machine learning for radiotherapy of malignant brain tumors. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 856-867.	1.0	76

#	ARTICLE	IF	CITATIONS
4240	Hemoglobin Levels and Red Blood Cells Distribution Width Highlights Glioblastoma Patients Subgroup With Improved Median Overall Survival. <i>Frontiers in Oncology</i> , 2020, 10, 432.	1.3	15
4241	Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival. <i>APL Bioengineering</i> , 2020, 4, 026106.	3.3	5
4242	The biological and clinical basis for early referral of low grade glioma patients to a surgical neuro-oncologist. <i>Journal of Clinical Neuroscience</i> , 2020, 78, 20-29.	0.8	3
4243	Molecular characteristics of diffuse lower grade gliomas: what neurosurgeons need to know. <i>Acta Neurochirurgica</i> , 2020, 162, 1929-1939.	0.9	10
4244	IDH-Mutant Gliomas. , 2020, , .		4
4245	Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes. <i>Neurological Sciences</i> , 2020, 41, 3625-3632.	0.9	4
4246	Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 948-952.	0.6	6
4247	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. <i>Clinical Cancer Research</i> , 2020, 26, 5287-5296.	3.2	88
4248	Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 871-893.	1.8	52
4249	New strategies for managing adult gliomas. <i>Journal of Neurology</i> , 2021, 268, 3666-3674.	1.8	14
4250	Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 473-480.	1.4	2
4251	The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status. <i>Applied Radiation and Isotopes</i> , 2020, 163, 109204.	0.7	9
4252	Genomic analyses of early responses to radiation in glioblastoma reveal new alterations at transcription, splicing, and translation levels. <i>Scientific Reports</i> , 2020, 10, 8979.	1.6	11
4253	&lt;p&gt;Upregulation of miR-340 Inhibits Tumor Growth and Mesenchymal Transition via Targeting c-MET in Glioblastoma&lt;p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 3343-3352.	0.9	3
4254	Next Generation Sequencing and Machine Learning Technologies Are Painting the Epigenetic Portrait of Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 798.	1.3	26
4255	A Radiosensitivity Gene Signature and XPO1 Predict Clinical Outcomes for Glioma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 871.	1.3	5
4256	Apelin Controls Angiogenesis-Dependent Glioblastoma Growth. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4179.	1.8	19
4257	Glioblastomas located in proximity to the subventricular zone (SVZ) exhibited enrichment of gene expression profiles associated with the cancer stem cell state. <i>Journal of Neuro-Oncology</i> , 2020, 148, 455-462.	1.4	24



#	ARTICLE	IF	CITATIONS
4258	Computational identification and characterization of glioma candidate biomarkers through multi-omics integrative profiling. <i>Biology Direct</i> , 2020, 15, 10.	1.9	22
4259	A Neural Network Approach to Identify the Peritumoral Invasive Areas in Glioblastoma Patients by Using MR Radiomics. <i>Scientific Reports</i> , 2020, 10, 9748.	1.6	25
4260	Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. <i>Frontiers in Immunology</i> , 2020, 11, 1402.	2.2	156
4261	Landscape of Genomic Alterations in <i>IDH</i> Wild-Type Glioblastoma Identifies PI3K as a Favorable Prognostic Factor. <i>JCO Precision Oncology</i> , 2020, 4, 575-584.	1.5	15
4262	PARP inhibition suppresses the emergence of temozolomide resistance in a model system. <i>Journal of Neuro-Oncology</i> , 2020, 148, 463-472.	1.4	7
4263	Modeling Oncolytic Viral Therapy, Immune Checkpoint Inhibition, and the Complex Dynamics of Innate and Adaptive Immunity in Glioblastoma Treatment. <i>Frontiers in Physiology</i> , 2020, 11, 151.	1.3	33
4264	Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 263-276.	2.6	21
4265	Natural products as promising targets in glioblastoma multiforme: a focus on NF- $\kappa$ B signaling pathway. <i>Pharmacological Reports</i> , 2020, 72, 285-295.	1.5	38
4266	Single-molecule analysis of nucleic acid biomarkers – A review. <i>Analytica Chimica Acta</i> , 2020, 1115, 61-85.	2.6	34
4267	Radiomics prognostication model in glioblastoma using diffusion- and perfusion-weighted MRI. <i>Scientific Reports</i> , 2020, 10, 4250.	1.6	50
4268	Targeting Epigenetic Dependencies in Solid Tumors: Evolutionary Landscape Beyond Germ Layers Origin. <i>Cancers</i> , 2020, 12, 682.	1.7	7
4269	Artificial intelligence in glioma imaging: challenges and advances. <i>Journal of Neural Engineering</i> , 2020, 17, 021002.	1.8	26
4270	Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 653-661.	1.4	16
4271	Expression of Olig2, Nestin, NogoA and AQP4 have no impact on overall survival in IDH-wildtype glioblastoma. <i>PLoS ONE</i> , 2020, 15, e0229274.	1.1	9
4272	<p></p>Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 719-731.	1.0	11
4273	Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol through the Modulation of EGFR and CSC Signaling Pathways. <i>Cells</i> , 2020, 9, 681.	1.8	23
4274	MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. <i>Neuro-Oncology</i> , 2020, 22, 1580-1590.	0.6	55
4275	Tumor-Specific T Cell Activation in Malignant Brain Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 205.	2.2	36

#	ARTICLE	IF	CITATIONS
4276	Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 45.	1.8	44
4277	Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma—Case Report and Review of the Literature. <i>Frontiers in Endocrinology</i> , 2020, 11, 61.	1.5	20
4278	MicroRNA-144 represses gliomas progression and elevates susceptibility to Temozolomide by targeting CAV2 and FGF7. <i>Scientific Reports</i> , 2020, 10, 4155.	1.6	15
4279	Why Great Mitotic Inhibitors Make Poor Cancer Drugs. <i>Trends in Cancer</i> , 2020, 6, 924-941.	3.8	33
4280	A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status. <i>Molecular Biology Reports</i> , 2020, 47, 5263-5271.	1.0	1
4281	Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy. <i>Scientific Reports</i> , 2020, 10, 10783.	1.6	23
4282	Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa046.	0.4	7
4283	Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. <i>Nature Communications</i> , 2020, 11, 3288.	5.8	44
4284	Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance. <i>Cancers</i> , 2020, 12, 1707.	1.7	18
4285	Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 129.	3.5	27
4286	Current status of development of methylation biomarkers for in vitro diagnostic IVD applications. <i>Clinical Epigenetics</i> , 2020, 12, 100.	1.8	44
4287	Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 293-316.	0.6	5
4288	Interferon- $\beta$ exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa043.	0.4	3
4289	Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz060.	0.4	8
4290	Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas. <i>Cancers</i> , 2020, 12, 1817.	1.7	43
4291	Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 342-359.	1.3	19
4292	Novel strategies of Raman imaging for monitoring the therapeutic benefit of temozolomide in glioblastoma. <i>Journal of Molecular Structure</i> , 2020, 1217, 128381.	1.8	9
4293	Liposome Consolidated with Cyclodextrin Provides Prolonged Drug Retention Resulting in Increased Drug Bioavailability in Brain. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4408.	1.8	19

#	ARTICLE	IF	CITATIONS
4294	Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 639-646.	1.1	2
4295	Immunotherapy for glioma: Current management and future application. <i>Cancer Letters</i> , 2020, 476, 1-12.	3.2	351
4296	Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. <i>Gastroenterology</i> , 2020, 158, 1682-1697.e1.	0.6	58
4297	Extracellular Vesicles in Glioblastoma Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 3137.	2.2	88
4298	Integrative analyses identify a DNA damage repair gene signature for prognosis prediction in lower grade gliomas. <i>Future Oncology</i> , 2020, 16, 367-382.	1.1	11
4299	Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas: A German Survey. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e660-e675.	1.8	34
4300	Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Glioblastoma. <i>Cancers</i> , 2020, 12, 520.	1.7	38
4301	Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1507.	1.8	17
4302	Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. <i>PLoS ONE</i> , 2020, 15, e0229534.	1.1	13
4303	Advancements in predicting outcomes in patients with glioma: a surgical perspective. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 167-177.	1.1	9
4304	EGFRVIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. <i>Oncogene</i> , 2020, 39, 3041-3055.	2.6	42
4305	Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. <i>Frontiers in Oncology</i> , 2020, 10, 66.	1.3	4
4306	Immunohistochemistry for O6-methylguanin-DNA methyltransferase in glioblastomas defined by WHO2016: Correlation with promoter methylation status and patients' progression-free survival with the cut-off value determined by ROC analysis. <i>Journal of Clinical Neuroscience</i> , 2020, 73, 231-236.	0.8	0
4307	DNA inhibitors for the treatment of brain tumors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 195-207.	1.5	3
4308	Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 478-492.	1.8	59
4309	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. <i>Frontiers in Oncology</i> , 2019, 9, 1568.	1.3	18
4310	The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study. <i>Genes</i> , 2020, 11, 173.	1.0	3
4311	The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation. <i>Frontiers in Oncology</i> , 2019, 9, 1569.	1.3	16

#	ARTICLE	IF	CITATIONS
4312	Glioblastome Multiforme: A Bibliometric Analysis. <i>World Neurosurgery</i> , 2020, 136, 270-282.	0.7	65
4313	Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 685.	1.8	18
4314	A robust two-gene signature for glioblastoma survival prediction. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3593-3605.	1.2	7
4315	Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3K <sup>Î³</sup> inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. <i>Brain Tumor Pathology</i> , 2020, 37, 41-49.	1.1	37
4316	Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma. <i>Molecules</i> , 2020, 25, 490.	1.7	31
4317	Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells. <i>Nature Communications</i> , 2020, 11, 550.	5.8	45
4318	Efficacy of sequential radiation and chemotherapy in treating glioblastoma with poor performance status. <i>Journal of Neuro-Oncology</i> , 2020, 147, 91-95.	1.4	1
4319	Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study. <i>BMC Cancer</i> , 2020, 20, 79.	1.1	8
4320	Relationships between recurrence patterns and subventricular zone involvement or CD133 expression in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 489-499.	1.4	18
4321	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 843-859.	0.5	51
4322	O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1547.	1.3	140
4323	Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 495.	3.4	325
4324	Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1004-1009.	1.0	16
4325	A quantitative framework for modeling COVID-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. <i>Neuro-Oncology</i> , 2020, 22, 918-927.	0.6	15
4326	Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification. <i>Cancer</i> , 2020, 126, 3255-3264.	2.0	19
4327	Clinical and Biological Significances of a Methyltransferase-Related Signature in Diffuse Glioma. <i>Frontiers in Oncology</i> , 2020, 10, 508.	1.3	2
4328	Genomic copy number variation correlates with survival outcomes in WHO grade IV glioma. <i>Scientific Reports</i> , 2020, 10, 7355.	1.6	6
4329	The Emerging Roles of RNA Modifications in Glioblastoma. <i>Cancers</i> , 2020, 12, 736.	1.7	83

#	ARTICLE	IF	CITATIONS
4330	Expression and prognostic value of mRNAs in lower grade glioma with MGMT promoter methylated. <i>Journal of Clinical Neuroscience</i> , 2020, 75, 45-51.	0.8	7
4331	Circulating microRNAs in oncogenic viral infections: potential diagnostic biomarkers. <i>SN Applied Sciences</i> , 2020, 2, 1.	1.5	16
4332	Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy. <i>International Journal of Pharmaceutics</i> , 2020, 581, 119283.	2.6	29
4333	The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. <i>Trends in Genetics</i> , 2020, 36, 429-441.	2.9	58
4334	Deep Learning AI Applications in the Imaging of Glioma. <i>Topics in Magnetic Resonance Imaging</i> , 2020, 29, 115-00.	0.7	47
4335	Integrated Analysis to Evaluate the Prognostic Value of Signature mRNAs in Glioblastoma Multiforme. <i>Frontiers in Genetics</i> , 2020, 11, 253.	1.1	11
4336	RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the Proton-Coupled Folate Carrier. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2717.	1.8	5
4337	Engineering a Biodegradable Nanocarrier for Enhancing the Response of T98G Cells to Temozolomide. <i>ACS Applied Bio Materials</i> , 2020, 3, 3337-3344.	2.3	5
4338	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
4339	Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. <i>PLoS ONE</i> , 2020, 15, e0230492.	1.1	10
4340	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). <i>Neuro-Oncology</i> , 2020, 22, 1851-1861.	0.6	64
4341	The association between 11C-methionine uptake, IDH gene mutation, and MGMT promoter methylation in patients with grade II and III gliomas. <i>Clinical Radiology</i> , 2020, 75, 622-628.	0.5	4
4342	Enhanced fatty acid oxidation provides glioblastoma cells metabolic plasticity to accommodate to its dynamic nutrient microenvironment. <i>Cell Death and Disease</i> , 2020, 11, 253.	2.7	67
4343	Preoperative Survival Prediction in Patients With Glioblastoma by Routine Inflammatory Laboratory Parameters. <i>Anticancer Research</i> , 2020, 40, 1161-1166.	0.5	16
4344	Human Glioma Cells Acquire Temozolomide Resistance After Repeated Drug Exposure <i>via</i> DNA Mismatch Repair Dysfunction. <i>Anticancer Research</i> , 2020, 40, 1315-1323.	0.5	10
4345	Fundamentals of Radiation Oncology for Neurologic Imaging. <i>Radiographics</i> , 2020, 40, 827-858.	1.4	10
4346	Integrated Analysis of RNA-Binding Proteins in Glioma. <i>Cancers</i> , 2020, 12, 892.	1.7	48
4347	Impact of initial midline shift in glioblastoma on survival. <i>Neurosurgical Review</i> , 2021, 44, 1401-1409.	1.2	11

#	ARTICLE	IF	CITATIONS
4348	Radiomics in neuro-oncology: Basics, workflow, and applications. <i>Methods</i> , 2021, 188, 112-121.	1.9	85
4349	Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study. <i>Neurosurgical Review</i> , 2021, 44, 1447-1455.	1.2	11
4350	Fungal chitin-glucan nanopapers with heavy metal adsorption properties for ultrafiltration of organic solvents and water. <i>Carbohydrate Polymers</i> , 2021, 253, 117273.	5.1	43
4351	Analysis of gravel back-filled borehole heat exchanger in karst fractured limestone aquifer at local scale. <i>Geothermics</i> , 2021, 89, 101971.	1.5	7
4352	TO SHARE OR TO EXCHANGE: An analysis of the sharing economy characteristics of Airbnb and Fairbnb.coop. <i>International Journal of Hospitality Management</i> , 2021, 92, 102724.	5.3	10
4353	Preeclampsia and the crucial postpartum period for Covid-19 infected mothers: A case report. <i>Pregnancy Hypertension</i> , 2021, 23, 136-139.	0.6	9
4354	In-silico protein-ligand docking studies against the estrogen protein of breast cancer using pharmacophore based virtual screening approaches. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 400-407.	1.8	40
4355	Targeted quantification of B vitamins using ultra-performance liquid chromatography-selected reaction monitoring mass spectrometry in faba bean seeds. <i>Journal of Food Composition and Analysis</i> , 2021, 95, 103687.	1.9	8
4356	Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement. <i>Current Opinion in Pharmacology</i> , 2021, 56, 29-38.	1.7	8
4357	Making legitimacy: Drug user representation in United Nations drug policy settings. <i>International Journal of Drug Policy</i> , 2021, 87, 103014.	1.6	13
4358	Diode-like rectification characteristics of BiFeO <sub>3</sub> -based /Zn <sub>1</sub> -Ni Fe <sub>2</sub> O <sub>4</sub> bilayered films for application of ferroelectric field effect transistors. <i>Journal of Alloys and Compounds</i> , 2021, 851, 156818.	2.8	4
4359	Personality change during substance use disorder treatment is associated with improvements in abstinence self-efficacy post-treatment among U.S. military veterans. <i>Journal of Substance Abuse Treatment</i> , 2021, 120, 108187.	1.5	2
4360	Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling. <i>Neuro-Oncology</i> , 2021, 23, 837-847.	0.6	9
4361	One-equation model to assess population balance kernels in turbulent bubbly flows. <i>Chemical Engineering Science</i> , 2021, 229, 116096.	1.9	3
4362	The distribution of isocitrate dehydrogenase mutations, O <sub>6</sub> -methylguanine-DNA methyltransferase promoter methylation, and 1p/19q codeletion in different glioma subtypes and their correlation with glioma prognosis in Taiwanese population: A single center study. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2021, 23, 100922.	0.2	0
4363	Morphology-controllable cellulose/chitosan sponge for deep wound hemostasis with surfactant and pore-foaming agent. <i>Materials Science and Engineering C</i> , 2021, 118, 111408.	3.8	34
4364	Dissociation of proprioceptive drift and feelings of ownership in the somatic rubber hand illusion. <i>Acta Psychologica</i> , 2021, 212, 103192.	0.7	12
4365	Unravelling the effect of species mixing on water use and drought stress in Mediterranean forests: A modelling approach. <i>Agricultural and Forest Meteorology</i> , 2021, 296, 108233.	1.9	30

#	ARTICLE	IF	CITATIONS
4366	Modelling the influence of the microstructure on the high cycle fatigue crack initiation in short fibre reinforced thermoplastics. <i>Composites Science and Technology</i> , 2021, 201, 108533.	3.8	9
4367	Measurement, simulation and uncertainty quantification of the neutron flux at the McMaster Nuclear Reactor. <i>Annals of Nuclear Energy</i> , 2021, 151, 107879.	0.9	7
4368	The mollification method based on a modified operator to the ill-posed problem for 3D Helmholtz equation with mixed boundary. <i>Applied Numerical Mathematics</i> , 2021, 160, 422-435.	1.2	0
4369	Surface strengthening and grain refinement of AZ31B magnesium alloy by ultrasonic cavitation modification. <i>Chinese Journal of Aeronautics</i> , 2021, 34, 508-517.	2.8	21
4370	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021, 79, 200-211.	0.9	76
4371	Active headrests with selective delayless subband adaptive filters in an aircraft cabin. <i>Mechanical Systems and Signal Processing</i> , 2021, 148, 107164.	4.4	14
4372	Overview of prognostic factors in adult gliomas. <i>Annals of Palliative Medicine</i> , 2021, 10, 863-874.	0.5	34
4373	A view of the epidemiologic landscape: how population-based studies can lend novel insights regarding the pathophysiology of glioblastoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 35-35.	0.4	0
4374	Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 253-262.	1.2	8
4375	MGMT-inhibitor in combination with TGF- $\beta$ RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. <i>Clinical and Translational Oncology</i> , 2021, 23, 612-619.	1.2	10
4376	MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas. <i>European Radiology</i> , 2021, 31, 1738-1747.	2.3	16
4377	lncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance. <i>Biochemical Pharmacology</i> , 2021, 189, 114228.	2.0	33
4378	A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma. <i>Molecular Cancer Research</i> , 2021, 19, 48-60.	1.5	8
4379	Technologies for targeting DNA methylation modifications: Basic mechanism and potential application in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188454.	3.3	23
4380	Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas. <i>Experimental Biology and Medicine</i> , 2021, 246, 187-196.	1.1	1
4381	Narrative review of palliative hypofractionated radiotherapy for high grade glioma. <i>Annals of Palliative Medicine</i> , 2021, 10, 846-862.	0.5	5
4382	Importance and Evidence of Extent of Resection in Glioblastoma. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2021, 82, 075-086.	0.4	18
4383	Smad1 Inhibits the Malignant Phenotypes of Human Glioblastoma Cells via Crosstalk with Notch1. <i>Molecular Neurobiology</i> , 2021, 58, 1438-1452.	1.9	2

#	ARTICLE	IF	CITATIONS
4384	Combining polarized Raman spectroscopy and micropillar compression to study microscale structure-property relationships in mineralized tissues. <i>Acta Biomaterialia</i> , 2021, 119, 390-404.	4.1	26
4385	Variable-rate control system for UAV-based granular fertilizer spreader. <i>Computers and Electronics in Agriculture</i> , 2021, 180, 105832.	3.7	25
4386	Novel non-destructive testing method using a two-electrode planar capacitive sensor based on measured normalized capacitance values. <i>Measurement: Journal of the International Measurement Confederation</i> , 2021, 167, 108455.	2.5	10
4389	The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2021, 20, 102716.	2.5	33
4390	Potential causal role of l-glutamine in sickle cell disease painful crises: A Mendelian randomization analysis. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 86, 102504.	0.6	14
4391	Major reduction of NKT cells in patients with severe COVID-19 pneumonia. <i>Clinical Immunology</i> , 2021, 222, 108630.	1.4	39
4392	Investigation of the spontaneous nanoemulsification process with medium- and long-chain triglycerides. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 197, 111432.	2.5	7
4393	High-performance and stable inverted perovskite solar cells using low-temperature solution-processed CuNbOx hole transport layer. <i>Journal of Power Sources</i> , 2021, 483, 229194.	4.0	12
4394	Authoritarian populism and emancipatory politics in the rural United States. <i>Journal of Rural Studies</i> , 2021, 82, 500-504.	2.1	11
4395	Facile preparation of worm-like mesoporous tin oxide films with super-hydrophilic surface. <i>Materials Science and Engineering B: Solid-State Materials for Advanced Technology</i> , 2021, 264, 114926.	1.7	5
4396	Speech frequency-following response in human auditory cortex is more than a simple tracking. <i>NeuroImage</i> , 2021, 226, 117545.	2.1	15
4397	No-till and carbon stocks: Is deep soil sampling necessary? Insights from long-term experiments. <i>Soil and Tillage Research</i> , 2021, 206, 104840.	2.6	13
4398	Knowledge and self-perception comparisons between students with and without prior technician experience in community pharmacy lab courses. <i>Currents in Pharmacy Teaching and Learning</i> , 2021, 13, 279-287.	0.4	0
4399	Advanced magnetic resonance imaging to support clinical drug development for malignant glioma. <i>Drug Discovery Today</i> , 2021, 26, 429-441.	3.2	1
4400	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	3.2	194
4401	Sutura laparoscópica mecanizada con FlexDex Surgical System® para ubicaciones anatómicamente difíciles. <i>Cirugía Española</i> , 2021, 99, 222-228.	0.1	2
4402	A comparison of two types of electrospun chitosan membranes and a collagen membrane in vivo. <i>Dental Materials</i> , 2021, 37, 60-70.	1.6	13
4403	Integrated gene-based and pathway analyses using UK Biobank data identify novel genes for chronic respiratory diseases. <i>Gene</i> , 2021, 767, 145287.	1.0	7



#	ARTICLE	IF	CITATIONS
4404	Multiple retrograde retinal artery emboli as a complication of coil embolization in the region of the ophthalmic artery. <i>Journal Francais D'Ophthalmologie</i> , 2021, 44, e51-e54.	0.2	0
4405	Single-wired array light detector based on photoacoustic effect. <i>Optics and Lasers in Engineering</i> , 2021, 139, 106460.	2.0	2
4408	The role of nitrogen in achieving sustainable food systems for healthy diets. <i>Global Food Security</i> , 2021, 28, 100408.	4.0	11
4409	Fibrin clot properties to assess the bleeding phenotype in unrelated patients with hypodysfibrinogenemia due to novel fibrinogen mutations. <i>Thrombosis Research</i> , 2021, 197, 56-64.	0.8	6
4410	Anxiety Sensitivity and Arousal Symptom Implicit Association Task Performance: An Event-Related Potential Study of Cognitive Processing of Anxiety-Relevant Stimuli. <i>Journal of Affective Disorders</i> , 2021, 280, 7-15.	2.0	8
4411	Balanced QSAR analysis to identify the structural requirements of ABBV-075 (Mivebresib) analogues as bromodomain and extraterminal domain (BET) family bromodomain inhibitor. <i>Journal of Molecular Structure</i> , 2021, 1229, 129597.	1.8	5
4413	Neural mechanisms of language learning from social contexts. <i>Brain and Language</i> , 2021, 212, 104874.	0.8	13
4414	Adaptive rag-bull rider: A modified self-adaptive optimization algorithm for epileptic seizure detection with deep stacked autoencoder using electroencephalogram. <i>Biomedical Signal Processing and Control</i> , 2021, 64, 102322.	3.5	13
4415	G protein-coupled estrogen receptor 1 mediates estrogen effect in red common carp ( <i>Cyprinus carpio</i> ). <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2021, 239, 108868.	1.3	1
4416	A basic review on systemic treatment options in WHO grade II-III gliomas. <i>Cancer Treatment Reviews</i> , 2021, 92, 102124.	3.4	44
4417	A UAV-based framework for crop lodging assessment. <i>European Journal of Agronomy</i> , 2021, 123, 126201.	1.9	22
4418	Soil organic carbon stocks maintained despite intensification of shifting cultivation. <i>Geoderma</i> , 2021, 388, 114804.	2.3	17
4419	Assessment of the cascade of uncertainty in future snow depth projections across watersheds of mountainous, foothill, and plain areas in northern latitudes. <i>Journal of Hydrology</i> , 2021, 598, 125735.	2.3	12
4420	Regulating lithium deposition via bifunctional regular-random cross-linking network solid polymer electrolyte for Li metal batteries. <i>Journal of Power Sources</i> , 2021, 484, 229186.	4.0	28
4421	Opinion leadership vs. para-social relationship: Key factors in influencer marketing. <i>Journal of Retailing and Consumer Services</i> , 2021, 59, 102371.	5.3	92
4422	Effects of Y and Ni co-doping in Bi <sub>2</sub> Fe <sub>4</sub> O <sub>9</sub> - BiFeO <sub>3</sub> based multiferroic ceramics. <i>Materials Today: Proceedings</i> , 2021, 46, 4716-4719.	0.9	3
4423	Radiosurgery for Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 117-128.	0.8	20
4424	Perioperative Management of Patients with Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 1-8.	0.8	10

#	ARTICLE	IF	CITATIONS
4425	Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression. <i>Neoplasia</i> , 2021, 23, 58-67.	2.3	13
4426	The market-reach of pandemics: Evidence from female workers in Ethiopia's ready-made garment industry. <i>World Development</i> , 2021, 137, 105179.	2.6	12
4428	Development and verification of a simulation toolkit for Self-Powered Neutron Detector. <i>Annals of Nuclear Energy</i> , 2021, 150, 107784.	0.9	12
4430	ZnO decorated on low carbonate NiAl-layered double hydroxide as efficient photocatalyst for methyl orange degradation. <i>Applied Clay Science</i> , 2021, 201, 105927.	2.6	16
4431	Cellulosic fiber based hybrid composites: A comparative investigation into their structurally influencing mechanical properties. <i>Construction and Building Materials</i> , 2021, 271, 121587.	3.2	8
4432	Synthesis of hydrophobic fluoro-substituted polyaniline filler for the long-term anti-corrosion performance enhancement of epoxy coatings. <i>Corrosion Science</i> , 2021, 178, 109094.	3.0	58
4433	Strategies for supporting the transition from small-group activity to student learning: A possible role for beyond-group sharing. <i>Learning, Culture and Social Interaction</i> , 2021, 28, 100471.	1.1	3
4434	A continuous-flow catalytic process with natural hematite-alginate beads for effective water decontamination and disinfection: Peroxymonosulfate activation leading to dominant sulfate radical and minor non-radical pathways. <i>Chemical Engineering Journal</i> , 2021, 411, 127738.	6.6	32
4435	Emerging functions of the wellbeing concept in regional development scholarship: A review. <i>Environmental Science and Policy</i> , 2021, 115, 143-150.	2.4	18
4436	LES investigation of a Passively Excited Impinging Jet. <i>International Journal of Heat and Mass Transfer</i> , 2021, 165, 120705.	2.5	3
4437	Revisiting the use of the provocative acetylcholine test in patients with chest pain and nonobstructive coronary arteries: A five-year follow-up of the AChPOL registry, with special focus on patients with MINOCA. <i>Translational Research</i> , 2021, 231, 64-75.	2.2	11
4438	Drought monitoring of the maize planting areas in Northeast and North China Plain. <i>Agricultural Water Management</i> , 2021, 245, 106636.	2.4	33
4439	Predictors of Colorectal Cancer Screening Modality Among Newly Age-Eligible Medicaid Enrollees. <i>American Journal of Preventive Medicine</i> , 2021, 60, 72-79.	1.6	4
4440	Lithium ion batteries with enhanced electrochemical performance by using carbon-coated SiO <sub>x</sub> /Ag composites as anode material. <i>Ceramics International</i> , 2021, 47, 1086-1094.	2.3	18
4441	New insight into the negative impact of imidazolium-based ionic liquid [C10mim]Cl on Hela cells: From membrane damage to biochemical alterations. <i>Ecotoxicology and Environmental Safety</i> , 2021, 208, 111629.	2.9	21
4442	Influence of hydrogen addition on methane coupling in a moderate pressure microwave plasma. <i>Fuel</i> , 2021, 288, 119674.	3.4	15
4443	Interaction activated interfacial charge transfer in 2D g-C <sub>3</sub> N <sub>4</sub> /GaN nanorods heterostructure for self-powered UV photodetector and room temperature NO <sub>2</sub> gas sensor at ppb level. <i>Sensors and Actuators B: Chemical</i> , 2021, 329, 129175.	4.0	68
4445	Effect of pearlitic morphology with varying fineness on the cavitation erosion behavior of eutectoid rail steel. <i>Ultrasonics Sonochemistry</i> , 2021, 71, 105399.	3.8	17

#	ARTICLE	IF	CITATIONS
4447	Tandem conversion of lignin to catechols via demethylation and catalytic hydrogenolysis. <i>Industrial Crops and Products</i> , 2021, 159, 113095.	2.5	27
4448	Efficient air epoxidation of cycloalkenes over bimetal-organic framework ZnCo-MOF materials. <i>Molecular Catalysis</i> , 2021, 499, 111300.	1.0	6
4449	Imaging Glioblastoma Posttreatment. <i>Neuroimaging Clinics of North America</i> , 2021, 31, 103-120.	0.5	23
4450	Fractionation of <i>Cynara cardunculus</i> ethanolic extracts using diafiltration. <i>Separation and Purification Technology</i> , 2021, 256, 117856.	3.9	4
4451	Numerical investigation of conventional and tapered Savonius hydrokinetic turbines for low-velocity hydropower application in an irrigation channel. <i>Sustainable Energy Technologies and Assessments</i> , 2021, 43, 100871.	1.7	16
4452	Resource assessment of the Copahue geothermal field. <i>Geothermics</i> , 2021, 90, 101987.	1.5	8
4453	Mechanical response of a compressed novel 3D tetrachiral structure processed by MJF 3D printing process. <i>Materials Today: Proceedings</i> , 2021, 46, 4776-4781.	0.9	4
4454	Advancing Imaging to Enhance Surgery. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 31-46.	0.8	7
4455	A novel microbiome metabolic modulator improves the growth performance of broiler chickens in multiple trials and modulates targeted energy and amino acid metabolic pathways in the cecal metagenome. <i>Poultry Science</i> , 2021, 100, 100800.	1.5	8
4456	Effects of muscle activity on lumbar spinal stiffness in asymptomatic adults: An investigation using a novel rolling device. <i>Musculoskeletal Science and Practice</i> , 2021, 52, 102301.	0.6	1
4457	Plastic deformation and energy absorption of polycrystalline-like lattice structures. <i>Materials and Design</i> , 2021, 198, 109321.	3.3	33
4458	Irreversible incorporation of L-dopa into the C-terminus of $\beta$ -tubulin inhibits binding of molecular motor KIF5B to microtubules and alters mitochondrial traffic along the axon. <i>Neurobiology of Disease</i> , 2021, 147, 105164.	2.1	9
4459	Climate change policy and entrepreneurial opportunities. <i>Technological Forecasting and Social Change</i> , 2021, 163, 120446.	6.2	29
4460	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	12.5	826
4461	Evaluating couch polyurethane foam for a potential passive sampler of semivolatile organic compounds. <i>Chemosphere</i> , 2021, 271, 129349.	4.2	1
4462	Message from the East About Anticoagulation After Deep Venous Stenting: The Agent Matters in Accomplishing the Mission. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 61, 490.	0.8	0
4463	Decoupling hydrodynamic and entanglement effects on the modulus reinforcement of grafted silica filled nanocomposites through Thermal and rheological features. <i>Polymer</i> , 2021, 213, 123323.	1.8	12
4466	Exploring the multilevel effects of triclosan from development, reproduction to behavior using <i>Drosophila melanogaster</i> . <i>Science of the Total Environment</i> , 2021, 762, 144170.	3.9	13

#	ARTICLE	IF	CITATIONS
4467	Does love become hate or forgiveness after a double deviation? The case of hotel loyalty program members. <i>Tourism Management</i> , 2021, 84, 104279.	5.8	24
4468	<i>MGMT</i> promoter methylation analysis for allocating combined <i>CCNU</i> / <i>TMZ</i> chemotherapy: Lessons learned from the <i>CeTeG</i> / <i>NOA</i> trial. <i>International Journal of Cancer</i> , 2021, 148, 1695-1707.	2.3	11
4471	Comment on "Tunability of linear and nonlinear optical absorption in laterally coupled AlxGa1-As/GaAs quantum wires". <i>J. Alloys Compd.</i> 746 (2018) 653-659]. <i>Journal of Alloys and Compounds</i> , 2021, 850, 156302.	2.8	4
4472	Preliminary analyses on decontamination factors during pool scrubbing with bubble size distributions obtained from EPRI experiments. <i>Nuclear Engineering and Technology</i> , 2021, 53, 509-521.	1.1	6
4473	DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. <i>Neuro-Oncology</i> , 2021, 23, 240-250.	0.6	31
4474	lncRNA LINC01057 promotes mesenchymal differentiation by activating NF- $\kappa$ B signaling in glioblastoma. <i>Cancer Letters</i> , 2021, 498, 152-164.	3.2	34
4475	Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. <i>Journal of Neuro-Oncology</i> , 2021, 151, 55-62.	1.4	42
4476	TGF- $\beta$ 1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated <i>MGMT</i> . <i>Neuro-Oncology</i> , 2021, 23, 435-446.	0.6	51
4477	Radiomic analysis of magnetic resonance fingerprinting in adult brain tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 683-693.	3.3	31
4478	Survival in patients with glioblastoma at a first progression does not correlate with <i>isocitrate dehydrogenase (IDH)1</i> gene mutation status. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 45-53.	0.6	16
4479	Current state and future perspective of drug repurposing in malignant glioma. <i>Seminars in Cancer Biology</i> , 2021, 68, 92-104.	4.3	35
4480	A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy. <i>Journal of Radiotherapy in Practice</i> , 2021, 20, 83-98.	0.2	7
4481	Cancer drug resistance: redox resetting renders a way. <i>Oncotarget</i> , 0, 7, 42740-42761.	0.8	144
4482	Epigenetic regulation of the cell cycle & DNA-repair in cancer. , 2021, , 521-531.		0
4483	Differential effect of vascularity between long- and short-term survivors with <i>IDH1/2</i> wild-type glioblastoma. <i>NMR in Biomedicine</i> , 2021, 34, e4462.	1.6	5
4484	An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas. <i>European Radiology</i> , 2021, 31, 1785-1794.	2.3	29
4485	Malignant Progression of an <i>IDH</i> Mutant Brainstem Glioma in Adult. <i>NMC Case Report Journal</i> , 2021, 8, 301-307.	0.2	3
4487	Overview of glioblastoma biological hallmarks and molecular pathology. , 2021, , 1-15.		0

#	ARTICLE	IF	CITATIONS
4488	Drug penetration through the blood-brain barrier after radiotherapy: New approaches to bypass glioblastoma chemoresistance. , 2021, , 689-705.		0
4490	Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2021, 27, 1912-1922.	3.2	26
4491	Intramolecular charge transfer enhancing strategy based MAO-A specific two-photon fluorescent probes for glioma cell/tissue imaging. Chemical Communications, 2021, 57, 11260-11263.	2.2	11
4492	Evolutionary Mechanisms of Cancer Suggest Rational Therapeutic Approaches. Cytogenetic and Genome Research, 2021, 161, 362-371.	0.6	4
4493	Evidence-based approaches to chemotherapy for gliomas. , 2021, , 38-52.		0
4494	Conventional and advanced imaging throughout the cycle of care of gliomas. Neurosurgical Review, 2021, 44, 2493-2509.	1.2	3
4495	DNA alkylation lesion repair: outcomes and implications in cancer chemotherapy. Journal of Zhejiang University: Science B, 2021, 22, 47-62.	1.3	15
4496	Shared Mechanisms of Disease. , 2021, , 385-414.		0
4497	Cancer Treatment: Preclinical & Clinical. Journal of the National Cancer Institute Monographs, 2021, 2021, 107-113.	0.9	7
4498	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
4499	Clinical and Genetic Features of Brainstem Glioma in Adults: A Report of 50 Cases in a Single Center.		

#	ARTICLE	IF	CITATIONS
4507	Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and methylguanine-DNA methyltransferase promoter methylation in patients with gliomas. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 197-205.	1.9	17
4509	Cell and gene therapies—Emerging technologies and drug delivery systems for treating brain cancer. , 2021, , 431-446.		0
4510	SAGE: Sequential Attribute Generator for Analyzing Glioblastomas Using Limited Dataset. , 2021, , .		1
4511	Intratumoral heterogeneity associated with glioblastoma drug response and resistance. , 2021, , 185-199.		0
4512	The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model. <i>In Vivo</i> , 2021, 35, 2015-2023.	0.6	8
4513	Tumors of the Central Nervous System. , 2021, , 121-145.		0
4514	Treatment evaluation and prognosis prediction using radiomics in clinical practice. , 2021, , 175-264.		0
4515	PTPRM methylation induced by FN1 promotes the development of glioblastoma by activating STAT3 signalling. <i>Pharmaceutical Biology</i> , 2021, 59, 902-909.	1.3	8
4516	Overarching therapeutic challenges and arachidonic acid metabolism as a novel target in glioblastoma. , 2021, , 41-63.		0
4517	The Role of Molecular Genetics of Glioblastoma in the Clinical Setting. <i>Molecular Pathology Library</i> , 2021, , 21-33.	0.1	0
4518	The Past, Present and Future of Flow Cytometry in Central Nervous System Malignancies. <i>Methods and Protocols</i> , 2021, 4, 11.	0.9	25
4519	Investigational new drugs against glioblastoma. , 2021, , 31-77.		0
4520	Understanding signal transduction pathways to overcome targeted therapy resistance in glioblastoma. , 2021, , 547-585.		0
4521	Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention. , 2021, , 319-334.		0
4522	On-chip analysis of glioblastoma cell chemoresistance. , 2021, , 473-490.		0
4523	Machine Learning Approaches Pertinent to Glioma Classification. <i>Molecular Pathology Library</i> , 2021, , 55-66.	0.1	0
4524	Targeted therapy in SDH-deficient GIST. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110232.	1.4	16
4525	Eight-year follow-up of a patient with glioblastoma multiforme who completed radical treatment. <i>Journal of Case Reports and Images in Medicine</i> , 2021, 7, 1-7.	0.0	0

#	ARTICLE	IF	CITATIONS
4526	Neuro-Oncologic Care During the COVID-19 Pandemic. , 2021, , 123-129.		0
4527	A Review of Newly Diagnosed Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 574012.	1.3	74
4528	The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme. <i>British Journal of Neurosurgery</i> , 2021, , 1-13.	0.4	1
4529	Adult Diffuse Astrocytic and Oligodendroglial Tumors. <i>Neurosurgery</i> , 2021, 89, 737-749.	0.6	1
4530	SCG3 Protein Expression in Glioma Associates With less Malignancy and Favorable Clinical Outcomes. <i>Pathology and Oncology Research</i> , 2021, 27, 594931.	0.9	2
4531	Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma. <i>Neurosurgical Review</i> , 2021, 44, 3335-3348.	1.2	6
4532	Low concentrations of vorinostat decrease EB1 expression in GBM cells and affect microtubule dynamics, cell survival and migration. <i>Oncotarget</i> , 2021, 12, 304-315.	0.8	2
4533	Reoperation for recurrent glioblastomas: What to expect?. , 2021, 12, 42.		3
4534	Prognostic and Predictive Value of Integrated Qualitative and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma. <i>Cancers</i> , 2021, 13, 722.	1.7	24
4535	Prognostic and predictive value of FCER1G in glioma outcomes and response to immunotherapy. <i>Cancer Cell International</i> , 2021, 21, 103.	1.8	18
4536	Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas. <i>Annals of Nuclear Medicine</i> , 2021, 35, 493-503.	1.2	12
4537	T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma. <i>Neuroradiology Journal</i> , 2021, 34, 392-400.	0.6	4
4538	Radiotherapy-induced glioblastoma: distinct differences in overall survival, tumor location, pMGMT methylation and primary tumor epidemiology in Hong Kong chinese patients. <i>British Journal of Neurosurgery</i> , 2021, , 1-8.	0.4	2
4539	Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. <i>Seminars in Cancer Biology</i> , 2022, 82, 162-175.	4.3	58
4540	The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 612337.	1.3	40
4541	Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 2044-2046.	0.6	1
4542	Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 600506.	1.8	5
4543	PRMT5 inhibition disrupts splicing and stemness in glioblastoma. <i>Nature Communications</i> , 2021, 12, 979.	5.8	77

#	ARTICLE	IF	CITATIONS
4544	Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. <i>Cancers</i> , 2021, 13, 761.	1.7	68
4545	High Hepatic leukemia factor expression indicates a favorable survival in glioma patients. <i>Medicine (United States)</i> , 2021, 100, e23980.	0.4	2
4546	DNA Repair Pathways in Cancer Therapy and Resistance. <i>Frontiers in Pharmacology</i> , 2020, 11, 629266.	1.6	172
4547	Forkhead box protein O3a promotes glioma cell resistance to temozolomide by regulating matrix metalloproteinase and $\beta$ -catenin. <i>Oncology Letters</i> , 2021, 21, 328.	0.8	2
4548	The Survival Benefit of Postoperative Bacterial Infections in Patients With Glioblastoma Multiforme: Myth or Reality?. <i>Frontiers in Neurology</i> , 2021, 12, 615593.	1.1	3
4549	MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features. <i>American Journal of Neuroradiology</i> , 2021, 42, 853-860.	1.2	12
4550	Immunohistochemical Analysis of DNA Repair- and Drug-Efflux-Associated Molecules in Tumor and Peritumor Areas of Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1620.	1.8	2
4551	Noninvasive Assessment of $O(6)$ -Methylguanine-DNA Methyltransferase Promoter Methylation Status in World Health Organization Grade IV Glioma Using Histogram Analysis of Inflow-Based Vascular Space Occupancy Combined with Structural Magnetic Resonance Imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 227-236.	1.9	4
4552	Maximal surgical resection and adjuvant surgical technique to prolong the survival of adult patients with thalamic glioblastoma. <i>PLoS ONE</i> , 2021, 16, e0244325.	1.1	6
4553	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. <i>Diagnostics</i> , 2021, 11, 342.	1.3	15
4554	RNA N6-Methyladenosine Regulator-Mediated Methylation Modifications Pattern and Immune Infiltration Features in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 632934.	1.3	22
4555	Evaluating Infectious, Neoplastic, Immunological, and Degenerative Diseases of the Central Nervous System with Cerebrospinal Fluid-Based Next-Generation Sequencing. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 207-229.	1.6	10
4556	Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies. <i>Carcinogenesis</i> , 2021, 42, 804-813.	1.3	21
4557	Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I). <i>Brain Sciences</i> , 2021, 11, 386.	1.1	14
4558	Cancer-specific loss of <i>TERT</i> activation sensitizes glioblastoma to DNA damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	28
4560	The Role of Network Science in Glioblastoma. <i>Cancers</i> , 2021, 13, 1045.	1.7	6
4561	Prediction of Lower Grade Insular Glioma Molecular Pathology Using Diffusion Tensor Imaging Metric-Based Histogram Parameters. <i>Frontiers in Oncology</i> , 2021, 11, 627202.	1.3	5
4562	Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3381-3390.	1.2	16



#	ARTICLE	IF	CITATIONS
4563	The Role of 2-Oxoglutarate Dependent Dioxygenases in Gliomas and Glioblastomas: A Review of Epigenetic Reprogramming and Hypoxic Response. <i>Frontiers in Oncology</i> , 2021, 11, 619300.	1.3	12
4564	Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3493.	1.8	4
4565	Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 433-468.	0.9	7
4566	Genomic Space of MGMT in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2492.	1.8	7
4567	Nanopore Sequencing Reveals Global Transcriptome Signatures of Mitochondrial and Ribosomal Gene Expressions in Various Human Cancer Stem-like Cell Populations. <i>Cancers</i> , 2021, 13, 1136.	1.7	14
4568	Prognostic value of test(s) for O6-methylguanineâ€“DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. <i>The Cochrane Library</i> , 2021, 2021, CD013316.	1.5	19
4569	Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. <i>Clinical Epigenetics</i> , 2021, 13, 52.	1.8	9
4570	DNA Methylation at ATP11A cg11702988 Is a Biomarker of Lung Disease Severity in Cystic Fibrosis: A Longitudinal Study. <i>Genes</i> , 2021, 12, 441.	1.0	3
4571	Favorable role of <i>IDH</i>1/2 mutations aided with <i>MGMT</i> promoter gene methylation in the outcome of patients with malignant glioma. <i>Future Science OA</i> , 2021, 7, FSO663.	0.9	10
4572	The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. <i>Acta Neuropathologica Communications</i> , 2021, 9, 35.	2.4	11
4573	Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. <i>Radiotherapy and Oncology</i> , 2021, 156, 258-265.	0.3	18
4574	Chemotherapy for adult patients with spinal cord gliomas. <i>Neuro-Oncology Practice</i> , 2021, 8, 475-484.	1.0	1
4575	Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma. <i>Cancers</i> , 2021, 13, 1152.	1.7	11
4576	TERT Promoter Alterations in Glioblastoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 1147.	1.7	31
4577	MRI-Based Deep-Learning Method for Determining Glioma <i>MGMT</i> Promoter Methylation Status. <i>American Journal of Neuroradiology</i> , 2021, 42, 845-852.	1.2	53
4578	Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma. <i>Molecular Medicine</i> , 2021, 27, 28.	1.9	8
4579	Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. <i>Stem Cell Research and Therapy</i> , 2021, 12, 206.	2.4	91
4580	Current FDA-Approved Therapies for High-Grade Malignant Gliomas. <i>Biomedicines</i> , 2021, 9, 324.	1.4	125

#	ARTICLE	IF	CITATIONS
4581	Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies. <i>Journal of Neuro-Oncology</i> , 2021, 152, 541-549.	1.4	1
4583	Baseline Serum C-Reactive Protein and Plasma Fibrinogen-Based Score in the Prediction of Survival in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 653614.	1.3	14
4584	Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas. <i>Journal of Clinical Neuroscience</i> , 2021, 85, 115-121.	0.8	9
4585	Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial. <i>Journal of Neuro-Oncology</i> , 2021, 152, 501-514.	1.4	47
4586	Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 166-174.	2.0	2
4587	Fine-Tuning Approach for Segmentation of Gliomas in Brain Magnetic Resonance Images with a Machine Learning Method to Normalize Image Differences among Facilities. <i>Cancers</i> , 2021, 13, 1415.	1.7	28
4588	MYD88 Is a Potential Prognostic Gene and Immune Signature of Tumor Microenvironment for Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 654388.	1.3	13
4589	Drug target ranking for glioblastoma multiforme. <i>BMC Biomedical Engineering</i> , 2021, 3, 7.	1.7	5
4590	Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. <i>Current Neuropharmacology</i> , 2021, 19, 513-537.	1.4	40
4591	Diagnosis and Management of Glioblastoma: A Comprehensive Perspective. <i>Journal of Personalized Medicine</i> , 2021, 11, 258.	1.1	23
4592	NDUFA4L2 promotes glioblastoma progression, is associated with poor survival, and can be effectively targeted by apatinib. <i>Cell Death and Disease</i> , 2021, 12, 377.	2.7	17
4593	MGMT-Methylation in Non-Neoplastic Diseases of the Central Nervous System. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3845.	1.8	10
4594	The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents. <i>Pathology and Oncology Research</i> , 2021, 27, 1609778.	0.9	5
4595	Epigenome-wide association study of COVID-19 severity with respiratory failure. <i>EBioMedicine</i> , 2021, 66, 103339.	2.7	90
4596	On the Prognosis of Multifocal Glioblastoma: An Evaluation Incorporating Volumetric MRI. <i>Current Oncology</i> , 2021, 28, 1437-1446.	0.9	6
4597	Diagnosis and treatment of refractory pituitary adenomas: a narrative review. <i>Gland Surgery</i> , 2021, 10, 1499-1507.	0.5	9
4598	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. <i>Clinical and Translational Science</i> , 2021, 14, 954-963.	1.5	5
4599	Clinical significance of <i>CDKN2A</i> homozygous deletion in combination with methylated <i>MGMT</i> status for <i>IDH</i> wildtype glioblastoma. <i>Cancer Medicine</i> , 2021, 10, 3177-3187.	1.3	21

#	ARTICLE	IF	CITATIONS
4600	An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. <i>Pharmaceuticals</i> , 2021, 14, 316.	1.7	13
4601	Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts. <i>Cancer Gene Therapy</i> , 2022, 29, 533-542.	2.2	5
4602	Telomerase reverse transcriptase promoter mutation and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?. <i>European Journal of Cancer</i> , 2021, 147, 84-94.	1.3	10
4603	The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3863.	1.8	31
4604	Contralesional Structural Plasticity in Different Molecular Pathologic Subtypes of Insular Glioma. <i>Frontiers in Neurology</i> , 2021, 12, 636573.	1.1	9
4605	A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning. <i>Biomolecules</i> , 2021, 11, 565.	1.8	10
4606	Identification of TNIK as a novel potential drug target in thyroid cancer based on protein druggability prediction. <i>Medicine (United States)</i> , 2021, 100, e25541.	0.4	5
4607	Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. <i>Journal of Neurochemistry</i> , 2021, 158, 522-538.	2.1	18
4608	Targeting glioblastoma: from dream to reality. <i>Biomarkers in Medicine</i> , 2021, 15, 385-388.	0.6	3
4609	Immunomodulatory Effect of Microglia-Released Cytokines in Gliomas. <i>Brain Sciences</i> , 2021, 11, 466.	1.1	23
4610	Molecularly Targeted Clinical Trials. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 191-210.	0.8	7
4611	Tumour immune landscape of paediatric high-grade gliomas. <i>Brain</i> , 2021, 144, 2594-2609.	3.7	21
4612	Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. <i>JCO Precision Oncology</i> , 2021, 5, 432-441.	1.5	16
4613	New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprogramming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs. <i>Cells</i> , 2021, 10, 893.	1.8	23
4614	The Cytotoxic Effect of <i>Polygonum cognatum</i> and Chemotherapeutic Effect of Doxorubicin on Glioblastoma Cells. <i>European Journal of Therapeutics</i> , 2021, 27, 50-54.	0.0	4
4615	Chemotherapy in NEN: still has a role?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 595-614.	2.6	13
4616	PI3K $\beta$ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	33
4617	State of Radiomics in Glioblastoma. <i>Neurosurgery</i> , 2021, 89, 177-184.	0.6	15

#	ARTICLE	IF	CITATIONS
4618	An Overview of High-grade Glioma: Current and Emerging Treatment Approaches. <i>Current Cancer Therapy Reviews</i> , 2021, 17, 35-48.	0.2	0
4619	<i>MGMT</i> promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. <i>Neuro-Oncology</i> , 2021, 23, 1457-1469.	0.6	36
4620	The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 171-180.	0.8	9
4621	ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. <i>Cancers</i> , 2021, 13, 1989.	1.7	26
4622	Improved local control in p16 negative oropharyngeal cancers with hypermethylated MGMT. <i>Radiotherapy and Oncology</i> , 2021, 157, 234-240.	0.3	0
4623	Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103283.	2.0	17
4624	The Management of Glioblastomas during the SARS-CoV-19 Pandemic: A Narrative Overview. <i>European Journal of Basic Medical Sciences</i> , 2021, 11, 19-22.	0.2	2
4625	Missing the target in cancer therapy. <i>Nature Cancer</i> , 2021, 2, 369-371.	5.7	19
4626	CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDKN1A Transcription. <i>Frontiers in Oncology</i> , 2021, 11, 638802.	1.3	3
4627	Downregulation of both mismatch repair and non-homologous end-joining pathways in hypoxic brain tumour cell lines. <i>PeerJ</i> , 2021, 9, e11275.	0.9	4
4628	Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data. <i>Acta Neurochirurgica</i> , 2021, 163, 1883-1894.	0.9	11
4629	<i>MGMT</i> promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2021, 23, 858-860.	0.6	8
4630	Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM. <i>Journal of Personalized Medicine</i> , 2021, 11, 290.	1.1	30
4631	Auger electron therapy of glioblastoma using [125I]5-iodo-2'-deoxyuridine and concomitant chemotherapy – Evaluation of a potential treatment strategy. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 35-40.	0.3	2
4632	Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 206-218.	2.1	7
4633	Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. <i>World Neurosurgery</i> , 2021, 149, e894-e912.	0.7	5
4634	Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. <i>EBioMedicine</i> , 2021, 67, 103365.	2.7	57
4635	Canine presumed glial brain tumours treated with radiotherapy: Is there an inferior outcome in tumours contacting the subventricular zone?. <i>Veterinary and Comparative Oncology</i> , 2022, 20, 29-37.	0.8	9

#	ARTICLE	IF	CITATIONS
4636	Historical Perspective on Surgery and Survival with Glioblastoma: How Far Have We Come?. World Neurosurgery, 2021, 149, 148-168.	0.7	24
4637	The Evolving Role of Targeted Therapies in Primary Central Nervous System Tumors. Advances in Oncology, 2021, 1, 203-212.	0.1	1
4638	Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2271-2280.	1.2	14
4639	Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma. Frontiers in Oncology, 2021, 11, 616625.	1.3	45
4640	Diagnosis of Pseudoprogression Following Lomustineâ€“Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. Clinical Cancer Research, 2021, 27, 3704-3713.	3.2	19
4641	DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas. Clinical Epigenetics, 2021, 13, 102.	1.8	24
4642	Radiogenomics of Gliomas. Radiologic Clinics of North America, 2021, 59, 441-455.	0.9	7
4643	Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells. PLoS ONE, 2021, 16, e0250649.	1.1	4
4644	Epigenetics and DNA Repair in Cancer. , 0, , .		0
4645	Prognostic and predictive markers in glioblastoma and ALK overexpression. Journal of Pathology and Translational Medicine, 2021, 55, 236-237.	0.4	3
4646	An artificial neural network model based on DNA damage response genes to predict outcomes of lower-grade glioma patients. Briefings in Bioinformatics, 2021, 22, .	3.2	5
4647	A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks. Genome Biology, 2021, 22, 156.	3.8	17
4648	Flavonoids Overcome Drug Resistance to Cancer Chemotherapy by Epigenetically Modulating Multiple Mechanisms. Current Cancer Drug Targets, 2021, 21, 289-305.	0.8	9
4649	Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells. Cancers, 2021, 13, 2570.	1.7	13
4650	Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma. Frontiers in Oncology, 2021, 11, 632663.	1.3	3
4651	Metabolomics in cancer research and emerging applications in clinical oncology. Ca-A Cancer Journal for Clinicians, 2021, 71, 333-358.	157.7	267
4652	Brainstem Infiltration Predicts Survival in Patients With High-grade Gliomas Treated With Chemoradiotherapy. Anticancer Research, 2021, 41, 2583-2589.	0.5	4
4653	Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis. Neurosurgery, 2021, 89, 300-307.	0.6	18

#	ARTICLE	IF	CITATIONS
4654	Mouse Models of Experimental Glioblastoma. , 0, , 15-46.		8
4655	DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets. Cellular Oncology (Dordrecht), 2021, 44, 961-981.	2.1	10
4656	Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration. Journal of Cellular and Molecular Medicine, 2021, 25, 5534-5546.	1.6	7
4657	Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. Cells, 2021, 10, 1226.	1.8	40
4658	Hyperbaric oxygen promotes not only glioblastoma proliferation but also chemosensitization by inhibiting HIF1 $\alpha$ /HIF2 $\alpha$ -Sox2. Cell Death Discovery, 2021, 7, 103.	2.0	5
4659	Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme. World Neurosurgery, 2021, 149, e1026-e1037.	0.7	6
4660	Classification of Diffuse Glioma Subtype from Clinical-Grade Pathological Images Using Deep Transfer Learning. Sensors, 2021, 21, 3500.	2.1	16
4661	IRON OXIDE MAGNETIC NANOPARTICLES AS DRUG DELIVERY SYSTEMS FOR BRAIN CANCER TREATMENT. Medico Oncology, 2021, 2, 55-66.	0.3	2
4662	Modulation of untranslated region alternative polyadenylation in glioma tumorigenesis. Biomedicine and Pharmacotherapy, 2021, 137, 111416.	2.5	3
4663	A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro-Oncology, 2021, 23, 1736-1749.	0.6	44
4664	Glioma-Specific Diffusion Signature in Diffusion Kurtosis Imaging. Journal of Clinical Medicine, 2021, 10, 2325.	1.0	6
4665	In Silico Mathematical Modelling for Glioblastoma: A Critical Review and a Patient-Specific Case. Journal of Clinical Medicine, 2021, 10, 2169.	1.0	19
4666	Perfusion Parameter Obtained on 3-Tesla Magnetic Resonance Imaging and the Ki-67 Labeling Index Predict the Overall Survival of Glioblastoma. World Neurosurgery, 2021, 149, e469-e480.	0.7	2
4667	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Frontiers in Oncology, 2021, 11, 679702.	1.3	8
4668	Imaging Findings of New Entities and Patterns in Brain Tumor. Radiologic Clinics of North America, 2021, 59, 305-322.	0.9	2
4669	The relationship between PLOD1 expression level and glioma prognosis investigated using public databases. PeerJ, 2021, 9, e11422.	0.9	6
4670	Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression. Nature Communications, 2021, 12, 3895.	5.8	28
4671	MRI Imaging Characteristics of Glioblastoma with Concurrent Gain of Chromosomes 19 and 20. Tomography, 2021, 7, 228-237.	0.8	0

#	ARTICLE	IF	CITATIONS
4672	Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. <i>Frontiers in Endocrinology</i> , 2021, 12, 650791.	1.5	17
4673	The immune landscape of common CNS malignancies: implications for immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 729-744.	12.5	50
4674	Transcriptional Pausing and Activation at Exons-1 and -2, Respectively, Mediate the MGMT Gene Expression in Human Glioblastoma Cells. <i>Genes</i> , 2021, 12, 888.	1.0	0
4675	Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival. <i>Cureus</i> , 2021, 13, e16061.	0.2	1
4676	DNA Repair Mechanisms and Therapeutic Targets in Glioma. <i>Current Oncology Reports</i> , 2021, 23, 87.	1.8	16
4677	Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. <i>Pharmaceuticals</i> , 2021, 14, 626.	1.7	14
4678	Bioinformatic Analyses Identify a Prognostic Autophagy-Related Long Non-coding RNA Signature Associated With Immune Microenvironment in Diffuse Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 694633.	1.8	10
4679	Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <math>\leq 55\%</math>: single-arm phase II study. <i>ESMO Open</i> , 2021, 6, 100119.	2.0	19
4680	The Roles Played by Long Non-Coding RNAs in Glioma Resistance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6834.	1.8	16
4681	Enhancement of Radio-Thermo-Sensitivity of 5-Iodo-2-Deoxyuridine-Loaded Polymeric-Coated Magnetic Nanoparticles Triggers Apoptosis in U87MG Human Glioblastoma Cancer Cell Line. <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 365-377.	1.0	3
4682	Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?. <i>Journal of Neuro-Oncology</i> , 2021, 153, 537-545.	1.4	3
4683	A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 213.	3.5	42
4684	<i>TP73-AS1</i> is induced by YY1 during TMZ treatment and highly expressed in the aging brain. <i>Aging</i> , 2021, 13, 14843-14861.	1.4	3
4685	Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments. <i>Cancers</i> , 2021, 13, 3209.	1.7	24
4686	CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS. <i>Siberian Journal of Oncology</i> , 2021, 20, 5-17.	0.1	2
4687	The inverse paradigm and the ancestral cell of IDH-wildtype glioblastoma. <i>Clinical and Translational Oncology</i> , 2021, , 1.	1.2	0
4688	Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6781.	1.8	6
4690	Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. <i>Journal of Neurosurgery</i> , 2022, 136, 1-8.	0.9	29

#	ARTICLE	IF	CITATIONS
4691	Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 695316.	1.3	6
4692	The Carbonic Anhydrase Inhibitor E7070 Sensitizes Glioblastoma Cells to Radio- and Chemotherapy and Reduces Tumor Growth. <i>Molecular Neurobiology</i> , 2021, 58, 4520-4534.	1.9	8
4693	Feasibility, Safety and Impact on Overall Survival of Awake Resection for Newly Diagnosed Supratentorial IDH-Wildtype Glioblastomas in Adults. <i>Cancers</i> , 2021, 13, 2911.	1.7	13
4694	Current Development of Glioblastoma Therapeutic Agents. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1521-1532.	1.9	15
4695	DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies. <i>Molecular Oncology</i> , 2022, 16, 11-41.	2.1	16
4696	Molecular and Circulating Biomarkers of Brain Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7039.	1.8	39
4697	Repurposing of Anticancer Stem Cell Drugs in Brain Tumors. <i>Journal of Histochemistry and Cytochemistry</i> , 2021, 69, 002215542110254.	1.3	5
4698	Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit. <i>Journal of Neuro-Oncology</i> , 2021, 153, 393-402.	1.4	3
4699	Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. <i>Cancers</i> , 2021, 13, 3016.	1.7	38
4700	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq1 <i>Oncology, The</i> , 2021, 22, 813-823.	1.0784314 5.1	132
4702	ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. <i>Cell Reports</i> , 2021, 36, 109455.	2.9	18
4703	Clinical outcomes and a therapeutic indication of intramedullary spinal cord astrocytoma. <i>Spinal Cord</i> , 2022, 60, 216-222.	0.9	10
4704	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021, 13, 3750.	1.7	16
4705	Systematic Profiling of mRNA Splicing Reveals the Prognostic Predictor and Potential Therapeutic Target for Glioblastoma Multiforme. <i>Journal of Oncology</i> , 2021, 2021, 1-15.	0.6	4
4706	Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1983-1994.	0.9	2
4707	Scientific and Clinical Challenges within Neuro-Oncology. <i>World Neurosurgery</i> , 2021, 151, 402-410.	0.7	3
4708	CD90low glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells. <i>Stem Cell Research and Therapy</i> , 2021, 12, 394.	2.4	16
4709	Foundations of Neuro-Oncology: A Multidisciplinary Approach. <i>World Neurosurgery</i> , 2021, 151, 392-401.	0.7	5



#	ARTICLE	IF	CITATIONS
4711	Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastoma. <i>Cancer Science</i> , 2021, 112, 3699-3710.	1.7	13
4713	Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). <i>Cancer Research and Treatment</i> , 2022, 54, 396-405.	1.3	2
4714	Imaging-Genomics in Glioblastoma: Combining Molecular and Imaging Signatures. <i>Frontiers in Oncology</i> , 2021, 11, 699265.	1.3	11
4715	Combination chemoradiotherapy with temozolomide, vincristine, and interferon- $\beta$ might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma. <i>BMC Cancer</i> , 2021, 21, 867.	1.1	3
4716	Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 682084.	1.6	29
4717	Phosphorous Magnetic Resonance Spectroscopy and Molecular Markers in IDH1 Wild Type Glioblastoma. <i>Cancers</i> , 2021, 13, 3569.	1.7	8
4718	Identification of the Prognostic Signatures of Glioma With Different PTEN Status. <i>Frontiers in Oncology</i> , 2021, 11, 633357.	1.3	15
4719	Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on 11C-methionine PET: a retrospective, single-center study. <i>Scientific Reports</i> , 2021, 11, 14554.	1.6	11
4720	MGMT testing always worth an emotion. <i>Neuro-Oncology</i> , 2021, 23, 1417-1418.	0.6	2
4721	The Prognostic Role of Peritumoral Edema in Patients with Newly Diagnosed Glioblastoma: A Retrospective Analysis. <i>Journal of Clinical Neuroscience</i> , 2021, 89, 249-257.	0.8	3
4722	Chromatin insulation dynamics in glioblastoma: challenges and future perspectives of precision oncology. <i>Clinical Epigenetics</i> , 2021, 13, 150.	1.8	9
4723	Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival. <i>Medicine and Pharmacy Reports</i> , 2021, 94, 318-324.	0.2	1
4724	The influence of methylation status on a stochastic model of MGMT dynamics in glioblastoma: Phenotypic selection can occur with and without a downshift in promoter methylation status. <i>Journal of Theoretical Biology</i> , 2021, 521, 110662.	0.8	1
4725	Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1789-1799.	1.9	14
4726	Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103372.	2.0	19
4727	Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines. <i>Nutrition and Cancer</i> , 2022, 74, 1071-1078.	0.9	8
4729	The Renin-Angiotensin System in the Tumor Microenvironment of Glioblastoma. <i>Cancers</i> , 2021, 13, 4004.	1.7	11
4730	A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma. <i>Cureus</i> , 2021, 13, e17595.	0.2	2

#	ARTICLE	IF	CITATIONS
4731	Targeted Delivery of Liposomal Temozolomide Enhanced Anti-Glioblastoma Efficacy through Ultrasound-Mediated Blood-Brain Barrier Opening. <i>Pharmaceutics</i> , 2021, 13, 1270.	2.0	19
4732	Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma. <i>Cancer Cell International</i> , 2021, 21, 456.	1.8	32
4733	High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase. <i>Radiation Oncology</i> , 2021, 16, 157.	1.2	4
4734	Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity. <i>Cells</i> , 2021, 10, 1975.	1.8	6
4735	Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1478-1495.	0.9	11
4736	Joint application of biochemical markers and imaging techniques in the accurate and early detection of glioblastoma. <i>Pathology Research and Practice</i> , 2021, 224, 153528.	1.0	1
4737	Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 671838.	1.8	6
4738	BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme. <i>Biomolecules</i> , 2021, 11, 1188.	1.8	13
4739	The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8324.	1.8	17
4740	Deep learning applications in neuro-oncology. , 2021, 12, 435.		0
4741	The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results. <i>Chinese Clinical Oncology</i> , 2021, 10, 38-38.	0.4	5
4742	Reactive oxygen species produced by altered tumor metabolism impacts cancer stem cell maintenance. <i>Redox Biology</i> , 2021, 44, 101953.	3.9	39
4743	Hypermutated recurrences: Identifying the clinical relevance. <i>Neuro-Oncology</i> , 2021, 23, 1805-1806.	0.6	3
4744	Mutational burden and immune recognition of gliomas. <i>Current Opinion in Oncology</i> , 2021, 33, 626-634.	1.1	5
4745	Case of multifocal glioblastoma with four fusion transcripts of ALK, FGFR2, NTRK2, and NTRK3 genes stresses the need for tumor tissue multisampling for transcriptomic analysis. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006100.	0.5	8
4746	Adjusting the Molecular Clock: The Importance of Circadian Rhythms in the Development of Glioblastomas and Its Intervention as a Therapeutic Strategy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8289.	1.8	10
4747	Algorithmically Deduced FREM2 Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas. <i>Cancers</i> , 2021, 13, 4117.	1.7	9
4748	Primary Cilia-Related Pathways Moderate the Development and Therapy Resistance of Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 718995.	1.3	5

#	ARTICLE	IF	CITATIONS
4749	The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme. <i>Future Oncology</i> , 2021, 17, 4405-4413.	1.1	5
4750	Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series. <i>Clinical Neurology and Neurosurgery</i> , 2021, 207, 106735.	0.6	38
4751	Large-scale preparation of fluorescence multiplex host cell reactivation (FM-HCR) reporters. <i>Nature Protocols</i> , 2021, 16, 4265-4298.	5.5	12
4752	MethylSPWNet and MethylCapsNet: Biologically Motivated Organization of DNAm Neural Networks, Inspired by Capsule Networks. <i>Npj Systems Biology and Applications</i> , 2021, 7, 33.	1.4	12
4753	Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 703764.	1.3	27
4754	A novel nomogram for predicting the risk of epilepsy occurrence after operative in gliomas patients without preoperative epilepsy history. <i>Epilepsy Research</i> , 2021, 174, 106641.	0.8	3
4755	Crosstalk of the Wnt/ $\beta$ 2-Catenin Signaling Pathway in the Induction of Apoptosis on Cancer Cells. <i>Pharmaceuticals</i> , 2021, 14, 871.	1.7	25
4756	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. <i>Lancet Oncology</i> , The, 2021, 22, 1103-1114.	5.1	91
4757	The Interplay between Glioblastoma and Its Microenvironment. <i>Cells</i> , 2021, 10, 2257.	1.8	57
4758	Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 695325.	1.8	27
4759	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1265-1272.	1.1	4
4760	Peritumoral edema status of glioblastoma identifies patients reaching long-term disease control with specific progression patterns after tumor resection and high-dose proton boost. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3503-3516.	1.2	5
4761	The Prognostic Effect of Dexamethasone on Patients With Glioblastoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 727707.	1.6	11
4762	Natural Small Molecules Targeting NF- $\kappa$ B Signaling in Glioblastoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 703761.	1.6	13
4763	Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102261.	3.4	7
4764	Molecular Pathology of Gliomas. <i>Surgical Pathology Clinics</i> , 2021, 14, 379-386.	0.7	18
4765	Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab133.	0.4	24
4766	Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines. <i>Veterinary Medicine and Science</i> , 2021, 7, 2124-2134.	0.6	5

#	ARTICLE	IF	CITATIONS
4767	Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 747690.	1.3	10
4768	Neurosurgical Advances for Malignant Gliomas. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 364-370.	1.0	2
4769	Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells. <i>Cell Death and Disease</i> , 2021, 12, 884.	2.7	10
4770	Prognostic and Predictive Biomarkers in Gliomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10373.	1.8	110
4772	The Role of Delayed Radiotherapy Initiation in Patients with Newly Diagnosed Glioblastoma with Residual Tumor Mass. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2021, , .	0.4	0
4773	Construction of Novel Methylation-Driven Gene Model and Investigation of PARVB Function in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 705547.	1.3	5
4774	Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells. <i>Pharmacological Research</i> , 2021, 171, 105764.	3.1	30
4775	Alternative polyadenylation: An enigma of transcript length variation in health and disease. <i>Wiley Interdisciplinary Reviews RNA</i> , 2022, 13, e1692.	3.2	15
4776	The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. <i>Cell Death and Disease</i> , 2021, 12, 885.	2.7	22
4777	Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. <i>Npj Genomic Medicine</i> , 2021, 6, 76.	1.7	10
4778	ER expression associates with poor prognosis in male lung squamous carcinoma after radical resection. <i>BMC Cancer</i> , 2021, 21, 1043.	1.1	2
4779	Multomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches. <i>Frontiers in Genetics</i> , 2021, 12, 741325.	1.1	0
4780	Role of Lamin A/C as Candidate Biomarker of Aggressiveness and Tumorigenicity in Glioblastoma Multiforme. <i>Biomedicines</i> , 2021, 9, 1343.	1.4	8
4781	MiR-379 targets microsomal glutathione transferase 1 (MGST1) to regulate human glioma in cell proliferation, migration and invasion and epithelial-mesenchymal transition (EMT). <i>Biochemical and Biophysical Research Communications</i> , 2021, 568, 8-14.	1.0	9
4782	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	3.2	18
4783	The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 63-75.	0.9	1
4784	Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. <i>Supportive Care in Cancer</i> , 2022, 30, 1365-1375.	1.0	8
4785	Predicting drug sensitivity of cancer cells based on DNA methylation levels. <i>PLoS ONE</i> , 2021, 16, e0238757.	1.1	5

#	ARTICLE	IF	CITATIONS
4786	Biologic Pathways Underlying Prognostic Radiomics Phenotypes from Paired MRI and RNA Sequencing in Glioblastoma. <i>Radiology</i> , 2021, 301, 654-663.	3.6	38
4787	XAB2 promotes Ku eviction from single-ended DNA double-strand breaks independently of the ATM kinase. <i>Nucleic Acids Research</i> , 2021, 49, 9906-9925.	6.5	8
4788	Extracellular vesicles: The key for precision medicine in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 184-196.	0.6	22
4789	Diagnosis and management of adrenocorticotrophic hormone-secreting pituitary carcinoma: a case report and review of the literature. <i>Future Rare Diseases</i> , 2021, 1, .	0.1	1
4790	Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). <i>JCI Insight</i> , 2021, 6, .	2.3	7
4791	Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study. <i>CNS Oncology</i> , 2021, 10, CNS76.	1.2	5
4792	Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma. <i>CNS Oncology</i> , 2021, 10, CNS74.	1.2	8
4793	Efficacy of Whole-Ventricular Radiotherapy in Patients Undergoing Maximal Tumor Resection for Glioblastomas Involving the Ventricle. <i>Frontiers in Oncology</i> , 2021, 11, 736482.	1.3	2
4794	Prognostic Impact of the Combination of <i>MGMT</i> Methylation and <i>TERT</i> Promoter Mutation in Glioblastoma. <i>Journal of Neurosciences in Rural Practice</i> , 2021, 12, 694-703.	0.3	3
4795	Telomerase as a therapeutic target in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 2004-2013.	0.6	17
4796	CD74 Correlated With Malignancies and Immune Microenvironment in Gliomas. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 706949.	1.6	17
4797	Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial. <i>BMC Cancer</i> , 2021, 21, 1010.	1.1	10
4798	Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. <i>Laboratory Investigation</i> , 2022, 102, 126-133.	1.7	69
4799	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	3.2	67
4800	Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 343-357.	1.3	7
4801	Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53-PUMA Apoptosis Pathway. <i>Frontiers in Oncology</i> , 2021, 11, 722754.	1.3	11
4802	Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDH<sup>wt</sup> glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab127.	0.4	5
4803	Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10672.	1.8	5

#	ARTICLE	IF	CITATIONS
4804	The Prognostication Potential of BRCA Genes Expression in Gliomas: A Genetic Survival Analysis Study. <i>World Neurosurgery</i> , 2022, 157, e123-e128.	0.7	6
4805	Glioblastoma with deep supratentorial extension is associated with a worse overall survival. <i>Journal of Clinical Neuroscience</i> , 2021, 93, 82-87.	0.8	3
4806	Brg1 mutation alters oxidative stress responses in glioblastoma. <i>Neurochemistry International</i> , 2021, 150, 105189.	1.9	3
4807	Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas. <i>Magnetic Resonance Imaging</i> , 2021, 83, 189-195.	1.0	13
4808	N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113817.	2.6	4
4809	Genotoxic therapy and resistance mechanism in gliomas. , 2021, 228, 107922.		46
4810	Health-related quality of life of glioblastoma patients receiving post-operative concomitant chemoradiotherapy plus adjuvant chemotherapy: A longitudinal study. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2021, 26, 101339.	0.2	1
4811	TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway. <i>Translational Oncology</i> , 2021, 14, 101214.	1.7	6
4812	Chemokine receptor antagonists as immunotherapy agents and adjuncts for glioblastoma. , 2022, , 153-161.		0
4813	A systematic analysis of ATPase Cation transporting 13A2 (ATP13A2) transcriptional expression and prognostic value in human brain cancer. <i>Biomedical Signal Processing and Control</i> , 2022, 71, 103183.	3.5	3
4814	Mesenchymal stem cell-glioblastoma interactions mediated via kinin receptors unveiled by cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 152-163.	1.1	6
4815	Texture Analysis in Brain Tumor MR Imaging. <i>Magnetic Resonance in Medical Sciences</i> , 2022, 21, 95-109.	1.1	8
4816	Approach to the high-grade glioma patient. , 2021, , 153-171.		0
4817	The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3027-3035.	0.8	4
4818	DNA Methylation Analysis Identifies Patterns in Progressive Glioma Grades to Predict Patient Survival. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1020.	1.8	17
4819	Brain Neoplasm. , 2021, , 521-625.		1
4820	Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy. <i>Neurologia Medico-Chirurgica</i> , 2021, 61, 453-460.	1.0	1
4821	The complexity and regulation of repair of alkylation damage to nucleic acids. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2021, 56, 125-136.	2.3	8

#	ARTICLE	IF	CITATIONS
4822	Advancements in Neuroimaging to Unravel Biological and Molecular Features of Brain Tumors. <i>Cancers</i> , 2021, 13, 424.	1.7	21
4824	The role of E3 ubiquitin ligases in the development and progression of glioblastoma. <i>Cell Death and Differentiation</i> , 2021, 28, 522-537.	5.0	43
4825	A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care. <i>Journal of Neuro-Oncology</i> , 2021, 151, 103-112.	1.4	10
4826	An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas. <i>Brain</i> , 2022, 145, 1151-1161.	3.7	75
4827	TERT Promoter Mutation in Adult Glioblastomas: It's Correlation with Other Relevant Molecular Markers. <i>Neurology India</i> , 2021, 69, 126.	0.2	2
4828	Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours. <i>Journal of Neuro-Oncology</i> , 2021, 151, 123-133.	1.4	9
4829	Novel Magnetic Resonance Imaging and Positron Emission Tomography in the RT Planning and Assessment of Response of Malignant Gliomas. , 2021, , 1031-1048.		2
4831	Diffusion Kurtosis Imaging Reflects GFAP, TopoII $\alpha$ , and MGMT Expression in Astrocytomas. <i>Neurology India</i> , 2021, 69, 119.	0.2	0
4832	DNA direct reversal repair and alkylating agent drug resistance. , 2021, 4, 414-423.		7
4834	Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 27-36.	1.4	7
4835	Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas. <i>Oncolmmunology</i> , 2021, 10, 1902071.	2.1	8
4836	Glioma stem cells and associated molecular mechanisms in Glioblastoma Chemoresistance. , 2021, , 135-151.		0
4837	Chemoresistance mechanisms in mouse models of glioblastoma. , 2021, , 497-506.		0
4838	The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma. <i>Journal of Neurosurgical Sciences</i> , 2021, 64, 502-508.	0.3	4
4839	Epigenetic biomarkers of disease. , 2021, , 117-141.		0
4840	Predictive value of MGMT promoter methylation on the survival of TMZ treated &lt;i>&lt;i>IDH</i>-mutant glioblastoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 271-282.	1.4	31
4841	Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab011.	0.4	10
4842	Monosomy of Chromosome 10 Associated With Dysregulation of Epidermal Growth Factor Signaling in Glioblastomas. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 276.	3.8	60

#	ARTICLE	IF	CITATIONS
4845	Applications in Malignant Brain Tumors. , 2006, , 165-186.		1
4846	Overcoming Therapeutic Resistance in Malignant Gliomas: Current Practices and Future Directions. Cancer Treatment and Research, 2008, , 169-185.	0.2	7
4847	Mechano-Biological Features in a Patient-Specific Computational Model of Glioblastoma. Neuromethods, 2021, , 265-287.	0.2	1
4848	Characterizing Imaging Data. , 2010, , 197-255.		2
4849	Epigenetic Changes During Cell Transformation. Advances in Experimental Medicine and Biology, 2013, 754, 179-194.	0.8	22
4850	A20 Expressing Tumors and Anticancer Drug Resistance. Advances in Experimental Medicine and Biology, 2014, 809, 65-81.	0.8	10
4851	Adult High-Grade (Diffuse) Glioma. Molecular Pathology Library, 2015, , 77-93.	0.1	2
4852	Genomic Instability, DNA Repair Pathways and Cancer. , 2008, , 269-279.		1
4853	Of Escherichia coli and Man: Understanding Glioma Resistance to Temozolomide Therapy. , 2009, , 679-711.		3
4854	Convection-Enhanced Drug Delivery to the Brain. Neuromethods, 2010, , 291-318.	0.2	3
4855	Gene Signatures in Colorectal Cancer. , 2012, , 115-136.		2
4856	Streptozocin-Based Chemotherapy: Still a Standard of Care for Neuroendocrine Tumours?. , 2014, , 65-75.		1
4857	CEST, pH, and Glucose Imaging as Markers for Hypoxia and Malignant Transformation. , 2020, , 161-172.		1
4858	Radiomics and Machine Learning. , 2020, , 241-249.		2
4859	Primary Central Nervous System Tumors. , 2020, , 295-325.		1
4860	Clinical MR Biomarkers. Recent Results in Cancer Research, 2020, 216, 719-745.	1.8	2
4861	Classification of Brain Tumors and Corresponding Treatments. , 2009, , 503-528.		1
4862	Stereotactic Biopsies for Tumors: Indications, Limits, Diagnosis with Histopathology and other Laboratory Techniques. , 2009, , 529-547.		3



#	ARTICLE	IF	CITATIONS
4863	Nuclear Medicine Imaging of CNS: Basis and Clinical Applications. , 2015, , 595-670.		1
4864	Glioblastoma in the Elderly. Cancer Treatment and Research, 2015, 163, 159-170.	0.2	2
4865	Emerging Strategies for the Treatment of Tumor Stem Cells in Central Nervous System Malignancies. Advances in Experimental Medicine and Biology, 2015, 853, 167-187.	0.8	2
4866	Therapeutic Paradigm Underscoring Glucosinolate Sulforaphane in Chemo- and Radiosensitization of Cancer: Preclinical and Clinical Perspective. Reference Series in Phytochemistry, 2017, , 339-379.	0.2	3
4867	Diagnostic Applications of Nuclear Medicine: Brain Tumors. , 2017, , 467-505.		1
4868	Clinical, Pathological, and Molecular Prognostic Parameters in Glioblastoma Patients Undergoing Chemo- and Radiotherapy. Current Clinical Pathology, 2016, , 101-120.	0.0	2
4869	Molecular-Genetic Classification of Gliomas and Its Practical Application to Diagnostic Neuropathology. , 2017, , 73-100.		2
4870	The Role of Integrins in Angiogenesis. , 2017, , 23-36.		1
4871	Astrocytic Tumors. Recent Results in Cancer Research, 2009, 171, 3-24.	1.8	21
4872	Radiation Therapy. Recent Results in Cancer Research, 2009, 171, 125-140.	1.8	8
4873	Adjuvant Therapy. Recent Results in Cancer Research, 2009, 171, 141-153.	1.8	2
4874	Other Experimental Therapies for Glioma. Recent Results in Cancer Research, 2009, 171, 155-164.	1.8	6
4875	Adult Gliomas. Medical Radiology, 2008, , 483-499.	0.0	2
4876	Zentrales Nervensystem und Sinnesorgane. , 2013, , 373-430.		1
4877	Treatment of High-Grade Gliomas in Adults. , 2009, , 355-382.		1
4878	Predicting MGMT Methylation Status of Glioblastomas from MRI Texture. Lecture Notes in Computer Science, 2009, 12, 522-530.	1.0	35
4881	Could Be Systems-Directed Therapy Approaches Promising in Glioblastoma Patients?. , 2010, , 133-157.		2
4883	PTTG (Securin) as Cancer Biomarker. Biomarkers in Disease, 2015, , 203-231.	0.0	1

#	ARTICLE	IF	CITATIONS
4884	Predictive Role of O6-Methylguanine DNA Methyltransferase Status for the Treatment of Brain Tumors. , 2015, , 251-279.		5
4885	DNA Methylation and Carcinogenesis: Current and Future Perspectives. , 2019, , 153-171.		4
4886	MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 133, 615-622.	1.4	12
4887	Reduced expression of DNA repair genes and chemosensitivity in 1p19q codeleted lower-grade gliomas. Journal of Neuro-Oncology, 2018, 139, 563-571.	1.4	17
4888	The Essentials of Molecular Testing in CNS Tumors: What to Order and How to Integrate Results. Current Neurology and Neuroscience Reports, 2020, 20, 23.	2.0	9
4889	Cancer of the Central Nervous System. , 2008, , 1075-1136.		1
4890	Neuroepidemiology. , 2008, , 763-780.		3
4891	Cancer and the Nervous System. , 2008, , 1313-1333.		1
4892	Brain Tumor Immunology and Immunotherapy. , 2011, , 1087-1101.		1
4893	Neuroepidemiology. , 2012, , 687-703.		1
4894	Interaction of Chemotherapy and Radiation. , 2012, , 65-82.		9
4895	Cancer of the Central Nervous System. , 2014, , 938-1001.e16.		1
4896	Epigenetics and Cancer. , 2008, , 57-65.		5
4897	Genomic Biomarker Assessment in Gliomas. Surgical Pathology Clinics, 2020, 13, 209-215.	0.7	4
4898	MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma. Yearbook of Neurology and Neurosurgery, 2006, 2006, 138-139.	0.0	1
4899	Sensitive Detection and Conjoint Analysis of Promoter Methylation by Conjugated Polymers for Differential Diagnosis and Prognosis of Glioma. ACS Applied Materials & Interfaces, 2021, 13, 9291-9299.	4.0	10
4900	Fishing for Contact: Modeling Perivascular Glioma Invasion in the Zebrafish Brain. ACS Pharmacology and Translational Science, 2021, 4, 1295-1305.	2.5	11
4902	A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma. Nature Biomedical Engineering, 2021, 5, 26-40.	11.6	38

#	ARTICLE	IF	CITATIONS
4903	Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells. <i>Scientific Reports</i> , 2020, 10, 22185.	1.6	10
4904	Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features. <i>Scientific Data</i> , 2018, 5, 180245.	2.4	18
4905	Aggressive Treatment in Glioblastoma: What Determines the Survival of Patients?. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2021, 82, 112-117.	0.4	3
4906	Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma. <i>American Journal of Clinical Pathology</i> , 2017, 148, 296-307.	0.4	5
4907	Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. <i>Anti-Cancer Drugs</i> , 2021, 32, 330-336.	0.7	4
4908	Concurrent Temozolomide and Radiation, a Reasonable Option for Elderly Patients With Glioblastoma Multiforme?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 265-270.	0.6	41
4909	Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	2.1	9
4910	Long-Term Survival After Glioblastoma Multiforme. <i>Southern Medical Journal</i> , 2008, 101, 971-972.	0.3	10
4918	Dual-modality optical biopsy of glioblastomas multiforme with diffuse reflectance and fluorescence: <i>in vivo</i> retrieval of optical properties. <i>Journal of Biomedical Optics</i> , 2017, 22, 027002.	1.4	18
4919	Radiogenomic characterization of response to chemo-radiation therapy in glioblastoma is associated with PI3K/AKT/mTOR and apoptosis signaling pathways. , 2019, , .		2
4920	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	3.2	22
4921	Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth <i>in vivo</i> . <i>JCI Insight</i> , 2017, 2, .	2.3	94
4922	Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial. <i>JCI Insight</i> , 2018, 3, .	2.3	54
4923	DNA repair defects and implications for immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 4236-4242.	3.9	59
4924	Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt. <i>Journal of Clinical Investigation</i> , 2020, 130, 3069-3086.	3.9	15
4925	Alkylpurineâ€œDNAâ€œN-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. <i>Journal of Clinical Investigation</i> , 2012, 122, 253-266.	3.9	140
4926	18 Brain tumor imaging with ALA. <i>Series in Cellular and Clinical Imaging</i> , 2017, , 347-384.	0.2	2
4927	Combined radiotherapy and chemotherapy. , 2009, , 246-258.		5

#	ARTICLE	IF	CITATIONS
4928	High-grade Gliomas. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 1548-1563.	0.4	49
4929	Adult Gliomas. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1452-1475.	0.4	8
4930	Diagnosis and treatment in neuro-oncology: an oncological perspective. British Journal of Radiology, 2011, 84, S82-S89.	1.0	49
4931	Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials. Medical Science Monitor, 2016, 22, 3486-3492.	0.5	7
4932	Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma. Medical Science Monitor, 2019, 25, 3624-3635.	0.5	56
4933	Advances in treating glioblastoma. F1000prime Reports, 2014, 6, 46.	5.9	42
4934	Drug Resistance in Cancer Therapy and the Role of Epigenetics. Journal of Nippon Medical School, 2020, 87, 244-251.	0.3	39
4935	Role of MGMT as biomarker in colorectal cancer. World Journal of Clinical Cases, 2014, 2, 835.	0.3	27
4936	Rindopepimut. Drugs of the Future, 2013, 38, 147.	0.0	19
4937	DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform. PLOS Currents, 2010, 2, RRN1186.	1.4	6
4938	Homogeneous MGMT Immunoreactivity Correlates with an Unmethylated MGMT Promoter Status in Brain Metastases of Various Solid Tumors. PLoS ONE, 2009, 4, e4775.	1.1	23
4939	O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation. PLoS ONE, 2011, 6, e17156.	1.1	97
4940	Acquisition of Chemoresistance in Gliomas Is Associated with Increased Mitochondrial Coupling and Decreased ROS Production. PLoS ONE, 2011, 6, e24665.	1.1	123
4941	Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma. PLoS ONE, 2012, 7, e33449.	1.1	120
4942	The Prognostic Value of Epigenetic Silencing of p16 Gene in NSCLC Patients: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e54970.	1.1	44
4943	Expression and Functional Heterogeneity of Chemokine Receptors CXCR4 and CXCR7 in Primary Patient-Derived Glioblastoma Cells. PLoS ONE, 2013, 8, e59750.	1.1	31
4944	Modulation of HJURP (Holliday Junction-Recognizing Protein) Levels Is Correlated with Glioblastoma Cells Survival. PLoS ONE, 2013, 8, e62200.	1.1	41
4945	Genetic and Epigenetic Alterations in Primary "Progressive Paired Oligodendroglial Tumors. PLoS ONE, 2013, 8, e67139.	1.1	6

#	ARTICLE	IF	CITATIONS
4946	Early Assessment of the Efficacy of Temozolomide Chemotherapy in Experimental Glioblastoma Using [18F]FLT-PET Imaging. PLoS ONE, 2013, 8, e67911.	1.1	32
4947	IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis. PLoS ONE, 2013, 8, e68782.	1.1	96
4948	Cerebral Blood Volume Calculated by Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging: Preliminary Correlation Study with Glioblastoma Genetic Profiles. PLoS ONE, 2013, 8, e71704.	1.1	58
4949	NETRIN-4 Protects Glioblastoma Cells FROM Temozolomide Induced Senescence. PLoS ONE, 2013, 8, e80363.	1.1	20
4950	Novel Anti-Apoptotic MicroRNAs 582-5p and 363 Promote Human Glioblastoma Stem Cell Survival via Direct Inhibition of Caspase 3, Caspase 9, and Bim. PLoS ONE, 2014, 9, e96239.	1.1	95
4951	Translational Validation of Personalized Treatment Strategy Based on Genetic Characteristics of Glioblastoma. PLoS ONE, 2014, 9, e103327.	1.1	25
4952	Enhanced Anti-Tumor Effect of Zoledronic Acid Combined with Temozolomide against Human Malignant Glioma Cell Expressing O6-Methylguanine DNA Methyltransferase. PLoS ONE, 2014, 9, e104538.	1.1	23
4953	Elimination of Cancer Stem-Like Cells and Potentiation of Temozolomide Sensitivity by Honokiol in Glioblastoma Multiforme Cells. PLoS ONE, 2015, 10, e0114830.	1.1	27
4954	The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells. PLoS ONE, 2015, 10, e0131441.	1.1	29
4955	Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival. PLoS ONE, 2015, 10, e0131872.	1.1	91
4956	Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma. PLoS ONE, 2016, 11, e0151815.	1.1	42
4957	MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. PLoS ONE, 2016, 11, e0156422.	1.1	16
4958	Introduction of High Throughput Magnetic Resonance T2-Weighted Image Texture Analysis for WHO Grade 2 and 3 Gliomas. PLoS ONE, 2016, 11, e0164268.	1.1	36
4959	The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2016, 11, e0168264.	1.1	9
4960	APNG as a prognostic marker in patients with glioblastoma. PLoS ONE, 2017, 12, e0178693.	1.1	11
4961	The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS ONE, 2017, 12, e0189670.	1.1	51
4962	Complex Underdetermination and the Units of Clinical Translation. Theoria (Spain), 2015, 30, 207.	0.2	4
4963	MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histology and Histopathology, 2009, 24, 511-8.	0.5	37

#	ARTICLE	IF	CITATIONS
4964	Diagnostic markers for glioblastoma. <i>Histology and Histopathology</i> , 2011, 26, 1327-41.	0.5	16
4965	Beyond Alkylating Agents for Gliomas: Quo Vadimus?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 175-186.	1.8	7
4966	Current Standards of Care in Glioblastoma Therapy. , 0, , 197-241.		114
4967	Constitutional Mosaic Epimutations â€“ a hidden cause of cancer?. <i>Cell Stress</i> , 2019, 3, 118-135.	1.4	22
4968	DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance. <i>Genetics and Molecular Biology</i> , 2020, 43, e20190066.	0.6	17
4970	Glioblastoma and Increased Survival with Longer Chemotherapy Duration. <i>Kansas Journal of Medicine</i> , 2019, 12, 65-69.	0.1	13
4971	Genetic secrets of long-term glioblastoma survivors. <i>Bosnian Journal of Basic Medical Sciences</i> , 2019, 19, 116-124.	0.6	15
4972	Immunohistochemical Expression of Nestin as Cancer Stem Cell marker in Gliomas. <i>Journal of Neurology Neurological Science and Disorders</i> , 2019, 5, 047-051.	1.2	3
4973	The History of Neuroscience and Neurosurgery in Japan. <i>International Neuroscience Journal</i> , 2015, 1, 31-40.	0.4	5
4975	MRI-Guided Stereotactic Biopsy of Murine GBM for Spatiotemporal Molecular Genomic Assessment. <i>Tomography</i> , 2017, 3, 9-15.	0.8	7
4976	Reactive oxygen species metabolism-based prediction model and drug for patients with recurrent glioblastoma. <i>Aging</i> , 2019, 11, 11010-11029.	1.4	9
4977	Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma. <i>Aging</i> , 2020, 12, 1656-1684.	1.4	20
4978	HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines. <i>Genes and Cancer</i> , 2014, 5, 165-174.	0.6	32
4979	NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. <i>Oncotarget</i> , 2016, 7, 48081-48092.	0.8	94
4980	Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. <i>Oncotarget</i> , 2016, 7, 55169-55180.	0.8	45
4981	Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling. <i>Oncotarget</i> , 2016, 7, 55555-55571.	0.8	17
4982	Integrin Î±VÎ²3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. <i>Oncotarget</i> , 2017, 8, 27754-27771.	0.8	28
4983	Significant impact of amount of PCR input templates on various PCR-based DNA methylation analysis and countermeasure. <i>Oncotarget</i> , 2016, 7, 56447-56455.	0.8	13

#	ARTICLE	IF	CITATIONS
4984	Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. <i>Oncotarget</i> , 2016, 7, 61295-61311.	0.8	15
4985	Inhibition of PlexA1-mediated brain tumor growth and tumor-associated angiogenesis using a transmembrane domain targeting peptide. <i>Oncotarget</i> , 2016, 7, 57851-57865.	0.8	30
4986	Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines. <i>Oncotarget</i> , 2016, 7, 61988-61995.	0.8	11
4987	Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. <i>Oncotarget</i> , 2016, 7, 74860-74871.	0.8	5
4988	GBM-associated mutations and altered protein expression are more common in young patients. <i>Oncotarget</i> , 2016, 7, 69466-69478.	0.8	27
4989	Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. <i>Oncotarget</i> , 2016, 7, 69518-69535.	0.8	51
4990	Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. <i>Oncotarget</i> , 2013, 4, 2261-2270.	0.8	67
4991	Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells. <i>Oncotarget</i> , 2017, 8, 7533-7539.	0.8	32
4992	Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. <i>Oncotarget</i> , 2017, 8, 37923-37934.	0.8	23
4993	c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas. <i>Oncotarget</i> , 2017, 8, 6940-6954.	0.8	21
4994	O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis. <i>Oncotarget</i> , 2017, 8, 19674-19683.	0.8	14
4995	Biological basis and clinical study of glycogen synthase kinase-3 <sup>β</sup> -targeted therapy by drug repositioning for glioblastoma. <i>Oncotarget</i> , 2017, 8, 22811-22824.	0.8	38
4996	EFEMP1 induces $\beta$ -secretase/Notch-mediated temozolomide resistance in glioblastoma. <i>Oncotarget</i> , 2014, 5, 363-374.	0.8	41
4997	Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma. <i>Oncotarget</i> , 2017, 8, 37140-37153.	0.8	24
4998	BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. <i>Oncotarget</i> , 2017, 8, 29558-29573.	0.8	36
4999	Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. <i>Oncotarget</i> , 2014, 5, 2428-2435.	0.8	46
5000	Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma. <i>Oncotarget</i> , 2017, 8, 35639-35655.	0.8	27
5001	Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. <i>Oncotarget</i> , 2017, 8, 34896-34910.	0.8	48

#	ARTICLE	IF	CITATIONS
5002	Efficacy and safety of long-term therapy for high-grade glioma with temozolomide: A meta-analysis. <i>Oncotarget</i> , 2017, 8, 51758-51765.	0.8	26
5003	A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. <i>Oncotarget</i> , 2017, 8, 79298-79304.	0.8	119
5004	A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. <i>Oncotarget</i> , 2014, 5, 4026-4039.	0.8	62
5005	Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma. <i>Oncotarget</i> , 2017, 8, 89595-89606.	0.8	16
5006	Targeting transferrin receptor delivery of temozolomide for a potential glioma stem cell-mediated therapy. <i>Oncotarget</i> , 2017, 8, 74451-74465.	0.8	41
5007	Potential of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. <i>Oncotarget</i> , 2014, 5, 5674-5685.	0.8	159
5008	Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era. <i>Oncotarget</i> , 2014, 5, 5764-5781.	0.8	8
5009	The molecular classification of astrocytic tumors. <i>Oncotarget</i> , 2017, 8, 96340-96350.	0.8	9
5010	Temozolomide encapsulated and folic acid decorated chitosan nanoparticles for lung tumor targeting: improving therapeutic efficacy both <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 111318-111332.	0.8	23
5011	A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models. <i>Oncotarget</i> , 2018, 9, 11387-11401.	0.8	9
5012	Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O6-methylguanine-DNA methyltransferase with a double arm hybrid molecule. <i>Oncotarget</i> , 2018, 9, 35041-35055.	0.8	5
5013	Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth <i>in vivo</i> . <i>Oncotarget</i> , 2014, 5, 10934-10948.	0.8	43
5014	Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide. <i>Oncotarget</i> , 2018, 9, 27000-27015.	0.8	43
5015	Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis. <i>Oncotarget</i> , 2014, 5, 11681-11694.	0.8	50
5016	Tumour treating fields in a combinational therapeutic approach. <i>Oncotarget</i> , 2018, 9, 36631-36644.	0.8	26
5017	Regression of <i>BRAF</i> V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. <i>Oncotarget</i> , 2019, 10, 3818-3826.	0.8	33
5018	Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. <i>Oncotarget</i> , 2020, 11, 3959-3971.	0.8	8
5019	Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies. <i>Oncotarget</i> , 2020, 11, 4544-4553.	0.8	10



#	ARTICLE	IF	CITATIONS
5020	A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. <i>Oncotarget</i> , 2015, 6, 7657-7674.	0.8	46
5021	Radiation-induced PGE <sub>2</sub> sustains human glioma cell growth and survival through EGF signaling. <i>Oncotarget</i> , 2015, 6, 6840-6849.	0.8	38
5022	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. <i>Oncotarget</i> , 2015, 6, 11676-11682.	0.8	28
5023	<i>SEL1L</i> SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy. <i>Oncotarget</i> , 2015, 6, 12452-12467.	0.8	12
5024	<i>TERT</i> promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. <i>Oncotarget</i> , 2015, 6, 16663-16673.	0.8	100
5025	Inhibition of DNA-repair genes <i>Ercc1</i> and <i>Mgmt</i> enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. <i>Oncotarget</i> , 2015, 6, 29456-29468.	0.8	23
5026	A five-miRNA signature with prognostic and predictive value for <i>MGMT</i> promoter-methylated glioblastoma patients. <i>Oncotarget</i> , 2015, 6, 29285-29295.	0.8	49
5027	The radiosensitivity index predicts for overall survival in glioblastoma. <i>Oncotarget</i> , 2015, 6, 34414-34422.	0.8	100
5028	IDH mutation and <i>MGMT</i> promoter methylation in glioblastoma: results of a prospective registry. <i>Oncotarget</i> , 2015, 6, 40896-40906.	0.8	116
5029	Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance. <i>Oncotarget</i> , 2015, 6, 40998-41017.	0.8	52
5030	Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide. <i>Oncotarget</i> , 2012, 3, 1112-1123.	0.8	123
5031	Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. <i>Oncotarget</i> , 2016, 7, 8944-8955.	0.8	60
5032	miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of <i>NRAS</i> . <i>Oncotarget</i> , 2016, 7, 19531-19547.	0.8	36
5033	Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. <i>Oncotarget</i> , 2016, 7, 21556-21569.	0.8	24
5034	KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4. <i>Oncotarget</i> , 2016, 7, 24646-24655.	0.8	33
5035	Supra-complete surgery <i>via</i> dual intraoperative visualization approach (DiVA) prolongs patient survival in glioblastoma. <i>Oncotarget</i> , 2016, 7, 25755-25768.	0.8	69
5036	miRNA array screening reveals cooperative <i>MGMT</i> -regulation between miR-181d-5p and miR-409-3p in glioblastoma. <i>Oncotarget</i> , 2016, 7, 28195-28206.	0.8	34
5037	Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma. <i>Oncotarget</i> , 2013, 4, 636-646.	0.8	54

#	ARTICLE	IF	CITATIONS
5038	Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2020, 3, 48-62.	0.9	20
5039	In search of effective therapies to overcome resistance to Temozolomide in brain tumours. , 2019, 2, 1018-1031.		7
5040	Drug resistance in glioblastoma: are persisters the key to therapy?. , 2020, 3, 287-301.		23
5041	The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas. , 2021, 4, 1-16.		8
5042	Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. , 2021, 4, 17-43.		95
5043	Alterations of DNA damage repair in cancer: from mechanisms to applications. <i>Annals of Translational Medicine</i> , 2020, 8, 1685-1685.	0.7	44
5044	Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients. <i>Annals of Translational Medicine</i> , 2019, 7, 541-541.	0.7	39
5045	ONC201: a new treatment option being tested clinically for recurrent glioblastoma. <i>Translational Cancer Research</i> , 2017, 6, S1239-S1243.	0.4	31
5046	MORPHOLOGIC AND MOLECULAR FEATURES OF PRIMARY GLIOBLASTOMA IN PATIENTS SURVIVING MORE THAN 3 YEARS. <i>Siberian Journal of Oncology</i> , 2019, 18, 34-44.	0.1	3
5047	Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. <i>Cancer Management and Research</i> , 2009, 1, 137.	0.9	7
5048	Epigenomics in cancer management. <i>Cancer Management and Research</i> , 2010, 2, 255.	0.9	29
5049	Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities. <i>Current Drug Metabolism</i> , 2020, 20, 1114-1131.	0.7	20
5050	Glycobiology in Malignant Gliomas: Expression and Functions of Galectins and Possible Therapeutic Options. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 2299-2307.	0.9	13
5051	Oncolytic Adenovirus: Preclinical and Clinical Studies in Patients with Human Malignant Gliomas. <i>Current Gene Therapy</i> , 2009, 9, 422-427.	0.9	99
5052	Gene Therapy and Targeted Toxins for Glioma. <i>Current Gene Therapy</i> , 2011, 11, 155-180.	0.9	66
5053	Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy. <i>Current Molecular Imaging</i> , 2013, 2, 107-116.	0.7	1
5054	KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer. <i>Anticancer Research</i> , 2017, 37, 1349-1358.	0.5	10
5055	Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors. <i>Anticancer Research</i> , 2017, 37, 2491-2500.	0.5	16

#	ARTICLE	IF	CITATIONS
5056	Survival Analysis of Glioblastoma Multiforme. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2613-2617.	0.5	59
5057	Distribution of tumor-infiltrating immune cells in glioblastoma. CNS Oncology, 2018, 7, CNS21.	1.2	42
5058	Insular gliomas: a surgical reappraisal based on a systematic review of the literature. Journal of Neurosurgical Sciences, 2019, 63, 566-580.	0.3	2
5059	Glioblastoma: from volumetric analysis to molecular predictors. Journal of Neurosurgical Sciences, 2022, 66, .	0.3	9
5060	3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors. Radiology and Oncology, 2011, 45, 213-9.	0.6	4
5061	Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation. Asian Pacific Journal of Cancer Prevention, 2020, 21, 755-760.	0.5	3
5062	Characterizing tumor invasiveness of glioblastoma using multiparametric magnetic resonance imaging. Journal of Neurosurgery, 2020, 132, 1465-1472.	0.9	39
5063	Comparison of 5-aminolevulinic acid and sodium fluorescein for intraoperative tumor visualization in patients with high-grade gliomas: a single-center retrospective study. Journal of Neurosurgery, 2020, 133, 1324-1331.	0.9	22
5064	Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery. Journal of Neurosurgery, 2020, , 1-10.	0.9	20
5065	Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma. Journal of Neurosurgery, 2007, 106, 488-494.	0.9	14
5066	Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. Journal of Neurosurgery, 2008, 109, 106-117.	0.9	37
5067	Methylation Status of the O6-Methylguanine- Deoxyribonucleic Acid Methyltransferase Gene Promoter in World Health Organization Grade III Gliomas. Journal of Korean Neurosurgical Society, 2009, 46, 385.	0.5	6
5068	Prognostic Role of Methylation Status of the <i>MGMT</i> Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients. Journal of Korean Neurosurgical Society, 2016, 59, 26.	0.5	24
5069	Malignant Glioma with Neuronal Marker Expression : A Clinicopathological Study of 18 Cases. Journal of Korean Neurosurgical Society, 2015, 59, 44.	0.5	4
5070	The Value of Tumor Treating Fields in Glioblastoma. Journal of Korean Neurosurgical Society, 2020, 63, 681-688.	0.5	6
5071	Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?. Frontiers in Neurology, 2012, 3, 188.	1.1	17
5072	Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged. Cancers, 2021, 13, 32.	1.7	27
5073	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. Cancers, 2021, 13, 47.	1.7	106

#	ARTICLE	IF	CITATIONS
5074	Molecular Mechanisms of Treatment Resistance in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 351.	1.8	106
5075	The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 157-164.	0.6	2
5076	Canadian Recommendations for the Treatment of Glioblastoma Multiforme. <i>Current Oncology</i> , 2007, 14, 110-117.	0.9	98
5077	National trends in radiation dose escalation for glioblastoma. <i>Radiation Oncology Journal</i> , 2019, 37, 13-21.	0.7	23
5078	Long noncoding RNA TSLNC8 suppresses cell proliferation and metastasis and promotes cell apoptosis in human glioma. <i>Molecular Medicine Reports</i> , 2018, 18, 5536-5544.	1.1	10
5079	Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model. <i>Oncology Letters</i> , 2017, 13, 3767-3773.	0.8	6
5080	Receptor tyrosine kinase expression in high-grade gliomas before and after chemoradiotherapy. <i>Oncology Letters</i> , 2019, 18, 6509-6515.	0.8	3
5081	Downregulation of FHL1 protein in glioma inhibits tumor growth through PI3K/AKT signaling. <i>Oncology Letters</i> , 2020, 19, 3781-3788.	0.8	4
5082	MRI manifestations correlate with survival of glioblastoma multiforme patients. <i>Cancer Biology and Medicine</i> , 2012, 9, 120-3.	1.4	23
5083	Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?. <i>Annals of Translational Medicine</i> , 2015, 3, 7.	0.7	31
5084	Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. <i>Annals of Translational Medicine</i> , 2015, 3, 95.	0.7	85
5085	Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. <i>Annals of Translational Medicine</i> , 2016, 4, 54.	0.7	46
5087	Gliomatosis cerebri type II: two case reports. <i>Journal of Medical Case Reports</i> , 2009, 3, 7225.	0.4	4
5088	Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: A single institutional analysis of 27 cases. <i>Indian Journal of Cancer</i> , 2015, 52, 599.	0.2	21
5089	Influence of Oncotherapy and Clinical Parameters on Survival of Glioblastoma Patients: A Single Center Experience. <i>Neurology India</i> , 2019, 67, 1066.	0.2	2
5090	Glioblastoma in the elderly: Therapeutic dilemmas. , 2015, 6, 573.		7
5091	A potential role of karyopherin $\alpha 2$ in the impaired maturation of dendritic cells observed in glioblastoma patients. <i>Neuroimmunology and Neuroinflammation</i> , 2015, 2, 8.	1.4	1
5092	Management of glioma patients during the coronavirus disease 2019 pandemic. <i>Glioma (Mumbai, India)</i> , 2020, 3, 31.	0.0	2

#	ARTICLE	IF	CITATIONS
5093	Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report. <i>Glioma (Mumbai, India)</i> , 2019, 2, 167.	0.0	5
5094	Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells. <i>Glioma (Mumbai, India)</i> , 2018, 1, 175.	0.0	5
5095	O-6-methylguanine-DNA methyltransferase promoter methylation can change in glioblastoma recurrence due to intratumor heterogeneity. <i>Glioma (Mumbai, India)</i> , 2018, 1, 208.	0.0	2
5096	Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 78-83.	0.3	7
5097	Adjunctive markers for classification and diagnosis of central nervous system tumors: results of a multi-center neuropathological survey in Korea. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 165-170.	0.4	1
5098	A Consideration of MGMT Gene Promotor Methylation Analysis for Glioblastoma Using Methylation-Specific Polymerase Chain Reaction and Pyrosequencing. <i>Korean Journal of Pathology</i> , 2011, 45, 21.	1.2	4
5099	MGMT Gene Promoter Methylation Analysis by Pyrosequencing of Brain Tumour. <i>Korean Journal of Pathology</i> , 2011, 45, 455.	1.2	1
5100	The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells & In Vitro and & In Vivo. <i>Cancer Research and Treatment</i> , 2016, 48, 687-697.	1.3	23
5101	Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro. <i>Cancer Research and Treatment</i> , 2019, 51, 696-705.	1.3	16
5102	Epigenetic Modifications: Are we Closer to Clinical Applicability?. <i>Journal of Pharmacogenomics &amp; Pharmacoproteomics</i> , 2016, 07, .	0.2	2
5103	Preclinical Efficacy of Nimotuzumab, an Anti-Egfr Monoclonal Antibody as a Single Agent Therapy in Human GBM u87mg Xenografts. <i>Journal of Cancer Therapy</i> , 2012, 03, 245-255.	0.1	5
5104	A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Recurrent Glioblastoma Multiforme: Final Report (Protocol BT-21). <i>Journal of Cancer Therapy</i> , 2014, 05, 946-956.	0.1	16
5105	Issues to Consider in Designing Immunotherapy Clinical Trials for Glioblastoma Management. <i>Journal of Cancer Therapy</i> , 2016, 07, 573-585.	0.1	1
5106	Novel diagnostic and therapeutic approaches to malignant glioma. <i>Swiss Medical Weekly</i> , 2011, 141, w13210.	0.8	46
5107	O 6 -methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma. <i>Annals of Saudi Medicine</i> , 2019, 39, 410-416.	0.5	4
5108	Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers. , 2012, 31, 206-209.		8
5109	Clinical neuropathology practice guide 1-2013: Molecular subtyping of glioblastoma: ready for clinical use?. , 2013, 32, 5-8.		3
5110	Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. , 2013, 32, 148-158.		25

#	ARTICLE	IF	CITATIONS
5111	Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. , 2014, 33, 6-14.		45
5112	Neuropathological biomarker candidates in brain tumors: key issues for translational efficiency. , 2010, 29, 41-54.		13
5113	FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice â€” a publication under the auspices of the Research Committee of the		

#	ARTICLE	IF	CITATIONS
5129	Prognostic Factors for Long-Term Survival after Glioblastoma. , 2008, 12, 45-48.		124
5130	Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard-versus Abbreviated-Course Radiotherapy. , 2015, 19, 15-20.		21
5131	Epidemiology and Standard Therapy in Gliomas(<Special Issue>Current Status and Perspectives of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.0	1
5132	Potential Molecular and Cellular Mechanism of Psychotropic Drugs. Clinical Psychopharmacology and Neuroscience, 2014, 12, 94-110.	0.9	15
5133	Systematic analysis of the long noncoding RNA (lncRNA)-miRNA-mRNA competing endogenous RNA network to identify prognostic biomarkers and the potential regulatory axis in glioblastoma multiforme. Translational Cancer Research, 2021, 10, 4739-4755.	0.4	2
5134	BrainBase: a curated knowledgebase for brain diseases. Nucleic Acids Research, 2022, 50, D1131-D1138.	6.5	11
5135	Preoperative Apparent Diffusion Coefficient of Peritumoral Lesion Associate with Recurrence in Patients with Glioblastoma. Neurologia Medico-Chirurgica, 2022, 62, 28-34.	1.0	3
5136	Application of Cluster Analysis of Time Evolution for Magnetic Resonance Imaging -Derived Oxygen Extraction Fraction Mapping: A Promising Strategy for the Genetic Profile Prediction and Grading of Glioma. Frontiers in Neuroscience, 2021, 15, 736891.	1.4	6
5137	Glioma: molecular signature and crossroads with tumor microenvironment. Cancer and Metastasis Reviews, 2022, 41, 53-75.	2.7	63
5138	Zika Virus: A New Therapeutic Candidate for Glioblastoma Treatment. International Journal of Molecular Sciences, 2021, 22, 10996.	1.8	14
5139	Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 335.	3.5	8
5141	Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant. Journal of Neuro-Oncology, 2021, 155, 267-276.	1.4	10
5142	Unboxing the molecular modalities of mutagens in cancer. Environmental Science and Pollution Research, 2022, 29, 62111-62159.	2.7	19
5143	Utilization of Pharmacological Ascorbate to Enhance Hydrogen Peroxide-Mediated Radiosensitivity in Cancer Therapy. International Journal of Molecular Sciences, 2021, 22, 10880.	1.8	9
5144	Precision Neurosurgery: A Path Forward. Journal of Personalized Medicine, 2021, 11, 1019.	1.1	2
5145	A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). BMC Cancer, 2021, 21, 1105.	1.1	6
5146	Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy. International Journal of Molecular Sciences, 2021, 22, 11180.	1.8	19
5147	New Approaches to Glioblastoma. Annual Review of Medicine, 2022, 73, 279-292.	5.0	14

#	ARTICLE	IF	CITATIONS
5148	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. <i>Neuro-Oncology</i> , 2021, 23, iii1-iii105.	0.6	804
5149	Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults. <i>Neurology</i> , 2022, 98, .	1.5	20
5150	Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma. <i>Nature Communications</i> , 2021, 12, 6130.	5.8	14
5151	Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma. <i>Laboratory Investigation</i> , 2022, 102, 194-203.	1.7	8
5152	In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection. <i>Med</i> , 2021, 2, 1171-1193.e11.	2.2	24
5153	Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2022, 156, 33-48.	1.4	14
5154	P2Y12 Purinergic Receptor and Brain Tumors: Implications on Glioma Microenvironment. <i>Molecules</i> , 2021, 26, 6146.	1.7	7
5155	A szemelyre szabott terápia legjobban lehetőségei a molekuláris onkológiában. <i>Scientia Et Securitas</i> , 2021, 2, 191-199.	0.1	0
5156	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab142.	0.4	15
5157	Regulation of autophagy as a therapeutic option in glioblastoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2021, 26, 574-599.	2.2	12
5158	American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors. <i>Future Oncology</i> , 2021, 17, 4425-4429.	1.1	0
5159	Electrolyte and renal disorders in patients with newly diagnosed glioblastoma. <i>Future Oncology</i> , 2021, 17, 4711-4719.	1.1	1
5160	Transcriptomic Analysis Identified Two Subtypes of Brain Tumor Characterized by Distinct Immune Infiltration and Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 734407.	1.3	4
5161	Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours. <i>Lancet Neurology</i> , The, 2021, 20, 943-955.	4.9	47
5162	Comprehensive pharmacogenomics characterization of temozolomide response in gliomas. <i>European Journal of Pharmacology</i> , 2021, 912, 174580.	1.7	6
5164	TEMOZOLOMIDE CHEMOTHERAPY TRIAL SETS NEW STANDARD OF CARE FOR RECENTLY DIAGNOSED GLIOMAS. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2005, 5, 26.	0.0	0
5165	ZNS-Tumoren. , 2006, , 597-604.		0
5166	Glioblastoma Multiforme—Past, Present, and Future. <i>Oncology &amp; Hematology Review</i> , 2006, 00, 1.	0.2	1



#	ARTICLE	IF	CITATIONS
5167	An Overview of Innovative Techniques to Improve Cervical Cancer Screening. Analytical Cellular Pathology, 2006, 28, 233-246.	0.7	9
5169	Recent advances in the medical therapy of high-grade gliomas. Future Neurology, 2006, 1, 831-842.	0.9	0
5171	Cytotoxic Chemotherapy for Diffuse Gliomas. , 2007, , 153-170.		0
5172	The DNA Damage Response, DNA Repair, and AML. , 2007, , 97-131.		1
5174	Brain Tumors: Recent Advances in Diagnosis and Classification. Archives of Pathology and Laboratory Medicine, 2007, 131, 225-227.	1.2	1
5176	Advances in the Treatment of Brain Metastases. Translational Medicine Series, 2007, , 207-230.	0.0	0
5179	Malignant Glioma: Chemotherapy Perspective. , 2008, , 223-231.		0
5180	Pineal Region Tumors: Chemotherapy Perspective. , 2008, , 377-382.		0
5182	DNA Methylation Profiles as Prognostic Markers for Cancer. , 2008, , 333-346.		0
5183	Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathology and Applied Neurobiology, 2008, 35, no-no.	1.8	33
5184	Molecular Neurooncology and Neoangiogenesis of Malignant Gliomas. , 2009, , 23-55.		0
5185	The Future of Molecular Neuro-Oncology. , 2009, , 3201-3228.		0
5186	Mechanisms of Treatment Resistance: Molecular and Clinical Examples for Radio- and Chemotherapy. Medical Radiology, 2009, , 243-250.	0.0	0
5187	Novel Strategies for the Treatment of Brain Cancer. , 2009, , 85-102.		0
5189	A Case Report of Recurrent Glioblastoma treated with Bevacizumab and Irinotecan. Japanese Journal of Neurosurgery, 2009, 18, 145-150.	0.0	0
5190	Epigenetic Profiling of Gliomas. , 2009, , 615-650.		1
5191	Genomic Medicine, Brain Tumors and Gliomas. , 2009, , 956-966.		0
5192	Molecular Markers of Gliomas. , 2009, , 157-177.		0

#	ARTICLE	IF	CITATIONS
5193	Personalized Therapy for Cancer. , 2009, , 165-254.		0
5194	Cancer Biomarkers Associated with Damage Response Genes. , 2009, , 307-330.		0
5195	Comprehensive Brain Tumor Management. , 2009, , 735-748.		0
5196	Radiosensitizers in Neurooncology. , 2009, , 987-1005.		0
5197	Neuro-oncogenesis Induced by Nitroso Compounds in Rodents and Strain-Specific Genetic Modifiers of Predisposition. , 2009, , 207-226.		0
5198	Tumori cerebrali. , 2009, , 297-314.		0
5199	Neuro-oncology. , 2009, , 289-340.		0
5201	Update on Diagnostic Practice: Tumors of the Nervous System. Archives of Pathology and Laboratory Medicine, 2009, 133, 1062-1077.	1.2	18
5202	Aberrations of the Epigenome in Gliomas: Novel Targets for Therapy. , 2010, , 185-202.		1
5203	Molecular Mechanisms of Pathogenesis in Glioblastoma and Current Therapeutic Strategies. , 2010, , 85-93.		0
5205	Recent Advances in Chemotherapy for Malignant Glioma(<SPECIAL ISSUE>Progress in Treatment for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.0	0
5206	Intracranial Tumors. , 2010, , 533-538.		0
5207	Retrochiasmal disorders. , 2010, , 293-337.		0
5208	Radiotherapy and Chemotherapy. , 2010, , 82-94.		0
5209	Recent Advances in Biological Research on Malignant Glioma and Their Therapeutic Relevance(<SPECIAL ISSUE>Progress in Treatment for Malignant Gliomas). Japanese Journal of Neurosurgery, 2010, 19, 880-886.	0.0	1
5210	What Does Awake Surgery bring to Glioma Surgery?(<SPECIAL ISSUE>Progress in Treatment for) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.0	0
5211	Neoplasms of the Central Nervous System. , 2010, , 484-528.		0
5212	Contribuci3n de la epigen3tica al manejo personalizado del c4ncer. , 2010, , 301-320.		0

#	ARTICLE	IF	CITATIONS
5215	Anaplastic Oligodendrogliomas and Mixed Gliomas. , 2011, , 233-248.		0
5216	Combined Modality Therapy in Cancer Management. , 2011, , 483-517.		0
5217	High-Grade Astrocytomas. , 2011, , 195-232.		0
5218	Epidemiology and Risk Factors. , 2011, , 3-25.		1
5219	Role of MGMT in Glioblastomas. , 2011, , 131-136.		0
5220	Long-term survival with unmethylated MGMT glioblastoma multiforme. International Journal of Case Reports and Images, 2011, 2, 8.	0.0	1
5221	Glioblastoma Patients: Role of Methylated MGMT. , 2011, , 73-79.		0
5222	Glioblastoma Patients: p15 Methylation as a Prognostic Factor. , 2011, , 399-404.		0
5223	Glioblastoma Patients: Chemotherapy with Cisplatin, Temozolomide and Thalidomide. , 2011, , 255-260.		0
5224	Assessment of DNA Repair Mechanisms to Determine the Susceptibility of Non-small Cell Lung Cancer to Alkylating Agents. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	1
5225	Malignant Gliomas: Present and Future Therapeutic Drugs. , 2011, , 207-214.		0
5226	Tumoren van het zenuwstelsel. , 2011, , 501-512.		0
5227	Gliomagenesis: Advantages and Limitations of Biomarkers. , 2011, , 11-24.		1
5230	Low- and High-Grade Gliomas: Extensive Surgical Resection. , 2011, , 229-237.		0
5231	Glioblastoma Cancer Stem Cells: Response to Epidermal Growth Factor Receptor Kinase Inhibitors. , 2011, , 213-226.		0
5232	Hirntumoren. , 2011, , 687-721.		0
5235	ProgrÃ©s rÃ©cents dans la gÃ©nÃ©mique et dans le traitement mÃ©dical des gliomes cÃ©rÃ©braux. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 11-21.	0.0	0
5236	Glioblastoma Multiforme. , 2011, , 233-241.		0

#	ARTICLE	IF	CITATIONS
5237	Inhibitors of DNA Repair and Response to Ionising Radiation. , 2011, , 143-171.		0
5240	Molecular targeting of cancer stem cells. , 2011, , 202-216.		0
5241	Stem Cell Distribution and MGMT Expression in Glioblastoma: Role of Intratumoral Hypoxic Gradient. , 2012, , 139-147.		0
5242	Biomarker Discovery, Validation and Clinical Application for Patients Diagnosed with Glioma. , 0, , .		0
5243	Genetic Diversity of Glioblastoma Multiforme: Impact on Future Therapies. , 0, , .		0
5244	Predictive Biomarkers as a Guide to Future Therapy Selection in Melanoma. , 2012, , 27-40.		0
5245	Diagnostic Evaluation of Diffuse Gliomas. , 0, , .		1
5246	Bone Marrow-Derived Cells Support Malignant Transformation of Low-Grade Glioma. , 0, , .		0
5247	Genomic Abnormalities in Gliomas. , 0, , .		0
5248	Somatic Alterations and Targeted Therapy. , 2012, , 51-101.		0
5251	Cancer and the Nervous System. , 2012, , 1116-1136.		0
5252	Aberrant DNA Methylation in Ependymomas. , 2012, , 287-295.		0
5253	Low Leukocyte MGMT Accompanies Temozolomide-Induced Myelotoxicity in Brain Tumor Patients. Journal of Cancer Research Updates, 0, , .	0.3	0
5254	Management of Malignant Glioma in the Temozolomide Era(<Special Issue>Current Status and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.0	0
5255	Central Nervous System Tumors. , 2012, , 1-18.		1
5257	Problems to Be Solved in Molecular Oncology. , 2012, , 237-252.		0
5258	High-Grade Gliomas. , 2012, , 461-472.		0
5259	Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia and Glioma. , 2012, , 431-451.		0

#	ARTICLE	IF	CITATIONS
5260	Temozolomide in the Treatment of Aggressive Pituitary Tumors—An Overview of Existing Knowledge and Future Perspectives. <i>US Endocrinology</i> , 2012, 08, 112.	0.3	0
5261	Cancer and the Nervous System. , 2012, , 1141-1157.		0
5264	Current approaches to improve the anticancer chemotherapy with alkylating agents: state of the problem in world and Ukraine. <i>Biopolymers and Cell</i> , 2012, 28, 83-92.	0.1	3
5265	The Potential and Challenges of siRNA-Based Targeted Therapy for Treatment of Patients with Glioblastoma. , 0, , .		0
5268	Managing the Elderly Patient. , 2013, , 171-196.		0
5269	Personalized Neurology. , 2013, , 575-612.		0
5270	Kombination von Zytostatika mit Strahlentherapie: Radiochemotherapie. , 2013, , 249-269.		0
5271	TYPES OF DNA DAMAGE. , 2013, , 115-118.		0
5272	NUCLEOTIDE EXCISION REPAIR (NER). , 2013, , 26-38.		0
5273	Role of Integrins in Angiogenesis. , 2013, , 79-91.		1
5274	IGF-I Antisense and Triple-Helix Gene Therapy of Glioblastoma. , 0, , .		1
5275	Bridging Science and Clinical Practice: How to Use Molecular Markers When Caring for a Patient with Brain Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 108-113.	1.8	0
5276	BRCA Mutation and PARP Inhibitors. , 2013, , 417-447.		0
5277	Recent Approaches and Novel Therapeutic Targets in Human Glioma. <i>Advances in Cancer: Research &amp; Treatment</i> , 2013, , 1-18.	0.0	0
5278	Drugs for Primary Brain Tumors: An Update. <i>Tumors of the Central Nervous System</i> , 2014, , 291-299.	0.1	0
5279	MR Perfusion Imaging: ASL, T2*-Weighted DSC, and T1-Weighted DCE Methods. , 2014, , 3-25.		0
5280	Immunotherapies for Brain Cancer: From Preclinical Models to Human Trials. <i>Tumors of the Central Nervous System</i> , 2014, , 239-251.	0.1	0
5282	Blood—Brain Barrier and CNS Malignancy. <i>Cancer Drug Discovery and Development</i> , 2014, , 519-539.	0.2	0

#	ARTICLE	IF	CITATIONS
5283	MR Imaging Evaluation of Posttreatment Changes in Brain Neoplasms. , 2014, , 603-640.		0
5284	Immunotherapy of Malignant Tumors Using Antisense Anti-IGF-I Approach: Case of Glioblastoma. Journal of Cancer Therapy, 2014, 05, 685-705.	0.1	2
5286	Novel Therapeutic Approaches to Malignant Gliomas. , 2014, , 315-350.		0
5287	Molecular Testing in CNS tumors. , 2014, , 243-255.		0
5288	PTTG (Securin) as Cancer Biomarker. , 2014, , 1-24.		0
5289	Autophagy in Glioma Cells. , 2014, , 117-149.		1
5290	Clinical Activity of Metronomic Chemotherapy in Central Nervous System Cancers. , 2014, , 143-155.		0
5291	DNA Methylation as a Biomarker in Cancer. Biomarkers in Disease, 2015, , 107-133.	0.0	0
5292	Novel Strategies in Chemotherapy for Gliomas. Japanese Journal of Neurosurgery, 2015, 24, 386-398.	0.0	0
5294	A Single Nucleotide Polymorphism in the MGMT Gene is a Novel Prognostic Biomarker in Patients with Metastatic Colorectal Cancer. British Journal of Medicine and Medical Research, 2015, 5, 604-611.	0.2	0
5295	Integrated Diagnostic Approach for Adult Oligodendroglioma and Oligoastrocytoma. Brain Disorders & Therapy, 2015, 04, .	0.1	2
5296	Analysis of Prognostic Marker Panel for High-Grade Serous Ovarian Cancer through Age-Dependent DNA Methylation. Journal of Phylogenetics & Evolutionary Biology, 2015, 03, .	0.2	1
5298	Severe and Prolonged Myelosuppression during Concomitant Temozolomide and Radiotherapy Treatment in a Patient with Glioblastoma Multiforme. International Journal of Medical and Pharmaceutical Case Reports, 2015, 2, 95-100.	0.0	0
5299	Glioblastoma multiforme (GBM). , 2015, , 225-236.		0
5300	Acute Liver Injury during Co-treatment with Levetiracetam and Temozolomide. Liver Research - Open Journal, 2015, 1, 21-25.	0.2	3
5301	Techniques in the Resection of Gliomas. Neuro-Oncology Practice, 2015, 5, 3-12.	1.0	0
5303	A Review of Standard Therapeutic Approaches and Clinical Trials for treating Gliomas with an Eye towards the Immunotherapy Future. Japanese Journal of Neurosurgery, 2016, 25, 922-927.	0.0	0
5304	Imaging Targeted Therapy Response and Resistance in Glioblastoma. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 175-198.	0.1	0

#	ARTICLE	IF	CITATIONS
5305	Diagnostic Applications of Nuclear Medicine: Brain Tumors. , 2016, , 1-40.		0
5306	Glioblastoma. , 2016, , 22-39.		0
5307	Translating Molecular Biomarkers of Gliomas to Clinical Practice. , 2016, , 33-53.		0
5308	Therapeutic Paradigm Underscoring Glucosinolate Sulforaphane in Chemo- and Radiosensitization of Cancer: Preclinical and Clinical Perspective. , 2016, , 1-41.		0
5309	Neoplastic Diseases. , 2016, , 229-244.		0
5310	Principles of Surgical Treatment. , 2016, , 167-175.		0
5311	MGMT Promoter Gene Methylation Assay. , 2016, , 4-26-4-27.		0
5312	Gliomas. , 2016, , 507-514.		0
5313	Hirntumoren. Springer-Lehrbuch, 2016, , 311-365.	0.1	1
5314	Chemotherapeutics and Their Efficacy. , 2016, , 133-141.		0
5315	Overview of CNS Gliomas in Childhood. Clinical Pediatric Hematology-Oncology, 2016, 23, 8-16.	0.0	0
5316	Bcl-xL inhibition - a novel strategy for glioma therapy. Aging, 2016, 8, 1830-1831.	1.4	3
5317	Title is missing!. , 2017, , .		0
5318	Cytotoxic Chemotherapy and Targeted Therapy for Aggressive Pituitary Tumors. , 2017, , 581-594.		0
5319	Molecular Epidemiology of Diffuse Low-Grade Glioma. , 2017, , 55-72.		0
5320	How to understand the Results of Basic Glioma Genome Sequence Data. Japanese Journal of Neurosurgery, 2017, 26, 806-816.	0.0	2
5321	Unusual Presentation of a High Grade Spinal Cord Glioma: Case Report. Journal of Pain Management & Medicine, 2017, 03, .	0.2	0
5322	Lysophosphatidic Acid Signalling Enhances Glioma Stem Cell Properties. Pancreatic Islet Biology, 2017, , 171-189.	0.1	0

#	ARTICLE	IF	CITATIONS
5323	Tumoren van het zenuwstelsel. , 2017, , 499-512.		0
5324	3.0T Imaging of Brain Gliomas. , 2017, , 271-319.		0
5325	Cancer Epigenomics on Precision Medicine and Immunotherapy. , 2017, , 1-21.		0
5326	Molecular Testing for Glioblastoma. , 2017, , 339-347.		0
5327	Molecular genetic markers of gliomas. Molekuliarnaia Genetika, Mikrobiologija I Virusologija, 2017, 35, 132.	0.1	1
5328	Prognostic effects of O6-Methylguanine DNA methyltransferase promoter hypermethylation in high-grade glioma patients with carmustine wafer implants. Formosan Journal of Surgery, 2017, 50, 45.	0.1	0
5329	Modulated radiotherapy with concurrent and adjuvant temozolomide for anaplastic gliomas: Indian single-center data. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 495.	0.1	0
5331	Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations. Journal of Neuro-Oncology, 2017, 134, 551-557.	1.4	1
5332	A Retrospective Study Evaluating Effectiveness of Concurrent And Adjuvant Temozolamide in Newly Diagnosed Glioblastoma Multiforme in Indian Population.. IOSR Journal of Dental and Medical Sciences, 2017, 16, 11-12.	0.0	0
5333	BET-inhibitors as sensitizers for BH3-mimetics. Aging, 2017, 9, 1475-1476.	1.4	0
5336	Chapter 15: Photoablation of Glioblastoma Stem Cells by Single-Walled Carbon Nanotubes Functionalized with CD133 Antibody. , 2017, , 389-410.		0
5338	Photoablation of Glioblastoma Stem Cells by Single-Walled Carbon Nanotubes Functionalized with CD133 Antibody. , 2017, , 389-410.		0
5339	Chemotherapeutic Strategies in Brain Tumors. , 2018, , 89-104.		0
5341	Activation of Lxrr Causes Metabolic Reprogramming and Sensitizes Solid Tumors to Bcl-xL Inhibition Mediated Apoptosis. SSRN Electronic Journal, 0, , .	0.4	0
5343	High-Grade Gliomas. , 2018, , 83-102.		0
5344	The State-of-the-Art Treatments for Brain Tumors using Cell Atlas and Artificial Intelligence. Japanese Journal of Neurosurgery, 2018, 27, 889-895.	0.0	0
5345	Pediatric Glioma. Pediatric Oncology, 2018, , 171-202.	0.5	0
5346	High-Grade Gliomas. , 2018, , 580-585.e2.		0



#	ARTICLE	IF	CITATIONS
5347	Glioblastoma treatment: Where to now?. Integrative Cancer Science and Therapeutics, 2018, 5, .	0.1	0
5348	Be cautious to bid farewell to GBMO: evidence from a propensity score analysis. Glioma (Mumbai, Tj ETQq1 1 0.784314 rgBT/Overlo	0.0	0
5349	DNA direct repair pathways in cancer. AIMS Medical Science, 2018, 5, 284-302.	0.2	0
5350	Outcomes of Treatment for Glioblastoma Multiforme in Adult Patients: A Single Institution Experience from the Eastern Black Sea Region of Turkey. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2018, 28, 30-35.	0.1	2
5351	The prolonged use of temozolomide in glioblastoma patients. Jbnc - Jornal Brasileiro De Neurocirurgia, 2018, 24, 107-112.	0.0	0
5352	Glioblastoma Multiforma Tedavisinde Kanser Kâ¼k Hâ¼crelerinin Temozolomide Karâ¼± Oluâ¼turduklarâ¼± Direnâ¼. Sakarya Medical Journal, 2018, 8, 379-387.	0.1	0
5353	Geriatrik Hastalarda Nâ¼ronkolojik Sorunlar. Sâ¼leyman Demirel Âœniversitesi Tâ¼p Fakâ¼ltesi Dergisi, 0, , .	0.0	0
5356	THE VALUE OF PROGNOSTIC FACTORS FOR GLIOBLASTOMA TREATED WITH CONCURRENT THERMOCHEMORADIOTHERAPY. Siberian Journal of Oncology, 2018, 17, 27-36.	0.1	0
5357	Genomic Applications in Brain Tumors. , 2019, , 289-308.		0
5358	Diffusion Kurtosis Imaging Reflects Glial Fibrillary Acidic Protein (GFAP), Topo IIâ¼±, and Oâ¼-Methylguanine-DNA Methyltransferase (MGMT) Expression in Astrocytomas. Medical Science Monitor, 2018, 24, 8822-8830.	0.5	1
5360	Techniques/Tools to Study Epigenetic Biomarkers in Human Cancer Detection. , 2019, , 327-351.		0
5361	Computer-assisted brain surgery (neuronavigation) in Abuja, North Central Nigeria: A 3-year retrospective review and practical challenges. Nigerian postgraduate medical journal, The, 2019, 26, 174.	0.1	5
5362	The role of the deficient DNA mismatch repair system as a factor of sensitivity to targeted therapy for glioblastoma multiforme. Onkologiya Zhurnal Imeni P A Gertsena, 2019, 8, 379.	0.0	0
5363	The Evaluation of the Effects of Temozolomide on MGMT Gene Expression in MCF-7 and SKBR3 Human Breast Cancer Cell Lines. Journal of Cancer Therapy, 2019, 10, 215-228.	0.1	0
5364	Impact of stereotactic radiosurgery on first recurrence of glioblastoma. Glioma (Mumbai, India), 2019, 2, 145.	0.0	0
5366	Quantitative Proteomics Reveals Global Reduction of Endocytic Machinery Components in Gliomas. SSRN Electronic Journal, 0, , .	0.4	0
5367	Age: A Criterion to Offer Surgical Treatment as aâ¼Cyoreductive Tool for Malignant Primary Brain Tumour?. , 2019, , 41-54.		0
5368	Central Nervous System Cancers. , 2019, , 83-131.		1

#	ARTICLE	IF	CITATIONS
5369	Gliome. Springer Reference Medizin, 2019, , 1-14.	0.0	0
5370	Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 259-289.	0.1	1
5374	The importance of MGMT Promoter Methylation Status for Glioblastomas Prognosis: meta-analysis. Jbnc - Jornal Brasileiro De Neurocirurgia, 2020, 29, 595-611.	0.0	0
5375	Immunohistochemical expression of Nestin as Cancer Stem Cell Marker in gliomas. Journal of Neuroscience and Neurological Disorders, 2019, 3, 162-166.	0.1	1
5376	Imaging Genomics. , 2020, , 223-239.		0
5377	Diagnosis, treatment, and survival in spinal dissemination of primary intracranial glioblastoma: systematic literature review. Journal of Neurosurgery: Spine, 2019, 31, 723-732.	0.9	11
5378	Carnosine increases efficiency of temozolomide and irradiation treatment of isocitrate dehydrogenase-wildtype glioblastoma cells in culture. Future Oncology, 2019, 15, 3683-3691.	1.1	0
5379	Indications and Limitations of Conventional Imaging“ Current Clinical Practice in the“Context of Standard Therapy. , 2020, , 1-15.		1
5380	Chemotherapy and Future Developments. , 2020, , 29-37.		0
5382	CNS Tumors in Older Adults. , 2020, , 813-821.		0
5383	Gliome. Springer Reference Medizin, 2020, , 1-14.	0.0	0
5384	Tumors: Brain. , 2020, , 1-8.		0
5387	Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy. Current Medicinal Chemistry, 2020, 27, 2814-2825.	1.2	1
5389	The effects of O <sup>6</sup> -methyl guanine DNA-methyl transferase promotor methylation and CpG1, CpG2, CpG3 and CpG4 methylation on treatment response and their prognostic significance in patients with glioblastoma. Balkan Journal of Medical Genetics, 2020, 23, 33-41.	0.5	3
5390	Immunohistochemical expression of MGMT in Gliomas. Cellular and Molecular Biology, 2020, 66, 20.	0.3	0
5397	Modern Treatments for Gliomas Improve Outcome. Current Cancer Therapy Reviews, 2020, 16, 221-245.	0.2	0
5398	Overview of Modern Surgical Management of Central Nervous System Tumors: North American Experience. Current Cancer Therapy Reviews, 2020, 16, 207-220.	0.2	0
5399	TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy. Cancers, 2021, 13, 5362.	1.7	13

#	ARTICLE	IF	CITATIONS
5400	Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients. <i>Cancers</i> , 2021, 13, 5358.	1.7	7
5401	Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT. <i>Cancers</i> , 2021, 13, 5420.	1.7	6
5402	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 36, 113-132.	0.9	2
5403	Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 770561.	1.3	51
5404	MGMT promoter methylation in large-cell neuroendocrine carcinoma. <i>Medicine, Case Reports and Study Protocols</i> , 2021, 3, e0178.	0.0	0
5405	Liquid Biopsy and Primary Brain Tumors. <i>Cancers</i> , 2021, 13, 5429.	1.7	29
5406	NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction. <i>Cancer Biology and Therapy</i> , 2021, 22, 587-597.	1.5	17
5407	Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival. <i>BMC Neurology</i> , 2021, 21, 424.	0.8	18
5408	Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. <i>Frontiers in Immunology</i> , 2021, 12, 770390.	2.2	44
5409	Current Status of Adjuvant Therapy for Glioblastoma and Potential Novel Therapies. <i>Japanese Journal of Neurosurgery</i> , 2020, 29, 188-197.	0.0	0
5410	Primäre Hirntumoren: Grundlagen. <i>Springer Reference Medizin</i> , 2020, , 1-9.	0.0	0
5411	A Serum Proteomic Signature Predicting Survival in Patients with Glioblastoma. <i>Journal of Biochemistry and Analytical Studies</i> , 2020, 4, .	0.1	4
5413	Role of Intensity Modulated Radiotherapy (IMRT) in the Treatment of High-Grade Gliomas. <i>Al-Azhar International Medical Journal</i> , 2020, .	0.0	1
5414	Research progress on radiotherapy technology and dose fraction scheme for advanced gliomas. <i>Translational Cancer Research</i> , 2020, 9, 7642-7651.	0.4	0
5415	Chemotherapy for Brain Tumors. , 2021, , 357-383.		0
5416	Localization of Brain Tumors. , 2021, , 265-282.		0
5417	Drug Repositioning for the Treatment of Glioma: Current State and Future Perspective. , 0, , .		0
5418	Radiotherapy in Brain Tumors. , 2021, , 313-334.		1

#	ARTICLE	IF	CITATIONS
5420	An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa117.	0.4	1
5423	Endoplasmic Reticulum Stress and Autophagy in Cancer. , 2020, , 355-402.		0
5424	Gliome. Springer Reference Medizin, 2020, , 997-1010.	0.0	0
5426	Basic Radiobiology and Radiation Physics Primer. , 2020, , 271-279.		0
5427	Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa137.	0.4	2
5428	Tumeurs cÃ©rÃ©brales, gliomes malins. , 2020, , 227-237.e2.		0
5429	Evolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma. , 2020, , 1047-1066.		0
5430	Glioblastoma. , 2020, , 173-182.		0
5431	Staging and Target Volume Definition by Imaging in CNS Tumors. <i>Medical Radiology</i> , 2020, , 151-168.	0.0	0
5432	Precision Oncology. <i>RSC Detection Science</i> , 2020, , 345-362.	0.0	1
5437	IDHâ€œwild-type glioblastoma cell density and infiltration distribution influence on supramarginal resection and its impact on overall survival: a mathematical model. <i>Journal of Neurosurgery</i> , 2022, 136, 1567-1575.	0.9	20
5438	A Predictive Clinical-Radiomics Nomogram for Survival Prediction of Glioblastoma Using MRI. <i>Diagnostics</i> , 2021, 11, 2043.	1.3	12
5439	Stereotactic radiosurgery for glioblastoma considering tumor genetic profiles: an international multicenter study. <i>Journal of Neurosurgery</i> , 2022, 137, 42-50.	0.9	4
5440	Context Mattersâ€œWhy We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 760705.	1.8	3
5441	A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 756817.	1.3	4
5442	Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11938.	1.8	11
5443	Revisiting the HIF switch in the tumor and its immune microenvironment. <i>Trends in Cancer</i> , 2022, 8, 28-42.	3.8	67
5444	Long lasting thrombocytopenia after transient treatment pancytopenia induced by short term concomitant radiotherapy and temozolomide. <i>European Journal of Case Reports in Internal Medicine</i> , 2019, 7, 001785.	0.2	2

#	ARTICLE	IF	CITATIONS
5449	Molecular Classifications. , 2007, , 37-42.		1
5453	Intracranial Mass Lesions. , 2021, , 377-389.		0
5454	DNA methylation-based age estimation in pediatric healthy tissues and brain tumors. <i>Aging</i> , 2020, 12, 21037-21056.	1.4	22
5455	Determination of the cutoff point of the absolute value of MGMTmRNA for predicting the therapeutic resistance to temozolomide in glioblastoma. <i>Journal of Neurosurgical Sciences</i> , 2020, 64, 434-439.	0.3	1
5456	Current Translational Insights into MGMT Methylation Regulating Temozolomide Sensitivity and Resistance in Glioblastoma Multiforme. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2020, 17, 76-93.	0.2	0
5457	Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report. <i>Croatian Medical Journal</i> , 2006, 47, 305-9.	0.2	2
5459	Current available therapies and future directions in the treatment of malignant gliomas. <i>Biologics: Targets and Therapy</i> , 2009, 3, 15-25.	3.0	8
5462	Role of bevacizumab therapy in the management of glioblastoma. <i>Cancer Management and Research</i> , 2010, 2, 97-104.	0.9	16
5463	Current data and strategy in glioblastoma multiforme. <i>Journal of Medicine and Life</i> , 2009, 2, 386-93.	0.4	133
5464	Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. <i>Discovery Medicine</i> , 2010, 10, 293-304.	0.5	38
5466	Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know?. <i>Sultan Qaboos University Medical Journal</i> , 2008, 8, 137-48.	0.3	8
5467	Antiangiogenesis in recurrent glioblastoma: proof of principle. <i>Neurology International</i> , 2009, 1, e21.	0.2	1
5468	2011 american society of clinical oncology. <i>P and T</i> , 2011, 36, 508-17.	1.0	0
5469	Harnessing the cell death pathway for targeted cancer treatment. <i>American Journal of Cancer Research</i> , 2011, 1, 43-61.	1.4	20
5471	Next-generation sequencing for cancer diagnostics: a practical perspective. <i>Clinical Biochemist Reviews</i> , 2011, 32, 177-95.	3.3	271
5473	Glioblastoma genetics: in rapid flux. <i>Discovery Medicine</i> , 2010, 9, 125-31.	0.5	11
5474	What is the clinical value of cancer stem cell markers in gliomas?. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 334-48.	0.5	59
5476	Potential clinical role of telomere length in human glioblastoma. <i>Translational Medicine @ UniSa</i> , 2011, 1, 243-70.	0.8	6

#	ARTICLE	IF	CITATIONS
5477	Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 169-78.	0.0	10
5478	Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population. <i>American Health and Drug Benefits</i> , 2014, 7, 140-9.	0.5	37
5479	Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma. <i>Journal of Research in Medical Sciences</i> , 2014, 19, 426-32.	0.4	1
5480	Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4204-12.	0.5	8
5481	Molecular biology of gliomas: present and future challenges. <i>Translational Medicine @ UniSa</i> , 2014, 10, 29-37.	0.8	33
5482	Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 6662-70.	0.5	30
5483	Down-regulation of vinculin upon MK886-induced apoptosis in LN18 glioblastoma cells. <i>Neoplasma</i> , 2007, 54, 517-26.	0.7	18
5484	Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 636-42.	0.5	10
5485	Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 1790-6.	0.5	10
5486	Motivating the additional use of external validity: examining transportability in a model of glioblastoma multiforme. <i>AMIA ... Annual Symposium proceedings</i> , 2014, 2014, 1930-9.	0.2	2
5487	Immunohistochemical and genetic markers to distinguish hemangiopericytoma and meningioma. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 3291-9.	1.3	9
5488	Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 6553-62.	1.3	1
5489	Overexpression of DNA methyltransferase 1 (DNMT1) protein in astrocytic tumour and its correlation with O6-methylguanine-DNA methyltransferase (MGMT) expression. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 6095-106.	0.5	4
5490	Formononetin sensitizes glioma cells to doxorubicin through preventing EMT via inhibition of histone deacetylase 5. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 6434-41.	0.5	19
5491	Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation. <i>American Journal of Cancer Research</i> , 2015, 5, 2745-55.	1.4	2
5492	Towards a Role for Clinical Pathology Diagnostics for Childhood Maltreatment. <i>Austin Journal of Clinical Pathology</i> , 2015, 2, .	0.0	3
5493	Alternative polyadenylation can regulate post-translational membrane localization. <i>Trends in Cell &amp; Molecular Biology</i> , 2015, 10, 37-47.	0.5	6
5494	Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. <i>Oncology</i> , 2015, 29, 331-40.	0.4	45

#	ARTICLE	IF	CITATIONS
5495	High expression of WDR1 in primary glioblastoma is associated with poor prognosis. American Journal of Translational Research (discontinued), 2016, 8, 1253-64.	0.0	11
5496	In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme. Iranian Journal of Medical Sciences, 2017, 42, 258-265.	0.3	7
5497	Management and treatment recommendations for World Health Organization Grade III and IV gliomas. International Journal of Health Sciences, 2017, 11, 54-62.	0.4	4
5498	Intensity-modulated fractionated stereotactic radiotherapy with reduced margin for high grade gliomas: dosimetric analysis of sparing optic nerve & chiasm. Journal of Radiosurgery and SBRT, 2013, 2, 307-314.	0.2	0
5499	MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2018, 23, 331-342.	0.7	19
5500	VHA Practice Guideline Recommendations for Diffuse Gliomas. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2018, 35, S28-S35.	0.6	1
5501	Î2-arrestin 1 Overexpression Increases Temozolomide Resistance in Human Malignant Glioma Cells. Current Health Sciences Journal, 2017, 43, 112-119.	0.2	3
5502	Biomarkers for glioblastoma multiforme: status quo. Journal of Clinical and Translational Research, 2016, 2, 3-10.	0.3	10
5503	Regression of mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. Oncotarget, 2019, 10, 3818-3826.	0.8	16
5504	Glioblastoma and Increased Survival with Longer Chemotherapy Duration. Kansas Journal of Medicine, 2019, 12, 65-69.	0.1	7
5506	Combined effects of mesenchymal stem cells carrying cytosine deaminase gene with 5-fluorocytosine and temozolomide in orthotopic glioma model. American Journal of Cancer Research, 2020, 10, 1429-1441.	1.4	3
5507	Newly Diagnosed Glioblastoma: A Review on Clinical Management. Oncology, 2019, 33, 91-100.	0.4	42
5508	Differentiated embryonic chondrocyte-expressed gene 1 promotes temozolomide resistance by modulating the SP1-MGMT axis in glioblastoma. American Journal of Translational Research (discontinued), 2021, 13, 2331-2349.	0.0	3
5509	Hydrogel-Based Spheroid Models of Glioblastoma for Drug Screening Applications. Missouri Medicine, 2021, 118, 346-351.	0.3	0
5510	Blood-â€‘brain barrier penetrating liposomes with synergistic chemotherapy for glioblastoma treatment. Biomaterials Science, 2022, 10, 423-434.	2.6	23
5511	Perspectives and future directions of translational epigenetics in personalized and precision medicine. , 2022, , 1-18.		0
5512	Methylated circulating tumor DNA biomarkers for the blood-based detection of cancer signals. , 2022, , 471-512.		0
5513	Oncometabolites as Regulators of DNA Damage Response and Repair. Seminars in Radiation Oncology, 2022, 32, 82-94.	1.0	3

#	ARTICLE	IF	CITATIONS
5514	Gliome. , 2022, , 448-454.		0
5515	High-frequency irreversible electroporation brain tumor ablation: exploring the dynamics of cell death and recovery. <i>Bioelectrochemistry</i> , 2022, 144, 108001.	2.4	5
5516	Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma. <i>Scientific Reports</i> , 2021, 11, 22057.	1.6	1
5517	Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors. <i>Laboratory Investigation</i> , 2022, 102, 160-171.	1.7	21
5518	Extracranial multiorgan metastasis from primary glioblastoma: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 10300-10307.	0.3	3
5519	An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach. <i>Clinical and Translational Oncology</i> , 2022, 24, 742-756.	1.2	2
5520	Integration of Raman spectra with transcriptome data in glioblastoma multiforme defines tumour subtypes and predicts patient outcome. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10846-10856.	1.6	5
5521	Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas. <i>Cancers</i> , 2021, 13, 5678.	1.7	6
5523	Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. <i>Journal of Neuro-Oncology</i> , 2021, 155, 307-317.	1.4	9
5524	Hypoxia: The Cornerstone of Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12608.	1.8	62
5525	Comprehensive analysis of expression, prognosis and immune infiltration for TIMPs in glioblastoma. <i>BMC Neurology</i> , 2021, 21, 447.	0.8	8
5526	A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres. <i>Journal of Neuro-Oncology</i> , 2022, 156, 139-151.	1.4	2
5527	Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study. <i>Journal of Neuro-Oncology</i> , 2021, 155, 343-351.	1.4	4
5528	Newly Diagnosed IDH-Wildtype Glioblastoma and Temporal Muscle Thickness: A Multicenter Analysis. <i>Cancers</i> , 2021, 13, 5610.	1.7	11
5529	Advanced Magnetic Resonance Imaging in Pediatric Glioblastomas. <i>Frontiers in Neurology</i> , 2021, 12, 733323.	1.1	11
5530	DNA methylation-based classification of malformations of cortical development in the human brain. <i>Acta Neuropathologica</i> , 2022, 143, 93-104.	3.9	18
5531	Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale " a bicentric retrospective study. <i>BMC Neurology</i> , 2021, 21, 446.	0.8	6
5532	Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. <i>Bioengineered</i> , 2021, 12, 10791-10798.	1.4	9



#	ARTICLE	IF	CITATIONS
5533	Applications of Radiomics and Radiogenomics in High-Grade Gliomas in the Era of Precision Medicine. <i>Cancers</i> , 2021, 13, 5921.	1.7	29
5535	The Prognostic Value of NANO Scale Assessment in IDH-Wild-Type Glioblastoma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 790458.	1.3	2
5536	Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma. <i>Progress in Retinal and Eye Research</i> , 2022, 89, 101030.	7.3	18
5537	METTL3/14 and IL-17 signaling contribute to CEBPA-enhanced oral cancer cisplatin resistance. <i>Oral Diseases</i> , 2023, 29, 942-956.	1.5	11
5538	Preclinical models of glioblastoma: limitations of current models and the promise of new developments. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e20.	1.6	20
5539	Tumors: Brain. , 2021, , 5208-5215.		0
5541	Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab171.	0.4	8
5542	Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. <i>Journal of Clinical Neuroscience</i> , 2022, 95, 48-54.	0.8	17
5543	Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples. <i>Anticancer Research</i> , 2020, 40, 6229-6236.	0.5	1
5544	Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 476-481.	1.0	2
5545	Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2022, 156, 407-417.	1.4	0
5546	Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells. <i>Cancers</i> , 2021, 13, 6287.	1.7	8
5547	Surgical and oncological score to estimate the survival benefit of resection and chemoradiotherapy in elderly (>70 years) glioblastoma patients: a preliminary analysis. <i>Neuro-Oncology Advances</i> , 2022, 4, vda007.	0.4	3
5548	Intratumor morphologic and molecular genetic heterogeneity in astrocytomas of different grade of malignancy in the material from the first operation. <i>Siberian Journal of Oncology</i> , 2022, 20, 55-68.	0.1	0
5549	Epigenetic Drugs and Their Immune Modulating Potential in Cancers. <i>Biomedicines</i> , 2022, 10, 211.	1.4	5
5550	Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis. <i>Radiation Oncology</i> , 2022, 17, 15.	1.2	7
5551	Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management. <i>Current Oncology</i> , 2022, 29, 360-376.	0.9	11
5552	Long-Acting Recombinant Human Interleukin-7, NT-17, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. <i>Clinical Cancer Research</i> , 2022, 28, 1229-1239.	3.2	26

#	ARTICLE	IF	CITATIONS
5553	MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines. <i>Biology</i> , 2022, 11, 70.	1.3	5
5554	Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac002.	0.4	3
5555	Preoperative Stereotactic Radiosurgery for Glioblastoma. <i>Biology</i> , 2022, 11, 194.	1.3	7
5556	Ensembles of Convolutional Neural Networks for Survival Time Estimation of High-Grade Glioma Patients from Multimodal MRI. <i>Diagnostics</i> , 2022, 12, 345.	1.3	7
5557	Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation. <i>Journal of Cancer</i> , 2022, 13, 354-363.	1.2	13
5559	CNS High Grade Glioma. , 0, , .		0
5560	Relationship between molecular characteristics of glioblastoma multiforme and the subventricular zone. <i>British Journal of Neurosurgery</i> , 2022, , 1-8.	0.4	0
5561	Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study. <i>Journal of Neuro-Oncology</i> , 2022, 156, 625-634.	1.4	2
5562	Autophagy Regulation on Cancer Stem Cell Maintenance, Metastasis, and Therapy Resistance. <i>Cancers</i> , 2022, 14, 381.	1.7	17
5563	The clinical characteristics and outcomes of incidentally discovered glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 551-557.	1.4	4
5564	A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 812422.	1.8	5
5565	Connexin 43 confers chemoresistance through activating PI3K. <i>Oncogenesis</i> , 2022, 11, 2.	2.1	11
5566	The effectiveness of gamma knife radiosurgery for the management of residual high-grade gliomas: A single institutional study. <i>Journal of Clinical Neuroscience</i> , 2022, 95, 159-163.	0.8	1
5567	Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review. <i>Biomedicines</i> , 2022, 10, 285.	1.4	17
5568	<i>MGMT</i> promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. <i>Neuro-Oncology</i> , 2022, 24, 665-667.	0.6	5
5569	The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2022, 156, 257-267.	1.4	9
5570	Surface Modification of Nanoparticles Enhances Drug Delivery to the Brain and Improves Survival in a Glioblastoma Multiforme Murine Model. <i>Bioconjugate Chemistry</i> , 2022, 33, 1957-1972.	1.8	10
5571	Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab. <i>CNS Oncology</i> , 2022, , CNS81.	1.2	8

#	ARTICLE	IF	CITATIONS
5572	Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. <i>Journal of Neurosurgery</i> , 2022, 137, 914-923.	0.9	7
5573	Quenching Epigenetic Drug Resistance Using Antihypoxic Microparticles in Glioblastoma Patient-Derived Chips. <i>Advanced Healthcare Materials</i> , 2021, , 2102226.	3.9	5
5574	Brain tumor IDH, 1p/19q, and MGMT molecular classification using MRI-based deep learning: an initial study on the effect of motion and motion correction. <i>Journal of Medical Imaging</i> , 2022, 9, 016001.	0.8	2
5575	Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives. <i>Cancers</i> , 2022, 14, 443.	1.7	48
5576	Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas. <i>Brain Tumor Pathology</i> , 2022, 39, 121-129.	1.1	7
5577	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 403-426.	0.8	67
5578	Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma. <i>Journal of Neuro-Oncology</i> , 2022, 157, 137-146.	1.4	8
5579	Follow-Up of High-Grade Glial Tumor; Differentiation of Posttreatment Enhancement and Tumoral Enhancement by DCE-MR Perfusion. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-9.	0.4	3
5580	Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide. <i>Cancers</i> , 2022, 14, 770.	1.7	2
5581	Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard?. <i>Brain Tumor Research and Treatment</i> , 2022, 10, 12.	0.4	6
5582	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 235-247.	1.9	3
5583	Genome-Wide Expression and Anti-Proliferative Effects of Electric Field Therapy on Pediatric and Adult Brain Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1982.	1.8	8
5584	Glioma targeted therapy: insight into future of molecular approaches. <i>Molecular Cancer</i> , 2022, 21, 39.	7.9	274
5585	Treatment Response and Prognosis Evaluation in High-Grade Glioma: An Imaging Review Based on MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 325-340.	1.9	16
5586	Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas. <i>Cells</i> , 2022, 11, 561.	1.8	18
5587	Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture. <i>ACS Chemical Biology</i> , 2022, 17, 299-313.	1.6	4
5588	Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology. <i>Acta Neuropathologica Communications</i> , 2022, 10, 19.	2.4	11
5589	High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 275-287.	1.1	3

#	ARTICLE	IF	CITATIONS
5590	Newly Diagnosed Glioblastoma in Elderly Patients. <i>Current Oncology Reports</i> , 2022, 24, 325-334.	1.8	3
5592	Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1711.	1.8	34
5593	Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 1979-1990.	3.2	10
5594	OMICS Applications for Medicinal Plants in Gastrointestinal Cancers: Current Advancements and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2022, 13, 842203.	1.6	5
5595	Brain Tumor Imaging: Applications of Artificial Intelligence. <i>Seminars in Ultrasound, CT and MRI</i> , 2022, 43, 153-169.	0.7	10
5596	A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac008.	0.4	10
5597	Potential Therapeutic Effects of PPAR Ligands in Glioblastoma. <i>Cells</i> , 2022, 11, 621.	1.8	11
5598	DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis. <i>Genomics</i> , 2022, 114, 110289.	1.3	3
5600	Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1.	1.4	17
5601	Ferroptosis related genes are regulated by methylation and predict the prognosis of glioblastoma patients. <i>Translational Cancer Research</i> , 2021, 11, 0-0.	0.4	3
5602	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac025.	0.4	18
5603	A novel nomogram based on DNA damage response-related gene expression in patients with O-6-methylguanine-DNA methyltransferase unmethylated glioblastoma receiving temozolomide chemotherapy: A population-based analysis. <i>Glioma (Mumbai, India)</i> , 2022, 5, 20.	0.0	0
5604	Targeting the Replication Stress of Glioblastoma. <i>World Journal of Cancer Research</i> , 2022, 12, 42-51.	0.1	0
5605	Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. <i>Genes and Immunity</i> , 2022, 23, 255-259.	2.2	16
5606	MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study. <i>European Radiology</i> , 2022, 32, 5577-5587.	2.3	1
5607	Mechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 564.	1.4	24
5608	New treatment strategies for advanced-stage gastrointestinal stromal tumours. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 328-341.	12.5	43
5609	Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma. <i>Chinese Neurosurgical Journal</i> , 2022, 8, 6.	0.3	0

#	ARTICLE	IF	CITATIONS
5610	Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics. <i>Clinical Epigenetics</i> , 2022, 14, 26.	1.8	3
5611	The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2001.	1.8	4
5612	Molecular Pathogenesis of Glioblastoma in Adults and Future Perspectives: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2607.	1.8	13
5613	A clinically compatible drug screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. <i>EMBO Molecular Medicine</i> , 2022, 14, e14552.	3.3	12
5614	Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. <i>Neuro-Oncology Practice</i> , 2022, 9, 165-182.	1.0	40
5615	Innovating Strategies and Tailored Approaches in Neuro-Oncology. <i>Cancers</i> , 2022, 14, 1124.	1.7	3
5617	Identification of a Nomogram with an Autophagy-Related Risk Signature for Survival Prediction in Patients with Glioma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 1517-1535.	0.8	2
5618	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 547-574.	1.2	25
5619	Efficient Radiomics-Based Classification of Multi-Parametric MR Images to Identify Volumetric Habitats and Signatures in Glioblastoma: A Machine Learning Approach. <i>Cancers</i> , 2022, 14, 1475.	1.7	9
5620	Systematic identification of biomarker-driven drug combinations to overcome resistance. <i>Nature Chemical Biology</i> , 2022, 18, 615-624.	3.9	14
5621	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. <i>Neurology</i> , 2022, 98, .	1.5	2
5622	Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 628-645.	0.8	6
5623	Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?. <i>Cancers</i> , 2022, 14, 1533.	1.7	5
5624	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. <i>Frontiers in Oncology</i> , 2022, 12, 849993.	1.3	1
5625	Production and Stabilization of Specific Upregulated Long Noncoding RNA HOXD-AS2 in Glioblastomas Are Mediated by TFE3 and miR-661, Respectively. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2828.	1.8	1
5626	MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients—the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use. <i>World Neurosurgery</i> , 2022, 159, e324-e333.	0.7	3
5627	RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1261-1272.	0.6	6
5628	Radiomics Profiling Identifies the Incremental Value of MRI Features beyond Key Molecular Biomarkers for the Risk Stratification of High-Grade Gliomas. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-12.	0.4	3

#	ARTICLE	IF	CITATIONS
5629	Surgical Neuro-Oncology. <i>Neurologic Clinics</i> , 2022, 40, 437-453.	0.8	6
5630	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1533-1545.	0.6	13
5631	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome including in elderly patients. <i>Acta Neuropathologica Communications</i> , 2022, 10, 39.	2.4	6
5632	Increased Ascorbate Content of Glioblastoma Is Associated With a Suppressed Hypoxic Response and Improved Patient Survival. <i>Frontiers in Oncology</i> , 2022, 12, 829524.	1.3	4
5633	Luminescent Pyrrole-based Phosphaphenylene Gold Complexes: A Versatile Anticancer Tool with a Wide Applicability. <i>Chemistry - A European Journal</i> , 2022, , .	1.7	5
5634	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O <sup>6</sup> -Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	0.8	52
5635	Epidemiology, risk factors, and prognostic factors of gliomas. <i>Clinical and Translational Imaging</i> , 2022, 10, 467-475.	1.1	16
5636	PRP4 Induces Epithelial-Mesenchymal Transition and Drug Resistance in Colon Cancer Cells via Activation of p53. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3092.	1.8	9
5637	EGFR Amplification Is a Phenomenon of IDH Wildtype and TERT Mutated High-Grade Glioma: An Integrated Analysis Using Fluorescence In Situ Hybridization and DNA Methylation Profiling. <i>Biomedicines</i> , 2022, 10, 794.	1.4	4
5638	Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma. <i>NMR in Biomedicine</i> , 2022, 35, e4719.	1.6	11
5639	Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials. <i>Cancer</i> , 2022, 128, 2367-2374.	2.0	4
5640	The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression. <i>Biomedicines</i> , 2022, 10, 806.	1.4	35
5641	Cancer Genetics and Genomics – Part 1. <i>Clinical Oncology</i> , 2022, , .	0.6	1
5642	Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. <i>Laboratory Investigation</i> , 2022, 102, 741-752.	1.7	8
5643	Ethical implications of epigenetics in the era of personalized medicine. <i>Clinical Epigenetics</i> , 2022, 14, 44.	1.8	61
5644	Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2270-2277.	3.2	30
5645	Radiogenomic Predictors of Recurrence in Glioblastoma – A Systematic Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 402.	1.1	5
5647	LRRFIP1, an epigenetically regulated gene, is a prognostic biomarker and predicts malignant phenotypes of glioma. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 873-883.	1.9	1

#	ARTICLE	IF	CITATIONS
5648	The AlkB Family: Potential Prognostic Biomarkers and Therapeutic Targets in Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 847821.	1.3	1
5649	The Time Toxicity of Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 1611-1615.	0.8	77
5650	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. <i>Neuro-Oncology</i> , 2022, 24, 1689-1699.	0.6	11
5651	Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression. <i>Cell Death and Disease</i> , 2022, 13, 293.	2.7	20
5652	Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma. <i>Scientific Reports</i> , 2022, 12, 5827.	1.6	9
5653	RNA Editing in Glioma as a Sexually Dimorphic Prognostic Factor That Affects mRNA Abundance in Fatty Acid Metabolism and Inflammation Pathways. <i>Cells</i> , 2022, 11, 1231.	1.8	0
5654	Ultra-High-Field MRI in the Diagnosis and Management of Gliomas: A Systematic Review. <i>Frontiers in Neurology</i> , 2022, 13, 857825.	1.1	14
5655	Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme. <i>Neuroscience</i> , 2022, 491, 240-270.	1.1	22
5656	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
5657	Case-Control Studies in Neurosurgery: the Issue of Effect Estimates. <i>World Neurosurgery</i> , 2022, , .	0.7	0
5658	Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma. <i>Cancers</i> , 2022, 14, 1821.	1.7	3
5659	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2527-2535.	3.2	27
5660	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. <i>Journal of Neuro-Oncology</i> , 2022, 157, 499-510.	1.4	2
5661	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. <i>Neuro-Oncology</i> , 2022, 24, 1219-1229.	0.6	9
5662	Applications of chemical exchange saturation transfer magnetic resonance imaging in identifying genetic markers in gliomas. <i>NMR in Biomedicine</i> , 2023, 36, e4731.	1.6	13
5663	Novel electrochemical immunosensor for O6-methylguanine-DNA methyltransferase gene methylation based on graphene oxide-magnetic nanoparticles- $\beta$ -cyclodextrin nanocomposite. <i>Bioelectrochemistry</i> , 2022, 146, 108111.	2.4	4
5664	Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials. <i>Cancers</i> , 2022, 14, 52.	1.7	11
5665	The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 54-60.	0.9	1

#	ARTICLE	IF	CITATIONS
5666	Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?. Journal of Neuro-Oncology, 2022, 156, 317-327.	1.4	5
5667	Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors. Clinical Epigenetics, 2021, 13, 228.	1.8	14
5668	Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers, 2021, 13, 6311.	1.7	30
5669	Targeting DNA repair pathway in cancer: Mechanisms and clinical application. MedComm, 2021, 2, 654-691.	3.1	34
5670	Immunotherapy against Gliomas. , 0, , .		0
5671	AI in spotting high-risk characteristics of medical imaging and molecular pathology. Precision Clinical Medicine, 2021, 4, 271-286.	1.3	2
5672	Catalase Overexpression Drives an Aggressive Phenotype in Glioblastoma. Antioxidants, 2021, 10, 1988.	2.2	17
5673	<i>ITGB3BP</i> is a potential biomarker associated with poor prognosis of glioma. Journal of Cellular and Molecular Medicine, 2022, 26, 813-827.	1.6	1
5674	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 2022, 24, 358-383.	0.6	1
5675	High expression of TXNDC11 indicated unfavorable prognosis of glioma. Translational Cancer Research, 2021, 10, 5040-5051.	0.4	4
5676	Sulfonated Amphiphilic Poly( $\beta$ -glutamate Amine) A Potential siRNA Nanocarrier for the Treatment of Both Chemo-Sensitive and Chemo-Resistant Glioblastoma Tumors. Pharmaceutics, 2021, 13, 2199.	2.0	2
5677	Early Detection and Prevention of Schizophrenic Psychosis A Review. Brain Sciences, 2022, 12, 11.	1.1	7
5678	MicroRNAs Regulate Cell Cycle and Cell Death Pathways in Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 13550.	1.8	18
5679	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 2022, 4, vdab186.	0.4	1
5680	Hippo Pathway in Regulating Drug Resistance of Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 13431.	1.8	15
5681	Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches. Cancers, 2021, 13, 6156.	1.7	8
5682	ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma. Frontiers in Oncology, 2021, 11, 769592.	1.3	12
5683	Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy. Cancers, 2021, 13, 6217.	1.7	9



#	ARTICLE	IF	CITATIONS
5684	A Continuous Correlation Between Residual Tumor Volume and Survival Recommends Maximal Safe Resection in Glioblastoma Patients: A Nomogram for Clinical Decision Making and Reference for Non-Randomized Trials. <i>Frontiers in Oncology</i> , 2021, 11, 748691.	1.3	6
5685	Association of <i>MGMT</i> Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type <i>IDH</i> Glioblastoma. <i>Anticancer Research</i> , 2022, 42, 335-341.	0.5	5
5686	Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma. <i>Cancer Research</i> , 2022, 82, 377-390.	0.4	5
5687	Brusatol Inhibits Proliferation and Invasion of Glioblastoma by Down-Regulating the Expression of ECM1. <i>Frontiers in Pharmacology</i> , 2021, 12, 775680.	1.6	12
5688	The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. <i>Journal of Neuro-Oncology</i> , 2022, 157, 177-185.	1.4	21
5693	First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis. <i>Brain Sciences</i> , 2022, 12, 499.	1.1	2
5694	Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma. <i>Cancers</i> , 2022, 14, 1958.	1.7	7
5695	Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. <i>Radiation Oncology</i> , 2022, 17, 79.	1.2	3
5696	A Qualitative Signature to Identify TERT Promoter Mutant High-Risk Tumors in Low-Grade Gliomas. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 806727.	1.6	1
5697	Emerging therapies for glioblastoma: current state and future directions. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 142.	3.5	103
5698	Emerging Biomarkers for Immunotherapy in Glioblastoma. <i>Cancers</i> , 2022, 14, 1940.	1.7	6
5699	Early repeat resection for residual glioblastoma: decision-making among an international cohort of neurosurgeons. <i>Journal of Neurosurgery</i> , 2022, 137, 1618-1627.	0.9	4
5700	The Profiles of Tet-Mediated DNA Hydroxymethylation in Human Gliomas. <i>Frontiers in Oncology</i> , 2022, 12, 621460.	1.3	3
5701	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	0.6	150
5702	<i>MGMT</i> gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. <i>Journal of Neuro-Oncology</i> , 2022, 157, 561-571.	1.4	5
5703	Survival after reoperation for recurrent glioblastoma multiforme: A prospective study. <i>Surgical Oncology</i> , 2022, 42, 101771.	0.8	5
5704	The central nervous system. , 0, , 3185-3317.		0
5806	Systemic Treatment for Cancer. , 0, , 76-107.		0

#	ARTICLE	IF	CITATIONS
5807	Brain and Spinal Cord. , 0, , 173-196.		0
5809	Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. <i>Neuro-Oncology</i> , 2022, 24, 1989-2000.	0.6	27
5811	Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. <i>Histology and Histopathology</i> , 2006, 21, 1199-207.	0.5	9
5812	Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series. <i>Tumori</i> , 2012, 98, 756-61.	0.6	4
5813	Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma. <i>Tumori</i> , 2013, 99, 480-7.	0.6	7
5814	Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients. <i>Journal of Neurosurgery</i> , 2022, 137, 1628-1638.	0.9	4
5815	Biomarker-based trials in neuro-oncology. <i>Chinese Clinical Oncology</i> , 2015, 4, 38.	0.4	0
5817	Glioblastoma multiforme of spinal cord - Case series in a tertiary cancer centre.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 792-796.	0.3	1
5818	DNA damage and metabolic mechanisms of cancer drug resistance. <i>Cancer Drug Resistance (Alhambra)</i> , Tj ETQq0 0,0 rgBT /Qverlock 10	0.9	7
5819	Accurate Measurement of DNA Methylation: Challenges and Bias Correction. <i>Methods in Molecular Biology</i> , 2022, 2432, 25-47.	0.4	1
5820	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. <i>Cancer Treatment and Research</i> , 2022, 183, 161-184.	0.2	2
5821	Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. <i>Cancers</i> , 2022, 14, 2233.	1.7	19
5822	Effectiveness of Bioinks and the Clinical Value of 3D Bioprinted Glioblastoma Models: A Systematic Review. <i>Cancers</i> , 2022, 14, 2149.	1.7	3
5823	Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. <i>Journal of Neuro-Oncology</i> , 2022, 158, 111-116.	1.4	5
5824	Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma. <i>Cancers</i> , 2022, 14, 2134.	1.7	1
5825	Carboplatin Plus Vincristine as an Alternative Chemotherapeutic Scheme in Patients With Glioblastoma. <i>Cureus</i> , 2022, , .	0.2	1
5826	Epigenetic Underpinnings of Inflammation: A Key to Unlock the Tumor Microenvironment in Glioblastoma. <i>Frontiers in Immunology</i> , 2022, 13, 869307.	2.2	9
5827	Effects of microRNAs and long non-coding RNAs on chemotherapy response in glioma. <i>Epigenomics</i> , 2022, 14, 549-563.	1.0	11

#	ARTICLE	IF	CITATIONS
5828	Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. <i>Frontiers in Oncology</i> , 2022, 12, 839302.	1.3	3
5829	Associations among smoking, IDH mutations, MGMT promoter methylation, and grading in glioma: a cross-sectional study. <i>F1000Research</i> , 0, 11, 473.	0.8	0
5830	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. <i>Cancers</i> , 2022, 14, 2241.	1.7	26
5831	Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis. <i>Journal of Neuro-Oncology</i> , 2022, , 1.	1.4	2
5832	Genome-wide DNA Methylation Differences in Nonfunctioning Pituitary Adenomas With and Without Postsurgical Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2318-2328.	1.8	6
5833	Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. <i>Cancers</i> , 2022, 14, 2393.	1.7	8
5834	Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC. <i>Molecules</i> , 2022, 27, 2958.	1.7	3
5835	Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review. <i>Current Oncology</i> , 2022, 29, 3472-3488.	0.9	7
5836	Carbohydrate Metabolism Parameters of Adult Glial Neoplasms According to Immunohistochemical Profile. <i>Biomedicines</i> , 2022, 10, 1007.	1.4	0
5837	DNA polymerase eta protects human cells against DNA damage induced by the tumor chemotherapeutic temozolomide. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2022, 878, 503498.	0.9	4
5838	Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5238.	1.8	4
5839	Circulating Tumor DNA in Adults With Glioma: A Systematic Review and Meta-Analysis of Biomarker Performance. <i>Neurosurgery</i> , 2022, Publish Ahead of Print, .	0.6	1
5840	Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI). <i>Journal of Neuro-Oncology</i> , 2022, 158, 349-357.	1.4	10
5841	Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2022, 9, 354-363.	1.0	3
5842	Reconfiguration from emergency to urgent elective neurosurgery for glioblastoma patients improves length of stay, surgical adjunct use and extent of resective surgery. <i>Neuro-Oncology Practice</i> , 0, , .	1.0	0
5843	Long Term Survivals in Aggressive Primary Brain Malignancies Treated With an Adjuvant Ketogenic Diet. <i>Frontiers in Nutrition</i> , 2022, 9, 770796.	1.6	4
5844	Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression. <i>Cancers</i> , 2022, 14, 2339.	1.7	17
5845	Epidemiology of Glioblastoma Multiforme – Literature Review. <i>Cancers</i> , 2022, 14, 2412.	1.7	141

#	ARTICLE	IF	CITATIONS
5846	The use of radiosensitizing agents in the therapy of glioblastoma multiforme—a comprehensive review. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 507-526.	1.0	8
5847	Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 158, 331-339.	1.4	1
5848	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. <i>Neuro-Oncology</i> , 2022, 24, 1935-1949.	0.6	165
5849	Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study. <i>Cancers</i> , 2022, 14, 2425.	1.7	7
5851	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. <i>CNS Oncology</i> , 2022, 11, CNS87.	1.2	15
5852	Resibufogenin Targets the ATP1A1 Signaling Cascade to Induce G2/M Phase Arrest and Inhibit Invasion in Glioma. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	3
5853	Fate mapping of neural stem cell niches reveals distinct origins of human cortical astrocytes. <i>Science</i> , 2022, 376, 1441-1446.	6.0	25
5854	A manzamine-derived compound as a potential therapeutic agent for glioma by inducing apoptosis and cell cycle arrest.. <i>American Journal of Cancer Research</i> , 2022, 12, 1740-1751.	1.4	0
5855	Recent Advances in Research on Spinal Cord Gliomas. <i>Spinal Surgery</i> , 2022, 36, 18-23.	0.0	0
5856	Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance. <i>Therapeutic Delivery</i> , 0, , .	1.2	4
5857	Viability of Glioblastoma Cells and Fibroblasts in the Presence of Imidazole-Containing Compounds. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5834.	1.8	3
5858	Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 892-906.	1.0	6
5860	Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. <i>CNS Oncology</i> , 2022, 11, .	1.2	5
5861	Updates in IDH-Wildtype Glioblastoma. <i>Neurotherapeutics</i> , 2022, 19, 1705-1723.	2.1	26
5862	MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers. <i>Molecular Oncology</i> , 2022, 16, 2733-2746.	2.1	2
5863	DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	6
5864	Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidene-phthalide in a Recurrent GBM. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	1
5866	A Potential New Treatment for High-Grade Glioma: A Study Assessing Repurposed Drug Combinations against Patient-Derived High-Grade Glioma Cells. <i>Cancers</i> , 2022, 14, 2602.	1.7	4

#	ARTICLE	IF	CITATIONS
5867	Standard clinical approaches and emerging modalities for glioblastoma imaging. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	7
5868	The sexâ€dependent role of the androgen receptor in glioblastoma: results of molecular analyses. <i>Molecular Oncology</i> , 2022, 16, 3436-3451.	2.1	4
5869	Molecular Biology in Glioblastoma Multiforme Treatment. <i>Cells</i> , 2022, 11, 1850.	1.8	2
5870	Glioblastoma. , 2023, , 388-392.		0
5874	Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 390-414.	1.0	9
5875	O6-Methylguanine-DNA Methyltransferase and ATP-Binding Cassette Membrane Transporter G2 Promotor Methylation: Can Predict the Response to Chemotherapy in Advanced Breast Cancer?. <i>Reports of Biochemistry and Molecular Biology</i> , 2022, 11, 20-29.	0.5	2
5876	Spatial heterogeneity in DNA methylation and chromosomal alterations in diffuse gliomas and meningiomas. <i>Modern Pathology</i> , 2022, 35, 1551-1561.	2.9	13
5877	Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults. <i>Epilepsy Currents</i> , 0, , 153575972211077.	0.4	0
5879	High-dose salvage re-irradiation in recurrent/progressive adult diffuse gliomas: development of a novel prognostic scoring system. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 994-1001.	0.6	3
5881	Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	6
5882	Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. <i>Nature Reviews Neurology</i> , 2022, 18, 515-529.	4.9	100
5883	Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors. <i>Cancers</i> , 2022, 14, 3015.	1.7	10
5884	Prognostic impact of <i>PDGFRA</i> gain/amplification and <i>MGMT</i> promoter methylation status in patients with <i>IDH</i> wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	3
5885	Chaperone protein P4HB predicts temozolomide response and prognosis in malignant glioma. <i>Oncology Letters</i> , 2022, 24, .	0.8	5
5886	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. <i>Immunotherapy</i> , 0, , .	1.0	3
5887	A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	1
5888	Predicting MGMT Promoter Methylation in Diffuse Gliomas Using Deep Learning with Radiomics. <i>Journal of Clinical Medicine</i> , 2022, 11, 3445.	1.0	17
5889	H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis. <i>World Neurosurgery</i> , 2022, 165, e251-e264.	0.7	6

#	ARTICLE	IF	CITATIONS
5890	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2539-2545.	0.8	23
5891	Theranostic Potential of Adaptive Cold Atmospheric Plasma with Temozolomide to Checkmate Glioblastoma: An In Vitro Study. <i>Cancers</i> , 2022, 14, 3116.	1.7	6
5892	Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches. , 2022, 39, .		8
5893	Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. <i>Journal of Neuro-Oncology</i> , 0, , .	1.4	1
5894	Temozolomide â€œ Just a Radiosensitizer?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
5895	Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung. <i>JCO Precision Oncology</i> , 2022, , .	1.5	4
5896	The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies. <i>Molecular Neurobiology</i> , 2022, 59, 5326-5365.	1.9	13
5897	High RPMB Predicts Better Disease-Free Survival of N1/2 Non-Small Cell Lung Cancer after Adjuvant Chemotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
5898	Prediction of MGMT Methylation Status of Glioblastoma Using Radiomics and Latent Space Shape Features. <i>Lecture Notes in Computer Science</i> , 2022, , 222-231.	1.0	3
5900	Neuronavigation-Guided Transcortical-Transventricular Endoport-Assisted Endoscopic Resection for Thalamic Lesions: Preliminary Experience. <i>World Neurosurgery</i> , 2022, 166, 19-27.	0.7	6
5901	Survival Outcomes and Prognostic Factors in Glioblastoma. <i>Cancers</i> , 2022, 14, 3161.	1.7	33
5902	MGMT and Whole-Genome DNA Methylation Impacts on Diagnosis, Prognosis and Therapy of Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7148.	1.8	18
5903	Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7046.	1.8	19
5904	Certain aspects of radiomics and radiogenomics in glioblastoma: what the images hide?. <i>Translational Medicine</i> , 2022, 9, 70-80.	0.1	0
5905	Updates in the Management of Recurrent Glioblastoma Multiforme. <i>Journal of Neurological Surgery, Part A: Central European Neurosurgery</i> , 2023, 84, 174-187.	0.4	3
5906	Ubiquitin-Specific Protease 6 n-Terminal-like Protein (USP6NL) and the Epidermal Growth Factor Receptor (EGFR) Signaling Axis Regulates Ubiquitin-Mediated DNA Repair and Temozolomide-Resistance in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1531.	1.4	3
5907	Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification. <i>Cancers</i> , 2022, 14, 3149.	1.7	2
5909	Integrated MRIâ€œImmuneâ€œGenomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma. <i>Cancers</i> , 2022, 14, 3249.	1.7	1

#	ARTICLE	IF	CITATIONS
5910	Immune surveillance in glioblastoma: Role of the <sc>NKG2D</sc> system and novel cell-based therapeutic approaches. <i>Scandinavian Journal of Immunology</i> , 2022, 96, .	1.3	13
5911	Molecular landscape of <sc>IDH</sc>-wild type, <sc>TERT</sc>-wild type adult glioblastomas. <i>Brain Pathology</i> , 2022, 32, .	2.1	9
5912	Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and meta-analysis. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 1476-1491.	1.9	5
5913	The Sesquiterpene Lactone Cynaropicrin Manifests Strong Cytotoxicity in Glioblastoma Cells U-87 MG by Induction of Oxidative Stress. <i>Biomedicines</i> , 2022, 10, 1583.	1.4	5
5914	Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
5915	Glioblastoma " treatment and obstacles. <i>Reports of Practical Oncology and Radiotherapy</i> , 0, , .	0.3	6
5916	Molecular and Circulating Biomarkers in Patients with Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7474.	1.8	19
5917	DNA methylation alterations across time and space in paediatric brain tumours. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	6
5918	Low-intensity ultrasound: A novel technique for adjuvant treatment of gliomas. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113394.	2.5	2
5920	DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. <i>Neuro-Oncology</i> , 2023, 25, 315-325.	0.6	13
5921	Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1763.	1.4	4
5922	Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, , .	1.2	1
5923	GNG12 as A Novel Molecular Marker for the Diagnosis and Treatment of Glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
5924	Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases. <i>Advanced Science</i> , 2022, 9, .	5.6	19
5925	An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases. <i>JCI Insight</i> , 2022, 7, .	2.3	5
5926	Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network. <i>Oncologist</i> , 2022, 27, 930-939.	1.9	5
5928	Mitochondria-targeting nano therapy altering IDH2-mediated EZH2/EZH1 interaction as precise epigenetic regulation in glioblastoma. <i>Biomaterials Science</i> , 2022, 10, 5301-5317.	2.6	2
5929	A Video Data Based Transfer Learning Approach for Classification of MGMT Status in Brain Tumor MR Images. <i>Lecture Notes in Computer Science</i> , 2022, , 306-314.	1.0	0

#	ARTICLE	IF	CITATIONS
5930	Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma. <i>Cancers</i> , 2022, 14, 3705.	1.7	6
5931	Mechanism-based design of agents that selectively target drug-resistant glioma. <i>Science</i> , 2022, 377, 502-511.	6.0	30
5932	Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
5933	DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomas. <i>Nature Communications</i> , 2022, 13, .	5.8	5
5934	In Vitro Effects of Fungal Phytotoxins on Cancer Cell Viability: First Insight into Structure Activity Relationship of a Potent Metabolite of <i>Cochliobolus australiensis</i> Radicinin. <i>Toxins</i> , 2022, 14, 517.	1.5	3
5935	Targeted inhibition of ubiquitin signaling reverses metabolic reprogramming and suppresses glioblastoma growth. <i>Communications Biology</i> , 2022, 5, .	2.0	6
5936	Improving MGMT methylation status prediction of glioblastoma through optimizing radiomics features using genetic algorithm-based machine learning approach. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
5937	Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification. <i>Journal of Neuro-Oncology</i> , 2022, 159, 695-703.	1.4	9
5938	Case Report: Clinicopathological and Genetic Features of IDH-Mutant Brainstem Glioma in Adults: Report of Five Cases. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	3
5939	Modulating glioblastoma chemotherapy response: Evaluating long non-coding RNA effects on DNA damage response, glioma stem cell function, and hypoxic processes. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	2
5940	New Approaches in the Treatment of Glioblastoma Multiforme. , 0, , .		0
5941	Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns. <i>Clinical Cancer Research</i> , 2022, 28, 4565-4573.	3.2	0
5942	Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle. <i>Diagnostics</i> , 2022, 12, 2064.	1.3	20
5943	Potential 18F-RGD PET/CT and DCE-MRI Imaging-Based Biomarkers for Postoperative Survival Prediction Among Patients With Newly Diagnosed Glioblastoma Treated With Bevacizumab and Chemoradiotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
5944	National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. <i>Neuro-Oncology</i> , 2023, 25, 799-807.	0.6	24
5945	Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. <i>International Reviews of Immunology</i> , 2022, 41, 582-605.	1.5	12
5946	Computational identification of immune-related lncRNA signature for predicting the prognosis and immune landscape of human glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
5947	Comprehensive development and validation of gene signature for predicting survival in patients with glioblastoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6



#	ARTICLE	IF	CITATIONS
5948	Characterization and comparison of human glioblastoma models. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
5949	Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era. <i>Biomedicines</i> , 2022, 10, 1927.	1.4	16
5950	The Brain Protein Atlas: A conglomerate of proteomics datasets of human neural tissue. <i>Proteomics</i> , 2022, 22, .	1.3	8
5951	Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	8
5952	Emerging immune-based technologies for high-grade gliomas. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 957-980.	1.1	1
5953	Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8835.	1.8	20
5954	MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study. <i>Biomedicines</i> , 2022, 10, 2030.	1.4	12
5955	Multiparametric MR radiomics in brain glioma: models comparison to predict biomarker status. <i>BMC Medical Imaging</i> , 2022, 22, .	1.4	8
5956	Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
5957	The Association of Preoperative Frailty and Neighborhood-Level Disadvantage with Outcome in Patients with Newly Diagnosed High Grade Glioma. <i>World Neurosurgery</i> , 2022, 166, e949-e957.	0.7	4
5958	World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas. <i>JAMA Oncology</i> , 2022, 8, 1493.	3.4	76
5959	Challenges in Glioblastoma Radiomics and the Path to Clinical Implementation. <i>Cancers</i> , 2022, 14, 3897.	1.7	3
5960	First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	6
5961	FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8675.	1.8	7
5962	Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO <i>resect</i> group. <i>Neuro-Oncology</i> , 2023, 25, 940-954.	0.6	59
5963	Ascorbate content of clinical glioma tissues is related to tumour grade and to global levels of 5-hydroxymethyl cytosine. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
5964	Progress in research and development of temozolomide brain-targeted preparations: a review. <i>Journal of Drug Targeting</i> , 2023, 31, 119-133.	2.1	3
5965	PROSPECTS OF USING THE ELEMENTAL STATUS OF BLOOD TO ASSESS THE MOLECULAR GENETIC PROFILE OF GLIOMAS. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2023, 67, 497-503.	0.2	0

#	ARTICLE	IF	CITATIONS
5966	Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme. <i>Journal of Controlled Release</i> , 2022, 350, 494-513.	4.8	12
5967	Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy. <i>ESMO Open</i> , 2022, 7, 100566.	2.0	6
5968	Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome. <i>Translational Oncology</i> , 2022, 26, 101535.	1.7	2
5969	Epigenetic Biomarkers. , 2023, , 303-321.		0
5970	Identification of upregulated genes in glioblastoma and glioblastoma cancer stem cells using bioinformatics analysis. <i>Gene</i> , 2023, 848, 146895.	1.0	4
5971	Epigenetic therapy and DNA damage response. , 2022, , 227-252.		0
5972	Research Progress of p53 Gene and Tumor. <i>World Journal of Cancer Research</i> , 2022, 12, 147-152.	0.1	0
5973	Diffusion magnetic resonance imaging in brain tumours. , 2022, , 319-349.		0
5974	Opportunities and Challenges for Deep Learning in Brain Lesions. <i>Lecture Notes in Computer Science</i> , 2022, , 25-36.	1.0	0
5975	Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies. <i>Cancers</i> , 2022, 14, 4222.	1.7	10
5976	Protein Quality Control in Glioblastoma: A Review of the Current Literature with New Perspectives on Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9734.	1.8	1
5977	MCPIP1 Suppresses the NF- $\kappa$ B Signaling Pathway Through Negative Regulation of K63-Linked Ubiquitylation of TRAF6 in Colorectal Cancer. <i>Cancer Gene Therapy</i> , 2023, 30, 96-107.	2.2	3
5978	ZEB1 loss increases glioma stem cell tumorigenicity and resistance to chemoradiation. <i>Journal of Neurosurgery</i> , 2022, , 1-12.	0.9	0
5980	Relationship between Glutathione-Dependent Enzymes and the Immunohistochemical Profile of Glial Neoplasms. <i>Biomedicines</i> , 2022, 10, 2393.	1.4	0
5981	Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy. <i>Biomolecules</i> , 2022, 12, 1379.	1.8	0
5982	Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF- $\beta$ signaling in recurrent tumors. <i>Neuro-Oncology</i> , 2023, 25, 662-673.	0.6	9
5983	Factors affecting the radiation response in glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	6
5984	Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	0

#	ARTICLE	IF	CITATIONS
5985	The predictive value of partial <i>MGMT</i> promoter methylation for IDH-wild-type glioblastoma patients. <i>Neuro-Oncology Practice</i> , 2023, 10, 126-131.	1.0	1
5986	Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDHWT glioblastoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
5987	cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. <i>F1000Research</i> , 0, 11, 1010.	0.8	1
5988	Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period. <i>Neuro-Oncology Practice</i> , 2023, 10, 50-61.	1.0	4
5989	Biological Mechanisms to Reduce Radioresistance and Increase the Efficacy of Radiotherapy: State of the Art. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10211.	1.8	10
5990	A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. <i>International Journal of Cancer</i> , 0, , .	2.3	6
5991	Treatments against Polymorphosal discrepancies in Glioblastoma Multiforme. <i>Metabolic Brain Disease</i> , 2023, 38, 61-68.	1.4	4
5992	Influence of clinical and molecular genetic characteristics on the first relapse-free period in patients with glioblastoma in the era of modern chemoradiotherapy. , 2022, 2, 23-34.		2
5993	Current and promising treatment strategies in glioma. <i>Reviews in the Neurosciences</i> , 2022, .	1.4	3
5994	Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	7
5996	Current therapeutic options for glioblastoma and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1629-1640.	0.9	5
5997	On optimal temozolomide scheduling for slowly growing glioblastomas. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	1
5998	Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 733-743.	12.5	8
5999	[ <sup>68</sup> Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [ <sup>177</sup> Lu]Lu-PSMA therapy in relapsing high-grade glioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
6000	Prognostic Impact of Low-Level p53 Expression on Brain Astrocytomas Immunopositive for Epidermal Growth Factor Receptor. <i>Current Issues in Molecular Biology</i> , 2022, 44, 4142-4151.	1.0	0
6001	U-Net Based Segmentation and Characterization of Gliomas. <i>Cancers</i> , 2022, 14, 4457.	1.7	10
6002	Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth. <i>Cancer Gene Therapy</i> , 0, , .	2.2	0
6003	Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6

#	ARTICLE	IF	CITATIONS
6004	Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	3
6005	Integrating Radiosensitivity Gene Signature Improves Glioma Outcome and Radiotherapy Response Prediction. <i>Medicina (Lithuania)</i> , 2022, 58, 1327.	0.8	1
6006	Perspective Chapter: RNA Therapeutics for Cancers. , 0, , .		2
6007	Surgical approaches to intramedullary spinal cord astrocytomas in the age of genomics. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
6008	Preferential <i>MGMT</i> hypermethylation in SDH-deficient wild-type GIST. <i>Journal of Clinical Pathology</i> , 0, , jcp-2022-208462.	1.0	0
6009	Integrative genomic analysis facilitates precision strategies for glioblastoma treatment. <i>Science</i> , 2022, 25, 105276.	1.9	0
6010	Clinical, Therapeutic, and Prognostic Experience in Patients With Glioblastoma. <i>Cureus</i> , 2022, , .	0.2	0
6011	Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study. <i>Oncologist</i> , 2023, 28, e45-e53.	1.9	0
6012	Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States. <i>Neuro-Oncology Practice</i> , 0, , .	1.0	1
6013	Immunotherapies catering to the unmet medical need of cold colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
6014	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019. <i>Neuro-Oncology</i> , 2022, 24, v1-v95.	0.6	385
6015	Impact of new molecular criteria on diagnosis and survival of adult glioma patients. <i>IBRO Neuroscience Reports</i> , 2022, 13, 299-305.	0.7	6
6016	Chemotherapeutic Protocols for the Treatment of Neurological Cancer. , 2022, , 307-320.		0
6017	Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report. <i>Veterinary Sciences</i> , 2022, 9, 541.	0.6	1
6018	Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2022, 160, 473-480.	1.4	3
6019	The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1566-1589.	1.3	1
6020	Temozolomide in aggressive pituitary tumours and pituitary carcinomas. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101713.	2.2	9
6021	Clinical implementation of artificial intelligence in neuroradiology with development of a novel workflow-efficient picture archiving and communication system-based automated brain tumor segmentation and radiomic feature extraction. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	12

#	ARTICLE	IF	CITATIONS
6022	Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 5961.	1.0	5
6023	Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	3
6024	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
6025	Validation of MRI-Based Models to Predict MGMT Promoter Methylation in Gliomas: BraTS 2021 Radiogenomics Challenge. <i>Cancers</i> , 2022, 14, 4827.	1.7	5
6027	Differentiation of Intracerebral Tumor Entities with Quantitative Contrast Attenuation and Iodine Mapping in Dual-Layer Computed Tomography. <i>Diagnostics</i> , 2022, 12, 2494.	1.3	1
6028	Can Extended Chemotherapy Improve Glioblastoma Outcomes? A Retrospective Analysis of Survival in Real-World Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 1670.	1.1	2
6030	Exploiting radiation immunostimulatory effects to improve glioblastoma outcome. <i>Neuro-Oncology</i> , 2023, 25, 433-446.	0.6	5
6031	Reirradiation for Recurrent Glioblastoma: What We Know and What We Do Not. <i>Journal of Clinical Oncology</i> , 2023, 41, 1183-1188.	0.8	7
6032	NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells. <i>Journal of Neuro-Oncology</i> , 0, , .	1.4	4
6033	Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors. <i>Cell Research</i> , 2022, 32, 1047-1067.	5.7	18
6034	Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	7
6035	The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. <i>History and Philosophy of the Life Sciences</i> , 2022, 44, .	0.6	4
6036	Aggressive Gliomatosis Peritonei Arising from Ovarian Mature Teratoma with NF1 Mutation: A Case Report and Literature Review. <i>Cancer Management and Research</i> , 0, Volume 14, 2979-2986.	0.9	1
6037	Glioma radiogenomics and artificial intelligence: road to precision cancer medicine. <i>Clinical Radiology</i> , 2023, 78, 137-149.	0.5	4
6038	Feasibility and Safety of a Combined Metabolic Strategy in Glioblastoma Multiforme: A Prospective Case Series. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	0
6039	Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma IDH Wildtype. <i>Cancers</i> , 2022, 14, 5227.	1.7	7
6040	Chronotherapy: Circadian Rhythms and Their Influence in Cancer Therapy. <i>Cancers</i> , 2022, 14, 5071.	1.7	20
6044	Methylome Profiling of PD-L1-Expressing Glioblastomas Shows Enrichment of Post-Transcriptional and RNA-Associated Gene Regulation. <i>Cancers</i> , 2022, 14, 5375.	1.7	2

#	ARTICLE	IF	CITATIONS
6045	Biopsy of paediatric brainstem intrinsic tumours: Experience from a Singapore Children's Hospital. <i>Journal of Clinical Neuroscience</i> , 2022, 106, 8-13.	0.8	0
6046	Role of DNMTs in the Brain. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 363-394.	0.8	5
6047	Basic principles of contemporary chemotherapy of malignant gliomas of the brain. <i>Ukrainian Neurosurgical Journal</i> , 2022, 28, 3-8.	0.1	0
6048	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. <i>Current Opinion in Neurology</i> , 2022, 35, 803-813.	1.8	7
6049	Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. <i>Cancers</i> , 2022, 14, 5494.	1.7	6
6050	The role of RNA modification in the generation of acquired drug resistance in glioma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
6051	Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. <i>Cancers</i> , 2022, 14, 5522.	1.7	3
6052	Surgical cytoreduction of deep-seated high-grade glioma through tubular retractor. <i>Journal of Neurosurgery</i> , 2022, , 1-12.	0.9	0
6053	Stem cell phenotype predicts therapeutic response in glioblastomas with MGMT promoter methylation. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	2
6054	Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
6055	The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13577.	1.8	8
6056	Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). <i>Neuro-Oncology</i> , 2023, 25, 580-592.	0.6	10
6057	Predicting survival of glioblastoma from automatic whole-brain and tumor segmentation of MR images. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
6058	Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02. <i>Clinical Oncology</i> , 2022, , .	0.6	0
6059	Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. <i>Neuro-Oncology</i> , 2023, 25, 687-698.	0.6	7
6061	CALN1 hypomethylation as a biomarker for high-risk bladder cancer. <i>BMC Urology</i> , 2022, 22, .	0.6	1
6062	DNA damage in IDH-mutant gliomas: mechanisms and clinical implications. <i>Journal of Neuro-Oncology</i> , 2023, 162, 515-523.	1.4	6
6063	Leptomeningeal metastases in glioma revisited: incidence and molecular predictors based on postcontrast fluid-attenuated inversion recovery imaging. <i>Journal of Neurosurgery</i> , 2022, , 1-11.	0.9	4

#	ARTICLE	IF	CITATIONS
6064	A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
6065	Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2022, 160, 433-443.	1.4	6
6066	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
6067	Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma. <i>Biochemistry and Biophysics Reports</i> , 2022, 32, 101386.	0.7	3
6068	Determining venous thromboembolism risk in patients with adult-type diffuse glioma. <i>Blood</i> , 2023, 141, 1322-1336.	0.6	3
6069	MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients. <i>Cancer Genetics</i> , 2023, 270-271, 22-30.	0.2	6
6070	Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2023, 9, 112.	3.4	133
6071	Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14224.	1.8	10
6072	Epigenetic basis for PARP mutagenesis in glioblastoma: A review. <i>European Journal of Pharmacology</i> , 2023, 938, 175424.	1.7	1
6073	Impact of EGFR289T/V mutation on relapse pattern in glioblastoma. <i>ESMO Open</i> , 2023, 8, 100740.	2.0	1
6074	Tristetraprolin expression levels and methylation status in breast cancer. <i>Gene Reports</i> , 2023, 30, 101718.	0.4	0
6075	Glioblastoma Antigen Expression for Tumor Targeting. , 2022, , .		0
6076	Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated <i>MGMT</i> promoter. <i>Epigenomics</i> , 2022, 14, 1233-1247.	1.0	1
6077	A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. <i>Biomedicines</i> , 2022, 10, 2977.	1.4	2
6078	Cost Matrix of Molecular Pathology in Glioma—Towards AI-Driven Rational Molecular Testing and Precision Care for the Future. <i>Biomedicines</i> , 2022, 10, 3029.	1.4	1
6079	DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14672.	1.8	26
6080	Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
6081	Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations. <i>Cancers</i> , 2022, 14, 5679.	1.7	7

#	ARTICLE	IF	CITATIONS
6082	Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes. , 2023, 40, .		6
6083	The LUMIERE dataset: Longitudinal Glioblastoma MRI with expert RANO evaluation. Scientific Data, 2022, 9, .	2.4	4
6084	Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance. International Journal of Cancer, 2023, 153, 476-488.	2.3	8
6085	Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology. Biomedicines, 2022, 10, 3205.	1.4	2
6086	Cancer epigenetics in clinical practice. Ca-A Cancer Journal for Clinicians, 2023, 73, 376-424.	157.7	43
6087	Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	6
6088	Prolonged survival in patients with local chronic infection after high-grade glioma treatment: Two case reports. Frontiers in Oncology, 0, 12, .	1.3	0
6089	2,5-Bis(2,2,2-trifluoroethoxy)phenyl-tethered 1,3,4-Oxadiazoles Derivatives: Synthesis, In Silico Studies, and Biological Assessment as Potential Candidates for Anti-Cancer and Anti-Diabetic Agent. Molecules, 2022, 27, 8694.	1.7	1
6090	Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2023, 41, 1453-1465.	0.8	27
6091	MGMT Gene rs1625649 Polymorphism in Iranian Patients with Brain Glioblastoma: A Case Control Study. Avicenna Journal of Medical Biotechnology, 0, , .	0.2	0
6092	Recent Therapeutic Advances in Pituitary Carcinoma. Journal of Immunotherapy and Precision Oncology, 2022, , .	0.6	3
6093	Ô³Ö-Ö«Ö,ÖçÖ-Ö;Ö½Ö;Ö´Ö; Ö-Ö©Ö«Ö,Ö-Ö,Ö±Ö«Ö;Ö¶, ÖÖ;Ö½Ö;Ö´Ö;Ö€Ö±Ö,Ö´Ö”, Ö-Ö-Ö«Ö¶Ö«Ö-Ö¶;Ö¶ ÖºÖ;ÖçÖ		
6094	Lipid droplets and ferroptosis as new players in brain cancer glioblastoma progression and therapeutic resistance. Frontiers in Oncology, 0, 12, .	1.3	10
6095	Diagnostic Accuracy and Field for Improvement of Frameless Stereotactic Brain Biopsy: A Focus on Nondiagnostic Cases. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2024, 85, 048-061.	0.4	0
6097	Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data. Cancers, 2022, 14, 6180.	1.7	0
6099	NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity. Cancers, 2022, 14, 6065.	1.7	3
6100	BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression. Cell Death and Disease, 2022, 13, .	2.7	6
6101	Quantitative analysis of <sc><i>MGMT</i></sc> promoter methylation status changes< by pyrosequencing in recurrent glioblastoma. Neuropathology, 2023, 43, 306-312.	0.7	2



#	ARTICLE	IF	CITATIONS
6102	Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker. <i>Journal of Neuro-Oncology</i> , 0, , .	1.4	0
6103	Recent advances in epigenetic anticancer therapeutics and future perspectives. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
6104	Pharmacogenetics for Oncology Practice. <i>Annals of the Academy of Medicine, Singapore</i> , 2011, 40, 348-349.	0.2	1
6105	Reconciling the Contemporary Molecular Diagnosis of Glioblastoma With Past Clinical Trial Data. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
6106	Injectable local drug delivery systems for glioblastoma: a systematic review and <i>meta</i> -analysis of progress to date. <i>Biomaterials Science</i> , 2023, 11, 1553-1566.	2.6	4
6107	Proteome-based insights for IDH-mutant glioma classification. <i>Cell Reports Medicine</i> , 2023, 4, 100909.	3.3	0
6108	Signaling pathways in brain tumors and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	13
6109	Clinical activity of regorafenib in elderly patients with recurrent glioblastoma. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	1
6110	Apparent Diffusion Coefficient as Imaging Biomarker for Identifying <i>IDH</i> Mutation, 1p19q Codeletion, and <i>MGMT</i> Promoter Methylation Status in Patients With Glioma. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 732-738.	1.9	4
6111	The dual role of DNA repair protein MGMT in cancer prevention and treatment. <i>DNA Repair</i> , 2023, 123, 103449.	1.3	12
6112	NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2023, 21, 12-20.	2.3	44
6113	DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities. <i>Cancers</i> , 2023, 15, 448.	1.7	7
6114	The Epidemiology of Brain and Spinal Cord Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 19-39.	0.8	3
6115	Editorial for “Apparent Diffusion Coefficient as Imaging Biomarker for Identifying <i>IDH</i> Mutation, 1p19q Codeletion, and <i>MGMT</i> Promoter Methylation Status in Patients With Glioma” <i>Journal of Magnetic Resonance Imaging</i> , 2023, 58, 739-740.	1.9	0
6116	DNA methylation and cancer: transcriptional regulation, prognostic, and therapeutic perspective. , 2023, 40, .		9
6117	A Comparison of Three Different Deep Learning-Based Models to Predict the <i>MGMT</i> Promoter Methylation Status in Glioblastoma Using Brain MRI. <i>Journal of Digital Imaging</i> , 2023, 36, 837-846.	1.6	5
6119	Key Clinical Principles in the Management of Glioblastoma. <i>JCO Oncology Practice</i> , 2023, 19, 180-189.	1.4	12
6120	Pro- vs. Anti-Inflammatory Features of Monocyte Subsets in Glioma Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1879.	1.8	3

#	ARTICLE	IF	CITATIONS
6121	Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
6122	Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. <i>Current Oncology</i> , 2023, 30, 1381-1394.	0.9	3
6123	Cystic Glioblastoma: A Mimicker of Infection? A Case Report and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2023, 2023, 1-8.	0.2	0
6124	A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma. <i>Cancer Research Communications</i> , 2023, 3, 130-139.	0.7	5
6125	The Role of Cellular Immunity and Adaptive Immunity in Pathophysiology of Brain and Spinal Cord Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 51-72.	0.8	0
6126	Palliative care in brain tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 69-80.	1.0	2
6127	ProNGF Expression and Targeting in Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1616.	1.8	2
6128	Fused deep learning paradigm for the prediction of o6-methylguanine-DNA methyltransferase genotype in glioblastoma patients: A neuro-oncological investigation. <i>Computers in Biology and Medicine</i> , 2023, 153, 106492.	3.9	8
6129	Systemic Treatment in Glioblastoma. , 0, , .		0
6130	Nanobodies targeting ABCC3 for immunotargeted applications in glioblastoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
6131	Improved Median Survival for Glioblastoma Multiforme Following Introduction of Adjuvant Temozolomide Chemotherapy. <i>Annals of the Academy of Medicine, Singapore</i> , 2007, 36, 338-342.	0.2	20
6132	Molecular pathology and clinical implications of diffuse glioma. <i>Chinese Medical Journal</i> , 2022, 135, 2914-2925.	0.9	9
6133	Computational imaging applications in brain and breast cancer. , 2023, , 29-45.		0
6135	Repeat resection for recurrent glioblastoma in the temozolomide era: a real-world multi-centre study. <i>British Journal of Neurosurgery</i> , 0, , 1-9.	0.4	1
6136	G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells. <i>Radiation Oncology</i> , 2023, 18, .	1.2	3
6137	Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. <i>Journal of Neuro-Oncology</i> , 2023, 161, 147-153.	1.4	2
6138	Natural Course and Prognosis of Primary Spinal Glioblastoma. <i>Neurology</i> , 2023, 100, .	1.5	2
6139	Plasma nanoDSF Denaturation Profile at Baseline Is Predictive of Glioblastoma EGFR Status. <i>Cancers</i> , 2023, 15, 760.	1.7	2

#	ARTICLE	IF	CITATIONS
6140	Cancer Registration, Molecular Marker Status, and Adherence to the WHO 2016 Classification of Pathology Reports for Glioma Diagnosed during 2017–2019 in Belgium. <i>Pathobiology</i> , 2023, 90, 365-376.	1.9	0
6142	Surgeon experience in glioblastoma surgery of the elderly—a multicenter, retrospective cohort study. <i>Journal of Neuro-Oncology</i> , 2023, 161, 563-572.	1.4	4
6143	Biallelic MGMT loss in a case of IDH-wild-type adult glioblastoma: a case for concurrent epigenomic and molecular karyotype testing. <i>Pathology</i> , 2023, .	0.3	0
6144	A Comparison of MGMT Testing by MSP and qMSP in Paired Snap-Frozen and Formalin-Fixed Paraffin-Embedded Gliomas. <i>Diagnostics</i> , 2023, 13, 360.	1.3	0
6145	Coculture with Neural Stem Cells May Shift the Transcription Profile of Glioblastoma Multiforme towards Cancer-Specific Stemness. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3242.	1.8	2
6146	Cellular and molecular features related to exceptional therapy response and extreme long-term survival in glioblastoma. <i>Cancer Medicine</i> , 2023, 12, 11107-11126.	1.3	7
6147	Characterization of perioperative glycemic status and dexamethasone use with associated postoperative complications in glioblastoma patients. <i>Acta Neurochirurgica</i> , 2023, 165, 1031-1040.	0.9	2
6148	The Glioma-IRE project – Molecular profiling in patients with glioma: steps toward an individualized diagnostic and therapeutic approach. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	5
6149	Prognostic evaluation of patients with glioblastoma using a new score prediction model. <i>European Journal of Surgical Oncology</i> , 2023, .	0.5	0
6150	Histopathologic and Molecular Evaluation of Meningioma. <i>Neurosurgery Clinics of North America</i> , 2023, .	0.8	0
6151	PSMA Expression Correlates with Improved Overall Survival and VEGF Expression in Glioblastoma. <i>Biomedicines</i> , 2023, 11, 1148.	1.4	0
6152	MRI-Based Deep Learning Tools for MGMT Promoter Methylation Detection: A Thorough Evaluation. <i>Cancers</i> , 2023, 15, 2253.	1.7	1
6153	Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells. <i>Pathology Research and Practice</i> , 2023, 245, 154427.	1.0	6
6154	Radiotherapy opens the blood–brain barrier and synergizes with anlotinib in treating glioblastoma. <i>Radiotherapy and Oncology</i> , 2023, 183, 109633.	0.3	3
6155	Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114555.	2.5	3
6156	RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance. <i>Cancer Letters</i> , 2023, 557, 216078.	3.2	6
6157	Standardizing analysis of intra-tumoral heterogeneity with computational pathology. <i>Genes Chromosomes and Cancer</i> , 2023, 62, 526-539.	1.5	1
6159	CKAP4-mediated activation of FOXM1 via phosphorylation pathways regulates malignant behavior of glioblastoma cells. <i>Translational Oncology</i> , 2023, 29, 101628.	1.7	2

#	ARTICLE	IF	CITATIONS
6160	Management of Patients with High-Grade Glioma. <i>European Medical Journal Oncology</i> , 0, , 91-99.	0.0	1
6161	Telomerase inhibition is an effective therapeutic strategy in <i>TERT</i> promoter-mutant glioblastoma models with low tumor volume. <i>Neuro-Oncology</i> , 2023, 25, 1275-1285.	0.6	8
6162	Study of Strawberry Notch homolog 1 and 2 expression in human glioblastoma. <i>Journal of Neuro-Oncology</i> , 2023, 161, 515-523.	1.4	0
6163	T1-Weighted Contrast Enhancement, Apparent Diffusion Coefficient, and Cerebral-Blood-Volume Changes after Glioblastoma Resection: MRI within 48 Hours vs. beyond 48 Hours. <i>Tomography</i> , 2023, 9, 342-351.	0.8	2
6164	Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. <i>PLoS ONE</i> , 2023, 18, e0281166.	1.1	5
6166	MGMT methylation: Is it time to embrace the shades of grey?. <i>Neuro-Oncology Practice</i> , 2023, 10, 111-112.	1.0	0
6167	Autophagy-dependent ferroptosis as a potential treatment for glioblastoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
6168	The Immunology of Brain Tumors. , 2023, , .		0
6170	Modeling glioblastoma complexity with organoids for personalized treatments. <i>Trends in Molecular Medicine</i> , 2023, 29, 282-296.	3.5	7
6171	The Prognostic Impact of Gender, Therapeutic Strategies, Molecular Background, and Tumor-Infiltrating Lymphocytes in Glioblastoma: A Still Unsolved Jigsaw. <i>Genes</i> , 2023, 14, 501.	1.0	5
6172	Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma. <i>BMC Neurology</i> , 2023, 23, .	0.8	0
6173	Deep learning MRI signature to predict survival and treatment benefit from temozolomide in IDH-wildtype glioblastoma. <i>Displays</i> , 2023, 77, 102399.	2.0	2
6174	Glioblastoma and Other Primary Brain Malignancies in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 574.	3.8	123
6176	Artificial Intelligence in Brain Tumor Imaging: A Step toward Personalized Medicine. <i>Current Oncology</i> , 2023, 30, 2673-2701.	0.9	11
6177	Update for astrocytomas: medical and surgical management considerations. , 0, , 1-26.		2
6179	Targeting <i>XBP1</i> mRNA splicing sensitizes glioblastoma to chemotherapy. <i>FASEB BioAdvances</i> , 2023, 5, 211-220.	1.3	1
6180	Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
6181	Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide. <i>Anticancer Research</i> , 2023, 43, 1131-1138.	0.5	1

#	ARTICLE	IF	CITATIONS
6182	Analysis of Prognostic Factors and Surgical Management of Elderly Patients with Low-Grade Gliomas. <i>World Neurosurgery</i> , 2023, , .	0.7	1
6183	Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1585-1601.	1.8	9
6185	CDC14B is a favorable biomarker for recurrence and prognosis of GBM. <i>Clinical Neurology and Neurosurgery</i> , 2023, 227, 107665.	0.6	1
6186	Myelotoxicity of Temozolomide Treatment in Patients with Glioblastoma Is It Time for a More Mechanistic Approach?. <i>Cancers</i> , 2023, 15, 1561.	1.7	1
6187	Prognosis of MGMT-Positive Gene in Patients with Brain Tumors of Grade III and Grade IV. <i>South Asian Journal of Cancer</i> , 0, , .	0.2	0
6188	Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity. <i>Journal of Clinical Medicine</i> , 2023, 12, 2061.	1.0	2
6189	Gliosarcoma with extensive extracranial metastatic spread and familial coincidence: A case report. <i>Pathology Research and Practice</i> , 2023, 244, 154399.	1.0	0
6190	Ketogenic therapies for glioblastoma: Understanding the limitations in transitioning from mice to patients. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	0
6192	The dark side of mRNA translation and the translation machinery in glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	0
6193	Nucleolin promotes angiogenesis and endothelial metabolism along the oncofetal axis in the human brain vasculature. <i>JCI Insight</i> , 2023, 8, .	2.3	0
6195	Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme. <i>Cells</i> , 2023, 12, 897.	1.8	2
6196	Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics. <i>Acta Neurochirurgica</i> , 2023, 165, 1075-1085.	0.9	3
6197	Glioblastoma multiforme tanÄ±lÄ± olgularÄ±mÄ±zda saÄŸkalÄ±m ve prognostik faktÄ±rlerin deÄŸerlendirilmesi: retrospektif ÅŸalÄ±ÅŸma. <i>UludaÄŸ Äceniversitesi TÄ±p FakÄŸltesi Dergisi</i> , 0, , .	0.2	0
6198	H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series. <i>Acta Neurochirurgica</i> , 2023, 165, 1615-1633.	0.9	2
6199	Quinolate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPAR <sup>Î³</sup> signaling axis. <i>Nature Communications</i> , 2023, 14, .	5.8	9
6200	Prediction of O-6-methylguanine-DNA methyltransferase and overall survival of the patients suffering from glioblastoma using MRI-based hybrid radiomics signatures in machine and deep learning framework. <i>Neural Computing and Applications</i> , 2023, 35, 13647-13663.	3.2	4
6201	Retrospective examination of pseudoprogression in <i>IDH</i> mutant gliomas. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	0
6202	Astrocytic neoplasms. , 2013, , 705-728.		1

#	ARTICLE	IF	CITATIONS
6203	Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6184.	1.8	3
6204	Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma. <i>Genome Medicine</i> , 2023, 15, .	3.6	5
6205	Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data. <i>Radiation Oncology</i> , 2023, 18, .	1.2	0
6207	Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. <i>Lancet Oncology</i> , The, 2023, 24, e161-e171.	5.1	4
6208	ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery. <i>Pharmacological Reviews</i> , 2023, 75, 815-853.	7.1	7
6209	Chemotherapy in Cutaneous Melanoma: Is There Still a Role?. <i>Current Oncology Reports</i> , 2023, 25, 609-621.	1.8	8
6210	Non-operable glioblastoma: Proposition of patient-specific forecasting by image-informed poromechanical model. <i>Brain Multiphysics</i> , 2023, 4, 100067.	0.8	1
6211	Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies. <i>Cancer and Metastasis Reviews</i> , 0, , .	2.7	0
6212	Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas. <i>Brain Tumor Pathology</i> , 2023, 40, 56-65.	1.1	2
6213	Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression. <i>Human Genomics</i> , 2023, 17, .	1.4	1
6215	Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview. <i>Metabolites</i> , 2023, 13, 543.	1.3	2
6216	Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade 4 glioma using multi-parametric MRI. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	1
6217	Recent advances in the use of liquid biopsy to fight central nervous system tumors. <i>Cancer Treatment and Research Communications</i> , 2023, 35, 100709.	0.7	2
6218	Defining subventricular zone involvement to predict the survival of patients in isocitrate dehydrogenase-wild type glioblastoma: validation in a prospective registry. <i>European Radiology</i> , 2023, 33, 6448-6458.	2.3	0
6221	Effect of tumor genetics, pathology, and location on fMRI of language reorganization in brain tumor patients. <i>European Radiology</i> , 0, , .	2.3	2
6222	Immunotherapy in glioblastoma treatment: Current state and future prospects. <i>World Journal of Clinical Oncology</i> , 0, 14, 138-159.	0.9	13
6223	Cell Cycle-Related FAM64A Could be Activated by TGF- $\beta^2$ Signaling to Promote Glioma Progression. <i>Cellular and Molecular Neurobiology</i> , 2023, 43, 2975-2987.	1.7	2
6224	Brain Tumor Radiogenomic Classification of O <sup>6</sup> -Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning. <i>Cancer Control</i> , 2023, 30, 107327482311691.	0.7	1

#	ARTICLE	IF	CITATIONS
6225	Low-coverage and cost-effective whole-genome sequencing assay for glioma risk stratification. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
6226	Transcriptional Profiling of a Patient-Matched Cohort of Glioblastoma (IDH-Wildtype) for Therapeutic Target and Repurposing Drug Identification. <i>Biomedicines</i> , 2023, 11, 1219.	1.4	0
6230	The intra-tumoral heterogeneity in glioblastoma " a limitation for prognostic value of epigenetic markers?. <i>Acta Neurochirurgica</i> , 0, , .	0.9	0
6242	Personalized epigenetic therapy" chemosensitivity testing. , 2023, , 637-649.		0
6246	Chemical Exchange Saturation Transfer (CEST) Imaging. , 2023, , 293-308.		0
6248	Clinical Applications of Dynamic Contrast-Enhanced (DCE) Permeability Imaging. , 2023, , 175-200.		1
6253	Newly diagnosed glioblastoma: A review on clinical management. , 2023, , 101-123.		0
6254	An overview of current drug delivery strategies for glioblastoma treatment and barriers to progress. , 2023, , 405-434.		0
6255	Practice guidelines for the diagnosis of glioblastoma. , 2023, , 11-32.		0
6261	Glioblastoma heterogeneity at single cell resolution. <i>Oncogene</i> , 2023, 42, 2155-2165.	2.6	17
6274	Clinical cases in neuro-oncology. , 2023, , 467-698.		0
6298	Quantitative and Physiological Magnetic Resonance Imaging in Glioma. , 2023, , 433-457.		0
6299	Neuroimaging of Brain Tumors in the Era of Radiogenomics. , 2023, , 1275-1311.		0
6316	Malignant Glioma. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 1-30.	0.8	8
6319	Cellular senescence in glioma. <i>Journal of Neuro-Oncology</i> , 2023, 164, 11-29.	1.4	4
6320	Chromosome 10. , 2023, , 307-343.		0
6321	The Role of Artificial Intelligence in Neuro-oncology Imaging. <i>Neuroinformatics</i> , 2023, , 963-976.	0.2	0
6324	Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2023, 164, 1-9.	1.4	4

#	ARTICLE	IF	CITATIONS
6325	Pathology of the Tumors of the Central Nervous System. , 2023, , 71-110.		0
6344	Nature-Nurture and the Epigenome. , 2023, , 43-47.		0
6355	Antitumour imidazotetrazines: past, present and future?. RSC Chemical Biology, 2023, 4, 736-741.	2.0	1
6374	From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	3
6382	Spinal cord motor disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 3-42.	1.0	0
6414	Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients. Methods in Cell Biology, 2023, , .	0.5	0
6416	Molecular testing for gliomas. , 2024, , 385-396.		0
6417	Epigenetic processes-driven disorders and therapeutics. , 2024, , 599-628.		0
6429	An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence. Npj Precision Oncology, 2023, 7, .	2.3	1
6448	Ganciclovir as a potential treatment for glioma: a systematic review and meta-analysis. Journal of Neuro-Oncology, 0, , .	1.4	0
6470	Fluorescent molecular rotors detect <i>O</i> <sup>6</sup> -methylguanine dynamics and repair in duplex DNA. Chemical Communications, 0, , .	2.2	0
6471	PET Agents for Primary Brain Tumor Imaging. , 0, , 1-62.		0
6486	Glioma. , 2024, , 184-192.		0
6506	Molecular mechanisms of sensitivity and resistance to radiotherapy. Clinical and Experimental Metastasis, 0, , .	1.7	0
6510	Multiomics in precision medicine, 2024, , 195-207.		0
6511	Gliome. , 2024, , 23-28.		0
6533	A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives. Neurological Sciences, 0, , .	0.9	0
6539	Malignome des zentralen Nervensystems (ZNS)., 2024, , 1071-1107.		0



#	ARTICLE	IF	CITATIONS
6541	Brain Gliomas of Adulthood. , 2023, , 1-20.		0
6547	Feasibility of Predicting O-6-methylguanine-DNA Methyltransferase Status in Glioblastoma Using MRI-based Radiomics Features. , 2023, , .		0